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ABSTRACT 
Thiopurines azathioprine and 6-mercaptopurine are effective immune-modulators 
and cytotoxic agents widely used in the treatment of autoimmune diseases, graft 
rejection, and cancer. Of concern is the growing epidemiologic evidence that chronic 
exposure to these agents increases the risk of mesenchymal and solid tumors.  Although 
in vitro and in vivo animal studies suggest that these agents are mutagenic and have the 
potential to select for mismatch repair deficient mutants, their in vivo mechanism(s) of 
carcinogenicity in humans remain(s) unclear.  
We investigated the in vivo mutagenicity of thiopurines in a cross-sectional study 
of 119 children and adults with inflammatory bowel disease by determining the 
frequency and spectra of somatic mutations at the HPRT locus using the T-cell cloning 
assay.  We observed a significant increase in the frequency of somatic mutations that was 
related to total dose (p<0.001) and duration of treatment (p<0.001) among 56 thiopurine 
treated subjects compared to 63 untreated subjects.  By mutation spectra comparison of 
1020 mutant isolates, we also observed a significant dose-dependent increase in the 
proportion of G:C to A:T transitions (p<0.001) that is consistent with the in vitro 
mutagenic signature of these drugs.  Although in vivo selection for HPRT mutants may 
have confounded the absolute mutation frequency since this is a ratio value, the 
significant thiopurine dose-dependent correlations with frequency and mutation spectra 
shift strongly suggest that thiopurine treatment is mutagenic in vivo. 
We also investigated the prevalence of in vivo clonal proliferation by the 
combined analyses of HPRT mutations and TCRβ CDR3 regions from mutant isolates 
and observed a higher prevalence of cell proliferation in association with chronic 
thiopurine therapy.  Thiopurine treated subjects displayed expansions of precursor or 
committed progenitor cells and post-β rearrangement thymocytes or mature T-cells while 
untreated adult subjects showed only post-β rearrangement expansions of thymocytes or 
mature T-cells.  Thiopurine treated subjects also uniquely displayed clonal expansions of  
“hyper-mutable” thymocytes or mature T-cells that gave rise to progenies with 
independent mutations either through extensive proliferation or from genetic instability.  
This pattern predominated in children and exhibited the highest occurrences of G:C to 
A:T mutations. G:C to A:T transitions were also observed in both early precursors or 
committed progenitors and post-β rearrangement thymocytes or mature T-cells from 
thiopurine treated subjects compared to untreated subjects who displayed a low frequency 
of G:C to A:T mutations unrelated to thiopurine therapy in post-β rearrangement 
thymocytes or mature T-cells. 
These data provide direct evidence that thiopurine treatment is mutagenic in vivo 
by mutation induction that may be enhanced through its effects on cell proliferation, and 
provide the first mechanistic evidence for the carcinogenicity of these therapeutic agents 
in humans.  Our observations also suggest the potential risks to proliferating precursor 
and mature cells.  In children, we may be capturing a subpopulation of “hypermutable” 
T-cells with a higher propensity to progress to lymphoma, which occur at highest 
frequency following transplantation. 
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CHAPTER ONE: COMPREHENSIVE LITERATURE REVIEW 
History and Clinical Applications 
 Thiopurines (Figure 1), 6-mercaptopurine and 6-thioguanine, were initially 
synthesized by Elion and Hitchings in the early 1950’s with the aim for use as 
antimetabolites of nucleic acid bases to selectively kill rapidly proliferating cancer cells.  
As analogs of hypoxanthine and guanine, their efficacies against leukemic cells have led 
to their use in the treatment of childhood acute lymphoblastic leukemia and adult acute 
myelogenous leukemia (Elion 1989).  With the parallel conception of an antiproliferative 
effect on activated immune cells, 6-mercaptopurine was later demonstrated to also have 
immunosuppressive activity by Robert Schwartz (Schwartz and Dameshek 1959; 
Schwartz et al. 1958).  In attempt to increase the in vivo efficacy of 6-mercaptopurine 
against leukemia, Elion and Hitchings then synthesized a 1-methyl-4-nitro-5-imidazole 
derivative, azathioprine, that retained comparable anti-leukemic effects and in addition, 
has immunosuppressive activity superior to 6-mercaptopurine (Elion 1993).  
Subsequently in the 1960’s, azathioprine was included in immunosuppressive regimens 
to prevent kidney transplant rejection (Murray et al. 1963).   
Following demonstrated in vivo efficacy in the treatment of leukemia and 
prolonging the survival of kidney transplants, 6-mercaptopurine and azathioprine have 
been widely used in the clinical management of many immunological conditions in 
children and adults.  Their uses have been extended to the prevention of heart (Al-khaldi 
and Robbins 2006), lung (Webber et al. 2006) and liver transplant rejection (Garcia et al. 
  2 
2000).  They have also been therapeutically beneficial in the treatment of autoimmune 
diseases, including systemic lupus erythematosus (Contreras et al. 2005; Goldblatt and 
Isenberg 2005), multiple sclerosis (Casetta et al. 2007), pemphigus vulgaris (Chams-
Davatchi et al. 2007), autoimmune chronic liver diseases (Ishibashi et al. 2007; Montano 
Loza and Czaja 2007), myasthenia gravis (Palace et al. 1998), and inflammatory bowel 
disease (Dubinsky 2008; Kozuch and Hanauer 2008).  On the other hand, due to higher 
associated adverse effects, 6-thioguanine has been primarily used as a second line agent 
in the treatment of adult acute myelogenous leukemia, and in some instances as a 
substitute for 6-mercaptopurine. 
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 Azathioprine (Aza) 6-mercaptopurine (6-MP)  6-thioguanine (6-TG) 
 






Molecular Weight:  277.26 g/mol    152.18 g/mol     167.19 g/mol 
Molecular Formula: C9H7N7O2S    C5H4N4S     C5H5N5S 
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Metabolism of Thiopurines 
 The metabolism of inactive prodrugs azathioprine, 6-mercaptopurine, and 6-
thioguanine is interrelated by the proposed pathways depicted in Figure 2.  Azathioprine 
is non-enzymatically thiolysed by sulfhydryl containing groups including glutathione and 
cysteine to form 1-methyl-4-nitro-5-imidazole and 6-mercaptopurine (Chalmers 1974; 
Elion 1993), which enters cells and undergoes several competing catabolic and anabolic 
pathways.  6-mercaptopurine may become inactivated through either methylation with S-
adenosylmethionine by thiopurine S-methyltransferase (TPMT) to form 6-
methylmercaptopurine (6-MeMP) or oxidation by xanthine oxidase (XO) to form inactive 
thioxanthine (TX) and then thiouric acid (TUA).  Alternatively, 6-mercaptopurine (6-MP) 
is activated through phosphoribosylation with phosphoribosyl pyrophosphate (PRPP) to 
form thioinosine monophosphate (6-TIMP) by hypoxanthine-guanine phosphoribosyl 
transferase (HPRT), an enzyme that salvages purines hypoxanthine and guanine.  
Thioinosine monophosphate may become methylated by TPMT to form 
methylthioinosine monophosphate (6-MeTIMP) (Krynetski et al. 1995) or oxidized by 
inosine monophosphate dehydrogenase (IMPDH) to thioxanthosine monophosphate (6-
TXMP).  Subsequent amination of thioxanthosine monophosphate by guanosine 
monophosphate synthetase (GMPS) results in the formation of thioguanosine 
monophosphate (6-TGMP), a product also generated from the phosphoribosylation of 6-
thioguanine with PRPP by HRPT.  Thioguanosine monophosphate can undergo 
methylation by TPMT (Krynetski et al. 1995) or phosphorylation and/or reduction to 
  5 
form precursor 6-thioguanine nucleotides that can become incorporated into RNA or 
DNA.  Once 6-thioguanine enters the cell, it can undergo activation by HPRT to form 
thioguanosine monophosphate or inactivation by guanase and TPMT to form 
thioxanthine and 6-methylthioguanine, respectively.  The direct conversion of 6-
thioguanine to thioguanosine monophosphate is thought play a role in the difference in 
mechanisms of action and adverse effects between 6-mercaptopurine and 6-thioguanine 
as described in more detailed in the sections of mechanisms of cytotoxicity and 
differential effects of thiopurine treatment. 
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XO (xanthine oxidase); TPMT (thiopurine S-methyltransferase); HPRT (hypoxanthine-guanine phosphoribosyl transferase); IMPDH (inosine 
monophosphate dehydrogenase); GMPS (guanosine monophosphate synthetase) 
 
Aza (azathioprine); 6-MP (6-mercaptopurine); 6-TG (6-thioguanine); 6-MeMP (6-methylmercaptopurine); 6-MeTG (6-methylthioguanine); 
6-TX (thioxanthine); 6-TUA (thiouric acid); 6-TIMP (thioinosine monophosphate); 6-MeTIMP (6-methylthioinosine monophosphate); 6-
TXMP (thioxanthosine 5’-monophosphate); 6-TGMP (thioguanosine 5’-monophosphate); 6-MeTGMP (6-methylthioguanosine 
5’monophosphate); TGDP (thioguanosine 5’-diphosphate); TGTP (thioguanosine 5’-triphosphate); TGDP (thioguanosine 5’-diphosphate); 
TdGDP (thio-deoxyguanosine 5’-diphosphate); TdGTP (thio-deoxyguanosine 5’-triphosphate)
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Mechanisms of Cytotoxicity/Immunosuppression of Thiopurines 
For nearly fifty years azathioprine, 6-mercaptopurine, and 6-thioguanine have 
been effective in the treatment of many disorders and yet their in vivo mechanisms of 
action are not clearly understood.  Some of their therapeutic effects may be explained by 
modulation of de novo purine biosynthesis, interference with DNA synthesis and repair, 
and alteration of cellular signaling to result in cytotoxicity and immunosuppression 
(Figure 3).  In vitro studies have shown that methylated metabolites of 6-mercaptopurine 
and 6-thioguanine nucleotides can inhibit de novo purine biosynthesis by primarily 
inhibiting the rate-limiting enzyme PRPP amidotransferase (Figure 3, Model 1).  This 
inhibition results in decreased DNA, RNA, and protein synthesis, reduced cell growth 
and proliferation, and ultimately cell death when the nucleotide pool is chronically or 
extremely perturbed (Bokkerink et al. 1993; Stet et al. 1993; Yamaoka et al. 2001).  
Among methylated nucleotide metabolites, 6-methylthioinosine monophosphate, a 
methylation product of 6-mercaptopurine ribonucleotides, is a potent inhibitor of PRPP 
amidotransferase (Henderson and Khoo 1965; Hill and Bennett 1969).  Although 
metabolites of 6-TG nucleotides also inhibit purine biosynthesis, this inhibition occurs to 
a lesser extent (Allan and Bennett 1971), and 6-TG is thought to cause cytotoxicity 
primarily through incorporation into DNA (Nelson et al. 1975).  Since 6-MP is also 
metabolized to 6-thioguanine nucleotides, there have been ongoing controversies over 
which of these mechanisms predominates in association with its use.  Early studies 
demonstrated that treatment with 6-mercaptopurine caused a delayed cytotoxic effect 
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which correlated with the level of 6-thioguanylate incorporation into DNA and that 
associated perturbations of purine biosynthesis reduced proliferation rate but were 
insufficient to cause cytotoxicity (Tidd and Paterson 1974a; Tidd and Paterson 1974b; 
Warnick and Paterson 1973).   
Cytotoxicity through incorporation of 6-thioguanine nucleotides into DNA is 
hypothesized to involve the events depicted in Figure 3, Model 2.  After incorporation 
into DNA, about 1 of 104 of 6-thioguanine becomes methylated by S-adenosylmethionine 
(Swann et al. 1996).    During the second cycle of replication, S6-methylthioguanine (6-
MeTG) can base pair at similar frequency with either cytosine or thymine (Swann et al. 
1996).  Formed 6-MeTG:T mispairs are recognized by hMutSα or the human homolog of 
bacterial MutSα, consisting of heterodimer MSH2 and MSH6, followed by the 
recruitment of hMutLα or the human homolog of bacterial MutL, consisting of 
heterodimer MLH1 and PMS2, which are components of the mismatch repair system 
involved in the correction of post-replication base mismatches and small 
insertion/deletion loops (Li 2003; Swann et al. 1996; Yan et al. 2003).  The binding of 
mismatch repair components may either directly signal the presence of DNA damage or 
additionally recruit other proteins to the lesion to engage in excision and repair of the 
mismatch.  In the latter hypothesis, futile attempts at strand-specific repair of daughter 
strand result in single strand breaks (Yan et al. 2003), the engagement of ATR and Chk1 
kinase (Yamane et al. 2004), G2-M arrest (Wotring and Roti Roti 1980), and subsequent 
cell death that is characterized as a “delayed cytotoxic reaction,” which occurs in the 
second cell cycle following the incorporation of 6-thioguanine nucleotides during the first 
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round of DNA replication.  Evidence in support of this mechanism include the reduced 
sensitivity to 6-thioguanine among mismatch repair deficient cell lines and animals when 
compared to mismatch repair proficient counterparts (Aebi et al. 1997; Krynetskaia et al. 
2003; Offman et al. 2004).  Also, some cell lines showing drug resistance are able to 
incorporate higher levels of 6-thioguanine nucleotides (O'Donovan et al. 2005; Swann et 
al. 1996).  
In an in vivo setting with dietary sources of nucleotides, it is difficult to discern 
the relative contribution of the two mechanisms to cytotoxicity.  For example, although 
Lennard and colleagues demonstrated a correlation between higher intracellular levels of 
6-thioguanine nucleotides and better disease outcome (Lennard and Lilleyman 1989; 
Lennard and Lilleyman 1990), several studies revealed equal efficacy between 6-
mercaptopurine and 6-thioguanine in the treatment of childhood lymphoblastic leukemia 
(Harms et al. 2003; Vora et al. 2006) despite a lower accumulation of intracellular 6-
thioguanine nucleotides with 6-mercaptopurine treatment (Erb et al. 1998).  Perhaps both 
mechanisms are important and may be synergistic in the therapeutic efficacy of 
thiopurines, since reducing the pool of natural purines would effectively increase the 
relative concentration of 6-thioguanine nucleotides to be utilized in DNA synthesis.  This 
synergism has been demonstrated in vitro (Bokkerink et al. 1993).  
On the other hand, one mechanism may predominate over another in different 
tissues depending on the availability of enzymes and repair systems.  For instance, bone 
marrow cells produce an abundance of HRPT and little PRPP amidotransferase, thus 
cytotoxicity by incorporation of 6-thioguanine nucleotides into DNA may be the primary 
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mechanism affecting these cells since they rely more on the salvage pathway for sources 
of purines (Stout and Caskey 1985). Petit and colleagues recently demonstrated greater 
cytotoxicity with concurrent induction of inosine monophosphate dehydrogenase 
(IMPDH) expression in human hepatocytes following azathioprine and 6-mercaptopurine 
treatment when compared to 6-thioguanine (Petit et al. 2008).  In this case, the stronger 
cytotoxic effects associated with azathioprine and 6-mercaptopurine may be explained by 
the concomitant inhibition of de novo purine biosynthesis at the rate-limiting step 
catalyzed by PRPP amidotransferase and the increased conversion of 6-TIMP to 6-TXMP 
from the induction of IMPDH to subsequently form 6-thioguanine nucleotides for DNA 
incorporation.  On the other hand, many in vitro studies performed in cell lines that are 
deficient or expressed low levels of mismatch repair protein components have 
demonstrated cytoxicity primarily by inhibition of de novo purine biosynthesis (Stet et al. 
1993; Dervieux et al. 2001; Matheson and Hall 2003). 
Thiopurines have also been demonstrated to exert a specific immunosuppressive 
activity on CD4 T-cells that are costimulated through CD28 by interfering with the 
function of Vav1, a GTP exchange factor of Rac1 (Figure 3, Model 3) (Poppe et al. 2006; 
Tiede et al. 2003).  In these studies, following the activation of T-cells, active metabolite 
6-thioguanosine triphosphate can be exchanged by Vav1 for bound GDP to activate Rac1 
GTPase.  However, once 6-thioguanosine triphosphate is hydrolyzed, Vav1 is unable to 
exchange the dephosphorylated analog nucleotide for another GTP or 6-SGTP.  This 
results in decreased activation of Rac1 downstream targets, including the mitogen 
activated protein kinase kinase (MEK)/NFκB pathway and STAT-3, reduction in the 
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expression of anti-apoptotic signal Bcl-XL, and subsequent induction of apoptosis of CD4 
T-cells. 
Thus far the presented mechanisms of action have involved common downstream 
metabolites of all three thiopurines.  Additional differences in the activity of azathioprine 
compared to 6-mercaptopurine have been attributed to the possible immunosuppressive 
roles of the reactions or products involved in the release of the 1-methyl-4-nitro-5-
imidazole group and/or the slow time release of 6-mercaptopurine from red blood cells 
following the thiolysis of azathioprine (Elion 1993). 
 
Differential Effects of Thiopurines on Tissues and Individuals 
The effects of thiopurines may vary in different tissues depending on enzyme 
availability and metabolic demand, among individuals depending on inherited 
disposition, and in the presence of other drugs that inhibit or compete for enzymes that 
catalyze reactions involving these agents.  The bioavailability of 6-mercaptopurine and 
azathioprine following oral administration are reduced by their inactivation from the 
abundance of xanthine oxidase in the intestinal mucosa and liver (Watts et al. 1965; 
Linder et al. 1999).  Xanthine oxidase, however, is not expressed or expressed at low 
levels in hematopoietic tissues, contributing to the adverse effects of myelosuppression 
associated with thiopurine treatment.  Rapidly dividing tissues may be more susceptible 
to the effects of drug treatment due to their increased need for nucleotides, such as 
proliferating cells of the bone marrow, which have been observed to incorporate higher 
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levels of 6-thioguanine nucleotides into DNA (Lepage 1960; LePage and Whitecar 1971), 
and tissues undergoing repeated cycles of damage and regeneration, as in the epithelia of 
patients with inflammatory bowel disease (Itzkowitz and Yio 2004) or chronic graft 
versus host disease (Ratanatharathorn et al. 2001).   
Genetic polymorphisms of thiopurine S-methyltransferase that result in variant 
enzyme activities and subsequently different levels of active metabolites from 
conventional drug doses have been well described.  Among Caucasians, a trimodal 
distribution of enzyme activity has been observed with 0.3-0.6% showing very low or no 
enzyme activity, about 10-11% with intermediate activity, and approximately 89-90% 
showing normal to high enzyme activity (Holme et al. 2002; Schaeffeler et al. 2004; 
Weinshilboum and Sladek 1980).  At present, 23 single nucleotide polymorphisms 
(TMPT*2 to *22) that result in variant enzyme activity have been identified, with most 
frequently observed alleles, TMPT*3A in 4.4% of Caucasians (Schaeffeler et al. 2004) 
and TMPT*3C in 5.4-7.6% of Africans and 0.3-3% in Asians (Teml et al. 2007).  
Differences in enzyme activity may have important clinical consequence, as observed in 
the associations between higher rates of relapse and higher TPMT activities (Lennard et 
al. 1990) and lower rates of positive minimal residual disease and heterozygosity for 
variant alleles of TPMT (Stanulla et al. 2005) among children treated for leukemia with 
6-mercaptopurine.  On the other hand, subjects with low enzyme activities experience 
severe myelosuppression, necessitating reduction to 10 to 15% of conventional drug 
doses (Teml et al. 2007). 
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Several drugs are known to modulate the bioavailability of 6-mercaptopurine and 
azathioprine.  Methotrexate, an antimetabolite that inhibits dihydrofolate reductase, when 
used in conjunction with 6-mercaptopurine during maintenance therapy of pediatric acute 
lymphoblastic leukemia, has been shown to increase the bioavailability of 6-
mercaptopurine and correlate with higher 6-thioguanine nucleotide levels by mechanisms 
that remain unclear (Balis et al. 1987; Dervieux et al. 2002).  An inhibitor of xanthine 
oxidase, allopurinol, commonly used in the treatment of hyperuricemia and tumor lysis 
syndrome, can increase the bioavailability of 6-mercaptopurine up to 5 fold (Elion 1989; 
Teml et al. 2007), requiring the reduction of standard doses of 6-mercaptopurine to 25%.  
Concurrent treatment with aminosalicylic acid, which inhibits thiopurine S-
methyltransferase, can also alter the effective concentration of 6-thioguanine nucleotides 
(Teml et al. 2007).  
Altogether the therapeutic or adverse effects of thiopurines on tissues and 
individuals will depend on the levels of metabolizing enzymes, metabolic demands of 
tissues, and participation of other competing compounds in relevant enzymatic reactions. 
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Figure 3.  Mechanisms of Cytotoxicity/Immunosuppression of Thiopurines. 
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Figure 3.  Mechanisms of Cytotoxicity/Immunosuppression of Thiopurines. 
 
Model 3.  Induction of Apoptosis of CD4+T-cells Activated by Costimulation of CD28 
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Cancer Risks Associated with Thiopurine Treatment 
Cancer risks in individuals reflect the complex interactions among inherited 
susceptibility including differences in capacities for DNA repair and drug 
metabolism/detoxification, physiological changes during development, the presence and 
extent of underlying diseases, and environmental exposure, which culminate in different 
frequencies of cancers observed among patient groups.  Such complexities present 
challenges in the study of cancer risks associated with a particular treatment in human 
subjects, which is further complicated by concurrent treatment with other agents.  Despite 
these challenges, progress in the understanding of cancer risks associated with thiopurine 
treatment has evolved from epidemiological studies of different patient groups and risk 
comparisons with other immune-modulators along with parallel controlled in vitro and in 
vivo animal investigations of drug metabolism and mechanisms of action and associated 
genotoxicity and tumor development. 
Early epidemiological evidence of the high incidences of skin cancers, 
lymphomas, leukemias, hepatobiliary carcinomas, and other mesenchymal and solid 
tumors among kidney transplant recipients and to a lesser extent, in patients with 
autoimmune diseases (Kinlen 1985; Penn 1988) resulted in the classification of 
azathioprine as a human carcinogen {IARC Monographs, 1981; IARC Monographs, 
1987}.  In these studies, azathioprine was either used in combination with prednisone to 
prevent kidney graft rejection or as monotherapy primarily in the treatment of rheumatoid 
arthritis.  The increased cancer risks in these patients were mainly attributed to the 
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immunosuppressive effects of treatment, hypothesized to result in decreased immune 
surveillance of aberrant or virus-infected cells, that may be enhanced in specific cancers 
by immune dysregulation in the presence of chronic antigenic stimulation from foreign 
graft or autoimmunity.  Much of this came from the findings of genetic materials of 
oncogenic viruses Epstein-Barr virus (EBV), Human Herpes Virus 8 (HHV8), and 
Human Papillomavirus (HPV16/18) in tumors including non-Hodgkin’s lymphomas, 
Kaposi Sarcomas, and squamous cell carcinomas, respectively (Euvrard et al. 2003).  
Evidence suggestive of the contribution of antigenic stimulation included the preferential 
localization of lymphomas in regions of the heart or lung after heart transplantation and 
kidney following renal transplantation (Opelz and Henderson 1993).   
In addition to their immunosuppressive effects, comparative epidemiological 
studies with other immune-modulators indicate that thiopurines may uniquely contribute 
to carcinogenesis.  When compared to prednisone in a randomized control study, 
azathioprine treatment was associated with higher incidences of different malignancies in 
patients treated for non-alcoholic liver disease (Tage-Jensen et al. 1987).   In the 
treatment of chronic graft versus host disease following hematopoietic stem cell 
transplantation for aplastic anemia, immunosuppressive regimens containing azathioprine 
showed significantly higher relative risk for squamous cell carcinoma when compared to 
those without azathioprine (Curtis et al. 2005).  Azathioprine use for maintenance 
immunosuppression post-renal transplantation also resulted in significant increase in the 
relative risk of non-melanoma skin cancer compared to cyclosporine, mycophenolate 
mofetil, tacrolimus and sirolimus, which showed either no change or significant 
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protective effects (Kasiske et al. 2004), in a three year follow-up study of cancer 
incidences among 35,765 patients in the United States.  In another important comparison 
with antimetabolite mycophenolate mofetil (MMF), which most closely resembles 
azathioprine in mechanism of action, azathioprine treatment resulted in significantly 
higher incidences of solid tumors (2.5% vs. 1.6%, P<0.001) and lymphoproliferative 
malignancies (0.6% vs. 0.3%, P=0.013) among 17,145 adult renal transplant patients with 
diabetes mellitus, who were evaluated using the Organ Procurement and Transplantation 
Network database (OPTN) (David et al. 2005). 
Cancer risks associated with thiopurine treatment among patients may be further 
complicated by drug metabolism, disease severity, developmental changes, and other 
environmental exposure.  Drug metabolism has been demonstrated to modify cancer risks 
as exemplified in the associations between low TPMT activity and the development of 
secondary acute myelogenous leukemia and brain tumors in children treated for acute 
lymphoblastic leukemia (Relling et al. 1999; Relling et al. 1998).  The contribution of 
disease severity is evident in the higher relative risk of squamous cell carcinoma among 
azathioprine treated subjects with severe compared to moderate chronic graft versus host 
disease (Curtis et al. 2005).  The significance of different stages of development is 
demonstrated in the higher incidence of non-Hodgkin’s lymphoma among children 
compared to the higher incidence of squamous cell carcinoma in adults following 
transplantation (Penn 1988; Penn 1998).  Environmental exposure also play an important 
role in modifying cancer risks as observed in the higher incidences of squamous cell 
carcinoma among transplant recipients who live in countries with more sun exposure 
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(Euvrard et al. 2003).  The interaction among these modifying factors along with total 
dose and duration of treatment exposure (Asten et al. 1999; Offman et al. 2004; Silman et 
al. 1988) likely culminate in different cancer risks that are reflected as variations in 
frequencies of cancers observed among different patient groups receiving thiopurine 
therapy. 
 
Thiopurine-Specific Mechanisms Contributing to Carcinogenesis 
In vitro and in vivo investigations suggest that thiopurine-specific carcinogenicity 
is likely associated with events following its incorporation into DNA, which result in the 
accumulation of mutations that may alter gene function and/or select for clones with 
mismatch repair deficiency.  Inherent in its mechanisms of action, once incorporated into 
DNA, methylated 6-thioguanine can mispair with thymine.  6-MeTG:T mispairs 
unprocessed by the mismatch repair system can result in the propagation of G:C to A:T 
transitions in daughter cells (Swann et al. 1996; Yuan and Wang 2008).  Unmethylated 6-
TG can also mispair with thymine, potentially inducing additional in G:C to A:T 
transitions (Rappaport 1993; Uribe-Luna et al. 1997; Yuan and Wang 2008).   
In vitro thiopurines have also been demonstrated to synergize the mutagenicity of 
ultraviolet A (UVA), the primary source of radiation from sun exposure (O'Donovan et 
al. 2005).   Upon exposure to UVA, incorporated 6-thioguanine generates reactive 
oxygen species (ROS) and is converted to a replication blocking photoproduct, 2-
aminopurine-6-sulfonate (G-6-SO3) that is mutagenic when bypassed by Y family DNA 
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polymerases, also resulting in G:C to A:T transitions  (O'Donovan et al. 2005).  In E. coli 
hosts, these lesions are efficiently bypassed even in the absence of pol IV and/or pol V 
with the induction G:C to A:T mutations (Yuan and Wang 2008).  Formed ROS can 
damage DNA (Cadet et al. 2003) and cross-link proteins as observed with subunits of 
proliferating cell nuclear antigen (PCNA), which may compromise DNA replication and 
repair (Montaner et al. 2007).  Consistent with these findings, azathioprine has been 
demonstrated to potentiate the carcinogenicity of UV light in the development of skin 
cancer in albino mouse (Reeve et al. 1985).  Higher incidences of squamous cell 
carcinoma of the skin among transplant recipients have also been observed following 
azathioprine treatment compared to other immune-modulators (Curtis et al. 2005; 
Kasiske et al. 2004).   
 Although these potentially mutagenic events have been demonstrated in vitro, it is 
difficult to predict the frequency of their occurrences in vivo.  Of potential clinical 
concern is the measurable accumulation of 6-thioguanine nucleotides in DNA of viable 
peripheral lymphocytes and skin epithelial cells from subjects who have been receiving 
thiopurine treatment (Cuffari et al. 2004; O'Donovan et al. 2005; Warren et al. 1995).  It 
is reasonable to hypothesize that with increasing accumulation below the threshold of 
cytotoxicity, cells harboring a higher level of incorporated 6-thioguanine nucleotides 
would accumulate more mutations.  Thus, how frequent these events occur in different 
tissues would depend on tissue-specific drug metabolism and proliferation rate.    
Several lines of evidence suggest that thiopurines may also be clastogenic.   
Following in vitro drug exposure, different cell lines have demonstrated both 
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chromosomal aberrations and sister chromatid exchanges (Maybaum and Mandel 1983; 
Vernole et al. 2003).  These events occur at higher frequency in mismatch repair 
proficient cell lines than mismatch repair deficient counterparts, indicating that formed 
lesions are related to the processing of DNA damage.  DNA double strand breaks have 
also been observed following thiopurine treatment independent of mismatch repair status 
(Yan et al. 2003).  Krynetskaia and colleagues showed that incorporated 6-thioguanine 
nucleotides can in a position-dependent manner promote or inhibit the activity of 
topoisomerase II (Krynetskaia et al. 2000), an enzyme that introduces double strand 
breaks in DNA during its catalytic cycle to prevent DNA tangling.  They further showed 
that thiopurine-associated stimulation of topoisomerase activity can be enhanced by the 
presence of etoposide, a cancer chemotherapy which binds to and prevents topoisomerase 
II from ligating cleaved DNA molecules resulting in single and double strand breaks.  It 
has also been demonstrated that DNA templates containing incorporated 6-thioguanine 
nucleotides can inhibit DNA ligase activity, potentially inhibiting the ligation endpoint of 
repair reactions (Ling et al. 1992).  
Cells that incur high levels of DNA damage are normally killed.  However, in an 
in vivo setting with differential drug exposure, it is unclear what fraction of cells are able 
to survive or the threshold level of damage that can persist in cells without causing cell 
death.  High dose thiopurine treatment in mice, rats, and Chinese hamsters has been 
shown to increase chromosomal damage in bone marrow cells (Frohberg and Schencking 
1975; Holden et al. 1973).    Many groups have measured the cumulative chromosomal 
aberrations in lymphocytes of subjects who received chronic azathioprine treatment and 
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found both increased and no change in the frequency of aberrations (Apelt et al. 1981; 
Voogd 1989).   Differences in the results among these studies have been attributed to 
variations in culture time and inconsistent criteria for classifying chromosomal 
aberrations.  Thus, it remains unclear to what extent thiopurines induce chromosomal 
aberrations in vivo.  However, Relling’s and colleagues’ observations of the associations 
between low TPMT activity or high 6-thioguanine nucleotide levels and the development 
of secondary acute myelogenous leukemia (AML) and brain tumors in children who were 
treated for acute lymphoblastic leukemia with regimens consisting of thiopurines and 
etoposide suggest a potential synergism between thiopurines and etoposide in inducing 
DNA damage in vivo (Relling et al. 1999; Relling et al. 1998).  
Since the mismatch repair system is implicated in the signaling of DNA damage 
to result in cytotoxicity, chronic thiopurine treatment may also enrich for drug resistant 
cells that are mismatch repair deficient.  Both in vitro and in vivo studies have 
demonstrated increased resistance to the cytotoxic effects of thiopurines among mismatch 
repair deficient cell lines and animals when compared to proficient counterparts (Aebi et 
al. 1997; Krynetskaia et al. 2003; Vernole et al. 2003).  Surviving cells with mismatch 
repair deficiency may exhibit a high mutation rate (Bhattacharyya et al. 1994), 
accelerating the acquisition of mutations at critical genes required for tumor 
development, similar to the cancer-predisposition among HNPCC patients, who have 
inherited a germline mutation in one of the genes encoding for components of the 
mismatch repair system (Lucci-Cordisco et al. 2003).  Consistent with this hypothesis are 
the findings of a higher frequency of microsatellite instability (MSI) among acute 
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myelogenous leukemia that have developed in transplant recipients who received 
azathioprine treatment (Offman et al. 2004). 
Independent of DNA incorporation, the 1-methyl-4-nitro-5-imidazole group in 
azathioprine has been suggested to be mutagenic.  The basis for this conjecture came 
from the observations that azathioprine was more mutagenic to Salmonella typhimurium 
TA100 under anaerobic compared to aerobic conditions (Speck and Rosenkranz 1976), 
followed by its demonstrated mutagenicity on facultative anaerobe Klebsiella 
pneumoniae, while 6-mercaptopurine was not found to be mutagenic (Voogd et al. 1979).  
This difference in mutagenicity between the two compounds under anaerobic conditions 
suggested that the reduced form of 1-methyl-4-nitro-5-imidazole is likely mutagenic in 
bacteria.  However, whether mammalian systems possess the required environment and 
enzymes to reduce the nitroimidazole group in order for similar reactions to occur in vivo 
in humans have been debated (Rosenkranz and Klopman 1991; Voogd 1981).   
 Lastly, perturbation of the natural nucleotide pool by inhibition of de novo purine 
biosynthesis by methylated metabolites of thiopurines may result in a higher frequency of 
mispairs and subsequent accumulation of mutations of unrepaired mismatches.  
Following thiopurine treatment, the concentrations of ATP and GTP have been observed 
to decrease, with the reduction of GTP occurring to a greater extent (Nelson et al. 1975; 
Warnick and Paterson 1973).  Along with these changes CTP and UTP were observed to 
initially increase likely as a result of available PRPP.  Uribe-Luna showed in vitro that in 
the absence of dGTP and presence of 6-thioguanine nucleotides, an increased frequency 
of G:C to A:T transitions was induced (Uribe-Luna et al. 1997). Inhibition of purine de 
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novo biosynthesis by 6-methylthioinosinic acid has also been demonstrated to favor the 
incorporation of available 6-thioguanine nucleotides into DNA, resulting in the induction 
of G:C to A:T mutations (Bokkerink et al. 1993).  Since the in vivo system involves a 
complex network of enzyme feedback inhibition and also derives sources of purines from 
dietary intake, it is difficult to predict whether these changes in nucleotide pool are 
reflective of the in vivo effects of chronic thiopurine treatment and will be tolerated or 
result in increased mutation events.  
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Research Proposal and Design 
Although in vitro studies have demonstrated several mechanisms by which 
thiopurines may be carcinogenic, to date its in vivo carcinogenicity in humans remains 
unclear.  We proposed to examine the genotoxicity and selection for mismatch repair 
deficient mutants as potential mechanisms of carcinogenicity associated with thiopurine 
treatment.  Subjects with inflammatory bowel disease (IBD) have been selected in whom 
to study these effects due to their increased risk of lymphoma associated with thiopurine 
treatment (Kandiel et al. 2005) and their less complex treatment regimen, allowing for the 
evaluation of thiopurines with fewer confounding effects of other therapies.  Also, these 
patients may represent other lower risk groups with autoimmune diseases, who are 
candidates for therapeutic intervention with thiopurines.   
The genotoxicity of thiopurine treatment has been evaluated by measuring the frequency 
of somatic mutations at the HPRT locus using the T-cell cloning assay and by comparing 
mutation spectra among treated and untreated IBD subjects and healthy subjects to 
examine specific mutation signature(s) related to drug exposure. We then examined the 
occurrences of exposure-specific mutagenic events in different cell lineages by 
comparative analyses of HPRT mutations and TCRβ CDR3 regions from mutant isolates, 
which also revealed the prevalence, extent, and patterns of in vivo clonal expansions.  
This study included both children and adult subjects to assess for differences in 
contribution of inflammatory bowel disease as well as response to the effects of 
thiopurine exposure in these age groups. 
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Possible thiopurine selection for mismatch repair deficiency has been evaluated by 
measuring the frequency of microsatellite instability, indicative of the functional 
deficiency of mismatch repair, in mutant T-cell clones and also continuing with isolated 
CD45RO T-cells using high-throughput microsatellite analysis that has been developed. 
Several factors anticipated to confound the evaluation of the mutagenicity of thiopurines 
were addressed by study design and statistical analysis. 
The effect of age on the frequency of mutants and mutation spectra.  
Others and we have previously observed an age-related contribution to the frequency of 
mutants and mutation spectra in healthy subjects, likely reflecting the interactions 
between background endogenous and exogenous environmental exposure and 
physiologic dynamics during different stages of development.  Using existing databases 
of frequency of mutants and mutation spectra for different age groups from healthy 
subjects, we have derived statistical algorithms to adjust for the contribution of age-
related changes. 
Severity of disease   
More severe disease in chronic inflammatory conditions such as rheumatoid arthritis and 
hepatitis C have been associated with increased DNA damage in peripheral lymphocytes 
(Altindag et al. 2007; Bolukbas et al. 2006).  To evaluate for the possible differences in 
contribution of disease severity, we have recruited subjects with different duration and 
extent of inflammatory bowel disease. 
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Drug metabolism 
Polymorphisms of thiopurine S-methyltransferase have been described in association 
with adverse effects, response to therapy, as well as cancer risks in previous sections.  
Since the frequency of heterozygotes and homozygotes for variant alleles are 
approximately 10% and 0.3-0.6%, respectively, we did not have enough representation in 
our study to examine the effects of drug metabolism. 
Genotoxicity of other therapeutic agents 
Most non-thiopurine medications received by IBD subjects in this study have not been 
demonstrated to be genotoxic except for ciprofloxacin and metronidazole.  These drugs 
have been observed to exert genotoxicity likely through double strand breaks and 
mutation induction in different model systems, respectively, which are discussed in the 
treatment section of inflammatory bowel disease.  The relevance of their genotoxicity to 
humans is further explored in this study.  
In vivo selection for HPRT mutants  
Thiopurines are prodrugs requiring activation by the HPRT enzyme prior to exerting its 
cytotoxic effects.  Inactivation of HPRT is one mechanism of drug resistance.  Since we 
are measuring mutation events at the HRPT locus, concerns of whether this gene will 
serve as a reliable in vivo marker of mutagenicity has been controversial due to the 
possibility of in vivo selection for HRPT mutants. We expect that in subjects receiving 
chronic thiopurine treatment, in vivo selection for cells with HPRT deficiency likely 
occur, favoring the expansion of HPRT mutants while killing proliferating non-mutants.  
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This enrichment may inflate the frequency of somatic mutations, which represent the 
ratio of unique mutants to the total population of cells, even following the correction for 
clonal expansion.  Although this phenomenon is likely to occur, the mutagenicity of 
thiopurines can still be evaluated at the nucleotide level by mutation spectra comparison.  
If selection were to solely occur, we expect the mutant and mutation frequencies to be 
elevated with no change in mutation spectra when comparing treated to untreated 
subjects.  On the contrary, if mutation induction is occurring in the presence of selection, 
we expect the elevated mutant and mutation frequencies to be confounded by the 
contribution of selection, however, the mutation spectra would change with respect to the 
specific mutation signature of the mutagenic agent. 
 
Inflammatory Bowel Disease 
Inflammatory bowel disease comprises the illnesses ulcerative colitis and Crohn’s 
disease, which are characterized by a chronic remitting and relapsing inflammation of the 
gastrointestinal tract.  These diseases are complex multifactorial conditions resulting 
from the interaction of genetic susceptibility and environmental factors hypothesized to 
involve either an aberrant immune response to normal instestinal microflora or a normal 
immune response to altered intestinal microflora. Several susceptibility loci for 
inflammatory bowel disease have been linked to chromosomes 3, 5, 7, 12, and 16 (Hugot 
et al. 1996; Rioux et al. 2000; Satsangi et al. 1996).  Among them NOD2 (nucleotide-
binding oligomerization domain 2, also known as CARD15 or caspase recruitment 
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domain 15) gene on chromosome 16 shows the closest association with Crohn’s disease.  
NOD2 protein is expressed in monocytes, macrophages, dendritic cells, and intestinal 
epithelial cells.  It encodes an intracellular pattern recognition receptor, which recognizes 
bacterial peptidoglycan component, muramyl dipeptide, of Gram-positive and Gram-
negative bacterial cell wall.  The activation of NOD2 by muramyl dipeptide activates NF-
κB signaling pathways, resulting in the expression of pro-inflammatory cytokines (Cho 
2008).  Three polymorphisms of NOD2, which alter bacterial product recognition and the 
activation of NF-κB, have been identified to increase the risk of Crohn’s Disease by 20 to 
40 fold in individuals who are homozygous for two variant alleles (Macdonald and 
Monteleone 2005).  Other candidate genes found to be associated with inflammatory 
bowel disease include the MHC locus and genes encoding mucin, cytokines IL-10 and 
TNFα (Podolsky 2002).  Environmental factors including commensal bacteria have been 
demonstrated to play important roles in colitis, as observed in genetically susceptible 
animal models, which do not develop colitis when grown in a germ free environment 
(Yang and Pei 2006).  Although specific microorganisms have been suggested to have an 
etiological role, increasing evidence shows that a complex interaction of microorganisms 
are likely responsible for eliciting the inflammation.  Smoking status has opposite effects 
on the risks for inflammatory bowel disease, with smoking increasing the risk for Crohn’s 
disease and non-smoking increasing the risk for ulcerative colitis (Calkins 1989).  
Annually about 4 per 100,000 children are diagnosed with inflammatory bowel 
disease, peaking in incidence in the second to third decade of life.  According to a recent 
study of 9 million Americans across 33 states, the prevalence of ulcerative colitis and 
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Crohn’s disease in children under 20 years of age are 28 and 43, and in adults are 238 and 
201 per 100,000 persons, respectively (Kappelman et al. 2007).  In ulcerative colitis 
(UC), inflammation primarily involves the mucosa, beginning in the rectum and can 
extend proximally to the rest of the colon.  Classification of disease is based on the extent 
of involvement of the colon, with inflammation limited to the rectum referred to as 
proctitis, extending to the splenic flexure as left sided colitis, extending beyond the 
splenic flexure as extensive colitis, and involvement of the colon up to the cecum as 
pancolitis.  For UC patients a cure is possible with a proctocolectomy or surgical removal 
of the rectum and colon.  In Crohn’s disease, inflammation can occur in any part of the 
gastrointestinal tract from the mouth to the anal region, involving the mucosa and 
extending into the submucosa to involve the entire gastrointestinal tract wall, sometimes 
resulting in fistulas.  About 80% of patients have inflammation involving the small 
bowel, 20% with disease limited to the colon, and 50% with involvement of the ileum 
and colon. Since Crohn’s disease has a propensity to recur following the removal of 
affected bowel, surgery does not offer a cure, and these patients are dependent on 
medications for control of their disease. 
Associated with their illness, patients with inflammatory bowel disease are at 
increased risk of cancer at affected sites of inflammation.  This increased risk correlates 
with duration of illness, extent of disease, and histological grade of disease.  Subjects 
with pancolitis have a higher risk for colon cancer than those with proctitis or left-sided 
colitis. Having primary sclerosing cholangitis additionally increase the risk of colon and 
hepatobiliary cancers.  Studies have demonstrated that histological degree of 
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inflammation more strongly correlates with increased risk for cancer while disease 
severity defined by clinical exacerbations is not an independent risk factor (Pinczowski et 
al. 1994; Rutter et al. 2004).  Epidemiological studies have documented cumulative 
cancer incidences ranging from 2.5 to 8% at 20 years and 7.6 to 18% following 30 years 
of disease, with higher incidences observed during the pre-surveillance period (Xie and 
Itzkowitz 2008).  Thus following seven years of disease, subjects are recommended to 
undergo surveillance colonoscopy for cancer screening.  In addition to cancers of the 
gastrointestinal tract, subjects with ulcerative colitis are at increased risk of myeloid 
leukemia (Askling et al. 2005).  Although the risk of lymphoma in association with 
inflammatory bowel disease is not clear, a four fold increased risk associated with 
thiopurine treatment was determined from a meta-analysis of 3189 patients (Kandiel et al. 
2005).  Aminosalicylic acid and derivatives have been shown to be chemoprotective in 
reducing the incidences of sporadic colon cancer (Ulrich et al. 2006) and may also have 
protective effects in inflammatory bowel disease.  There is evidence that steroid use can 
also reduce the risk of colon cancer (Velayos et al. 2006). 
 
Treatment of Inflammatory Bowel Disease 
The treatment of inflammatory bowel disease is guided by disease severity and 
patients’ response and tolerance to therapy (Kozuch and Hanauer 2008; Teml et al. 
2007).  For mild to moderate illness, 5-aminosalicylic acid and derivatives (5-ASA) are 
used for induction and maintenance of remission.  These drugs have anti-inflammatory 
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effects through the inhibition of cyclooxygenase and lipoxygenase, resulting in decreased 
production of inflammatory mediators prostaglandins, leukotrienes, and 
hydroxyeicosatetraenoic acid (5-HETE).  They may also scavenge reactive oxygen 
species, interfere with chemotaxis and phagocytosis of neutrophils and macrophages, and 
suppress cytokine synthesis by mononuclear cells (Hardman et al. 2001).   
Steroids are used to induce remission in subjects with severe disease and those 
refractory to 5-ASA treatments.  Glucocorticosteroids are lipophilic molecules, which 
enter the cell and bind to intracellular cytosolic receptors.  Bound receptor complexes 
traverse the nucleus, bind to glucocorticoid response elements, and alter gene expression 
of cytokines and enzymes important in mediating inflammatory responses.  The net 
effects include reduced production of prostaglandins, leukotrienes, and cytokines IL-1, 
IL-6, TNFα, and decreased release of immunoglobins, which ultimately suppress the 
inflammatory response by reducing the extravasation of leukocytes, chemotaxis, 
phagocytosis, and the formation of respiratory bursts (Hardman et al. 2001). 
Since thiopurines 6-mercaptopurine and azathioprine are slow acting drugs, they 
are primarily used in the maintenance of remission of refractory and steroid-dependent 
subjects with inflammatory bowel disease and for fistulous Crohn’s disease (Teml et al. 
2007).  Antimicrobials metronidazole and ciprofloxacin are indicated for the treatment of 
perianal Crohn’s disease.  Anti-TNFα antibody therapy, infliximab, has also been used 
alone and in combination with thiopurines in the induction and maintenance of remission 
of moderate to severe Crohn’s disease (Kozuch and Hanauer 2008).  
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Genotoxicity of Non-thiopurine Medications 
 Most non-thiopurine therapeutic agents have not been observed to be genotoxic 
except for ciproflaxin and metronidazole.  Ciprofloxacin is a fluoroquinolone, which has 
antimicrobial activity by inhibiting bacterial DNA gyrase (toposisomerase II).  Activities 
against eukaryotic topoisomerase II have also been demonstrated in vitro with other 
fluoroquinolones (Elsea et al. 1992).  In vitro treatment with ciprofloxacin has been 
observed to result in chromosomal aberrations in lymphocytes (Gorla et al. 1999), while 
in vivo studies did not show genotoxic effects in mice by the micronucleus test or 
chromosomal aberrations in bone marrow cells of Chinese hamsters (Herbold et al. 
2001).  However, one study of lymphocytes from patients with upper respiratory tract 
infection who were treated with ciprofloxacin showed an increase in the frequency of 
sister chromatid exchanges compared to healthy controls (Ikbal et al. 2004).  
Metronidazole is an antibacterial and antiprotozoal agent that is commonly used in the 
treatment of bacterial vaginosis, anaerobic bacterial infections, and as prophylaxis for 
surgical interventions.  It has been found to be mutagenic using base-pair tester strains in 
the presence of bacterial nitroreductases, and also to induce chromosomal aberrations 
under anaerobic conditions (Voogd 1981).  However, it was not found to be mutagenic to 
mammalian cells in vitro (Voogd 1981), and no cytogenetic effects were observed with 
the micronucleus assay in mice or chromosomal aberration studies of human 
lymphocytes in vitro (Hartley-Asp 1979).  Long-term treatment also showed no 
cytogenetic effects on lymphocytes of patients with Crohn’s disease (Mitelman et al. 
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1980).   Lastly, although there may be an increased risk of lymphoma associated with 
infliximab use (Kozuch and Hanauer 2008), this agent by mechanism of action is not 
mutagenic.   
 
In vivo Monitoring of Somatic Mutations 
 Several assays have been developed for the in vivo monitoring of somatic 
mutation events.  These assays determine the frequency of mutants by measuring 
phenotypic changes that result from mutation events at target reporter genes.  Thus the 
sensitivity of each method depends on the size and sequence context of the reporter gene, 
which dictates the classes of mutations or mutagenic mechanisms that may be captured.  
Two methods performed with red blood cells utilize immunological techniques to detect 
changes in expression of intracellular mutant hemoglobin protein or different forms of 
glycoprotein glycophorin A displayed on red blood cell surface.  Three other methods are 
performed with T-lymphocytes.  Two of these quantify the frequency of variants by using 
immunological techniques to selectively kill normal T-cells bearing wildtype HLA 
proteins and allow for mutants to survive or to detect mutants that have lost cell surface 
expression of the CD3 molecule following mutation events that affect T-cell receptor 
components.  The third T-lymphocyte assay uses a purine analog to select for surviving 
mutants with inactivated HPRT enzyme as a result of mutation events affecting the HPRT 
gene (Albertini and Hayes 1997; Albertini et al. 1993; Cole and Skopek 1994). 
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The Hemoglobin Assay 
Many variant forms of hemoglobin have been characterized in humans, which 
have arisen as a result of base substitutions and frameshift mutations.  The hemoglobin 
assay utilizes antibodies that recognize specific variant(s) expressed in mutant red blood 
cells to measure the frequency of mutants in vivo.  This is performed by detection of 
fluorescently labeled antibodies bound to variant hemoglobin using fluorescence 
microscopy or flow cytometry.  Since the assay measures mutant frequency by specific 
recognition of variant proteins, the measurement of mutation events is limited by the 
specific mutation that resulted in the mutant phenotype.  Therefore, mutant frequencies in 
this assay range in the low values of 1x10-7 to 10-8.  Also, since erythrocytes are 
anucleated, mutation events cannot be verified at the genetic level and utilized to examine 
the contribution of clonal expansion. 
The Glycophorin A Assay  
Glycophorins A are nonessential glycoproteins abundantly expressed on red cell 
surface.  Two forms M and N, differing by two amino acids, are codominantly expressed.  
The glycophorin A assay measures in heterozygous individuals expressing MN 
glycoproteins the loss of either allele or conversion to homozygous forms of M or N to 
give rise to hemizygous M0 or N0 or homozygous MM or NN phenotypes that are 
detected by antibody recognition of M and/or N glycoproteins.  This assay sensitively 
measures mutation events associated with somatic recombination or gene conversion and 
chromosome missegregation as well as base substitutions or deletions that result in 
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differential expression of glyocophorin A isoforms.  Similar to the hemoglobin assay, 
since the glycophorin A assay is performed with red blood cells, mutation events cannot 
be verified. 
The HLA T-lymphocyte Assay 
Mutation events have also been measured at the human major histocompatibility 
locus on chromosome 6.  Protein products of several Human Leukocyte Antigen (HLA) 
alleles of the major histocompatibility complex I (MHCI), including A2, A3, and A24, 
are codominantly expressed on T-cell surface.  In this assay the frequency of mutants is 
measured by the selective killing of non-mutant cells expressing wildtype HLA proteins 
through specific antibody binding along with complement treatment to cause 
complement-mediated cytotoxicity, allowing for survival of mutants expressing altered 
HLA proteins.  Performing this assay with T-lymphocytes allows for the verification of 
mutation events.  However, investigators have reported problems with complete selection 
against non-mutant cells resulting in inflated mutant frequency values that require repeat 
analyses. 
The T-Cell Receptor Assay 
This assay is based on the analysis of mutations at both T-cell receptor (TCR) 
alpha and beta gene loci on chromosomes 14 and 7, respectively, which interfere with the 
formation of the complete CD3/TCRα/TCRβ complex on T-cell surface.  If a mutation 
event renders one of the TCR components defective, CD3 cannot associate to form the 
complex and accumulates within the cytosol.  The frequency of mutants is determined by 
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detection of specific antibody binding to CD3 and another uninvolved surface marker, 
CD4, to allow differential labeling of wildtype cells from mutants that will not be labeled 
with anti-CD3 antibody.  Mutant frequencies observed in this assay are typically higher 
than other assays, at approximately 250x10-6.  It is unclear whether this is related to the 
larger sequence space that is being sampled for mutation events or that these loci are 
more mutable. 
 
The HPRT T-cell Cloning Assay 
The measurement of mutation events at the HPRT locus in T-cells is a well-
established approach of human monitoring for in vivo genotoxic effects from 
environmental exposure that was initially developed by Richard Albertini in the 1970’s 
(Strauss and Albertini 1977; Strauss and Albertini 1979).  The original T-lymphocyte 
assay was an autoradiographic assay which measures the frequency of HPRT mutants by 
monitoring the level of incorporated 3H-thymidine in T-cells that were stimulated to 
divide by phytohemagglutinin (PHA), in the presence or absence of purine analogs, 6-
thioguanine or 8-azaguanine which kills cells with intact HPRT enzyme. Since then, the 
assay has been modified into a cloning assay that allows for the expansion and isolation 
of surviving mutants (Albertini et al. 1985; O'Neill et al. 1987; O'Neill et al. 1990), which 
can be characterized for HPRT mutations to reveal possible mutagenic mechanisms.  The 
combined analyses of HPRT mutations with TCRβ CDR3 regions from mutant T-cell 
  38 
clones can also be utilized to determine clonality and trace the occurrence of mutagenic 
events in different cell lineages. 
The HPRT Gene 
The HPRT gene encodes the enzyme hypoxanthine-guanine phosphoribosyl 
transferase, which plays a role in maintaining purine nucleotide levels through the 
salvage of hypoxanthine and guanine bases (Stout and Caskey 1985).  HPRT is 
ubiquitously expressed at low levels (0.005-0.01% of mRNA) in most tissues. High 
levels are observed in the central nervous system (0.02-0.04%), suggesting its critical role 
in nervous tissue. Individuals who inherit germline mutations that result in complete 
deficiency of enzyme activity manifest Lesch Nyhan syndrome, characterized by 
developmental delay, spasticity, hyperreflexia, choreoathetoid movements, excessive 
self-mutilation, and hyperuricemia or elevated uric acid levels.  Others who inherit 
mutations that result in partial deficiency of enzyme activity manifest less severe disease, 
primarily exhibiting hyperuricemia that leads to nephrolithiasis and gout (Stout and 
Caskey 1985). Since hematopoietic cells within the bone marrow also rely on purine 
salvage for sources of purines, studies of carrier females suggest that selection against 
HPRT deficiency may occur at the precursor stage (Hakoda et al. 1995).  However, there 
is insufficient evidence to suggest selection against mature T-cells.   
The observations that germline mutations may result in different disease 
phenotypes led to the conception that the HPRT gene, consisting of 9 exons that span 
56.7kb of nucleotide sequence at q26.1 on the X-chromosome, may be utilized as an in 
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vivo biomarker of somatic mutation events that are selectable in vitro.  In addition since 
the HPRT gene is located on the X-chromosome, males are hemizygous and females are 
functionally hemizygous through X-inactivation, making the HPRT locus amenable to 
selection of mutant phenotype following single mutation event in the functional allele in 
both genders. To date, mutagenesis studies in different cell lines and animal models as 
well as human biomonitoring studies have identified a variety of mutations including 
base substitutions, insertions, microdeletions, frame-shift mutations at nucleotide repeats, 
large deletions, and illegitimate VDJ recombination events at cryptic consensus 
sequences at the HPRT locus (Cole and Skopek 1994).  However, due to its location on 
the X-chromosome, mutation events related to homologous recombination may not be 
captured.  
T-cells 
The utilization of T-cells, which circulate in blood throughout the human body, as 
a cellular system for the in vivo monitoring of genotoxic effects of exposure provided 
ease of sample acquisition through blood draw, genetic material from which to confirm 
mutation events at targeted reporter gene, and an independent marker of clonality from 
the analysis of uniquely rearranged T-cell receptor (TCR) gene sequence.   
Each mature T-cell that has acquired its unique T-cell receptor has undergone a 
coordinated process of T-cell development within the thymus involving the dynamic 
interactions between progenitor cells and thymic epithelial cells (Takahama 2006; 
Bhandoola et al. 2007).  This process entails the settling, proliferation, and diffentiation 
  40 
towards T-cell commitment of various bone-marrow derived progenitors that may enter 
the thymus at different stages of T-cell development including the double negative 1 
(DN1) and double negative 3 (DN3) stages, in which progenitor cells still retain a range 
of potential to differentiate into B-cell, natural killer cell, dendritic cell, and to a lesser 
extent myeloid cell lineages or are limited to only T-cell lineage, respectively.  Within the 
thymic microenvironment, the canonical developmental pathway involves progenitor cell 
proliferation and differentiation from DN1 to DN2 and then to DN3 stage, at which cells 
are committed to T-cell lineage and simultaneously undergo TCRβ, γ, and δ gene 
rearrangements (Bhandoola et al. 2007).  The productive rearrangement of TCRβ gene 
along with the assembly with invariant surrogate TCRα chain to form pre-TCR 
(TCRβ:pre-Tα) or the complete assembly of γδ-TCR determines further differentiation 
towards either αβ- or γδ- T-cell lineage, respectively (Janeway et al. 2001).  Majority of 
progenitor cells differentiate towards αβ-T-cell lineage.  Cells that successfully assemble 
and express pre-TCR complex, including signaling component CD3 (TCRβ:pre-Tα-
CD3),  on their cell surface are β-selected and undergo a proliferative burst to form 
double positive cells that co-express CD4 and CD8 coreceptors (Goldrath and Bevan 
1999).  These double positive thymocytes then rearrange TCRα gene segments.  
Following the productive rearrangement of TCRα, thymocytes display the complete αβ-
TCR and are subjected to positive and negative selection for low avidity interactions with 
self MHC-peptide complexes expressed on thymic epithelial cells and intra-thymic 
dendritic cells (Takahama 2006; Bhandoola et al. 2007).  Thymocytes that are positively 
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selected differentiate into single positive thymocytes, expressing either coreceptor CD4 
or CD8.  Majority of thymocytes undergo apoptosis from lack of TCR recognition or 
high avidity interactions with self MHC-peptide complexes, and about 2-5% of 
thymocytes survive the selection process and emigrate the thymus as single positive 
mature T-cells with its uniquely rearranged TCR (Janeway et al. 2001). 
The formation of T-cell receptors requires the combined successful 
rearrangements of gene segments at TCR β and α or γ and δ loci to form either 
heterodimeric αβ- or γδ- T-cell receptor, respectively.  This process involves the 
assembly of gene segments from V, D, and J gene regions for β and δ chains and from V 
and J gene regions for α and γ chains catalyzed by VDJ recombinase to form VDJ and VJ 
variable region exons, respectively, which are spliced to corresponding leader sequence 
and constant region exons during processing of the primary transcript of each chain 
(Janeway et al. 2001).  Since there are a variety of gene segments for each V, D, and J 
region, the recombination of these segments and the formation of heterodimeric TCRs 
generate enormous possibilities of T-cell receptors that provide us with the armamentum 
to recognize unknown foreign pathogens.  This diversity is further enhanced by 
nucleotide losses and additions at V-D, D-J, or V-J junctions by repair enzymes and 
terminal deoxynucleotidyl transferase during the recombination of gene segments.  The 
variable region of each chain forms three loops or complementarity determining regions, 
CDR1, CDR2, and CDR3 that bind to MHC-antigen peptide complex. CDR1 and CDR2 
are encoded by V gene segments and primarily contact MHC residues of the MHC-
peptide complex.  Complementarity determining region 3 is the most variable of the three 
  42 
loops, encoded by V-D or V-J junctions and DJ or J gene segments for β and α chains, 
respectively, that primarily contacts the most variable part of protruding antigen peptide 
(Goldrath and Bevan 1999).   
Utilizing the diversity and thus uniqueness of TCR sequences, we can 
approximate the in vivo prevalence and extent of clonal expansion and the occurrence of 
mutagenic events in different cell lineages by the combined analyses of HPRT mutations 
and TCR CDR3 regions from isolated mutant T-cell clones.  In our studies we have 
focused primarily on the CDR3 region of TCRβ, which is the first T-cell receptor gene to 
rearrange during development of αβ T-cells.  Based on this temporal relationship, we can 
hypothesize that if a mutagenic event occurred before β-rearrangement in a committed T-
cell progenitor or an early precursor that has proliferated, we would observe peripheral 
mutant T-cell clones that are progenies of that clonal expansion harboring the same 
HPRT mutation and diverse TCRβ CDR3 gene regions.  On the other hand, if a 
mutagenic event occurred following β-rearrangement in a more differentiated thymocyte 
(designated as thymocyte-TCRβ) or mature T-cell, we would observe peripheral mutant 
T-cell clones that are progenies of the clonal expansion harboring identical HPRT 
mutation and TCRβ CDR3 gene region.  We have also observed clonal expansions 
following β-rearrangement that result in peripheral mutant T-cell clones harboring 
identical TCRβ CDR3 gene region but independent HPRT mutations.  We refer to this 
pattern as a clonal proliferation of a “hyper-mutable” differentiated thymocyte 
(thymocyte-TCRβ) or mature T-cell that has undergone extensive cell division or harbor 
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genetic instability to result in the acquisition of multiple independent mutations (Finette 
et al. 2000; Finette et al. 2001).  This hypothesis is based on the estimated background 
mutation rate of 5x10-6 at the HPRT locus. 
The T-cell Cloning Assay 
The T-cell cloning assay is performed by plating mononuclear cells isolated by 
sedimentation in 96-well plates at limiting dilutions of 1, 2, 5, and 10 cells/well in the 
absence of selection and at higher density of 5-20,000 cells per well in the presence of 
10µM 6-thioguanine.  For subjects who received long-term thiopurine therapy, 
mononuclear cells were plated at lower densities to select for mutants, as these patients 
exhibit higher mutant frequencies with longer duration of treatment or higher total dose 
of treatment. Tissue cultures are performed in media containing 65% Roswell Park 
Memorial Institute medium (RPMI-1640), 20% nutrient medium HL-1, 5% calf serum, 
0.25ug/ml phytohemagglutinin (PHA, HA-16), 10% T-cell growth factor (TCGF) and 
10,000 irradiated (total 90 Gy) 36X4 lymphoblastoid cells with HPRT exons 1-9 deleted.  
Cells are grown in humidified incubators with 5-6% CO2 at 37-38ºC. On days 12-14 and 
17-21, plates are scored for colony growth.  The frequency of mutants is determined by 
taking the ratio of the cloning efficiency of mutants over the cloning efficiency of cells in 
the absence of selection.  Cloning efficiency (CE) is calculated using the Poisson 
relationship, P0=e
-x, where P0 is the fraction of wells without colony growth and x is the 
average number of clonable cells per well, to give the relationship CE=-lnP0/N, where 
N=the number of cells inoculated per well.  
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Frequency of Mutants of the Healthy Population  
 Since the analysis of somatic mutations at the HPRT locus in T-cells has become 
an accepted approach for human monitoring of genotoxic exposure, many studies have 
resulted in the compilations of databases of frequencies of mutants and mutation spectra 
of healthy subjects in different age groups from which to compare the effects of exposure 
in humans (Curry et al. 1999; Finette et al. 2002; Finette et al. 1994; McGinniss et al. 
1990; Robinson et al. 1994). These studies demonstrated a non-linear relationship 
between mutant frequency and age, with children from 0 to 15 years showing the highest 
rate of increase in mutant frequency with age, which continues to increase into adulthood 
at a lower rate (Finette et al. 1994; Robinson et al. 1994), and then levels off beginning at 
53 years of age (Curry et al. 1999).  Mean Mf values representing the number of mutants 
per million cells analyzed for healthy newborns and children 0-5 years were determined 
at 1.18 and 1.03, respectively, for children 6-11 years and 12-17 years at 2.43 and 2.51, 
respectively, and adults with mean ages of 34 and 53 years at 9 and 14.5, respectively 
(Finette et al. 1994; Branda et al. 1993; Robinson et al. 1994).  In these studies, mutant 
frequency values were also demonstrated to have an inverse relationship with non-
selected cloning efficiency (CE), which can vary with experimental conditions including 
mononuclear cell density, type of accessory cells and irradiation level, and concentrations 
and sources of serum, media, mitogens, and IL-2 (Robinson et al. 1994).  In order to 
evaluate the effect of an exposure, the contributions of age and cloning efficiency to 
mutant frequency are normally adjusted with statistical algorithms that have been derived 
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from the relationships among age, cloning efficiency, and mutant frequency from 
previously determined healthy control subjects as well as the studied population. 
Molecular Analysis of HPRT Mutations 
 The measured frequency of mutants provides an initial evaluation of the effect of 
exposure.  As this value may be influenced by in vivo clonal expansion and/or selection, 
the characterization of HPRT mutations is essential for the analyses of these biological 
phenomena and the potential mutagenic mechanisms related to exposure.  HPRT 
mutations are characterized by performing RT-PCR to identify mutations and exclusions 
or inclusions within the coding region.  Exclusions and inclusions are further 
characterized by performing single exon or multiplex genomic PCR of HPRT gene 
regions and VDJ specific genomic PCR to identify mutations responsible for splice 
alterations, deletions or insertions, and VDJ-mediated deletions (Finette et al. 1996; 
Gibbs et al. 1990).  More complex mutations can be identified by variations of Southern 
Blot analysis and genomic PCR, including microsatellite analysis. 
Frequency of Mutants versus Frequency of Somatic Mutations  
Since the frequency of mutants measures the ratio of mutants to the total 
population of T-cells analyzed, this value does not account for the in vivo expansions of 
unique mutants, which may overestimate the frequency of somatic mutation events.  
Early studies by O’Neill and others attempted to estimate the extent of clonal expansions 
by analysis of patterns of TCR gene rearrangement and demonstrated that a majority of 
healthy adults showed up to 20% of subgroups of mutants with identical TCR gene 
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rearrangement patterns that are involved in clonal expansions (O'Neill et al. 1994).  Then 
sequence analysis of TCR CDR3 regions of mutant isolates from subjects with diabetes 
mellitus who received azathioprine treatment showed that the extent of clonal expansions 
may be higher in those treated for an autoimmune disease (Falta et al. 1999).  Isolated 
TCR analysis, however, underestimates the extent of clonal expansions and the number 
of unique mutation events since clonal expansions may involve mutants with identical 
HPRT mutation that harbor different TCRβ CDR3 regions or mutants with identical 
TCRβ CDR3 region that harbor independent HPRT mutations (Finette et al. 2000; Finette 
et al. 2001), especially under conditions prone to mutation induction such as extensive 
cell proliferation, proliferation in the presence of a mutagen that miscodes during 
replication, or proliferation of an ancestral clone with genetic instability. To closely 
represent the in vivo frequency of independent mutation events, we correct for the clonal 
expansion of mutants by multiplying the frequency of mutants by the ratio of the number 
of unique or independent mutation events to the total mutants analyzed. 
HPRT Mutation Spectra of the Healthy Population 
 Many studies have contributed to the establishment of HPRT mutation databases, 
consisting of mutations analyzed in humans who are healthy, following exposure, and 
with cancer-prone predispositions as well as mutations induced during in vitro exposure 
(Cariello et al. 1998; Curry et al. 1999; Finette et al. 2002; Kendall et al. 2006; Noori et 
al. 2005; Podlutsky et al. 1998).  These datasets provide a reference from which to 
compare differences among human subpopulations and the effects of exposure. 
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 In the healthy population, in addition to displaying differences in the rate of 
increase in frequency of mutants, children exhibit age-specific mutation spectra whereas 
adults show less spectral changes from ages 19 years and older (Curry et al. 1999; Finette 
et al. 2002).  The mutation spectra of newborns show a predominance of VDJ-mediated 
deletions, accounting for more than 50% of all deletions, and a high proportion of CpG 
transitions, accounting for about 25% of the total substitutions.  The proportion of VDJ-
mediated events remains high at 56% of all deletions in children ages 0-5 years, but 
declines in older children, making up approximately 9% of all deletions in children 12-16 
years of age.  VDJ events are represented at a low proportion in adults.  The high 
proportion of CpG transitions in newborns rapidly declines to about 8% in children 0-5 
years and continues at that representation in children older than 6 years and into 
adulthood (Finette et al. 2002; Curry et al. 1999).  In addition to these changes in 
mutation spectra, children exhibit increases in the total proportion of transversions with 
age, while adults specifically show increases in the proportion of A:T to C:G 
transversions.  Unlike the children’s spectra, adults’ mutation spectra did not show 
significant changes in the proportion of other classes of mutations.  Gender-specific 
differences in spectra were observed in adults, with females showing a higher proportion 
of deletions > 1 bp compared to males, and also in pre-term newborns, among whom the 
proportion of VDJ events was significantly higher in females than males (Yoshioka et al. 
2001).   
Specific mutation spectra of healthy children and adults likely reflect both 
physiological changes in humans as well as the cumulative background exposure to 
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endogenous and exogenous mutagenic agents that occur with age.  The higher proportion 
of illegitimate VDJ-mediated recombination events at the HPRT locus in newborns and 
children 0-5 years of age parallels the peak immunological development in children, 
during which precursors of B and T cells are actively rearranging immunoglobulin and T 
cell receptor genes in reactions catalyzed by VDJ recombinase.   In addition to its high 
representation in newborns, CpG transitions predominate in mutation spectra of germline 
polymorphisms, cancer targeted genes, and disease causing mutations in humans 
(Antonarakis et al. 2000; Cooper 2002; Greenman et al. 2007).  C:G to T:A transitions at 
CpG dinucleotides can result from spontaneous deamination of methylcytosine to 
thymine or through nitrosative deamination from reactions with nitrogen oxide 
intermediates during oxidative stress (Grisham et al. 2000; Hussain et al. 2000).  Since a 
high proportion of these events were observed in newborns, it may be speculated that 
their occurrence is associated with increased T-cell proliferation during fetal development 
resulting in a higher frequency of spontaneous deamination of methylcytosine (O’Neill 
and Finette 1998).  
 The observed increase in total proportion of transversions with age in children 
and specifically A:T to C:G transversions in adults likely reflect the cumulative mutation 
load that result from the interactions between cellular processes and the background 
endogenous and exogenous environmental exposure.  G:C to T:A transversions have been 
reported following exposure to heterocyclic amines that are present in cooked meats, 
processed food flavorings (bouillon and gravy concentrates), wine, and cigarette smoke 
(Glaab et al. 2000; Yadollahi-Farsani et al. 1996).  Exposure to free radicals produced 
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during normal cellular metabolism and inflammatory responses may induce different 
classes of transversions including G:C to T:A, A:T to C:G, C:G to A:T, A:T to T:A, 
and/or G:C to C:G, which have been demonstrated to depend on the DNA polymerase 
encountering the formed DNA lesions (Feig and Loeb 1994).  Ultraviolet radiation B 
from sunlight, naturally occurring aflatoxins in contaminated cereals, oilseeds, spices, 
and tree nuts, and polycyclic aromatic hydrocarbons in cigarette smoke have also been 
demonstrated to form precursor lesions to or induce G:C to T:A transversions (Hattori et 
al. 1996; Smela et al. 2001; DeMarini 2004). 
Although gender-specific differences in mutation spectra have been observed, it is 
unclear what mechanisms are responsible for these differences. 
Complexities in Monitoring Somatic Mutations in Humans 
As T-cells and other cellular systems that have been discussed are biological 
entities within the human body, they are subjected to the variations of physiological 
responses that occur in vivo and differences in constitutional susceptibility among 
individuals within a particular age group.  These variations within and among diverse 
individuals are reflected in the measurements of frequency of mutants and mutation 
spectra when performing population studies.  For example, the measurement of mutation 
events depends on the survival of mutant cells harboring the HPRT mutation.  The 
frequency of mutants may vary within an individual depending on the cell lineage or 
developmental stage in which the mutagenic event had occurred.  If a mutation had 
occurred in a committed progenitor or stem cell, the persistence of the mutation may be 
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longer than if it had occurred in a mature T-cell, which also varies in life span depending 
on if it is an effector T-cell that undergoes apoptosis following antigen clearance or a 
central memory T-cell that is long-lived in a healthy subject.  In addition to differences in 
the observed Mf with respect to the persistence of mutant cells, the extent of in vivo 
clonal expansion may also affect the representation of mutation events that are assayed 
with each blood sample.  A mutant that has expanded to a greater extent has a higher 
probability of being sampled with each blood collection. In individuals with an 
autoimmune condition or following organ transplantation, mutant T-cells may survive for 
longer duration and have a higher probability of being represented from clonal expansion 
in the presence of persistent autoimmunity or exposure to foreign graft.  Therefore, the 
evaluation of the effects of exposure may be time-dependent and may also vary with 
respect to the underlying disease. 
Variations in the measured frequency of mutants and mutation spectra also reflect 
differences in individuals’ susceptibility that can be attributed to differences in DNA 
repair capacity, metabolism/detoxification of exposure, and physiological responses as 
well as the relative extent of exposure to different environment in addition to the 
influence of physiological changes and cumulative exposure that occur with age.  The 
collaborative analysis of healthy subjects by Robinson and colleagues from four different 
institutions demonstrated the extent of variation in Mfs among subpopulations residing in 
different geographic regions.  In this analysis, mutant frequency values for healthy adults 
ranged from 0.8-46 per million from the Sussex laboratory, 1.0-25.7 per million from the 
Vermont laboratory, 1.1-81.7 per million from the Leiden laboratory, and 2.9-42.7 per 
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million from the Paris laboratory (Robinson et al. 1994) while values for healthy children 
ranged from 0.5-39.5 per million from the Sussex laboratory and 0.2-9.0 per million from 
the Vermont laboratory.  Although experimental variation and the contribution of age 
(mean values for different age groups in Mf section) were also captured in these values, 
they demonstrate the endpoint variability encountered in the monitoring of human 
somatic mutations that reflect individuals’ susceptibility as well as differences in 
background environmental exposure.  Therefore, the successful evaluation of an exposure 
would involve the analysis of sufficient number of exposed subjects and healthy controls, 
who are age-matched (or corrected for the age-contribution) and reside within the same 
geographic region to minimize background variability and maximize the sensitivity of 
detection of an effect. 
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ABSTRACT 
The thiopurines, azathioprine and 6-mercaptopurine, are effective immune-
modulators and cytotoxic agents widely used in the treatment of autoimmune diseases, 
graft rejection, and cancer. There is growing epidemiological evidence that chronic 
exposure to these agents increases the risk for a variety of tumors by mechanisms that are 
unclear.  We investigated the in vivo mutagenicity of thiopurines by determining the 
frequency and spectra of somatic mutations at the HPRT locus and associated prevalence 
of clonal proliferation in a cross-sectional analysis of data from 119 children and adults 
with inflammatory bowel disease.  We observed a significant increase in the frequency of 
somatic mutations in 56 children and adults treated with thiopurines compared to 63 
subjects not treated with thiopurines, that was related to total dose (p<0.001) and duration 
of treatment (p<0.001). Comparative mutation spectra analysis of 1020 mutant isolates 
revealed a significant increase in the proportion of all transitions (p <0.001), specifically 
G:C to A:T transitions (p<0.001), the observed in vitro mutagenic signature of these 
drugs. Combined analyses of HPRT mutations and TCRβ CDR3 regions from mutant 
isolates also demonstrated a significant thiopurine treatment-dependent increase in the 
prevalence of clonal proliferation (p<0.001).  These data provide direct evidence that 
thiopurine treatment is mutagenic in humans by mutation induction that may be enhanced 
by increased cell proliferation, and provide the first mechanistic evidence for the 
carcinogenicity of these therapeutic agents. 
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TEXT 
Azathioprine and 6-mercaptopurine (6-MP) are extremely effective immune-
modulators and cytotoxic agents used extensively for the treatment of autoimmune 
diseases (1), transplant graft rejection (2), and cancer (3).  Their pharmacological effects 
are complex and involve both inhibition of purine biosynthesis and incorporation of 2-
deoxy-6-thioguanine nucleotides into DNA (4-6).  Cytotoxicity following thiopurine 
incorporation into DNA appears to require methylation of the thiol group, mispairing of 
S-methylthioguanine with thymine, with subsequent recognition and signaling by the 
mismatch repair system (5).  
Of continued concern is the broad based epidemiological evidence for duration 
(7) and dose-dependent (13, 39-40) increases in the incidences of  mesenchymal and solid 
tumors following thiopurine treatment (7-14, 39-41).  Associated cancer risks resulted in 
the classification of azathioprine as a human carcinogen (15).  It has been proposed that 
the carcinogenicity of these agents may be attributed to their immunosuppressive effects.  
Comparative epidemiological studies with other immune-modulators suggest a 
thiopurine-specific contribution to carcinogenesis (11, 12, 40-41).  In vitro and animal 
studies suggest that these agents are mutagenic (17-20, 46). Investigations in humans 
have observed a significant increase in the frequency of mutants associated with 
thiopurine treatment for transplant rejection (21), systemic lupus erythematosus (22) and 
diabetes mellitus (23), but the etiology of these observations was not determined.  To 
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date, the specific mechanism(s) responsible for the in vivo carcinogenicity of thiopurine 
treatment has not been elucidated.   
 In this study, we investigated potential in vivo carcinogenic mechanisms 
associated with thiopurine treatment by conducting a cross-sectional analysis of its 
mutagenicity in subjects with inflammatory bowel disease (IBD) in relation to type and 
duration of illness, treatment duration, and total thiopurine dose by determining the 
frequency and spectra of mutations at the hypoxanthine phosphoribosyltransferase 
(HPRT) locus.  We also investigated the prevalence of clonal expansion (Figure 1) by 
comparative analyses of HPRT mutations and TCR CDR3 regions from mutant isolates.  
  
Results 
In vivo frequency of HPRT mutants in subjects with IBD 
The in vivo mutagenicity of thiopurine treatment was examined in 119 children 
and adults with either ulcerative colitis (UC) or Crohn’s disease (CD), which are chronic 
inflammatory bowel syndromes associated with increased risks of cancer at affected sites 
of chronic inflammation (24) and lymphoma following thiopurine intervention (10).  
There were 56 thiopurine treated (TP) subjects who received azathioprine (n=40), 6-MP 
(n=11), or both (n=5), and 63 non-thiopurine treated (non-TP) subjects (Table 1). All 
subjects previously or concurrently received other treatment modalities that included: 5-
aminosalicylic acid derivatives (n=98), corticosteroids (n=72), infliximab (n=21), 
metronidazole (n=30) and/or ciprofloxacin (n=7). The total equivalent dose (mmoles) of 
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thiopurine exposure for subjects was determined by summing the total amount of 
thiopurines prescribed (grams) up to sample acquisition, divided by the molecular weight 
of each drug.  
Determination of in vivo somatic HPRT mutant frequency (Mf) using the HPRT T 
cell cloning assay and statistical analyses of these data have been previously described 
(25-27). Because HPRT Mf has a lognormal distribution, statistical analyses were based 
on its natural logarithm (lnMf), which has been shown to be related to age and non-
selected cloning efficiency (CE).  Table 1 provides a summary of the unadjusted HPRT 
Mf and lnMf data with respect to type of IBD and thiopurine treatment for the 119 
children and adults studied as well as previously reported data for normal controls (26, 
28, 29).   All statistical comparisons and regression analyses were performed on lnMf 
adjusted for age and non-selected CE.   
We initially assessed the effect of IBD and non-thiopurine treatment on the 
background in vivo Mf by comparing lnMf in non-TP subjects to normal controls.  We 
observed a statistically higher lnMf only in non-TP children with UC (p<0.05), while 
there was no significant increase in lnMf in the other non-TP IBD groups.  Statistical 
analysis of lnMf for non-TP IBD group as a whole supports the conclusion that 
inflammatory bowel disease and non-thiopurine interventions did not significantly 
contribute to the background HPRT Mf in these subjects. 
For the 56 TP subjects, total thiopurine dose ranged between 3.8-2379 mmoles 
over 0.04-14.1 years.  Mean lnMf in TP subjects was significantly higher than in normal 
controls and non-TP subjects (Table 1, p < 0.05), but did not differ significantly between 
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UC and CD for TP children or adults.  Regression analysis revealed no significant 
increases in lnMf with increasing duration of illness for non-TP subjects, Figure 2 (Panel 
A), (Supplemental Table 1).  For TP subjects, there was a significant increase in lnMf 
associated with duration of illness (p=0.004), Figure 2 (Panel A), but of importance, this 
association was not significant after adjustment for either duration of treatment or total 
thiopurine dose.  In contrast, increases in lnMf in TP treated subjects were significantly 
related to duration of treatment  (p<0.001), Figure 2 (Panel B), (Supplemental Table 1) 
and total dose of thiopurines (p<0.001), Figure 2 (Panel C), independent of duration of 
illness.  The rate of increase in lnMf in TP treated subjects was 0.776 per year of 
treatment, corresponding to a doubling in Mf. The estimated increase in lnMf with each 
100 mmole increase in total dose was 0.467, corresponding to a 67% increase in Mf.  The 
rates of increase in lnMf in treated subjects did not differ significantly between children 
and adults, or between UC and CD subjects.  The rates of increase were also not 
significantly different among subjects treated with only azathioprine, 6-MP or both 
agents, Figure 2 (Panel B), (Supplemental Table 1).  
In order to gain insight into the potential contribution of in vivo clonal 
proliferation and selection for HPRT mutants on treatment-specific increases in mutant 
frequencies, we investigated the prevalence of clonal proliferation and exposure-specific 
mutation spectra related to thiopurine treatment in TP and non-TP subjects. 
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Prevalence of in vivo Clonal proliferation  
 We previously demonstrated that a comparative analysis of both HPRT mutations 
and TCRβ CDR3 regions of mutant isolates allows for the unambiguous identification of 
the occurrence of in vivo clonal expansion in different cell lineages (30, 31) 
(Supplemental Figure 1).  We investigated whether treatment with thiopurines led to an 
increase in the prevalence of clonal proliferation by comparing 621 characterized HPRT 
mutations and 611 TCRβ regions from 876 mutants from 114 IBD non-TP and TP 
subjects (Supplemental Table 2). The percents of non-TP children and adults in which 
there were two or more HPRT mutant isolates associated with a clonal expansion(s) were 
0% and 14.6% respectively, Figure 3 (Panel A).  In contrast, there was a significant 
increase in the percents of TP children (72.2%) and adults (63.3%) with mutants involved 
in clonal expansions compared to non-TP subjects (p< 0.001) Figure 3 (Panel A).  There 
was also a significant dose-dependent increase in the proportion of subjects with clonal 
expansions (p<0.001), Figure 3 (Panel B). These data demonstrate that thiopurine 
treatment results in a significant dose-dependent increase in the prevalence of in vivo 
clonal proliferation in TP subjects, which may indicate both increased cell proliferation 
and/or cell survival in the presence of an autoimmune process and cytotoxicity from 
chronic therapeutic intervention. 
Frequency of independent somatic HPRT mutations  
The in vivo frequency of independent somatic mutation events (mutation 
frequency, MutFreq) was determined by correcting for the in vivo clonal proliferation of 
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mutants in each subject by multiplying Mf by the ratio of unique HPRT mutations to the 
total mutants analyzed.  We observed a significant difference between lnMf and 
lnMutFreq (p < 0.001) as a consequence of in vivo clonal expansion of HPRT mutants.  
But of importance, both lnMf and lnMutFreq in TP subjects showed significant 
relationships with treatment duration and total dose (p<0.001), Figure 2 (Panel C), 
(Supplemental Table 1).  This demonstrates that the significant increase in Mf and 
MutFreq associated with thiopurine treatment was not a result of in vivo clonal 
expansion.  
Mutation spectra analysis  
 The in vivo mutagenicity of thiopurine treatment was examined by comparing 648 
independent mutations from a composite of normal controls and 372 independent 
mutation events from 105 IBD subjects 12 years and older (Supplemental Tables 2 and 
3).  Nineteen percent of the randomly selected HPRT mutants from IBD subjects 
remained uncharacterized, which is consistent with previous studies (33, 34).  Reasons 
for the uncharacterized mutants include: 1) exon exclusions in mutants from female 
subjects in which splice alterations and deletions could not be confirmed or detected; 2) 
no cDNA detected, with genomic PCR products of exons 1 and 9 showing no mutations; 
3) cDNA revealed no mutation, and 4) incomplete analysis.  
There were no significant differences in the mutation spectra of mutants from 
non-TP subjects compared to normal controls, Figure 4 (Panel A), (Supplemental Tables 
2 and 3), indicating there is no detectable disease-associated or non-thiopurine treatment 
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related differences in the proportions of specific mutations. In contrast, there was a 
significant increase in the proportion of all transitions in TP subjects (52.9%) compared 
to non-TP subjects (39.8%), p=0.016, and normal controls (34.4%), p<0.001 after 
adjustment for age.  Specifically, there was a significant increase in the proportion of G:C 
to A:T transitions at non-CpG dinucleotides in TP subjects (38.3%) compared to non-TP 
subjects (27.7%), p=0.037, and normal controls (20.7%), p<0.001, Figure 4 (Panel A), 
(supplemental Tables 2 and 3).  There was no observed increase in G:C to A:T transitions 
at CpG dinucleotides in TP subjects compared to non-TP subjects.  There was also a 
concomitant significant decrease in the proportion of all transversions among TP subjects 
(22.8%) compared to normal controls (34.6%), p=0.021.   
We also observed a significant dose-dependent increase in the proportion of all 
transitions (p=0.013), in particular G:C to A:T transitions (p=0.045) at non-CpG 
dinucleotides (Figure 4, Panel B; supplemental Table 2), which supports our overall 
spectra findings.  This increase in G:C to A:T transitions is consistent with the in vitro 
mutagenic signature observed for these drugs (5, 18). 
 
Discussion 
Investigations attempting to link exposure specific mutations to carcinogenic risk 
in humans is extraordinarily difficult because of the necessity to control for a multitude of 
variables including the genetic and cellular effects of the underlying diseases, duration 
and total dose of each therapeutic intervention as well as the effects of other 
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environmental exposure(s).  In addition, tumors themselves are genomically unstable, 
making the primary and secondary cancer relevant mutations difficult to discern.  Hence, 
identifying the in vivo induction of exposure specific mutation events in non-transformed 
cells is extremely valuable for elucidating carcinogenic mechanisms in humans.  
Because we utilized the HPRT T-cell cloning assay to investigate the emergence 
of mutagenic mechanisms in subjects receiving thiopurine treatment, the possibility exists 
for the in vivo selection and enrichment of HPRT mutants with potential growth 
advantages, making the relative contribution of mutant selection on the observed Mf 
difficult to discern.  As a consequence of their underlying autoimmune disease, strong 
immunologic selection of T-cells is likely also occurring in these subjects.  Despite these 
potential limitations, our investigations established that thiopurine treatment results in a 
significant dose-dependent elevation in the in vivo frequency of somatic mutations as 
well as an exposure-specific increase in the proportion of G:C to A:T transitions.  These 
results unequivocally demonstrate the in vivo mutagenicity of this therapeutic 
intervention, since significant spectra changes would not occur if the effects of thiopurine 
treatment were simply enriching for the expansion of background HPRT mutants.  In 
addition, thiopurine treatment results in dose-dependent increases in both HPRT Mf and 
MutFreq, which provide critical additional evidence that the observed in vivo 
mutagenicity of thiopurine treatment was not a consequence of clonal expansion of 
mutant cells.  It is also important to note that all of these findings are independent of the 
underlying disease, duration of disease, and other therapeutic interventions. 
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We were unable to perform comparisons on other environmental exposures 
because of limited data.  The most important environmental exposure that could influence 
our observations would be environmental tobacco smoke (ETS), which has been 
demonstrated in human biomonitoring studies to result in either no spectra changes or an 
increase in the proportion of G:C to T:A transversions (36, 37), which contrasts to the 
significant proportional decrease in transversions and increase in G:C to A:T transitions 
in TP subjects.   
In addition to its immunosuppressive effects, our investigations suggest that the 
carcinogenicity of thiopurine intervention may occur through its in vivo mutagenicity and 
effects on cell proliferation. The induction of G:C to A:T transitions by thiopurine 
treatment likely result from the incorporation of 6-thioguanine nucleotides into DNA and 
subsequent mispairing with thymine in replicating cells (5, 18, 46).  The carcinogenic 
link for this thiopurine-specific mutagenic mechanism is supported by epidemiological 
evidence that azathioprine treatment is associated with significantly higher incidences of 
solid tumors, lymphoproliferative disorders, and skin cancers compared to the use of 
other immune-modulators including mycophenolate mofetil, which most closely 
resembles thiopurines’ mechanism of action (11-12, 40-41).  Mycophenolate mofetil 
primarily inhibits inosine monophosphate dehydrogenase resulting in the inhibition of 
purine biosynthesis, while azathioprine and 6-mercaptopurine exert their cytotoxicity by 
inhibiting purine biosynthesis and through incorporation into DNA, suggesting that the 
increased carcinogenicity of thiopurines may be related to their mutagenicity following 
DNA incorporation.  In addition, the increased prevalence of treatment-specific cell 
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proliferation may indicate an additional mechanism for accumulating G:T mismatches 
due to unrepaired replication errors (38) as well as enhance the genotoxicity of thiopurine 
treatment by allowing for the incorporation of 6-thioguanine nucleotides into DNA. 
Cellular resistance to thiopurines has been shown in vitro to select for cells defective in 
mismatch repair (MMR), and microsatellite instability has been observed in acute 
myelogenous leukemia from transplant patients who received azathioprine treatment (39).  
It is not known whether our findings could also be attributed to the in vivo selection of 
MMR defective cells with genomic instability. 
Of clinical significance is that thiopurine treatment may lead to somatic mutations 
at disease-specific loci in actively replicating cell populations, including proliferating 
cells within the bone marrow, which have been demonstrated to incorporate higher levels 
of 6-thioguanine nucleotides (32, 35), chronically activated disease-participating immune 
cells, and epithelial tissues undergoing repeated cycles of damage, repair, and 
regeneration especially in inflammatory bowel disease and chronic graft versus host 
disease (16, 24).  Lymphocytes and skin epithelia of patients who received thiopurine 
treatment have also been demonstrated to incorporate 6-thioguanine nucleotides (20, 42). 
In this study, we observed a higher occurrence of G:C to A:T transitions affecting both 
proliferating precursor and mature T-cell populations among TP subjects (unpublished 
results).  Altogether these observations provide a potential connection between the 
susceptibility of these cell populations and the increased risks of leukemia (39), 
lymphoma (9-10, 13), skin cancers (41), and squamous cell carcinoma at sites affected by 
chronic graft versus host disease (40) associated with thiopurine treatment. 
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Materials and Methods 
Study Population 
Subjects with IBD were recruited from the pediatric and adult gastroenterology 
clinics at Fletcher Allen Health Care at the University of Vermont, and consented with 
approved protocols by the Committee on Human Research. Diagnosis and therapeutic 
intervention were confirmed by participating gastroenterologists and a review of medical 
records.   Heparinized blood samples were collected from 39 children (<18 years old) and 
80 adults (>18 years old).  
The HPRT T-cell cloning assay for determining frequency of somatic mutations 
 The HPRT T cell cloning assay, determination of somatic HPRT mutant 
frequency (Mf), and statistical analyses of these data have been previously described (25-
27).  HPRT mutant isolates were expanded, pelleted at 1 x 104 cells, and then frozen at -
80oC for molecular analysis. 
Molecular analysis of HPRT mutations and determination of mutant cell 
proliferation 
Experimental approaches, methods, and interpretations for comparing HPRT 
mutations and TCRβ CDR3 regions of mutant isolates have been previously described 
(30, 31, 34).  HPRT mutation spectra were determined by analyzing up to 10 mutants per 
TP subject and up to 5 mutants per non-TP subjects.  HPRT mutations were characterized 
by performing RT-PCR from approximately 1 x 104 cell pellets to identify mutations and 
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exclusions or inclusions within the coding region.  Mutant isolates showing exclusions, 
inclusions, or no RT-PCR products were further characterized by performing single exon 
or multiplex genomic PCR of HPRT gene regions to identify mutations responsible for 
splice alterations and deletions or insertions (43).  HPRT mutant isolates that showed 
exclusion of exons 2-3 were screened for V(D)J recombinase-mediated deletions of 
HPRT exons 2-3 with specific primers spanning that region (44).   
 The rearrangement of T-cell receptor (TCR) genes in mutant isolates provides an 
independent measure of clonality and thus allows for the measurement of clonal 
proliferation that can be followed longitudinally (31).  TCRβ CDR3/variable regions of 
mutant isolates were determined by amplification of RT-PCR generated cDNA using a 
primer to the TCRβ constant region and a mix of 26 TCRβ V region primers (45).  PCR 
products were then processed and sequenced as described above.  
The prevalence of in vivo clonal expansion was determined by analyzing 621 
HPRT mutations and 611 T cell receptor β (TCRβ) locus CDR3 gene regions from 114 
subjects from whom two or more mutants were available (Supplemental Table 2). The in 
vivo frequency of independent mutations, MutFreq, was determined by multiplying each 
subject’s HPRT Mf by the ratio of independent mutation events to the total mutants 
analyzed to correct for in vivo clonal expansion.  
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Statistical Analysis  
Because HPRT Mf has a lognormal distribution, all statistical analyses were based 
on its natural logarithm (lnMf), which has been shown to be related to age and non-
selected cloning efficiency (CE) (26, 28, 29). We therefore adjusted for age and CE by 
including them as covariates in all analyses of lnMf (29). A summary of each subject’s 
gender, age, duration of illness, type and treatment duration, total dose of thiopurine, CE, 
Mf, lnMf, and MutFreq is provided (Supplemental Table 1).  Analysis of covariance was 
used to compare differences in lnMf among normal controls, non-TP and TP subjects, as 
well as between children and adults with UC and CD. The Student-Newman-Keuls test 
was used to adjust for multiple pair-wise comparisons.  In TP subjects, the effects of 
treatment duration and total dose on lnMf and MutFreq were assessed by regression 
analyses.  A Chi-square test was used to compare the percents of TP and non-TP subjects 
with mutant cell proliferation, and a Mantel-Haenzel test for linear association was used 
to assess the dose-dependence of increases in the percent with mutant cell expansions.  
Mutation spectra data were analyzed using logistic regression to assess the statistical 
significance of differences in the proportions of specific mutations among controls 
(Supplemental Table 3), non-TP and TP subjects.  Subjects under the age of 12 were 
excluded from mutation spectra analyses because differences in the age distributions of 
normal controls and IBD subjects precluded adjustment for age-related spectra changes in 
this group.  Age group (12-18.9 or ≥19 years) and sex were included in the regression 
models as covariates.  Although mutations from the same subjects may be correlated, we 
could not include subject as a random effect in these analyses because the spectra data for 
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adult controls did not contain unique subject identifiers. The effects of treatment were 
determined by comparing data only from the TP and non-TP subjects. Logistic regression 
models with age group (12-18 or ≥ 19 years), thiopurine treatment (yes or no) and 
treatment by age group interaction were fitted to determine if the effect of treatment 
differed in adults and children.  Similar models were fitted using thiopurine treatment 
categories based on the total dose (0, 1-133, 134-289, 290-727 and ≥ 728 mmoles) to 
determine if the proportion of a particular class of mutation displayed a dose-response 
relationship. The non-zero categories correspond to dose quartiles for all TP subjects.   
All of these models included study subject as a random effect to account for potential 
correlation between mutations from the same individual. 
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Figure Legends  
Figure 1. Research overview for investigating the in vivo mutagenicity and mutant 
cell clonal expansion in subjects treated with thiopurines for IBD. Mononuclear cells 
from peripheral blood are plated at limiting dilutions in the absence (non-selection) and at 
higher density in the presence of 6-thioguanine (selection).  HPRT Mf is determined by 
the ratio of mean cloning efficiency (CE) of selected mutant isolates to the mean non-
selected CE of T cells in the absence of selection. Both HPRT mutations and TCRβ 
CDR3 regions are utilized in determining in vivo mutant cell expansion, and only unique 
HPRT mutations are utilized in the calculation of mutation frequency (MutFreq) and in 
mutation spectra comparison.  
Figure 2.  Comparative analysis of adjusted HPRT mutant frequency, duration of 
illness, duration of treatment, and total dose of thiopurines.  Mf values have been 
adjusted for the effects of age and CE by normalizing to the average age and CE for the 
studied subjects (26).  Panel A) Relationships between adjusted Mf and duration of 
illness in non-TP and TP subjects.  Panel B) Relationships between adjusted Mf and 
duration of thiopurine treatment in IBD subjects, as well as the relationship between 
adjusted Mf and treatment duration of thiopurine intervention. Panel C) Relationships 
between adjusted Mf and MutFreq and total dose in IBD subjects.  
Figure 3.  Prevalence of in vivo mutant cell proliferation in TP and non-TP IBD 
subjects.  Panel A) The proportion of subjects with evidence of in vivo expansion of 
mutant cells in TP and non-TP subjects.  (*) 0% of children who receive no thiopurine 
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treatment had evidence of mutant cell expansions.  Panel B) The proportion of subjects 
with evidence of in vivo mutant cell expansion compared to total thiopurine dose. 
Figure 4.  Mutation spectra in TP and non-TP subjects (> 12 years of age) and 
normal controls.  Panel A) Mutation spectra distribution of children and adult normal 
controls, non-TP subjects, and TP subjects as well as separate distributions of children 
and adult subjects. The “Other Classes” of mutations include: exon deletions, micro-
deletions, duplications or nucleotide losses, insertions, and complex insertion/deletion 
mutations as characterized by PCR amplification and subsequent sequencing of cDNA 
and/or genomic DNA.  Panel B) The relationship between mutation spectra and total 
dose of thiopurine treatment.  
Table Legends 
Table 1.  Summary of duration illness, total dose, and mutant frequency in subjects 
with inflammatory bowel disease 
 
Supplemental Data 
Supplemental Figure 1. Analyses for determining the prevalence of clonal proliferation 
and frequency of in vivo independent mutation events to correct for clonal expansion. 
 
Supplemental Table 1. Summary of children and adults studied with respect to gender, 
age, duration of illness, treatment and frequency of somatic mutations. 
 
Supplemental Table 2. Summary of HPRT mutations and TCRβ CDR3 regions in 
children and adults with inflammatory bowel disease. 
 
Supplemental Table 3. Summary of HPRT mutations in normal children and adults. 
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Figure 3.  Prevalence of in vivo Clonal Proliferation 
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Figure 4.  Mutation spectra in TP and non-TP subjects (> 12 years of age) and 
normal controls. 
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Supplemental Figure 1 
 
B. 
 Frequency of Somatic Mutations = 
 
Number of Independent Mutations 
 
Total of Mutants Analyzed 
A 
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          Table 1.  Summary of Duration of Illness, Total Dose, and Mutant Frequency in Subjects with IBD.
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UC-062_B1 F 10.3 0.8 pred, 5-ASA 0.0 0.0 0.29 2.7 1.0 2.7
UC-030_B1 M 12.8 3.5 5-ASA (e) 0.0 0.0 0.07 9.2 2.2
UC-003_B1 F 13.8 3.3 5-ASA (o, e) 0.0 0.0 0.35 12.1 2.5
UC-059_B1 M 14.1 0.7 pred, 5-ASA 0.0 0.0 0.36 13.6 2.6 13.6
UC-024_B1 M 14.4 0.1 5-ASA, met 0.0 0.0 0.93 3.7 1.3 3.7
UC-057_B1 M 15.1 0.6 5-ASA, met 0.0 0.0 0.68 7.8 2.1 7.8
UC-058_B1 F 15.8 2.1 pred, 5-ASA, met 0.0 0.0 0.74 1.9 0.6 1.9
UC-033_B2 M 16.2 0.4 5-ASA 0.0 0.0 0.50 4.9 1.6 4.9
UC-061_B1 M 17.5 0.1 pred, 5-ASA, met 0.0 0.0 0.58 4.9 1.6 4.9
Average 14.4 1.3 0.50 6.8 1.7 5.6
SD 2.1 1.3 0.26 4.2 0.7 4.0
UC-071_B1 F 19.0 14.0 5-ASA 0.0 0.0 0.61 4.4 1.5 4.4
UC-010_B1 M 19.5 2.5 pred, 5-ASA, inflix 0.0 0.0 0.13 33.0 3.5
UC-043_B1 F 20.2 5.6 5-ASA, ster (e) 0.0 0.0 0.51 1.0 0.0 1.0
UC-008_B1 M 21.4 0.5 pred, 5-ASA 0.0 0.0 0.05 215.0 5.4
UC-050_B1 F 21.8 0.7 5-ASA 0.0 0.0 0.11 19.2 3.0 19.2
UC-013_B1 F 22.3 2.9 pred, 5-ASA 0.0 0.0 0.09 7.8 2.1
UC-037_B1 F 23.8 0.0 pred, 5-ASA 0.0 0.0 0.26 13.0 2.6 13.0
UC-038_B1 F 24.3 2.1 5-ASA (o, e) 0.0 0.0 1.10 0.6 -0.5 0.6
UC-068_B1 F 24.8 7.5 pred, 5-ASA, met 0.0 0.0 0.93 5.5 1.7 5.5
UC-011_B1 M 26.2 0.4 pred, 5-ASA (o, e) 0.0 0.0 0.19 12.4 2.5 12.4
UC-021_B1 M 26.4 11.5 pred, 5-ASA (o, e) 0.0 0.0 0.35 21.9 3.1 21.9
UC-069_B1 F 27.5 7.4 5-ASA 0.0 0.0 0.71 6.0 1.8 6.0
UC-034_B1 M 28.7 8.0 pred, 5-ASA 0.0 0.0 0.08 2.1 0.7
UC-051_B1 F 30.4 11.6 5-ASA (o, e) 0.0 0.0 0.21 25.1 3.2 16.7
UC-045_B1 F 30.5 2.3 5-ASA 0.0 0.0 0.38 3.7 1.3 3.7
UC-012_B1 M 32.6 0.1 pred, dacli 0.0 0.0 0.42 13.4 2.6 13.4
UC-025_B1 F 33.3 0.8 5-ASA, cip, met 0.0 0.0 0.37 7.2 2.0 7.2
UC-064_B1 F 34.9 16.0 5-ASA 0.0 0.0 0.32 16.9 2.8 16.9
Supplemental Table 1:  Summary of Children and Adults Studied with respect to Gender, Age, Duration of Illness and Treatment, and Mutant and Mutation 
Frequency
Subjects with Inflammatory Bowel Disease, Not Treated with Purine Analogs
Children with Ulcerative Colitis (N=9)
Adults with Ulcerative Colitis (N=37)
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UC-016_B1 F 38.5 13.0 5-ASA (o, e) 0.0 0.0 0.09 30.6 3.4
UC-049_B1 M 39.6 17.0 5-ASA (o, e) 0.0 0.0 0.42 6.3 1.8 6.3
UC-044_B1 F 41.9 4.3 5-ASA, ster (e) 0.0 0.0 0.38 7.7 2.0 7.7
UC-054_B1 M 42.6 3.5 5-ASA 0.0 0.0 0.64 7.4 2.0 7.4
UC-039_B1 M 45.9 12.7 5-ASA 0.0 0.0 0.23 11.3 2.4 11.3
UC-048_B1 F 46.1 3.2 5-ASA (o, e) 0.0 0.0 0.30 8.9 2.2 8.9
UC-046_B1 M 46.4 0.4 5-ASA 0.0 0.0 0.55 13.0 2.6 13.0
UC-015_B1 F 47.4 0.5 ster (e) 0.0 0.0 0.07 49.7 3.9
UC-035_B1 F 49.6 25.0 5-ASA 0.0 0.0 0.01 102.4 4.6 102.4
UC-040_B1 M 51.0 22.0 5-ASA, ster (e) 0.0 0.0 0.22 14.5 2.7 14.5
UC-041_B1 F 51.6 10.6 5-ASA, acupuncture 0.0 0.0 0.52 9.1 2.2 9.1
UC-028_B1 M 52.8 8.9 5-ASA (o, e) 0.0 0.0 0.09 53.4 4.0 53.4
UC-055_B1 F 53.5 8.4 5-ASA (o, e), inflix 0.0 0.0 0.47 8.0 2.1 4.8
UC-026_B1 F 54.5 38.0 pred 0.0 0.0 0.06 68.5 4.2 68.5
UC-022_B1 F 58.6 0.2 5-ASA 0.0 0.0 0.08 28.8 3.4 28.8
UC-023_B1 M 63.1 13.1 none 0.0 0.0 0.09 7.4 2.0 7.4
UC-027_B1 M 70.4 6.3 pred, 5-ASA 0.0 0.0 0.05 10.0 2.3
UC-020_B1 M 70.5 4.2 pd, pred, 5-ASA 0.0 0.0 0.05 13.2 2.6
UC-019_B1 F 76.4 1.9 pred, 5-ASA 0.0 0.0 0.12 17.0 2.8 17.0
Average 39.7 7.8 0.30 23.7 2.5 17.3
SD 15.9 8.2 0.26 38.3 1.1 21.9
CD-020_B1 F 14.0 0.2 met 0.0 0.0 0.45 3.5 1.3 3.5
CD-052_B1 M 16.0 0.2 5-ASA 0.0 0.0 0.43 4.9 1.6 4.9
CD-024_B1 M 16.5 4.2 5-ASA, met 0.0 0.0 0.48 5.1 1.6 5.1
CD-056_B1 M 16.5 0.4 pred, 5-ASA 0.0 0.0 0.27 2.1 0.7
Average 15.8 1.2 0.41 3.9 1.3 4.5
SD 1.2 2.0 0.09 1.4 0.4 0.8
CD-042_B1 M 26.5 0.0 5-ASA 0.0 0.0 0.57 17.8 2.9 13.4
CD-029_B1 F 27.5 1.6 ster (e), 5-ASA 0.0 0.0 0.39 8.2 2.1 8.2
CD-008_B1 M 28.4 17.0 5-ASA 0.0 0.0 0.38 8.0 2.1 8.0
CD-044_B1 F 35.6 4.3 5-ASA, ster (e), inflix 0.0 0.0 0.37 7.6 2.0 7.6
CD-030_B1 F 40.8 11.0 none 0.0 0.0 0.39 28.0 3.3 22.4
Children with Crohn's Disease (N=4)
Adults with Crohn's Disease (N=13)
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CD-033_B1 F 44.2 17.0 5-ASA, ster (e) 0.0 0.0 0.52 11.6 2.5 11.6
CD-049_B1 F 45.3 24.0 pred, 5-ASA (e), met, inflix 0.0 0.0 0.29 25.8 3.2 25.8
CD-039_B1 M 47.3 1.3 5-ASA, ster (e), inflix 0.0 0.0 0.54 8.0 2.1 8.0
CD-048_B1 M 47.5 27.0 5-ASA, ster (o, e) 0.0 0.0 0.16 4.8 1.6 4.8
CD-045_B1 F 50.3 9.9 5-ASA, ster (e), inflix 0.0 0.0 0.25 9.5 2.3 9.5
CD-032_B1 F 52.7 8.6 pred, 5-ASA, cipro, met 0.0 0.0 0.57 11.9 2.5 11.9
CD-011_B1 F 55.7 22.0 pred, inflix 0.0 0.0 0.16 6.5 1.9
CD-031_B1 F 55.8 2.3 5-ASA 0.0 0.0 0.27 16.0 2.8 16.0
Average 42.9 11.2 0.37 12.6 2.4 12.3
SD 10.4 9.3 0.14 7.3 0.5 6.3
UC-014_B1 M 6.4 0.8 Aza PD: pred, 5-ASA 19.2 0.6 0.49 2.1 0.8
UC-060_B1 F 13.0 3.7 Aza P: 5-ASA (o, e) 327.1 2.8 0.40 5.7 1.7
UC-007_B1 M 14.5 3.4 Aza P: pred (o, e), 5-ASA 317.6 1.6 0.19 53.1 4.0 41.3
UC-004_B1 M 15.0 1.4 Aza P: pred, 5-ASA, met 110.9 0.6 0.17 93.3 4.5 93.3
UC-009_B1 F 18.0 7.1 Aza PD: pred, 5-ASA 745.8 5.2 0.20 33612.9 10.4 13445.2
UC-056_B2 M 18.7 2.9 Aza D: pred 728.5 2.8 0.96 4584.2 8.4 3056.1
UC-005_B1 F 18.8 9.6 Aza PD: pred, 5-ASA, met 957.8 7.8 0.16 6031.5 8.7 5361.3
Average 14.9 4.1 458.1 3.1 0.37 6340.4 5.5 4399.4
SD 4.4 3.1 354.9 2.6 0.29 12287.0 3.7 5524.8
UC-002_B1 M 19.6 3.0 Aza pred, 5-ASA, cipro 252.5 1.0 0.51 41.1 3.7 32.0
UC-042_B1 F 20.0 4.5 6-MP PD: pred, 5-ASA 11.8 0.0 0.25 4.2 1.4 4.2
UC-001_B2 F 20.0 6.3 Aza P: cyc, pred 1322.9 6.2 0.61 74776.5 11.2 65429.5
UC-006_B1 M 21.7 5.4 Aza PD: cyc, pred, 5-ASA 703.6 3.7 0.30 1505.9 7.3 1204.7
UC-065_B1 M 22.6 3.7 P: Aza 5-ASA, P: met 23.8 0.1 0.41 4.7 1.5
UC-070_B1 F 23.0 1.3 Aza D: 5-ASA, P: cipro, met 41.9 0.6 0.80 2.2 0.8 2.2
UC-018_B1 M 28.0 3.3 Aza P: pred, 5-ASA 210.1 1.4 0.48 4.4 1.5 4.4
UC-066_B1 M 30.0 8.0 6-MP P: pred, 5-ASA, cipro 738.4 2.5 0.17 2000.8 7.6 2000.8
UC-029_B1 F 33.6 0.6 Aza PD: 5-ASA (e), ster (o, e) 10.1 0.1 0.28 7.4 2.0 7.4
UC-036_B1 M 39.7 13.3 6-MP PD: pred, 5-ASA 2378.8 10.5 0.26 2826.0 7.9 2543.4
UC-067_B1 M 43.9 0.7 6-MP P: 5-ASA (o, e) 44.1 0.3 0.40 15.0 2.7 5.6
UC-031_B1 F 47.3 5.2 Aza PD: 5-ASA (o, e), P: inflix 105.0 0.8 0.35 8.0 2.1 8.0
Subjects with Inflammatory Bowel Disease, Treated with Purine Analogs
Children with Ulcerative Colitis (N=7)
Adults with Ulcerative Colitis (N=13)
94








Other Treatmenta Total Dose of 
Aza or 6-MPb, 
(mmoles)
Duration of 









UC-047_B1 M 49.8 0.9 Aza P: pred 133.8 0.9 0.32 10.0 2.3 10.0
Average 30.7 4.3 459.8 2.2 0.40 6246.6 4.0 5937.7
SD 11.1 3.5 697.8 3.1 0.17 20612.6 3.3 18756.5
CD-013_B1 M 7.8 3.3 Aza P: 5-ASA 142.8 1.4 0.81 17.8 2.9 11.9
CD-050_B1 F 9.5 2.8 Aza D: pred, met 184.7 2.8 0.24 1166.2 7.1 816.3
CD-001_B2 M 10.2 1.4 Aza D: 5-ASA, inflix, met 196.8 1.1 0.36 33.0 3.5 18.3
CD-027_B1 M 11.7 4.4 Aza D: pred, 5-ASA 546.7 4.3 0.70 15.7 2.8 12.5
CD-035_B1 M 13.4 2.3 Aza PD: pred, met 290.2 2.2 0.66 58.8 4.1 47.0
CD-018_B1 F 13.6 10.4 Aza P: 5-ASA, ster (o, e) 90.3 1.1 1.07 74.4 4.3 22.3
CD-021_B1 M 13.6 2.7 Aza D: pred, met, inflix 267.8 2.7 0.49 161.0 5.1 144.9
CD-015_B1 F 14.3 7.5 Aza PD: pred, 5-ASA, P: met 805.9 4.2 0.54 405.8 6.0 270.5
CD-004_B2_2 F 15.1 3.0 Aza D: pred, met 391.1 3.0 0.84 1167.1 7.1 466.9
CD-016_B1 F 15.3 0.6 Aza PD: 5-ASA, met 3.8 0.1 0.15 7.0 1.9
CD-054_B1 F 16.6 0.4 Aza D: pred, met 15.5 0.2 0.21 15.2 2.7 12.2
CD-026_B1 F 17.0 5.5 P: 6-MP pred, 5-ASA, MTX 100.0 0.6 1.04 5.9 1.8 5.9
CD-028_B1 F 17.2 5.5 Aza D: pred, 5-ASA, met 319.6 4.5 0.31 1761.7 7.5 1761.7
CD-019_B1 F 17.4 4.2 Aza, 6-MP PD: pred, 5-ASA, met, inflix 70.0 0.6 0.43 8.2 2.1 8.2
CD-053_B1 F 17.8 0.7 Aza pred, 5-ASA, D: inflix 90.9 0.7 0.17 247.9 5.5 99.2
CD-025_B1 F 18.3 1.2 Aza D: pred, P: 5-ASA, met 35.3 0.0 0.29 8.1 2.1 8.1
CD-007_B1 F 18.6 2.1 Aza D: pred 135.3 1.1 1.24 4.3 1.5
CD-040_B1 F 18.8 1.4 6-MP P: pred, 5-ASA, inflix 71.3 0.6 0.60 9.6 2.3 9.6
CD-014_B1 M 18.8 14.2 Aza P: pred, 5-ASA, met 1265.7 9.3 0.87 1828.4 7.5 1645.5
Average 15.0 3.9 264.4 2.1 0.58 368.2 4.1 315.4
SD 3.3 3.6 314.7 2.3 0.33 617.2 2.1 565.3
CD-017_B1 F 19.1 2.1 Aza PD: pred, 5-ASA,  cipro, met 279.16 2.1 0.21 2269.05 7.7
CD-009_B1 F 19.2 7.9 Aza, 6-MP PD: pred, 5-ASA, met, inflix 880.0 5.4 0.52 26646.8 10.2
CD-051_B1 M 19.8 11.3 P: 6-MP inflix 8.2 0.1 0.29 19.8 3.0 8.5
CD-037_B1 F 21.0 1.2 6-MP PD: ster (o, e) 185.1 1.0 0.37 349.8 5.9 279.9
CD-023_B1 F 21.9 11.7 Aza PD: pred, 5-ASA, met 839.4 9.6 0.17 157177.2 12.0 157177.2
CD-005_B1 M 24.4 0.6 Aza P: pred, 5-ASA 45.4 0.3 0.45 4.7 1.6 4.7
CD-003_B1_2 F 26.2 9.6 Aza P: 5-ASA, met 330.7 2.0 0.51 1459.2 7.3 1459.0
CD-036_B1 F 27.6 10.0 6-MP 5.3 0.0 0.66 1.6 0.5 1.6
Children with Crohn's Disease (N=19)
Adults with Crohn's Disease (N= 17)
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CD-046_B1 M 28.7 3.3 Aza P: 5-ASA, inflix 86.2 0.6 0.34 20.1 3.0 20.1
CD-006_B1 F 31.1 8.4 Aza PD: pred, 5-ASA, inflix 813.8 3.7 0.40 2293.3 7.7 2293.3
CD-041_B1 M 33.7 13.5 Aza D: pred, 5-ASA, inflix 208.3 1.2 0.44 14.9 2.7 14.9
CD-010_B1_2 F 39.7 5.7 6-MP pred, 5-ASA (o, e), P: inflix 686.2 4.0 0.29 7311.3 8.9 4874.2
CD-012_B1 M 47.3 1.9 Aza D: pred, cipro, inflix 183.8 0.6 0.57 8.5 2.1 8.5
CD-043_B1 F 48.2 28.0 Aza, 6-MP P: 5-ASA, D: MTX, inflix 153.3 1.3 0.35 23.9 3.2 19.1
CD-047_B1 M 48.9 26.0 Aza D: pred 2086.01 14.1 0.19 7315.92 8.9
CD-034_B1 M 55.6 13.3 Aza, 6-MP PD: 5-ASA (o, e) 1250.0 9.1 0.10 62163.2 11.0 55946.9
CD-038_B1 M 58.6 5.0 Aza, 6-MP P: 5-ASA 480.0 2.7 0.56 979.8 6.9 489.9
Average 33.6 9.4 501.2 3.4 0.38 15768.2 6.0 15899.8
SD 13.4 7.9 548.7 4.0 0.16 39664.8 3.6 43258.6
aOther Treatment
o (oral) cipro (ciprofloxacin)
e (enema) cyc (cyclosporin)
P (treated with, previous to aza or 6-MP) dacli (daclizumab)
D (treated with, during aza or 6-MP) inflix (infliximab)
PD (treated with, previous to and during aza or 6-MP) met (metronidazole)
Aza (azathioprine) pred (prednisone)
6-MP (6-mercaptopurine) pd (primal defense)
5-ASA (aminosalicylates) ster (steroid)
c Mutation frequency adjusted for clonal expansion using data from 1 to 10 randomly selected mutants from each subject.  Calculated by multiplying Mf with the ratio of unique HPRT mutants/total mutants 
analyzed.
b Total equivalent dose (mmoles) of azathioprine or 6-mercaptopurine exposure determined by summing the total amount prescribed (grams) divided by the molecular weight of each drug to normalize for 
molecular weight differences between these agents.
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Subject ID Clone cDNA Analysis Genomic Analysis Final Mutation Class of Mutationb TCRβ CDR3 
Regionc
UC-062 B1 M1 617G->A 617G->A Transition (1) DTRVGG
M2 Exclusion of Exons 2, 3 Exon 2: 28-2A->G (mixed, check), 
Exon 3
Incompletely characterized (D)
M3 Incompletely characterized (D) RR
UC-030 B1 M1 Exclusion of Exon 6 Exon 6: 403-1G->C 403-1G->C Transversion (5) LGSTE
UC-003 B1 M1 Inclusion of ATTTTTTTTTATAG between 
Exons 8, 9
No mutation in Exon 8; Exon 9: 
610-16G->A
610-16G->A Transition (1)
UC-059 B1 M1 203T->C 203T->C Transition (2) PGRPI
M2 440T->C 440T->C Transition (2) RSG
M3 268, 589, 635G->A No mutations in Exons 3, 7, 8, 9 Incompletely characterized (D)








M7 Exclusion of Exons 2, 3 No mutation in Exon 2; No Exon 3 Deletion of Exon 3 Exon Deletion (8) FHR
UC-024 B1 M1 133 A->G 133A->G Transition (2) RRGLAGVA
M3 Exon 1: 27_27+2GGT->TAA 27_27+2GGT->TAA Tandem (13) GHGTSGSR
M5 Exclusion of Exon 4 Exon 4: 319-49_348del79 319-49_348del79 Microdeletion (9) ASTGAV
M6 All Exons present; Exon 9: 610-
2_610-75del74
610-2_610-75del74 Microdeletion (9) PVGGG
UC-057 B1 M1 67losT No mutation in Exon 3 67losT Loss (10) RD
M5 Exclusion of Exons 2, 3; 529hetG/A All Exons present; No mutation in 
Exons 2, 7, 8; Exon 3:135-
39_168del73
135-39_168del73 Microdeletion (9) YSRGA
UC-058 B1 M2 631losA 631losA Loss (10)
M3 27+5G->A; Inclusion of bp 
27+1_27+49
27+5G->A Transition (1) TPRAVS
UC-033 B2 M1 479T->A No mutation in Exons 3-4; Exon 6: 
479T->A
479T->A Transversion (6) SRLWIRAK
M2 Exclusion of Exon 4 Exon 4: 384+2T->A 384+2T->A Transversion (6) LGRAW
M3 Exclusion of Exon 8 Exon 8: 551C->T 551C->T Transition (1) ISGIFT
M4 222C->A 222C->A Transversion (4)
M7 27+2T->G 27+2T->G Transversion (7)
UC-061 B1 M15 Exclusion of bp 28_57 Exon 2: 28-1_57del31 28-1_57del31 Microdeletion (9) APRDFGT
M16 No mutation No mutation Incompletely characterized (C) FLFRGG, EKAD
M4 617G->A 617G->A Transition (1) LGTGAS
M5 No mutation No mutation Incompletely characterized (C) TQSGS
M9 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) RDPGTP
Summary of HPRT Mutations and TCRβ CDR3 Regions for Children and Adults with Inflammatory Bowel Diseasea
Supplemental Table 2:
Subjects with Inflammatory Bowel Disease, Not Treated with Purine Analogs
Untreated Children with Ulcerative Colitis (N=9)
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Subject ID Clone cDNA Analysis Genomic Analysis Final Mutation Class of Mutationb TCRβ CDR3 
Regionc
UC-071 B1 M2 143G->A 143G->A CpG Transition (3) QNPGTTY
M3 135G->C 135G->C Transversion (5) FA
M5 599G->A All Exons present; Exon 8: 
599hetG/A
599G->A Transition (1)
M9 611A->G 611A->G Transition (2) FSGLAA
M10 No mutation All Exons present No mutation Incompletely characterized (C) FNH
UC-043 B1 M1 No mutation in Exons 2-3; Exon 8: 
538G->A
538G->A Transition (1) KDSGGA
M3 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) RGGSTAG
UC-008 B1 M1 Exclusion of Exon 4 Deletion of Exon 4 Deletion of Exon 4 Exon Deletion (8) DERR
UC-050 B1 M1 589G->A 589G->A Transition (1) NSGTFGG
M2 112_113CC->TT 112_113CC->TT Tandem (13) DAGRAR
M12 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) VQGLAGD
UC-037 B1 M2 610C->T 610C->T Transition (1) PRSD
M3 Exclusion of Exon 3; Inclusion 32811-
32934 between Exons 5 and 6
RTDRAL
M4 501-507delGACCCCA Exon 7: 501-507delGACCCCA 501_507delGACCCCA YAGTN
M5 617G->A 617G->A Transition (1) LSG
M8 EPSGA
M10 529G->T 529G->T Transversion (4) PSGRG
M11 622_624dupATT 622_624dupATT DLGGN
M14 TKAPTITT
M17 152G->C 152G->C AGG
M20 Exclusion of Exon 4 Exon 4: 319-1G->T 319-1G->T Transversion (4)
UC-038 B1 M1 Incompletely characterized (D) EGM
M2 No mutation No mutation Incompletely characterized (C) TKGQG
UC-068 B1 M2 467A->G; Exclusion of Exons 2,3 All Exons present; No mutations in 
Exons 2, 3, 4, 6
Presumed deletion of Exons 2, 3 Incompletely characterized (A) SGPEEGGGR
M4 Exclusion of Exon 8 Exon 8: 551C->T 551C->T Transition (1) GIGRAY
M6 151C->T 151C->T CpG Transition (3)
M8 No mutation in Exon 3; Exon 8: 
609+1G->A
609+1G->A Transition (1)
M9 Exclusion of Exon 6 No mutation Presumed deletion of Exon 6 Incompletely characterized (A) DLKQGK
UC-011 B1 M3 Exclusion of Exons 2-3 Deletion of Exons 2-3 Deletion of Exons 2-3 Exon Deletion (8) QEQVPW
M4 233T->A 233T->A 233T->A GEPAR
M5 109_110delATinsC 109_110delATinsC Deletion/Insertion (12)
M6 529G->T 529G->T Transversion (4) VSGLAA
M7 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) GGGR
M8 233T->A 233T->A Transversion (6) GEPAR
UC-021 B1 M2 191C->A 191C->A Transversion (4)
M3 REPEAT 2ND RD PCR Incompletely characterized (D)
M4 MGAAS
M5 Incompletely characterized (D) AGGPV
Untreated Adults with Ulcerative Colitis (N=35)
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Subject ID Clone cDNA Analysis Genomic Analysis Final Mutation Class of Mutationb TCRβ CDR3 
Regionc
M7 Exclusion of Exons 7, 8; 268 G->A No Exons 7, 8, 9; No mutation in 
Exon 3
Deletion of Exons 7, 8 Exon Deletion (8) ERGSLRH
M8 Exclusion of Exons 2, 3 Exon 2: 115C->G; No mutation in 
Exon 3
115C->G Transversion (5)
M9 143G->T 143G->T 143G->T STTGRSS
M14 118G->A 118G->A 118G->A RLRLAG
UC069 B1 M1 151C->T 151C->T CpG Transition (3) GGR
M6 31_51del21insG 31_51del21insG Deletion/Insertion (12) EAGLAGR
M7 Exclusion of Exon 7; 227het C/T Exon 7: 486-12T->A 486-12T->A Transversion (6) RYR
M12 610-8_633del32 610-8_633del32 Microdeletion (9)
M13 542T->A 542T->A Transversion (6) GDGD
UC-034 B1 M1 538G->A 538G->A Transition (1)
UC-051 B1 M1 222C->A 222C->A Transversion (4) TLLAGGG
M2 222C->A 222C->A Transversion (4) TLLAGGG
M3 400G->A 400G->A Transition (1) SDY, IEMTGRG
UC-045 B1 M1 489_491dupGCT 489_491dupGCT Duplication (10) RPDRGI
M2 No mutation in Exon 9 Incompletely characterized (B) YGGE
M3 Exclusion of Exon 3; 521_522losAT Exon 3: 135-5_135-2delTGTA, 
Exon 7:No loss 521_522losAT
135-5_135-2delTGTA Microdeletion (9) EGGPK
M4 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B)
UC-012 B1 M1 48_49delTTinsC 48_49delTTinsC Deletion/Insertion (12)
M4 Exclusion of Exon 2 No Exon 2 Deletion of Exon 2 Exon Deletion (8) SRRVG
M6 48_49delTTinsC 48_49delTTinsC 48_49delTTinsC
M7 595T->A 595T->A Transversion (6) RQDSTFPIG
M9 242_246delACATinsTT 242_246delACATinsTT Deletion/Insertion (12) SPYKM
M17 418G->C 418G->C Transversion (5)
UC-025 B1 M1 208G->A 208G->A Transition (1) SHGVG
M2 RAPASAT
M4 146T->G 146T->G Transversion (7) RPGTN
M5 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) FLAS
M6 40_49del10; 173, 432 hetG/A No mutation in Exons 3, 6; Exon 
2: 40_49del10
40_49del10 Microdeletion (9) SGLGV
M7 88, 322 G->A No mutation in Exons 2, 4 Incompletely characterized (D)
UC-064 B1 M1 Incompletely characterized (D) GLP
M3 444hetC/T; 538G->A Exon 8: 538G->A, No mutation in 
Exon 6
538G->A Transition (1) FRRGD
M12 3G->A 3G->A Transition (1)
M14 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) SPGLTY
M17 Exclusion of Exon 8 Exon 8: 533-51_533-18del34 533-51_533-18del34 Microdeletion (9) LDPGDL
UC-016 B1 M2 Exclusion of Exons 2-3; 402+1 G->A, 
Inclusion 402+1_402+67
No mutation in Exons 2, 3 402+1G->A Transition (1)
UC-049 B1 M1 449T->A 449T->A Transversion (6)
M2 529G->T 529G->T Transversion (4) AHLRGL
M3 Deletion of Exon 1 Deletion of Exon 1 Exon Deletion (8) FGGPTVVW
M4 236_237TG->GT 236_237TG->GT Tandem (13) ARPH
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M7 569G->A 569G->A Transition (1) GPSRGYP
UC-044 B1 M1 TLADSL
M5 Exclusion of Exons 2-3 No mutation in Exons 2-3 Presumed del of Exons 2-3 Incompletely characterized (A)
M6 TLPGTGC
M7 218_219losAA; 52G->A 218_219losAA Loss (10) EWVVM
M9 601G->T 601G->T Transversion (4) TGTA
M10 197G->A 197G->A Transition (1) KGPF
M12 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) RRG
UC-054 B1 M1 143G->A 143G->A GPGQGFG
M3 Exclusion of Exon 8 Exon 8: 550_551CC->TT 550_551CC->TT Tandem (13)
M5 EER
M6 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) LGG
M9 RPGGVG
M11 611A->G 611A->G Transition (2) GGRAGWTY
M13 TEENSG
M15 168G->T; 208G->A Exon 3: 208G->A 208G->A Transition (1)
M16 QIPGI
M18 No mutation No mutation Incompletely characterized (C) IPGQGLLG
UC-039 B1 M1 PFDRSN
M3 611A->T 611A->T Transversion (6) SDPWG
M4 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) ERQSL
M6 Top band: 143G->A 143G->A CpG Transition (3) FSSGTLGG
M8 Incompletely characterized (D) GAAPQG
M9 RRVAG
M10 407_449delinsCAC 407_449delinsCAC Deletion/Insertion (12) GPTPPPSSSA
UC-048 B1 M1 459delT; 569, 580, 589, 599, 601, 606, 
628, 635G->A 
No mutation in Exons  7/8, 9; 
Exon 6: 459delT
459delT Microdeletion (9) SQAAGALIL
M2 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B)
M4 Incompletely characterized (D) MGQGAH
M5 134G->A 134G->A Transition (1) PGTLG
M10 Exclusion of Exon 4 Exon 4: 319-2A->T 319-2A->T Transversion (6)
UC-046 B1 M1 539G->T 539G->T SQQG
M2 539G->T 539G->T SQQG
M3 VASGGL, PLRD
M5 SQQG
M6 Exclusion of Exon 8 Exon 8: 539G->T 539G->T SQQG
M7 WDRVPPT
M8 539G->T 539G->T SQQG
M9 LLRTA
M10 539G->T 539G->T SQQG
M11 539G->T 539G->T SQQG
M12 581A->T 581A->T GGDP
M14 222C->G 222C->G STGY
M15 539G->T 539G->T SQQG
M16 SQQG









M33 Exclusion of Exons 2-6 All Exons present; No mutation in 
Exons 2, 4, 5;  Exon 6: 485G->A
485G->A Transition (1) RLGASAQN
M35 27+1delG; Inclusion of bp 
27+2_27+49
27+1losG Loss (10) GRGVGES
M36 Exclusion of bp 610_626; 606hetG&A Exon 9: 610-1 G->C; No mutation 
in Exon 8
610-1G->C Transversion (5) VASGGL
M42 498A->C Exon 7: 498A->C 498A->C Transversion (7) ASGR
M53 Exon 8: 539G->T 539G->T Transversion (4)
UC-015 B1 M1 Exclusion of bp 610_635, Inclusion 610-
42_610-33 AATATACTTT
610-32_635del58 610-32_635del58 Microdeletion (9)
UC-035 B1 M1 Exclusion of Exon 4 Exon 4: 337losG 337losG Loss (10)
M2 Exclusion of Exon 5 Exon 5: 385-1G->A 385-1G->A Transition (1) RLGEV
UC-040 B1 M2 551C->G 551C->G
M5 606G->C 606G->C
M7 Top band: 233 T->C, Middle band: 
Exclusion of Exons 2-6
Exon 3: 233T->C; No mutation in 
Exons 2, 4, 5, 6
233T->C Transition (2) DPSGGVGY
M9 499A->G 499A->G Transition (2) QGLAGGMD
M10 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) TPGGRLD
M12 133A->T 133A->T Transversion (6) TS
M25 Exclusion of bp 403_452; 393, 544, 
569, 589, 606, 633 het C/T
Exon 6: 403-1G->A 403-1G->A Transition (1) DG
UC-041 B1 M1 558_572del15 558_572del15 Microdeletion (9) VAGG
M2 Bot 179_180insGGCA 179_180insGGCA Insertion (11) RVGRGGD
M5 Top band: 43dupA, 131A->T Exon 2: 131A->T (43dupA is not 
real)
131A->T Transversion (6) WL
M7 Exclusion of Exon 5 Exon 5: 385-1G->A 385-1G->A Transition (1) GLAG
M10 119G->A 119G->A Transition (1) RKTGLE
M13 FKGGD
UC-028 B1 M1 Exclusion of Exon 8; 518het G/A LPRGAA
M2 554A->T Exon 8: 554A->T 554A->T
M3 Exclusion of Exon 8 Exon 8: 609+5G->A 609+5G->A Transition (1) ALAGS
M4 24_26delCGT 24_26delCGT
M11 582C->A 582C->A Transversion (4) DRGLR
M14 414_422delCACTGGCAA Exon 6: 414_422delCACTGGCAA 414_422delCACTGGCAA
M17 Exclusion of Exons 2, 3; Exclusion of 
Exon 8
No mutation in Exons 2, 3; Exon 
8: 533-2A->G; 547A->C
533-2A->G; 547A->C IGIWG
M18 611A->G 611A->G Transition (2) GTTRTG
UC-055 B1 M1 Exclusion of Exon 8 Exon 8: 551C->T 551C->T Transition (1) RLTSGGA
M2 PGGEP
M3 Exclusion of Exon 8 Exon 8: 486-25delA; Exon 8: 
609+1G->A
609+1G->A Transition (1) PGGEP
M4 DPGTE
M5 395T->C PLAGAT
M7 Exclusion of Exon 8 Exon 8: 609+1G->A 609+1G->A Transition (1) PGGEP
M8 PELTSGL
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M10 PGGEP
M11 202C->G 202C->G Transversion (5) AKPTGTG
M12 PGGEP
M13 202C->G 202C->G Transversion (5) AKPTGTG
UC-026 B1 M2 Exclusion of Exon 4 319-38_327del47 319-38_327del47 Microdeletion (9)
M5 Exclusion of Exon 8; 634G->A No mutation in Exons 8, 9 Presumed del of Exon 8 Incompletely characterized (A) DE
M6 Excl 610_626 610-1 G->A 610-1G->A Transition (1)
M9 Exclusion of Exons 7,8 No mutation in Exons 7, 8 Presumed deletion of Exons 7, 8 Incompletely characterized (A) RLTSGHG
M10 ETSGY
M11 508C->T 508C->T CpG Transition (3) SGGRT
UC-022 B1 M1 Exclusion of Exons 2, 3 Exon 3: 265delA; No mutation in 
Exon 2
265delA Microdeletion (9) SGWGPGV
M3 Exclusion of Exon 8; 501hetG/A No mutation in Exons 3, 7; Exon 
8: 556hetA/T
556A->T Transversion (6) ARQA, APGQGD
M4 195_212del18 195_212del18 Microdeletion (9) SQTG
UC-023 B1 M1 Exclusion of Exons 2, 3 Exon 3: 318+1 G->T; No mutation 
in Exon 2
318+1G->T Transversion (4) RTG
M2 Exclusion of Exons 2-6 Exon 6: 485+2 T->G; No mutation 
in Exons 2-5
485+2T->G Transversion (7) ALD
UC-027 B1 M1 Exclusion of Exon 4 Exon 4: 384+1 G->A, No mutation 
in Exons 3, 5
384+1G->A Transition (1) DRD
UC-020 B1 M1 611A->G 611A->G Transition (2) FAQGAY
UC-019 B1 M1 Top band: no mutation; Bottom band: 
Exclusion of Exon 8
No mutation in Exon 8 Presumed deletion of Exon 8 Incompletely characterized (A)
M2 623T->A 623T->A Transversion (6) PGQIP
CD-020 B1 M1 Exclusion of Exon 5 Exon 5: 385-1G->A 385-1G->A Transition (1) SQN
M2 151C->T 151C->T CpG Transition (3) WGAM
M3 Exclusion of Exon 5 Exon 5: 385-53_402+32del103 385-53_402+32del103 Microdeletion (9)
CD-052 B1 M1 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) GDGAA
M2 222C->A Exon 3: 222C->A; No mutation in 
Exon 4 
222C->A Transversion (4) DGASGV
M3 539G->T 539G->T Transversion (4) ETGGPD
M4 544G->A 544G->A Transition (1) GIVA
M5 508C->T All Exons present; Exon 8: 508C-
>T
508C->T CpG Transition (3) VQGAITS
CD-024 B1 M1 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B)
M2 425C->T 425C->T Transition (1) TEDSGRVH
M3 Exclusion of Exon 5 Exon 5: 385-1G->A 385-1G->A Transition (1)
M4 133A->G All Exons present; Exon 2: 133A-
>G
133A->G Transition (2) PGRGQ
M6 Exclusion of Exon 4 Exon 4: 319-2 A->C 319-2A->C Transversion (7)
CD042 B1 M5 1A->T 1A->T Transversion (6)
Untreated Children with Crohn's Disease (N=3)
Untreated Adults with Crohn's Disease (N=13)
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M12 475A->T 475A->T Transversion (6) PATVG
M14 143G->A 143G->A CpG Transition (3)
M26 143G->A 143G->A CpG Transition (3) STKW
CD-029 B1 M1 617G->A No mutation in Exon 3 617G->A Transition (1) STOP
M2 Inclusion of 27+1_27+49; 118, 399, 
599G->A
No mutation in Exons 2, 7, 8; 
waiting for Exons 1, 5
Incompletely characterized (D)
M3 Incompletely characterized (D) RRQG
 CD-008 B1 M1 DLRGRR
M3 Exclusion of Exons 4, 5 Deletion of Exons 4, 5 Deletion of Exons 4, 5 Exon Deletion (8) VGSGGI
M5 212 G->A 212G->A Transition (1) LNTGG
M6 REPEAT RT All Exons present; No mutation in 
Exons 1, 3, 4, 6
Incompletely characterized (D) RRGG
M7 176_187del12 176_187del12 Microdeletion (9)
M8 639_654+30del46 639_654+30del46 Microdeletion (9) ASTG
CD-044 B1 M1 393G->T 393G->T Transversion (4)
M2 191C->A 191C->A Transversion (4)
M4 612T->A 612T->A Transversion (6) GSSGRAMG, RGRIG
CD-030 B1 M4 51_52insGTAT 51_52insGTAT QGG
M7 51_52insGTAT 51_52insGTAT QGG
M15 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) DSPAKGN
M29 Exclusion of Exons 2-3; 17G->A Exon 2: 112_113CC->TT 112_113CC->TT RQRES
M35 Incompletely characterized (D) DPAGDV, PGLAG
CD-033 B1 M1 479T->A No mutation in Exons 3, 4 479T->A ALGGS
M5 3G->A No mutation in Exon 2 3G->A Transition (1) TGR
M8 617G->A; 119, 148, 190 hetG&A Exon 9: 617G->A; No mutations in 
Exons 2, 3
617G->A Transition (1) LQTGG
M11 628G->A 628G->A Transition (1)
M14 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) QGQTAV
CD-049 B1 M2 Exclusion of Exon 6 Exon 6: 485+1G->A 485+1G->A Transition (1) LQAGGQV
M3 611A->G 611A->G Transition (2) QGTGTSG
M6 368C->A; 400G->A; Exclusion of Exons 
2, 3
Exon 4: 368C->A; No mutation in 
Exons 2, 3, 5
368C->A Transversion (4) S
M10 All Exons present; No mutation in 
Exons 1, 9; Exon 7: 486-6T->G
486-6T->G Transversion (7) QAGR
CD-039 B1 M2 68, 85, 97, 139G->A No mutation in Exon 2 139G->A Transition (1) TAGGY
M10 620delT 620delT Microdeletion (9) LGTGSMG
M13 Exon 8: 539G->T 539G->T Transversion (4) ADQPTGG
M19 Inclusion of AG b/n Exons 8 and 9 No mutation in Exons 5, 6, 8; Exon 
9: 610-3T->G
610-3T->G Transversion (7)
M24 212dupG; 234,509 G->A Exon 3: 212dupG; No mutation at 
positions 234, 509
212dupG Duplication (10) RGRDRL
CD-048 B1 M1 Exclusion of bp 610-626 Exon 9: 610-1_610GC->TT 610-1_610GC->TT Tandem (13)
M2 209G->A 209G->A Transition (1)




Subject ID Clone cDNA Analysis Genomic Analysis Final Mutation Class of Mutationb TCRβ CDR3 
Regionc
M3 646delT 646delT Microdeletion (9) PGTK
M5 Exon 3: 265dupA; No mutation in 
Exons 4-6
265dupA Duplication (10)
M6 404A->G 404A->G Transition (2)
M7 Exclusion of Exon 8 Exon 8: 533-7_551del26 533-7_551del26 Microdeletion (9) AR
CD-032 B1 M1 No mutation No mutation Incompletely characterized (C) RAL
M2 454C->T, 352G->A 454C->T, 352G->A Transition (1)
M4 Exclusion of bp 28_32 Exon 2: 28-1G->A 28-1G->A Transition (1)
M9 405T->G 405T->G Transversion (7) TR
 CD-011 B1 M1 No mutation in Exon 3; Exon 7: 
532+5G->C
532+5G->C Transversion (5) SV
CD-031 B1 M8 616_642del27 616_642del27 Microdeletion (9) SPRLG
M9 195C->T; 197G->A Exon 3: 197G->A 197G->A Transition (1) GR
M11 Incompletely characterized (D) SHRDRA
M14 Exclusion of Exon 4 Exon 4: 384+5_384+14del10 384+5_384+14del10 Microdeletion (9)
M15 18T->G; 124A->T; 159,255G->A Exon 2: 124 A->T; No mutations in 
Exons 1, 3
124A->T Transversion (6) DVSDTD
UC-014 B1 M1 Exclusion of Exons 2-3; 379 G->T Exon 4: 379G->T; No mutation in 
Exons 2, 3
379G->T Transversion (4) SASGGRAD
UC-060 B1 M1 62T->G 62T->G Transversion (7)




M2 Exclusion of Exon 4 319-1G->A 319-1G->A Transition (1) EMFSGT
M4 No mutation in Exons 1, 4, and 9 Incompletely characterized (D) PLAGG
M5 621delC 621delC 621delC
M6 Exclusion of Exon 2 28-13_50del36 28-13_50del36 Microdeletion (9)
M7 606G->T 606G->T 606G->T Transversion (4) VMTSGND
M8 Exclusion of Exon 4 319-1G->C 319-1G->C Transversion (5) EDSLG
M9 Exclusion of Exon 4 319-1G->A 319-1G->A
M11 618delT 618delT 618delT Microdeletion (9)
M12 Exclusion of Exon 4 319-1G->A 319-1G->A EMFSGT
M13 Exclusion of Exon 2 No mutation in X2? Incompletely characterized (D) EMFSGT
M15 Exclusion of Exon 2 28-13_50del36 28-13_50del36 Microdeletion (9) PPVTGR
M19 196T->C 196T->C Transition (2)
UC-004 B1 M9 Exclusion of Exons 4-8 Deletion of Exons 4-8 Deletion of Exons 4-8 Exon Deletion (8)
M16 508hetC/T Incompletely characterized (C) DHWDIG
UC-009 B1 M3 411losT 411losT Loss (10)
M17 Exclusion of Exon 4 384+1G->A 384+1G->A Transition (1)
M18 Exclusion of Exon 4 384+1G->A 384+1G->A Transition (1)
M20 Exclusion of Exon 4 384+1G->A 384+1G->A Transition (1)
M26 Exclusion of Exon 4; 91, 97, 509, 628 
het G/A
384+1G->A, No mutation in Exons 
2, 7 
384+1G->A Transition (1)
Subjects with Inflammatory Bowel Disease, Treated with Purine Analogs
Treated Children with Ulcerative Colitis (N=7)
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UC-056 B2 M1 507delA 507delA Microdeletion (9) STOP
M2 212dupG 212dupG SQNPGQGVY
M3 YEGH
M5 617G->A 617G->A GRPLA
M8 151C->T 151C->T EPYRGH
M12 578 T->G 578T->G Transversion (7) PGQT
M13 Top band: 578T->G; Bottom band: 
Exclusion of Exon 2
Exon 2: 134+1 G->A; No mutation 
in Exon 8
134+1G->A Transition (1) FGRA
M21 Top band: 542T->C; Exclusion of Exons 
2-6
No mutations in Exons 2-6; Exon 
8: 542T->C
542T->C Transition (2)
M35 507delA 507delA Microdeletion (9) STOP
M37 617G->A 617G->A Transition (1) RYPDRP
M41 578T->G; 145, 195, 222, 366, 390 
hetC/T
Exon 8: 578T->G (het 
T/G?male_WT backgd); No 
mutations in Exons 3, 4, 5
578T->G Transversion (7) TLTGPFW
M42 Exclusion of Exons 7-8 Exon 8: 578T->G 578T->G Transversion (7) GSF
M47 428T->G 428T->G QRQGAGVFG
M48 Inclusion 27+1_27+49, 27+1G->T 27+1G->T Transversion (4)
UC-005 B1 M3 Exclusion of Exon 6 485G->A 485G->A
M4 197G->A 197G->A Transition (1)
M5 Exclusion of Exon 5 385-1G->A 385-1G->A LEDYY
M7 GQEG
M11 Exclusion of Exon 4 384+1G->A 384+1G->A Transition (1)
M19 No mutation in Exons 2 and 5, X4: 
384+1G->A; X3 did not seq




M30 Exclusion of Exons 2-3 No mutation in Exons 2-3 Presumed deletion of Exons 2 and 3 Incompletely characterized (A)
M31 34_42del19 No mutation in Exon 8 34_52del19 Microdeletion (9)
M32 143G->A 143G->A CpG Transition (3) LDPGYP
M34 197G->A; 159,361,393,606hetG/A; 
554G->A;
No mutation in Exons 3, 4, 8; Exon 
7 505hetC/G
197G->A Transition (1) GQEG
M35 197G->A 197G->A  197G->A Transition (1) GQEG, TPGGRGQAAP
M37 Exclusion of Exon 4 384+1G->A 384+1G->A
M38 Exclusion of Exon 4 No mutation in Exon 4 Presumed deletion of Exon 4 Incompletely characterized (A)
M40 Exclusion of Exons 2-3 Do genomic PCR of Exons 2-3 Incompletely characterized (D) YGRIAGRPG
UC-002 B1 M4 EETGLG
M6 64T->G 64T->G Transversion (7)
M7 No mutation No mutation Incompletely characterized (C)
M8 PRLRGTV
M9 No mutation No mutation Incompletely characterized (C)
M10 Exclusion of Exon 4 Exon 4: 324_325CC->TT 324_325CC->TT GRGTT
M12 Exclusion of Exons 7, 8 Deletion of Exons 7, 8, 9 Deletion of Exons 7, 8 Exon Deletion (8) SPLDREE
M13 Exclusion of Exon 7 526-532+5delCCAGATgtaag 526-532+5delCCAGATgtaag
M15 508C->T 508C>T VTGGATV
M18 Exclusion of Exon 8 Exon 8: 609+3A->C 609+3A->C Transversion (7) SRDLY
M19 269_270delAT; Incl IVS+9192-9230 269_270delAT Microdeletion (9) SPLWDRGT
M21 200T->G 200T->G
M22 Exclusion of Exons 7, 8 Deletion of Exons 7, 8, 9 Deletion of Exons 7, 8 Exon Deletion (8) SPLDREE
M23 196T->C 196T->C
Treated Adults with Ulcerative Colitis (N=13)
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M25 Exclusion of Exons 7, 8 Deletion of Exons 7, 8, 9 Deletion of Exons 7, 8 Exon Deletion (8)
M28 VQGAKISD
M29 272, 361, 384 G->A Deletion of Exon 9; No mutation in 
Exons 3, 4
Deletion of Exon 9 Exon Deletion (8) PIQGY
M30 EETGLG
UC-042 B1 M1 QGQS
M2 DRD
M3 398T->G 398T->G Transversion (7) SAGQAG
M6 Incompletely characterized (D) RFSSTYH
M7 Exclusion of Exon 8 Exon 8: 551C->T 551C->T Transition (1)
M8 118G->A 118G->A Transition (1)
M9 151C->T 151C->T CpG Transition (3) PVRDRD
UC-001 B2 M2 611A->G; Top band: Exclusion of Exons 
2-6
No mutation in Exon 9 Incompletely characterized (D)
M9 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B)
M12 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) LGG
M16 197G->A 197G->A Transition (1)
M17 LGG
M24 Incompletely characterized (D) LGG
M28 Exclusion of Exon 6 Exon 6: 485+1hetG/C 485+1G->C Transversion (5)
M43 ARSPWREDSWTEI
M82 Incompletely characterized (D) LLPG
M84 Incompletely characterized (D) DGGLID
UC-006 B1 M1 TYRGRGSA, ETSWTETN
M5 Exclusion of Exon 5 SPGQGA
M6 209G->A 209G->A 209G->A AQAPDRGK
M7 EVAGTST
M10 Exclusion of bp 533_553 LGGE
M11 NLQGVFG
M14 Exclusion of bp 28-32 28-1G->C 28-1G->C Transversion (5) FGQGA
M17 Exclusion of bp 28-32 28-1G->C 28-1G->C Transversion (5)
M18 Exclusion of Exon 6, 485G->A 485G->A 485G->A Transition (1)
M19 Incompletely characterized (D) EVAGTST
M20 27+1G->A 27+1G->A Transition (1) ATDTGKN
M22 IGLAGGK
M23 PASV
M24 Exclusion of Exons 2-7 361_363delGATinsTA; No mutation 
in Exons 2, 3, 5, 6, 7 
361_363delGATinsTA Deletion/Insertion (12) GGAV
M26 209G->A 209G->A Transition (1) DYPGM
M28 EVAGTST
M29 Exclusion of Exon 2 28-58_49del80 28-58_49del80 Microdeletion (9)
M30 Exclusion of Exon 2 28-58_49del80 28-58_49del80 Microdeletion (9) PRGLGG
M32 143G->A 143G->A CpG Transition (3) SPGQGA
M34 ASGTGTVRIY
M35 127_129delATGinsTT 127_129delATGinsTT
UC-065 B1 M5 Incompletely characterized (D) STGGR
UC-070 B1 M1 No mutation No mutation Incompletely characterized (C) TSDRGRG
M2 611_613delATGinsC 611_613delATGinsC Deletion/Insertion (12) IRQAQG
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UC-018 B1 M1 Exclusion of Exon 8; 374T->A; 635G-
>A
Exon 4: 374T->A; No mutation in 
Exon 8 or at 635G->A
374T->A Transversion (6) GFG
M2 530A->G 530A->G Transition (2)
M3 Deletion of Exon 9 Deletion of Exon 9 Exon Deletion (8) KTDGD
M4 151C->T 151C->T CpG Transition (3) PAGTARV
UC-066 B1 M6 Exclusion of Exon 2 Exon 2: 28-15_39del27 28-15_39del27 Microdeletion (9) RTGTGSS, DLAL
M27 Incompletely characterized (D) RTGAPFVGG
M28 Incompletely characterized (D) DRSL
M32 Exclusion of Exon 4 Exon 4: 319-2A->T 319-2A->T Transversion (6) LPTSGSL
M39 Exclusion of Exon 4 Exon4: 384+1G->A 384+1G->A Transition (1) ADRGG
M43 599G->A 599G->A Transition (1) NAQWG
M47 Exclusion of bp 610_626 Exon 9: 610-16G->A 610-16G->A Transition (1) PSGRWSG
M53 Exclusion of Exons 4, 5 Deletion of Exons 4, 5 Deletion of Exons 4, 5 Exon Deletion (8)
M58 Deletion of Exons 4-9 Deletion of Exons 4-9 Exon Deletion (8) RGTMV
M73 Exclusion of bp 28-32, middle mixed 
(repeat)
Exon 2: 28-1G->A; No mutation in 
Exon 6
28-1G->A Transition (1) FLTDAV
UC-029 B1 M1 Exclusion of Exon 4 Exon 4: 319-65_366del113insCTG 319-65_366del113insCTG Deletion/Insertion (12) VRRDRP
M3 487T->G 487T->G Transversion (7) RSEG
UC-036 B1 M1 400G->A 400G->A Transition (1)
M2 Exclusion of Exons 2, 3 Exon 3: 135-1G->A; No mutation 
in Exon 2
135-1G->A Transition (1)
M3 152G->C 152G->C Transversion (5) MRGY
M4 152G->C 152G->C Transversion (5) LLYRGLDPPN
M5 151C->T Exon 3: 151C->T 151C->T SLRDGN
M6 508C->T Exon 7: 508C->T 508C->T
M9 197G->A 197G->A PGGLAGGKS, PMTGGS
M12 202C->T 202C->T Transition (1) KPGDLAGGR
M13 233T->C 233T->C Transition (2)




M30 Exclusion of Exon 8 Do genomic PCR for Exon 8 Incompletely characterized (D)
M35 197G->T Exon 3: 197G->T 197G->T SVILAALH
M36 131A->T Exon 2: 131A->T 131A->T
M38 222C->A; Inclusion 36246-36281 
between Exons 6 and 7
Exon 3: 222C->A 222C->A
M39 521_522losAT 521_522losAT Loss (10) VGDRGPG




UC-067 B1 M1 Exclusion of bp 610_626 Exon 9: 610-1G->T 610-1G->T Transversion (4) STOP
M2 571_574dupTATG 571_574dupTATG Duplication (10) RETGD
M3 571_574dupTATG 571_574dupTATG Duplication (10) RETGD
M5 Exclusion of bp 610_626 Exon 9: 610-1G->T 610-1G->T Transversion (4) KGEK
M6 571_574dupTATG 571_574dupTATG Duplication (10) RETGD
M7 Incompletely characterized (D) EGRP
M8 571_574dupTATG 571_574dupTATG Duplication (10) RETGD
M9 571_574dupTATG 571_574dupTATG Duplication (10) RETGD
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UC-031 B1 M1 Exclusion of bp 610_626 Exon 9: 610-2A->G 610-2A->G Transition (2) IFWEAN
M2 3 G->C 3G->C Transversion (5) SYGQGAR
M3 119G->C Exon 2: 119het G/C 119G->C Transversion (5) SYTADT
M4 Exclusion of Exon 2 Do Exon 2 Incompletely characterized (D)
M5 Exon 9: 638_654+2del19insC; No 
mutation in Exons 1-8 
638_654+2del19insC Deletion/Insertion (12)
M6 SYGQGAR
UC-047 B1 M1 205A->T Exon 3: 205A->T 205A->T SQP
M3 TPGL
M4 212G->T Exon 3: 212G->T 212G->T RAG
M5 Exclusion of Exon 8 Exon 8: 594C->G 594C->G Transversion (5) RDILWTGGYA
M7 468delG 468delG Microdeletion (9) GPAQPS
M8 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) AV
M9 TSP
M10 GLTG
M11 Incompletely characterized (D) GPAQPS
M16 610C->T 610C->T GATGNA
 CD-013 B1 M1 212dupG 212dupG Duplication (10) SLLTIS
M2 Exclusion of exon 6, Inclusion of 28707-
28744 (b/n exons 4 and 5)
Exon 6: 485G->A 485G->A
M3 Exclusion of Exons 5, 6 Deletion of Exons 5, 6 Deletion of Exons 5, 6 Exon Deletion (8) NRLAGAG






M8 Exclusion of Exon 4 TLGGI
M9 GRGRGA
M10 555delC Exon 8: 555delC 555delC
M13 Exclusion of Exon 6 485G->A NRGEG
M15 Exclusion of Exon 6 485G->A Transition (1)
M17 1A->G 1A->G Transition (2) PGTGDA
M18 Exclusion of Exon 6 Exon 6: 485G->A 485G->A Transition (1)
M19 Exclusion of Exon 6 Exon 6: 485G->A 485G->A GRGRGA
M20 NRGEG
M21 151C->T Exon 3: 151C->T 151C->T
M22 Exclusion of Exon 6 Exon 6: 485G->A 485G->A
M24 Exclusion of Exon 6 Exon 6: 485G->A 485G->A
M25 Exclusion of Exons 2- 6 Exon 6: 485G->A; No mutation in 
Exon 2
485G->A
M26 Exclusion of Exon 6 Exon 6: 485G->A 485G->A
M32 Exclusion of Exon 6 Exon 6: 485G->A 485G->A SKWEPIL
M34 3G->A 3G->A Transition (1) PRTSGGVD
M35 KDSY
M36 Exclusion of Exon 5 LLAGG
M41 Exclusion of Exon 6 Exon 6: 485G->A 485G->A Transition (1) VWGRA, SDRQGA
M42 297lossT 297losT ELGGR
M43 Exclusion of Exon 6 485G->A RGGVSS
M44 Exclusion of Exon 6 Exon 6: 485G->A 485G->A Transition (1) GRGRGA
M45 Exclusion of Exon 6 Exon 6: 485G->A 485G->A GRGRGA
M46 212G->A Exon 3: 212G->A 212G->A LQGPPG
M47 TLGGI
M49 Exclusion of Exon 6 Exon 6: 485G->A 485G->A
M54 Exclusion of Exon 6 Exon 6: 485G->A 485G->A
Treated Children with Crohn's Disease (N=19)
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M55 Exclusion of Exon 6 Exon 6: 485G->A 485G->A
M56 WTY
M57 Exclusion of Exon 6 Exon 6: 485G->A 485G->A TADTTV
M58 Exclusion of Exon 6 Exon 6: 485G->A 485G->A
CD-050 B1 M5 229G->T 229G->T Transversion (4) PATGG





M26 197G->A; 21hetC/T No mutation in Exon 1 197G->A Transition (1) RRGAGRG
M34 Exclusion of bp 610_626 No mutation in Exon 9 Incompletely characterized (D) VLAS
M35 Exclusion of Exon 5; 361hetG/A Exon 5: 385-1G->A; No mutation 
in Exon 4
385-1G->A Transition (1) DGAGGY
M36 43_49delCCAGGTT 43_49delCCAGGTT Microdeletion (9) TKGGYG
M41 Exclusion of Exon 5 Exon 5: 385-1G->A 385-1G->A Transition (1) DGAGGY
M49 229G->T 229G->T Transversion (4) RRLGSEGQG
M70 Exclusion of Exon 5 Exon 5: 385-1G->A 385-1G->A Transition (1) DGAGGY
M77 271A->T 271A->T Transversion (6)
CD-001 B2 M7 Exclusion of Exon 2 Exon 2: 134+1G->C 134+1G->C Transversion (5) TGER
M9 Exclusion of Exon 8 Exon 8: 609+1G->C 609+1G->C Transversion (5) RPFLAE
M10 Incompletely characterized (D) SPLIG
M11 Exon 2: 134+9delG; No mutation 
in Exon 3
134+9delG Microdeletion (9) SPLIG
M16 Exclusion of Exon 2 Exon 2: 134+1G->C 134+1G->C Transversion (5) TGER
M20 Exclusion of Exon 4 Exon 4: 384+2T->G 384+2T->G Transversion (7)
M23 Incompletely characterized (D) SPLIG
M24 Exclusion of Exons 2-6 Deletion of Exons 2-4; No 
mutations in Exons 5, 6
Deletion of Exons 2-4 Exon Deletion (8) OUT OF FRAME
M26 Incompletely characterized (D) SPLIG
CD-027 B1 M1 Exclusion of Exon 5 Exon 5: 385-8_385-2del7 385-8_385-2del7 Microdeletion (9)
M2 37_49del13 37_49del13 Microdeletion (9) GFTGS
M3 151C->T 151C->T CpG Transition (3)
M4 Exclusion of Exon 4 Exon 4: 334_371del38 334_371del38 Microdeletion (9)
M6 Exclusion of Exons 4, 5 Exon 5: 390_402+382del395insTT 390_402+382del395insTT Deletion/Insertion (12)
M7 37_49del13 37_49del13 Microdeletion (9) GFTGS
M9 529G->T 529G->T Transversion (4) VQGQG
M10 117_127del11 117_127del11 Microdeletion (9) DGRN
M16 Incompletely characterized (D) DTA
M19 151C->T Exon 3: 151C->T 151C->T CpG Transition (3) OUT OF FRAME
CD-035 B1 M14 Exclusion of bp 28-32 Exon 2: 28-1G->A 28-1G->A Transition (1)
M15 No mutations in Exons 2, 4, 6, 9; 
Exon 3: 229G->T 
229G->T Transversion (4) RGTGG
M25 610C->T 610C->T Transition (1)
M30 Do Exons 8, 9 Incompletely characterized (D) RERRTS
M32 151C->T 151C->T CpG Transition (3) RVGSHLRRP
M33 Exon 2: 28-1G->A 28-1G->A Transition (1)
M38 Deletion of Exon 1 Deletion of Exon 1 Exon Deletion (8)
M40 Exclusion of Exon 6, 272G->A Exon 6: 485+2T->A; No mutation 
in Exon 3
485+2T->A Transversion (6)
M50 151C->T 151C->T CpG Transition (3)
M67 74C->T 74C->T Transition (1) SATGLWG
 CD-018 B1 M1 539G->A 539G->A DVGLAGGQRG
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M2 539G->A 539G->A DVGLAGGQRG
M3 539G->A 539G->A DVGLAGGQRG
M4 SPRRGH
M5 539G->A 539G->A DVGLAGGQRG
M6 DVGLAGGQRG
M7 539G->A 539G->A DVGLAGGQRG
M8 539G->A 539G->A DVGLAGGQRG
M9 539G->A 539G->A DVGLAGGQRG
M10 539G->A 539G->A
M11 539G->A 539G->A DVGLAGGQRG
M13 RTGAP
M14 539G->A 539G->A PTSGLR
M15 539G->A 539G->A DVGLAGGQRG
M16 539G->A 539G->A DVGLAGGQRG
M18 539G->A 539G->A DVGLAGGQRG
M19 539G->A 539G->A DVGLAGGQRG
M20 539G->A 539G->A DVGLAGGQRG
M21 539G->A 539G->A DVGLAGGQRG
M22 539G->A 539G->A RTGAP
M23 539G->A 539G->A RDRGS
M24 539G->A 539G->A DVGLAGGQRG
M25 539G->A 539G->A DVGLAGGQRG
M27 539G->A 539G->A Transition (1) DVGLAGGQRG
M28 539G->A 539G->A DVGLAGGQRG
M29 539G->A 539G->A DVGLAGGQRG
M30 539G->A 539G->A DVGLAGGQRG
M31 539G->A; 195hetC/T Exon 8: 539G->A; No mutation in 
Exon 3
539G->A Transition (1) DVGLAGGQRG
M32 143, 508 hetG/A, hetC/T No mutation in Exon 3; Exon 7: 
508hetC/T
508C->T (mixed) CpG Transition (3) RTGAP
M34 539G->A 539G->A DVGLAGGQRG
M37 QTGGTRT
M38 539G->A 539G->A DVGLAGGQRG
M39 539G->A 539G->A DVGLAGGQRG
M40 539G->A 539G->A DVGLAGGQRG
M41 539G->A 539G->A DVGLAGGQRG
M42 539G->A 539G->A DVGLAGGQRG
M43 539G->A 539G->A DVGLAGGQRG
M45 323A->T 323A->T
M47 539G->A 539G->A Transition (1) DVGLAGGQRG
M54 539G->A 539G->A Transition (1) DVGLAGGQRG
M79 539G->A 539G->A Transition (1)
M90 539G->A No mutation in Exon 3 539G->A Transition (1) DVGLAGGQRG
M91 539G->A 539G->A Transition (1) DVGLAGGQRG
M94 143G->A 143G->A CpG Transition (3) STOP
M97 539G->A 539G->A Transition (1) DVGLAGGQRG
CD-021 B1 M1 38_59delinsT 38_59delinsT
M4 197T->C 196T->C
M7 539G->A 539G->A
M9 235_248del14; Inclusion of bp 28708-
28745
235_248del14 Microdeletion (9) TLRRDRE
M11 38_59del22insT 38_59delinsT Deletion/Insertion (12) ESQGRV
M15 463C->T 463C->T
M16 38_59del22insT 38_59delinsT Deletion/Insertion (12)
M17 Exclusion of Exon 8 Exon 8: 553_554delGAinsAATC 553_554delGAinsAATC Deletion/Insertion (12)
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M20 415 A->G 415A->G Transition (2)
M21 Exclusion of Exon 4 Exon 4: 319-1 G->A 319-1G->A Transition (1) SGG
M23 197 G->A 197G->A Transition (1) LRGAD
M24 212dupG 212dupG
M26 113C->G 113C->G Transversion (5)
M28 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) TRGGS
M33 All Exons present; Exon 7: 508C-
>T; Exon 8: no mutation
508C->T CpG Transition (3) SRR
 CD-015 B1 M2 118G->A 118G->A Transition (1) RPYDLGTGVA
M4 Incompletely characterized (D) RPYDLGTGVA
M5 151C->T 151C->T CpG Transition (3)
M9 151C->T 151C->T CpG Transition (3) VDMGLV
M14 Exclusion of Exons 2-6 No mutation in Exons 2-5; X6: 403-
1 G->A
403-1 G->A Transition (1) PSKGPTG
M15 VDMGLV
M21 SWRQG




M30 568G->T 568G->T LGAM
M32 SMG
M34 118G->A 118G->A
M36 39_55delTGAACCAGGTTATGACC 39_55delTGAACCAGGTTATGACC Microdeletion (9)
M37 VDMGLV
M39 347_373del27 347_373del27
M42 51_572del522 51_572del522 KQSRGGTW
M44 NGRGPQ
M46 568G->T 568G->T Transversion (4) RGTGGL
M50 RVDSSA
M51 VDMGLV









 CD-004 B2_2 M2 539G->A 539G->A Transition (1)
M9 539G->A 539G->A Transition (1) VATG
M11 Exclusion of Exon 2 Exon 2: 28-1_53del27 28-1_53del27 Microdeletion (9)
M12 Exclusion of Exon 2 Exon 2: 28-1_53del27 28-1_53del27 Microdeletion (9)
M22 Exclusion of Exon 4 Exon 4: 319-2A->G 319-2A->G Transition (2) ISLG
M23 Exclusion of Exon 2 Exon 2: 28-1_53del27 28-1_53del27 Microdeletion (9)
M39 Exclusion of Exon 4 Exon 4: 319-2A->G 319-2A->G Transition (2) ISLG
M40 Exclusion of Exon 6 Exon 6: 485G->A 485G->A Transition (1) FPRGDM
M49 Exclusion of Exon 2 Exon 2: 28-1_53del27 28-1_53del27 Microdeletion (9)
M55 Exclusion of Exon 2 Exon 2: 28-1_53del27 28-1_53del27 Microdeletion (9) FPRGDM
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 CD-016 B1 M1 151C->T 151C->T CpG Transition (3) EPRGR
CD-054 B1 M1 119G->A 119G->A Transition (1) RQGSLG
M2 Exclusion of Exon 7 Exon 7: 532+3A->C 532+3A->C Transversion (7) PRTSKA
M4 459_460losTA No mutation in Exon 3 459_460losTA Loss (10) LGAG
M5 464losC; 361G->A Exon 4: No mutation 464losC Loss (10) VGA
M6 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B)
M7 610C->T 610C->T Transition (1) PPRAAF
M8 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) FRPLGR, RSSG
M9 Exclusion of Exon 7 Exon 7: 532+3A->C 532+3A->C Transversion (7) PRTSKA
M11 Exclusion of Exon 7 Exon 7: 532+3A->C 532+3A->C Transversion (7) PRTSKA
M12 539G->A 539G->A Transition (1) PNGQGA
CD-026 B1 M1 Incompletely characterized (D) LRATSGGTTT
M3 Exclusion of bp 28_71 Exon 2: 71T->G 71T->G Transversion (7)
M6 41_50del10 41_50del10 Microdeletion (9)
M9 Do Exons 2, 3, 8; No mutation in 
Exon 9
Incompletely characterized (D) SLQGQGDF
M11 Do Exon 5 Incompletely characterized (D) LSAAGGR
M12 Incompletely characterized (D) SSVEN
M17 Incompletely characterized (D) DNGGG
M19 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) SL
M22 Top band: 617G->A; Bottom band: 
617G->A, 352G->A; and Exclusion of 
Exons 2-3
No mutations in Exons 2, 3, 4; 
617G->A
617G->A Transition (1)
M24 Incompletely characterized (D) RPGQWL
CD-028 B1 M11 Incompletely characterized (D) DRTGQGL
M16 539G->A 539G->A Transition (1)
M23 113C->T 113C->T Transition (1)
M30 Exclusion of bp 120_134 Exon 2: 120_134del15 120_134del15 Microdeletion (9)
M32 626G->T 626G->T Transversion (4) LITGV
M33 Exclusion of bp 610_626 Exon 9: 610-1G->A 610-1G->A Transition (1) VKGFAN
CD-019 B1 M2 325C->T 325C->T Transition (1) KRDSTA, DWRGGP
M3 Exclusion of Exons 2-6 Exon 2: 100_134+28del64, No 
mutation in Exons 3-6
100_134+28del64 Microdeletion (9) S
M4 Exclusion of Exons 2-6 No mutation in Exons 2-6; No 
mutation in Exons 2-4, 6; Do Exon 
5
Incompletely characterized (D)
CD-053 B1 M9 Exclusion of exon 8; 97, 173G->A Exon 8: 609+5G->A; No mutation 
in Exons 2, 3
609+5G->A Transition (1)
M13 35_52del18 35_52del18 Microdeletion (9) QGGSL
M14 419G->A Exon 6: 419G->A 419G->A Transition (1) QGGSL
M15 419G->A No mutation in Exon 3 419G->A Transition (1) QGGSL
M34 419G->A 419G->A Transition (1) QGGSL
M42 Exclusion of Exon 8 Exon 8: 609+5G->A 609+5G->A Transition (1) PLAGGSG
M43 419G->A 419G->A Transition (1) QGGSL
M45 REPEAT 2ND RD PCR Incompletely characterized (D) ASGA
M52 419G->A; 501, 599hetG/A Do not need to sequence Exons 7, 
8
419G->A Transition (1) QGGSL
M56 Exclusion of Exon 8 Exon 8: 609+5G->A 609+5G->A Transition (1)
CD-025 B1 M1 Incompletely characterized (D) LQPAEGTSGRN
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M4 400G->A 400G->A Transition (1) EGAGGL
M6 539G->A 539G->A Transition (1) SARG
M8 602A->T 602A->T Transversion (6)
M9 All Exons present; No mutations in 
Exons 1, 2, 9
Incompletely characterized (B) PGQTP
 CD-007 B1 M2 Exclusion of Exons 2-6; 617G->A No mutation in Exons 2-6 617G->A Transition (1) MRGGR
CD040 B1 M4 135G->T 135G->T Transversion (4) SIGVGWG
M10 No mutation in Exons 7, 8 Incompletely characterized (D)
M11 Exclusion of Exon 4 No mutation in Exon 4 Presumed deletion of Exon 4 Incompletely characterized (A) PAGRG
M14 Exclusion of Exon 4 No mutation in Exon 4 Presumed deletion of Exon 4 Incompletely characterized (A) KKGLS
M17 No mutation No mutations in Exons 2-4 No mutation Incompletely characterized (C)
M20 Exclusion of Exon 8 No mutation in Exon 3, Exon 8: 
533-2A->G
533-2A->G Transition (2)
M22 463C->T 463C->T Transition (1) VDNQGAR
M32 Exclusion of bp 610 Exon 9: 610delC 610delC Microdeletion (9)
M33 454C->T 454C->T Transition (1) DLTGSV
M35 No mutation in Exon 2; Do Exon 3 Incompletely characterized (D) YG
 CD-014 B1 M3 Exclusion of Exon 4 Exon 4: 319-2A->G 319-2A->G Transition (2)
M4 AGGEKVP
M5 Exclusion of Exon 8 Exon 8: 609+5G->A 609+5G->A Transition (1) VGGSK, QEG
M6 Exclusion of Exon 2 No mutations in Exons 1, 3, 4, 6-9 
; Wait for Exon 5; Exon 
2:134+1hetG/A
134+1G->A (mixed) Incompletely characterized (D) VGGSK
M9 551C->T 551C->T 551C->T
M10 542T->G 542T->G Transversion (7)
M11 113C->T No mutation in Exon 3 113C->T Transition (1) CSTTLGQG
M12 568G->A 568G->A Transition (1) LARLLRTD
M14 VGGSK
M16 118G->A 118G->A
M17 209G->A 209G->A SEGGGITY
M18 113C->T 113C->T CSTTLGQG
M19 QQGG
M20 Exclusion of Exon 4 Exon 4: 384+1G->A 384+1G->A Transition (1) SATA
M21 VGGSK




M31 Deletion of Exons 4-9 Deletion of Exons 4-9 Exon Deletion (8) VGGSK
M37 518G->A; 632delC 518G->A; 632delC
M44 542T->G 542T->G IEVGGRAWG
M46 612T->G 612T->G Transversion (7) YGTSD
M48 Incompletely characterized (D) VGGSK
 CD-009 B1 M1 614T->A 614T->A
M3 614T->A 614T->A
M4 614T->A 614T->A PVRGPSG
M5 614T->A 614T->A YWGR
M6 614T->A 614T->A RRTL
M8 614T->A 614T->A RAGQSAT
 Treated Adults with Crohn's Disease (N=15) 
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M9 614T->A 614T->A RPGLAGGW
M11 614T->A 614T->A
M12 614T->A 614T->A Transversion (6)
M14 614T->A 614T->A DPGTGGPY
M15 614T->A 614T->A DHDRGA
M16 614T->A 614T->A Transversion (6) LGQGAR
M20 614T->A 614T->A RRSGT
M21 614T->A 614T->A TRLS
M22 614T->A 614T->A ALAS
M24 614T->A 614T->A NMYN
M25 QRGTGR
M27 614T->A 614T->A GQGG, GTGTR
M30 614T->A 614T->A SLGL
M31 614T->A 614T->A Transversion (6) ILGGN
M32 197G->T 197G->T
M33 614T->A 614T->A Transversion (6) GAGRLF
M34 614T->A 614T->A
M35 614T->A 614T->A TRLS
M37 614T->A 614T->A LELAD
M38 614T->A 614T->A LVQPGRTG
M41 614T->A 614T->A Transversion (6)
M42 614T->A 614T->A
M43 614T->A 614T->A nonfunctional
M44 614T->A 614T->A
M51 614T->A 614T->A ASGTP
M55 LF
M62 614T->A 614T->A ASGTP
M70 614T->A 614T->A Transversion (6)
M82 614T->A 614T->A Transversion (6)
M84 614T->A 614T->A ASGTP
M88 RRTGAT
M91 614T->A 614T->A
M103 614T->A 614T->A Transversion (6) VALGE
M104 614T->A 614T->A
M108 614T->A 614T->A
M110 614T->A 614T->A SLIG
M117 614T->A 614T->A Transversion (6)
CD-051 B1 M1 419G->A 419G->A Transition (1) RSNT
M3 419G->A 419G->A Transition (1) RSNT
M4 Deletion of Exon 1 Deletion of Exon 1 Exon deletion (8) LPGREEA
M5 419G->A 419G->A Transition (1) RSNT
M6 419G->A 419G->A Transition (1) RSNT
M8 419G->A 419G->A Transition (1) RSNT
M9 Exon 8: 533-7_563del38 533-7_563del38 Microdeletion (9) FPGPY
CD-037 B1 M4 463C->T 463C->T Transition (1)
M12 49T->G 49T->G Transversion (7)
M14 152G->C 152G->C Transversion (5) GVGL
M15 151C->T 151C->T CpG Transition (3) RGGQGAS
M19 Exon 2: 28-1G->A 28-1G->A Transition (1)
M24 Exclusion of Exon 2, 3 No mutation in Exon 2 Presumed deletion of Exon 2 Incompletely characterized (A)
M25 No mutation in Exon 4; Exon 
6:419hetG/A
419G->A Transition (1)
M27 152G->C 152G->C Transversion (5) GVGL
M29 152G->C No mutation in Exon 4 152G->C Transversion (5) GVGL
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M41 51T->G 51T->G 51T->G Transversion (7)
CD-023 B1 M3 Exclusion of Exon 6 Exon 6: 485 G->A 485G->A Transition (1) FGRAY
M11 Exclusion of Exon 7 Exon 7: 489_509del21 489_509del21 Microdeletion (9)
M15 Exclusion of Exon 5 No mutation in Exon 5 Presumed deletion of Exon 5 Incompletely characterized (A)
M22 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) SGSYG
M24 146T->A 146T->A Transversion (6)
M27 151C->T 151C->T CpG Transition (3) EGQHPY, RTSGGD
M32 Exclusion of Exons 2, 3, 6 No mutation in Exons 2, 3, 6 Presumed deletion of Exon 6 Incompletely characterized (A) SGSYG
M34 Exclusion of Exon 5 Exon 5: 385-2 A->G 385-2A->G Transition (2) SGSYG
 CD-005 B1 M1 463_464CC->TT; 255hetG/A No mutation in Exon 3 463_464CC->TT Tandem (13) LVTGV
M3 REPEAT 2ND RD PCR Incompletely characterized (D) SPSSGQV
M4 584_603delATAATGAATACTTCAGGGATin
sCTAA; 96hetG/A
No mutation in Exon 2 584_603delATAATGAATACTTCAGGGA
TinsCTAA
Deletion/Insertion (12) DWRGGP
M5 3G->A 3G->A Transition (1)
CD-003 B1_2 M1 212dupG Exon 3: 212dupG 212dupG
M2 325lossC Exon 4: 325lossC 325losC LPWGFA
M3 Exclusion of Exon 8 Exon 8: 533-3T->G 533-3T->G Transversion (7) YSTR
M4 151C->T 151C->T
M5 Exclusion of Exon 8 YSTR
M6 SDHGTLR
M8 508C->T 508C->T SFIAGG
M9 197G->A 197G->A QWDRG
M10 541T->C 541T->C NRRTGLI
M11 NRRTGLI
M12 NRRTGLI
M13 463C->T 463C->T AGGRG
M14 QRTE
M16 541T->C 541T->C VGGRDP, DRPS
M19 197G->A Exon 3: 197G->A 197G->A LGQK
M20 Exclusion of Exon 4 GASF
M21 113C->T Exon 2: 113C->T 113C->T MDLVS




M26 133delA Exon 2: 133delA 133delA SGTD
M27 166G->T Exon 3: 166G->T 166G->T RTA
M29 400G->A Exon 5: 400G->A 400G->A LAGS
M30 32_50delGTGATGATGAACCAGGTTA Exon 2: 
32_50delGTGATGATGAACCAGGTTA
32_50delGTGATGATGAACCAGGTTA RHSLAGVP
M31 151C->T Exon 3: 151C->T 151C->T
M32 Exclusion of Exon 7 MDLVS
M33 151C->T Exon 3: 151C->T 151C->T TSEREVGNQP
M34 RGTSGTT
M35 151C->T 151C->T
M36 463C->T 463C->T Transition (1) NSG
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M42 212G->T 212G->T Transversion (4) ATRDS
M46 151C->T 151C->T CpG Transition (3)
M52 197G->A 197G->A Transition (1)
M54 Exclusion of Exon 7 Exon 7: 486-8_507del29 486-8_507del29 Microdeletion (9)
M60 Exclusion of Exon 7 Exon 7: 532+1G->A 532+1G->A Transition (1) GKTGGSIGI
M83 Exclusion of Exon 6 Exon 6: 403-1G->A 403-1G->A Transition (1) RDRRAG
CD-036 B1 M1 3G->A 3G->A Transition (1)
M2 600G->A 600G->A Transition (1) GGGG
M3 27G->A; Inclusion of bp 27+1_27+49 27G->A Transition (1) SGLEGLF, AMGSGRVG
CD-046 B1 M1 All Exons present; Exon 1: 27+1G-
>A; No mutation in Exon 9
27+1G->A Transition (1)
M2 197G->A 197G->A Transition (1)
M3 51T->G No mutation in Exon 2 51T->G Transversion (7)
M5 305T->G No mutation in Exon 2 305T->G Transversion (7) QGQPPN
M6 Exclusion of Exon 8 Exon 8: 533-2A->G 533-2A->G Transition (2) EGGGG
M7 617G->A 617G->A Transition (1) FAVGLAGGQSR
 CD-006 B1 M2 ASGTGLL
M3 508C->T 508C->T







M20 151C->T 151C->T CpG Transition (3) QTGA
M23 SEPGY
M24 200T->A 200T->A PQDRVT
M25 LVQGS






 M37 Exclusion of Exon 7 Exon 7: 486-1G->T 486-1G->T Transversion (4) RGGTSGP
M39 Exclusion Exons 2, 3; Exclusion of Exon 
5
No mutation in Exons 2, 3; Exon 
5: 385-2A->G
385-2A->G Transition (2)
M40 152G->C 152G->C LGAAA
M41 481G->C 481G->C Transversion (5) AEDRG
M47
M53 122delT 122delT
 M54 Exclusion of Exon 8; 127het peaks No mutation in Exon 2; Exon 8: 
533-2A->G
533-2A->G Transition (2) SEPGY
 M65 TPRE
 M66 569G->T 569G->T
 M67 205A->T 205A->T QDGQIDG
 M82 151C->T 151C->T
CD041 B1 M2 Exclusion of Exon 8; 21, 152, 202 
hetC/T and G/A
Exon 8: 550_551CC->TT; No 
mutation in Exons 1, 3
550_551CC->TT Tandem (13) TLMD
M6 152G->A 152G->A Transition (3) DGA
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M14 146T->G 146T->G Transversion (7) QSGTTQ
M18 617G->T; 366, 490 hetC/T; 617G->T 
Reamp of 1st RD
No mutation in Exons 4, 7, 8 617G->T Transversion (4) PDRARW
 CD-010 B1_2 M1 100losA 100losA Loss (10) VKAVVE
M10 Exclusion of Exons 4-6 No mutations in Exons 4, 5, 6 Presumed deletion of Exons 4-6 Incompletely characterized (A) TPVRTGTGY
M15 Exclusion of Exon 4 Exon 4: 319-4_319-14del11 319-4_319-14del11 Microdeletion (9)
M16 Middle band: 197G->A 197G->A Transition (1) LIGQGS
M18 449T->G 449T->G Transversion (7)
M20 151C->T
M28 197G->A 197G->A Transition (1) LIGQGS
M29 SPGTPQ
M31 590A->T NLVGI
M33 Exclusion of Exon 4 Exon 4: 319-4_319-14del11 319-4_319-14del11 Microdeletion (9)
M34 197G->A 197G->A Transition (1) LIGQGS
M38 151C->T 151C->T




 CD-012 B1 M1 Exclusion of Exon 8 Exon 8: 609+5G->A 609+5G->A Transition (1)
M2 Exclusion of Exon 4 Exon 4: 319-2A->G 319-2A->G Transition (2) RDLAGG
M4 Exclusion of bp 134 or 135 Exon2: 134delG 134delG Microdeletion (9) TPPRGGSGG
CD043 B1 M3 All Exons present; No mutation in 
Exons 1, 9, X6: 403-1 G->A 
403-1 G->A Transition (1) TATG
M6 Exclusion of Exons 2, 3; 529, 544 G->A Exon 2: 134+1G->A; No mutation 
in Exons 3, 7, 8
134+1G->A Transition (1)
M15 Exclusion of G Exon 6: 403-1 G->A 403-1 G->A Transition (1) TATG
M24 463C->T 463C->T Transition (1)
M25 618T->G; 97,379,399G->A No mutation in Exon 4; Exons 2, 5, 
9
618T->G Transversion (7) SLSGTGGH
CD-034 B1 M15 618T->G; mixed in middle No mutation in Exons 6, 7, 8 618T->G Transversion (7) LGVTR
M16 539G->A 539G->A Transition (1) ATS
M18 Exclusion of bp 610_626 Exon 9: 610-1 G->A 610-1G->A Transition (1)
M20 No mutations in Exons 2-4; Exon 
6: 420delC, waiting for X5
420delC Microdeletion (9) GSGTPVG
M21 539G->A 539G->A Transition (1) ATS
M25 569G->A; 502hetC/T 569G->A Transition (1) SDY
M27 143G->C 143G->C Transversion (5)
M29 Exclusion of Exon 4 Exon 4: 319-2A->G 319-2A->G Transition (2) SGGL
M30 Exclusion of Exons 4, 5 DO GENOMIC PCR  Exons 4, 5 
(SEQ X4)
Incompletely characterized (D)
M35 Exclusion of Exon 2-4 Exon 4: 351dupT, No mutation in 
Exons 2, 3
351dupT Duplication (10) GPVG
CD-038 B1 M5 208G->A Exon 3: 208G->A 208G->A Transition (1) GGSGA
M10 All Exons present; No mutation in 
Exons 1, 9
Incompletely characterized (B) STH
M16 47G->A 47G->A Transition (1) STH
M18 3G->A 3G->A Transition (1) HYLVGSGTLP
M26 Incompletely characterized (D) STH
M36 568 G->A 568G->A Transition (1) APGGN
M45 3G->A No mutation in Exon 3 3G->A Transition (1) HYLVGSGTLP
M48 151C->T 151C->T CpG Transition (3)
M57 Incompletely characterized (D) STH
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M58 3G->A 3G->A Transition (1) HYLVGSGTLP
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Regionc




 Transition (1) G:C->A:T at nonCpG dinucleotides
Transition (2) A:T->G:C
CpG Transition (3) G:C->A:T at CpG dinucleotides
Transversions





Exon Deletion (8) Also considered as macrodeletion.  Methodology does not determine exact breakpoints of exon deletion.
Microdeletion (9) Deletion of 1 nucleotide or greater, but smaller than exon deletion.  Breakpoints are determined within exon or intron region.
Duplication or Loss (10) Expansion or contraction of nucleotide repeat tract (ie. mono-, di-, tri-, tetranucleotide, etc…)
Insertion (11) Insertion of new nucleotides into the original nucleotide sequence.
Deletion and Insertion (12) Deletion of original nucleotides and insertion of new nucleotides.
Tandem (13) Mutation involving consecutive nucleotides.
Incompletely characterized (16) Mutations that were not completely characterized for the following reasons.
(A) Exon exclusion in Females, Methods do not reveal mutation.
(B) No HPRT message, no mutation in X1 and X9.
(C) HPRT message without mutation.
(D) Incomplete analysis of mutant.
cTCRβ CDR3 Region
Nucleotide sequences of TCRβ CDR3 regions were blasted against reference TCRβ gene sequence (gi 21536269) to determine specific V, D, and J regions recombined by 
VDJ-recombinase.  These nucleotide sequences were then translated into amino acids.
Different patterns of clonal expansion are schematized in Supplemental Figure 1.
When only HPRT mutation or TCRβ CDR3 region is available, mutants with the same mutation or TCRβ CDR3 region are considered siblings.
Similar color highlights of HPRT mutation and/or TCRβ indicate clones that are siblings of one another according to one of the depicted relationships in Supplemental Figure 1.
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Subject Gender Age Mutant Frequency 
(10-6)
Class of Mutation Mutant Number cDNA Genomic
BF001B1 M 10.7 2.0 Transversion (4) M3 c.486C>A
BF001B1 M 10.7 2.0 Exon Deletion (8) M4  Deletion of exon(s) 5
BF001B1 M 10.7 2.0 Microdeletion (9) M1 c.549delT
BF001B1 M 10.7 2.0 Insertion (11) M2 c.589_590insT
BF012B1 F 9.0 9.0 Transition (1) M13 c.212G>A
BF012B1 F 9.0 9.0 Transition (1) M2 c.113C>T
BF012B1 F 9.0 9.0 Deletion/Insertion (12) M1 c.568_569delGGinsAA
BF012B1 F 9.0 9.0 Deletion/Insertion (12) M10 c.568_569delGGinsAA
BF012B1 F 9.0 9.0 Deletion/Insertion (12) M3 c.568_569delGGinsAA
BF012B1 F 9.0 9.0 Deletion/Insertion (12) M4 c.568_569delGGinsAA
BF012B1 F 9.0 9.0 Deletion/Insertion (12) M6 c.568_569delGGinsAA
BF012B1 F 9.0 9.0 Deletion/Insertion (12) M7 c.568_569delGGinsAA
BF012B1 F 9.0 9.0 Deletion/Insertion (12) M8 c.568_569delGGinsAA
BF012B1 F 9.0 9.0 Deletion/Insertion (12) M9 c.568_569delGGinsAA
BF015B1 F 7.7 8.7 Transversion (7) M1 c.389T>G
BF015B1 F 7.7 8.7 Microdeletion (9) M3 Exclusion:   Range: 1-14 g.1668_1685del18
BF015B1 F 7.7 8.7 Microdeletion (9) M4 Exclusion:   Range: 1-6 g.1666_1682del17
BF018B1 M 8.7 0.5 Transition (1) M1 Exclusion: 8 g.40115G>A
BF023B1 F 7.5 1.4 Transversion (4) M3 c.434C>A
BF023B1 F 7.5 1.4 Duplication (10) M2 c.304dupC
BF048B1 M 8.9 2.2 Transition (1) M4 c.209G>A
BF053B1 M 6.4 5.4 Transition (1) M4 c.3G>A
BF058B1 F 10.9 0.8 Transition (1) M1 Exclusion: 2,3 g.14779G>A
BF064B1 M 8.1 4.1 Transition (1) M10 c.568G>A
BF064B1 M 8.1 4.1 CpG Transition (3) M1 c.151C>T
BF064B1 M 8.1 4.1 CpG Transition (3) M12 c.151C>T
BF064B1 M 8.1 4.1 Transversion (4) M4 c.575C>A
BF064B1 M 8.1 4.1 Transversion (5) M19 c.569G>C
BF064B1 M 8.1 4.1 Transversion (7) M15 c.284T>G
BF064B1 M 8.1 4.1 Exon Deletion (8) M16  Deletion of exon(s) 3
BF064B1 M 8.1 4.1 Exon Deletion (8) M18  Deletion of exon(s) 2
BF064B1 M 8.1 4.1 Exon Deletion (8) M20  Deletion of exon(s) 5
Children 6-11 yrs.
Supplementary Table 3:
Summary of HPRT Mutations from Normal Childrena
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(10-6)
Class of Mutation Mutant Number cDNA Genomic
BF064B1 M 8.1 4.1 Exon Deletion (8) M5  Deletion of exon(s) 6
BF064B1 M 8.1 4.1 Insertion (11) M17 c.499_500insA
BF101B1 M 9.1 3.3 Incompletely Characterized (16) M3 Exclusion: 2,3,4,5,6,7,8,9
BF105B1 M 6.8 2.0 Transversion (6) M2 c.466A>T
BF105B1 M 6.8 2.0 Transversion (7) M4 c.484A>C
BF109B1 M 10.5 21.0 Exon Deletion (8) M3  Deletion of exon(s) 1,2,3,4,5,6,7,8,9
BF124B1 F 10.0 8.0 Insertion (11) M1 c.502_503insG
BF124B1 F 10.0 8.0 Incompletely Characterized (16) M2 Exclusion: 8
BF004B1 M 13.2 7.0 Transversion (6) M2 Exclusion:   Range: 610-626 g.41453A>T
BF004B1 M 13.2 7.0 Exon Deletion (8) M3  Deletion of exon(s) 6
BF005B1 F 13.9 1.2 Transition (1) M4 c.617G>A
BF005B1 F 13.9 1.2 Transversion (7) M2 c.136A>C
BF006B1 F 12.5 1.9 Microdeletion (9) M3 c.165_169delGGAGA
BF006B1 F 12.5 1.9 Loss (10) M5 c.402losA
BF006B1 F 12.5 1.9 Incompletely Characterized (16) M6 Exclusion: 8
BF006B1 F 12.5 1.9 Incompletely Characterized (16) M7 Exclusion: 2,3
BF007B1 M 12.5 4.0 Transition (1) M7 c.212G>A
BF007B1 M 12.5 4.0 Transversion (4) M6 c.135G>T
BF007B1 M 12.5 4.0 Transversion (5) M1 c.648C>G
BF007B1 M 12.5 4.0 Transversion (5) M2 Exclusion: 7 g.39813C>G
BF007B1 M 12.5 4.0 Exon Deletion (8) M10  Deletion of exon(s) 7,8,9
BF007B1 M 12.5 4.0 Exon Deletion (8) M5  Deletion of exon(s) 4
BF007B1 M 12.5 4.0 Exon Deletion (8) M9  Deletion of exon(s) 1,2,3,4,5,6,7,8,9
BF007B1 M 12.5 4.0 Incompletely Characterized (16) M8 Exclusion: 8
BF019B1 F 13.2 4.0 Transition (1) M10 Inclusion: 1+1 to 1+49 g.1704G>A
BF019B1 F 13.2 4.0 Transversion (6) M5 Exclusion: 8 g.40093T>A
BF021B1 F 15.2 4.3 CpG Transition (3) M10 c.508C>T
BF021B1 F 15.2 4.3 Transversion (4) M3 Exclusion: 7 g.39863G>T
BF021B1 F 15.2 4.3 Transversion (4) M5 Exclusion: 7 g.39863G>T
BF102B1 F 13.5 3.4 Transition (1) M2 g.27891G>A
BF102B1 F 13.5 3.4 Transversion (4) M4 c.617G>T
BF102B1 F 13.5 3.4 Microdeletion (9) M2 Exclusion: 2,3,4 g.27942_27957del16
BF104B1 M 15.7 4.2 Transversion (5) M1 Exclusion: 7 g.39813C>G
BF104B1 M 15.7 4.2 Exon Deletion (8) M5  Deletion of exon(s) 4,5,6,7,8,9
Children 12-16 yrs.
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BF113B1 F 13.5 6.5 Transition (1) M1 c.568G>A
BF113B1 F 13.5 6.5 Transition (1) M2 c.580G>A
BF113B1 F 13.5 6.5 Transversion (5) M5 c.190G>C
BF113B1 F 13.5 6.5 Loss (10) M4 c.484losA
122
Number ID SUBJECT SEX AGE MF CLASS BP_CHANG CDNA_ALT BP_POSIT DELETE_E REFERENCEc
311 2000H Male 23 20.0 Transition (1) g>a 580 1
303 900H Male 29 21.0 Transition (1) g>a 3 1
304 900H Male 29 21.0 Transition (1) g>a E8 loss 1
306 900H Male 29 21.0 Transition (1) g>a 134 1
79 sf21.1 Female 25 7.0 Transition (1) g>a 617 2
118 sm25.1 Male 22 7.0 Transition (1) C>T 74 2
69 nm28.1 Male 23 4.0 Transition (1) g>a 197 2
94 sm30.1 Male 24 7.0 Transition (1) g>a E4 loss 2
93 nm19.1 Male 31 5.0 Transition (1) g>a 400 2
105 sm5.1 Male 38 2.0 Transition (1) g>a 208 2
248 sf32 Female 29 5.0 Transition (1) g>a 617 4
244 nf45 Female 31 10.0 Transition (1) g>a E6 loss 4
241 sf33 Female 31 10.0 Transition (1) g>a I5 partia 4
245 sf34 Female 31 10.0 Transition (1) g>a 599 4
247 nf3 Female 45 4.0 Transition (1) g>a 3 4
243 nf43 Female 46 16.0 Transition (1) C>T 202 4
207 nm37 Male 20 4.0 Transition (1) g>a E8 loss 4
219 nm31 Male 21 5.0 Transition (1) g>a 197 4
229 nm29 Male 23 5.0 Transition (1) g>a 197 4
222 sm2 Male 25 14.0 Transition (1) g>a E7 loss 4
212 nm46 Male 26 19.0 Transition (1) C>T 551 4
238 nm17 Male 26 8.0 Transition (1) g>a 209 4
216 nm30 Male 27 5.0 Transition (1) g>a 617 4
231 nm35 Male 27 3.0 Transition (1) C>T 325 4
226 nm11 Male 29 9.0 Transition (1) g>a 197 4
214 sm45 Male 31 7.0 Transition (1) g>a 4
251 sm64 Male 32 12.0 Transition (1) g>a 212 4
215 sm77 Male 37 5.0 Transition (1) g>a 197 4
223 sm82 Male 37 13.0 Transition (1) g>a 197 4
208 sm79 Male 38 8.0 Transition (1) g>a 134 4
218 sm100 Male 39 12.0 Transition (1) g>a E2-3 loss 4
233 nm38 Male 40 4.0 Transition (1) g>a I5 partia 4
235 nm38 Male 40 4.0 Transition (1) g>a 617 4
213 sm41 Male 40 15.0 Transition (1) C>T E8 loss 551 4
224 sm91 Male 41 12.0 Transition (1) g>a 197 4
209 sm108 Male 42 11.0 Transition (1) g>a E3 loss 4
242 sm92 Male 43 14.0 Transition (1) g>a E8 loss 4
Supplementary Table 3:
Summary of HPRT Mutations from Normal Adultsb
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230 sm38 Male 45 18.0 Transition (1) g>a E7 loss 4
221 sm113 Male 46 6.0 Transition (1) C>T 463 4
236 sm75 Male 48 17.0 Transition (1) g>a E8 (5') - 4
225 sm90 Male 50 19.0 Transition (1) C>T 145 4
314 325 Male 50 13.0 Transition (1) C>T 464 5
319 325 Male 50 13.0 Transition (1) g>a 3 5
320 325 Male 50 13.0 Transition (1) g>a 539 5
334 325 Male 50 13.0 Transition (1) g>a 134 5
338 325 Male 50 13.0 Transition (1) g>a 208 5
341 325 Male 50 13.0 Transition (1) g>a 3 5
6 17S Female 37 3.0 Transition (1) g>a 580 6
297 42H Male 22 Transition (1) g>a E2-3 loss 7
286 89F42 Male 24 19.0 Transition (1) g>a 47 7
289 20A Male 25 Transition (1) g>a 212 7
296 53H Male 55 Transition (1) g>a 3 7
739 1M0 Female 66 27.0 Transition (1) g>a 197 8
752 14M0 Female 70 33.0 Transition (1) g>a 212 8
726 4M0 Male 55 78.0 Transition (1) g>a 197 8
786 4M0 Male 55 78.0 Transition (1) C>T 145 8
738 7M0 Male 62 34.0 Transition (1) C>T 454 8
777 7M0 Male 62 34.0 Transition (1) g>a 617 8
780 7M0 Male 62 34.0 Transition (1) g>a 568 8
773 3M0 Male 63 132.0 Transition (1) g>a 617 8
760 9M0 Male 77 28.0 Transition (1) g>a 3 8
778 9M0 Male 77 28.0 Transition (1) g>a 569 8
753 18M0 Male 82 45.0 Transition (1) C>T 74 8
59 16EO Female 75 18.0 Transition (1) g>a 400 9
39 22EO Male 66 32.0 Transition (1) g>a 197 9
28 8EO Male 68 73.0 Transition (1) g>a 380 9
14 9EO Male 69 9.0 Transition (1) g>a 617 9
32 3EO Male 77 25.0 Transition (1) g>a 212 9
13 24EO Male 78 26.0 Transition (1) g>a 197 9
51 1EO Male 80 18.0 Transition (1) g>a 173 9
52 1EO Male 80 18.0 Transition (1) g>a 27 9
694 V128 Male 31 6.0 Transition (1) g>a 192 10
698 V127 Male 31 11.0 Transition (1) g>a 190 10
711 V127 Male 31 11.0 Transition (1) g>a 189 10
713 V127 Male 31 11.0 Transition (1) g>a 193 10
672 V124 Male 39 5.0 Transition (1) g>a 197 10
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697 K28 Male 44 15.0 Transition (1) g>a 189 10
718 K33 Male 52 20.0 Transition (1) g>a E8 loss 10
695 K25 Male 54 11.0 Transition (1) g>a 193 10
645 K27 Male 23 6.0 Transition (1) g>a 599 11
547 K34 Male 30 6.0 Transition (1) g>a 568 11
625 K34 Male 30 6.0 Transition (1) g>a 47 11
636 K32 Male 30 1.0 Transition (1) g>a 47 11
571 V127 Male 31 11.0 Transition (1) g>a 617 11
612 K37 Male 32 5.0 Transition (1) g>a 539 11
642 K26 Male 33 5.0 Transition (1) g>a 197 11
559 V123 Male 35 6.0 Transition (1) g>a 209 11
551 K29 Male 36 6.0 Transition (1) g>a 539 11
584 K29 Male 36 6.0 Transition (1) g>a 208 11
602 V148 Male 37 9.0 Transition (1) g>a 173 11
569 V133 Male 38 14.0 Transition (1) C>T 464 11
601 V150 Male 38 3.0 Transition (1) g>a 119 11
638 V150 Male 38 3.0 Transition (1) g>a 197 11
640 V150 Male 38 3.0 Transition (1) g>a 208 11
610 K28 Male 44 15.0 Transition (1) g>a 197 11
588 K33 Male 52 20.0 Transition (1) C>T 463 11
624 V141 Male 52 16.0 Transition (1) C>T 454 11
650 V132 Male 52 9.0 Transition (1) g>a 617 11
590 K25 Male 54 11.0 Transition (1) g>a 209 11
575 V143 Male 61 8.0 Transition (1) g>a 119 11
600 V143 Male 61 8.0 Transition (1) g>a 617 11
615 V137 Male 63 7.0 Transition (1) C>T 463 11
570 V136 Male 64 23.0 Transition (1) g>a 197 11
472 E Male 23 5.0 Transition (1) g>a 400 12
473 E Male 23 5.0 Transition (1) g>a 599 12
495 E Male 23 5.0 Transition (1) g>a 212 12
497 E Male 23 5.0 Transition (1) g>a 617 12
396 87ES Male 31 6.0 Transition (1) g>a 197 13
404 88FG Male 39 4.0 Transition (1) g>a 197 13
395 88FX Male 40 25.0 Transition (1) g>a 3 13
283 13S Male 58 2.0 Transition (1) g>a 568 14
280 12S Male 59 5.0 Transition (1) C>T 610 14
263 Male 60 Transition (1) g>a 85 14
262 5S Male 70 13.0 Transition (1) g>a E2-3 loss 238 14
254 3S Male 73 6.0 Transition (1) g>a 197 14
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142 BC67 Female 35 15.0 Transition (1) g>a 568 15
370 34S Male 29 6.0 Transition (1) C>T E8 loss 551 16
374 34S Male 29 6.0 Transition (1) g>a E4 loss 16
375 437S Male 30 26.0 Transition (1) g>a E6 1st bp 16
350 42S Male 56 6.0 Transition (1) g>a E8 loss o 16
371 42S Male 56 6.0 Transition (1) C>T E8 loss 551 16
376 42S Male 56 6.0 Transition (1) g>a E6 loss 485 16
451 89MA Male 19 4.0 Transition (1) g>a 197 17
461 90MX Male 33 10.0 Transition (1) g>a E8 loss 17
426 89LN Male 39 6.0 Transition (1) g>a 285 17
427 89LN Male 39 6.0 Transition (1) C>T 464 17
449 88EZ Male 39 14.0 Transition (1) C>T 463 17
452 89LX Male 41 12.0 Transition (1) g>a 538 17
301 4215H Male 22 22.0 Transition (2) T>C 440 1
84 sf6.1 Female 20 8.0 Transition (2) T>C 233 2
78 sm6.1 Male 29 12.0 Transition (2) a>g E9 loss ( 2
239 sf27 Female 30 19.0 Transition (2) T>C 194 4
232 nf39 Female 35 6.0 Transition (2) A>G 611 4
234 nf40 Female 41 12.0 Transition (2) A>G 611 4
165 sm47 Male 26 7.0 Transition (2) A>G 499 4
166 sm34 Male 26 6.0 Transition (2) A>G 496 4
250 nm35 Male 27 3.0 Transition (2) A>G 404 4
152 nm91g Male 31 6.0 Transition (2) a>g E5 loss 4
220 sm73 Male 36 10.0 Transition (2) T>C 488 4
151 sm43 Male 37 18.0 Transition (2) a>g E9 loss 4
246 sm41 Male 40 15.0 Transition (2) T>C 194 4
210 sm95 Male 41 5.0 Transition (2) a>g E9 loss 4
249 sm62 Male 45 18.0 Transition (2) a>g E4 loss 4
340 325 Male 50 13.0 Transition (2) A>G 131 5
755 1M0 Female 66 27.0 Transition (2) A>G 611 8
771 1M0 Female 66 27.0 Transition (2) T>C 110 8
774 1M0 Female 66 27.0 Transition (2) T>C 437 8
756 14M0 Female 70 33.0 Transition (2) A>G 545 8
725 4M0 Male 55 78.0 Transition (2) A>G 611 8
791 7M0 Male 62 34.0 Transition (2) A>G 133 8
36 16EO Female 75 18.0 Transition (2) A>G 530 9
34 8EO Male 68 73.0 Transition (2) A>G 611 9
30 15EO Male 83 15.0 Transition (2) A>G 611 9
666 K34 Male 30 6.0 Transition (2) a>g E8 loss 10
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663 K30 Male 35 9.0 Transition (2) a>g 197 10
668 K30 Male 35 9.0 Transition (2) a>g E8 loss 10
709 V135 Male 37 9.0 Transition (2) a>g 192 10
667 K36 Male 40 7.0 Transition (2) t>c 193 10
627 K27 Male 23 6.0 Transition (2) T>C 236 11
603 K26 Male 33 5.0 Transition (2) T>C 146 11
620 V123 Male 35 6.0 Transition (2) T>C 146 11
607 V135 Male 37 9.0 Transition (2) A>G 611 11
617 V119 Male 38 14.0 Transition (2) A>G 131 11
555 V129 Male 45 5.0 Transition (2) A>G 475 11
619 V145 Male 45 8.0 Transition (2) T>C 236 11
552 V131 Male 46 4.0 Transition (2) T>C 146 11
608 V131 Male 46 4.0 Transition (2) T>C 122 11
592 K25 Male 54 11.0 Transition (2) T>C 146 11
593 K25 Male 54 11.0 Transition (2) A>G 131 11
550 V140 Male 64 8.0 Transition (2) T>C 146 11
564 V140 Male 64 8.0 Transition (2) T>C 95 11
475 E Male 23 5.0 Transition (2) A>G 499 12
476 E Male 23 5.0 Transition (2) A>G 505 12
491 E Male 23 5.0 Transition (2) T>C 491 12
410 87ET Male 37 7.0 Transition (2) T>C 65 13
256 Male 60 Transition (2) T>C 533 14
264 1S Male 74 3.0 Transition (2) T>C 233 14
123 BC8 Female 25 15.0 Transition (2) T>C 82 15
131 BC67 Female 35 15.0 Transition (2) A>G 611 15
128 BC5 Male 50 14.0 Transition (2) T>C 49 15
360 34S Male 29 6.0 Transition (2) T>C 65 16
361 34S Male 29 6.0 Transition (2) a>g E2-3 loss 16
358 42S Male 56 6.0 Transition (2) t>c I5 67bps 16
424 89MA Male 19 4.0 Transition (2) A>G 133 17
460 89LO Male 31 1.0 Transition (2) A>G 131 17
77 nf4.1 Female 33 12.0 CpG Transition (3) C>T 508 2
240 sf30 Female 24 7.0 CpG Transition (3) C>T 151 4
217 nm33 Male 22 1.0 CpG Transition (3) C>T 508 4
228 nm8 Male 28 26.0 CpG Transition (3) g>a 143 4
211 nm22 Male 31 11.0 CpG Transition (3) C>T 508 4
227 nm18 Male 32 7.0 CpG Transition (3) C>T 508 4
237 sm97 Male 36 14.0 CpG Transition (3) C>T 508 4
290 89F42 Male 24 19.0 CpG Transition (3) C>T 151 7
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287 61H Male 35 CpG Transition (3) C>T 151 7
298 22H Male 57 CpG Transition (3) g>a 143 7
724 14M0 Female 70 33.0 CpG Transition (3) C>T 508 8
787 3M0 Male 63 132.0 CpG Transition (3) C>T 151 8
730 6M0 Male 85 28.0 CpG Transition (3) C>T 508 8
31 24EO Male 78 26.0 CpG Transition (3) C>T 508 9
47 24EO Male 78 26.0 CpG Transition (3) g>a E2-6 loss 509 9
46 5EO Male 79 137.0 CpG Transition (3) C>T 508 9
678 V150 Male 38 3.0 CpG Transition (3) g>a E2-3 143 10
637 V127 Male 31 11.0 CpG Transition (3) g>a 143 11
631 V133 Male 38 14.0 CpG Transition (3) C>T 151 11
581 V124 Male 39 5.0 CpG Transition (3) C>T 508 11
635 V129 Male 45 5.0 CpG Transition (3) g>a 143 11
583 V130 Male 51 14.0 CpG Transition (3) C>T 508 11
661 V141 Male 52 16.0 CpG Transition (3) C>T 151 11
626 V137 Male 63 7.0 CpG Transition (3) C>T 508 11
391 88FC Male 34 14.0 CpG Transition (3) C>T 151 13
124 BC67 Female 35 15.0 CpG Transition (3) C>T 508 15
120 BC66 Female 49 33.0 CpG Transition (3) C>T 142 15
133 BC10 Male 25 33.0 CpG Transition (3) C>T 151 15
456 89MA Male 19 4.0 CpG Transition (3) C>T 508 17
440 88FH Male 48 8.0 CpG Transition (3) C>T 508 17
305 2000H Male 23 20.0 Transversion (4) G>T 118 1
308 900H Male 29 21.0 Transversion (4) G>T 617 1
73 nf32.1 Female 25 3.0 Transversion (4) G>T 617 2
71 sf9.1 Female 37 7.0 Transversion (4) G>T 197 2
98 nm32.1 Male 26 5.0 Transversion (4) G>T 529 2
167 sf35 Female 26 5.0 Transversion (4) G>T E2-3 loss 119 4
162 nf47 Female 27 11.0 Transversion (4) G>T 617 4
161 nf23 Female 33 10.0 Transversion (4) g>t E7 loss 4
159 sf2 Female 36 12.0 Transversion (4) G>T 143 4
160 sf44 Female 39 6.0 Transversion (4) G>T 118 4
156 sf1 Female 40 14.0 Transversion (4) G>T 197 4
169 nm47 Male 21 9.0 Transversion (4) G>T 601 4
164 sm110 Male 31 7.0 Transversion (4) g>t E4 loss 4
157 sm33 Male 34 12.0 Transversion (4) G>T 628 4
158 sm53 Male 35 22.0 Transversion (4) g>t 4
168 sm86 Male 36 10.0 Transversion (4) G>T 197 4
163 sm43 Male 37 18.0 Transversion (4) G>T 400 4
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170 sm93 Male 44 21.0 Transversion (4) G>T E8 loss 539 4
153 sm59 Male 46 36.0 Transversion (4) G>T 197 4
155 sm111 Male 46 10.0 Transversion (4) G>T 118 4
150 sm57 Male 54 30.0 Transversion (4) G>T 485 4
332 325 Male 50 13.0 Transversion (4) G>T E8 loss 580 5
293 20A Male 25 Transversion (4) G>T I5 partia 7
295 53H Male 55 Transversion (4) G>T 197 7
749 14M0 Female 70 33.0 Transversion (4) C>A 222 8
49 14EO Female 80 73.0 Transversion (4) G>T 47 9
33 17EO Male 73 26.0 Transversion (4) G>T 11 9
29 24EO Male 78 26.0 Transversion (4) G>T 143 9
716 V125 Male 30 2.0 Transversion (4) g>t 192 10
669 V126 Male 61 22.0 Transversion (4) g>t 191 10
675 V137 Male 63 7.0 Transversion (4) G>T E8 loss 544 10
674 V145 Male 64 8.0 Transversion (4) g>t 186 10
707 V140 Male 64 8.0 Transversion (4) g>t 192 10
573 K27 Male 23 6.0 Transversion (4) G>T 419 11
629 V144 Male 28 3.0 Transversion (4) G>T 143 11
566 K34 Male 30 6.0 Transversion (4) G>T 568 11
578 K37 Male 32 5.0 Transversion (4) G>T 197 11
587 K29 Male 36 6.0 Transversion (4) G>T 197 11
563 V119 Male 38 14.0 Transversion (4) G>T 606 11
653 K39 Male 39 11.0 Transversion (4) G>T 614 11
648 K36 Male 40 7.0 Transversion (4) G>T 529 11
480 E Male 23 5.0 Transversion (4) G>T 601 12
407 88FC Male 34 14.0 Transversion (4) C>A 222 13
414 87ET Male 37 7.0 Transversion (4) C>A 69 13
413 88FG Male 39 4.0 Transversion (4) G>T 166 13
275 Male 60 Transversion (4) G>T E2-3 loss 40 14
144 BC8 Female 25 15.0 Transversion (4) G>T 393 15
365 34S Male 29 6.0 Transversion (4) G>T 118 16
367 34S Male 29 6.0 Transversion (4) G>T E3 loss 209 16
85 nf15.1 Female 25 7.0 Transversion (5) G>C 574 2
81 nf14.1 Female 26 3.0 Transversion (5) C>G 551 2
87 nf13.1 Female 38 7.0 Transversion (5) C>G 222 2
95 nm23.1 Male 20 4.0 Transversion (5) g>c E6 loss 2
82 sm23.1 Male 21 7.0 Transversion (5) C>G 74 2
80 sm54.1 Male 27 16.0 Transversion (5) C>G 74 2
83 nm44.1 Male 33 11.0 Transversion (5) G>C 606 2
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96 sm26.1 Male 36 10.0 Transversion (5) C>G 551 2
154 nf38 Female 25 4.0 Transversion (5) C>G 464 4
194 sf31 Female 25 4.0 Transversion (5) G>C 568 4
195 nf9 Female 33 5.0 Transversion (5) C>G 486 4
197 sf41 Female 49 7.0 Transversion (5) C>G 610 4
204 nm17 Male 26 8.0 Transversion (5) g>c E8 loss 4
192 sm56 Male 32 6.0 Transversion (5) G>C 211 4
191 nm26 Male 33 3.0 Transversion (5) G>C 152 4
203 nm7 Male 37 24.0 Transversion (5) G>C 3 4
193 sm74 Male 37 11.0 Transversion (5) g>c E5 loss 4
190 sm27 Male 41 17.0 Transversion (5) G>C 3 4
196 sm91 Male 41 12.0 Transversion (5) G>C 606 4
189 sm101 Male 44 22.0 Transversion (5) c>g E7 loss 4
315 325 Male 50 13.0 Transversion (5) G>C 574 5
323 325 Male 50 13.0 Transversion (5) G>C 208 5
327 325 Male 50 13.0 Transversion (5) G>C 135 5
329 325 Male 50 13.0 Transversion (5) G>C 403 5
339 325 Male 50 13.0 Transversion (5) C>G 610 5
288 61H Male 35 Transversion (5) C>G 486 7
768 1M0 Female 66 27.0 Transversion (5) G>C 226 8
769 5M0 Female 68 13.0 Transversion (5) C>G 610 8
770 14M0 Female 70 33.0 Transversion (5) C>G E2-3 368 8
772 14M0 Female 70 33.0 Transversion (5) C>G 648 8
761 7M0 Male 62 34.0 Transversion (5) G>C 119 8
789 7M0 Male 62 34.0 Transversion (5) C>G 464 8
736 5M0 Female 68 13.0 Transversion (5) C>G 222 8
35 16EO Female 75 18.0 Transversion (5) T>C I 67bp fo 100 9
37 16EO Female 75 18.0 Transversion (5) G>C 3 9
40 16EO Female 75 18.0 Transversion (5) C>G 551 9
38 24EO Male 78 26.0 Transversion (5) G>C 208 9
715 K27 Male 23 6.0 Transversion (5) C>G E8 loss 594 10
719 K37 Male 32 5.0 Transversion (5) g>c 192 10
686 V130 Male 51 14.0 Transversion (5) g>c 192 10
639 K27 Male 23 6.0 Transversion (5) G>C 418 11
549 V144 Male 28 3.0 Transversion (5) G>C 208 11
572 K29 Male 39 6.0 Transversion (5) C>G 527 11
643 K36 Male 40 7.0 Transversion (5) G>C 135 11
568 K28 Male 44 15.0 Transversion (5) G>C 606 11
574 V145 Male 45 8.0 Transversion (5) G>C 569 11
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641 V131 Male 46 4.0 Transversion (5) G>C 599 11
646 V141 Male 52 16.0 Transversion (5) C>G 648 11
576 K25 Male 54 11.0 Transversion (5) G>C 418 11
644 V143 Male 61 8.0 Transversion (5) G>C 3 11
485 E Male 23 5.0 Transversion (5) G>C 212 12
412 87ES Male 31 6.0 Transversion (5) G>C 538 13
411 87ET Male 37 7.0 Transversion (5) G>C 568 13
268 Male 60 Transversion (5) G>C 481 14
276 Male 60 Transversion (5) G>C 14 14
255 8S Male 71 6.0 Transversion (5) G>C 4 14
122 BC8 Female 25 15.0 Transversion (5) G>C 119 15
420 90MS Male 35 4.0 Transversion (5) C>G 121 17
470 89LX Male 41 12.0 Transversion (5) G>C 211 17
307 256H Male 29 45.0 Transversion (6) A>T 124 1
90 nm27.1 Male 24 7.0 Transversion (6) T>A 437 2
91 nm11.1 Male 29 9.0 Transversion (6) T>A 449 2
67 sm19.1 Male 37 13.0 Transversion (6) T>A 563 2
70 sm40.1 Male 37 16.0 Transversion (6) A>T 421 2
206 nf49 Female 24 8.0 Transversion (6) A>T Multiple 1 4
205 nf26 Female 29 6.0 Transversion (6) a>t E8 (5') - 4
179 nm36 Male 19 7.0 Transversion (6) A>T 554 4
198 sm61 Male 24 4.0 Transversion (6) A>T 530 4
172 sm49 Male 31 4.0 Transversion (6) A>T 247 4
175 sm70 Male 31 5.0 Transversion (6) t>a E4 loss 4
199 sm50 Male 36 15.0 Transversion (6) A>T 554 4
202 sm97 Male 36 14.0 Transversion (6) A>T E8 loss 602 4
178 sm96 Male 37 8.0 Transversion (6) a>t E8 (5') - 4
201 sm46 Male 39 10.0 Transversion (6) t>a E4 loss 4
177 nm1 Male 41 7.0 Transversion (6) a>t Multiple 4
200 sm38 Male 45 18.0 Transversion (6) A>T 109 4
176 sm58 Male 53 19.0 Transversion (6) T>A 488 4
316 325 Male 50 13.0 Transversion (6) T>A 104 5
291 89F42 Male 24 19.0 Transversion (6) T>A 110 7
788 14M0 Female 70 33.0 Transversion (6) T>A 2 8
790 14M0 Female 70 33.0 Transversion (6) T>A 595 8
41 8EO Male 68 73.0 Transversion (6) T>A 104 9
691 V133 Male 38 14.0 Transversion (6) a>t E2-3 10
705 V133 Male 38 14.0 Transversion (6) a>t 197 10
692 V136 Male 64 23.0 Transversion (6) a>t 196 10
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599 K34 Male 30 6.0 Transversion (6) T>A 170 11
657 V127 Male 31 11.0 Transversion (6) A>T 131 11
634 V133 Male 38 14.0 Transversion (6) A>T 344 11
659 V150 Male 38 3.0 Transversion (6) A>T 602 11
658 K36 Male 40 7.0 Transversion (6) A>T 530 11
598 V145 Male 45 8.0 Transversion (6) T>A 216 11
652 V131 Male 46 4.0 Transversion (6) A>T 109 11
597 K132 Male 52 9.0 Transversion (6) A>T 530 11
651 K33 Male 52 20.0 Transversion (6) A>T 581 11
655 V141 Male 52 16.0 Transversion (6) A>T 307 11
656 K33 Male 52 20.0 Transversion (6) T>A 194 11
660 V41 Male 52 16.0 Transversion (6) A>T 131 11
649 V146 Male 56 8.0 Transversion (6) T>A 389 11
654 V137 Male 63 7.0 Transversion (6) T>A 612 11
474 E Male 23 5.0 Transversion (6) T>A 623 12
490 E Male 23 5.0 Transversion (6) T>A 623 12
493 E Male 23 5.0 Transversion (6) T>A 623 12
409 88FX Male 40 25.0 Transversion (6) T>A 542 13
281 11S Male 58 5.0 Transversion (6) T>A 290 14
269 Male 60 Transversion (6) A>T 639 14
125 BC7 Male 29 17.0 Transversion (6) A>T 133 15
149 BC5 Male 50 14.0 Transversion (6) A>T 120 15
351 34S Male 29 6.0 Transversion (6) T>A 536 16
373 325 Male 50 13.0 Transversion (6) T>A 494 16
372 42S Male 56 6.0 Transversion (6) T>A 612 16
437 90MX Male 33 10.0 Transversion (6) T>A 573 17
445 87DY Male 35 5.0 Transversion (6) T>A 573 17
432 88EZ Male 39 14.0 Transversion (6) T>A 23 17
429 89MG Male 42 4.0 Transversion (6) T>A 566 17
68 sf15.1 Female 34 16.0 Transversion (7) T>G 146 2
74 sm52.1 Male 48 15.0 Transversion (7) T>G 449 2
174 sf43 Female 35 7.0 Transversion (7) t>g E8 loss 4
171 sf24 Female 39 5.0 Transversion (7) T>G 473 4
173 sf36 Female 62 16.0 Transversion (7) T>G 543 4
181 nm44 Male 33 11.0 Transversion (7) T>G 585 4
180 sm82 Male 37 13.0 Transversion (7) T>G 95 4
184 sm88 Male 37 12.0 Transversion (7) T>G 146 4
187 sm71 Male 38 26.0 Transversion (7) T>G 146 4
186 sm78 Male 42 8.0 Transversion (7) T>G 62 4
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188 nm41 Male 46 21.0 Transversion (7) a>c E5 loss 4
185 sm65 Male 52 21.0 Transversion (7) t>g I8 (3') + 4
317 325 Male 50 13.0 Transversion (7) T>G 392 5
321 325 Male 50 13.0 Transversion (7) A>C 586 5
322 325 Male 50 13.0 Transversion (7) A>C 586 5
784 1M0 Female 66 27.0 Transversion (7) T>G 104 8
785 5M0 Female 68 13.0 Transversion (7) T>G 596 8
727 14M0 Female 70 33.0 Transversion (7) T>G 494 8
776 14M0 Female 70 33.0 Transversion (7) T>G 542 8
745 2M0 Male 76 49.0 Transversion (7) T>G 612 8
50 16EO Female 75 18.0 Transversion (7) T>G 23 9
48 7EO Male 67 67.0 Transversion (7) A>C 116 9
44 17EO Male 73 26.0 Transversion (7) A>C 116 9
53 5EO Male 79 137.0 Transversion (7) T>G 198 9
706 V150 Male 38 3.0 Transversion (7) t>g E8 loss 10
696 K28 Male 44 15.0 Transversion (7) a>c E8 loss 10
613 K32 Male 30 1.0 Transversion (7) T>G 541 11
611 K37 Male 32 5.0 Transversion (7) T>G 532 11
606 V139 Male 33 10.0 Transversion (7) T>G 428 11
647 K26 Male 33 5.0 Transversion (7) T>G 299 CORRECTIO 11
605 K29 Male 36 6.0 Transversion (7) T>G 29 11
623 V124 Male 39 5.0 Transversion (7) T>G 203 11
609 V130 Male 51 14.0 Transversion (7) T>G 220 11
604 V141 Male 52 16.0 Transversion (7) A>C 424 11
618 K33 Male 52 20.0 Transversion (7) T>G 110 11
621 K25 Male 54 11.0 Transversion (7) T>G 158 11
614 V136 Male 64 23.0 Transversion (7) T>G 64 11
486 E Male 23 5.0 Transversion (7) t>g I5 (5') + 12
408 87DZ Male 31 7.0 Transversion (7) T>G 533 13
259 15S Male 59 10.0 Transversion (7) T>G 122 14
258 Male 60 Transversion (7) T>G 125 14
277 Male 60 Transversion (7) T>G 60 14
141 BC8 Female 25 15.0 Transversion (7) T>G 487 15
356 437S Male 30 26.0 Transversion (7) t>g E8 loss 16
357 42S Male 56 6.0 Transversion (7) T>G 563 16
448 89LO Male 31 1.0 Transversion (7) T>G 146 17
444 90MS Male 35 4.0 Transversion (7) T>G 295 17
468 89LN Male 39 6.0 Transversion (7) T>G 65 17
458 88EZ Male 39 14.0 Transversion (7) A>C 484 17
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447 89LX Male 41 12.0 Transversion (7) T>G 295 17
454 89MG Male 42 4.0 Transversion (7) T>G 522 17
300 900H Male 29 21.0 Microdeletion (9) -3 E8 loss I7:-8  (4 1
302 900H Male 29 21.0 Microdeletion (9) -4 229 232 1
99 sf29.1 Female 20 8.0 Microdeletion (9) -77 E8 loss 533 609 2
112 sf4.2 Female 20 5.0 Microdeletion (9) -3 301 303 2
101 nf33.1 Female 24 7.0 Microdeletion (9) -291 E2-3 loss 28 318 2
111 nf28.1 Female 28 4.0 Microdeletion (9) 53 42 94 2
114 nf8.1 Female 28 10.0 Microdeletion (9) -2 288 289 2
102 sf18.1 Female 31 21.0 Microdeletion (9) -2 56 57 2
100 sf23.1 Female 33 15.0 Microdeletion (9) -3 622 624 2
115 sm31.1 Male 23 9.0 Microdeletion (9) -9 466 474 2
104 nm30.1 Male 27 5.0 Microdeletion (9) -291 E2-3 loss 28 318 2
116 sm2.1 Male 27 14.0 Microdeletion (9) -10 41 50 2
103 sm55.1 Male 35 15.0 Microdeletion (9) -6 103 108 2
117 nm40.1 Male 36 9.0 Microdeletion (9) -42 E8 (5') - 533 575 2
506 nf46 Female 34 8.0 Microdeletion (9) -4 41 44 3
534 sf19 Female 36 7.0 Microdeletion (9) -2 263 264 3
545 nf48 Female 41 5.0 Microdeletion (9) -2 316 317 3
509 sf37 Female 47 18.0 Microdeletion (9) -33 83 115 3
542 nm23.1 Male 20 4.0 Microdeletion (9) -26 39802 39827 3
514 nm47 Male 21 9.0 Microdeletion (9) -2 570 571 3
525 sn45 Male 22 4.0 Microdeletion (9) -8 11 18 3
521 nm48 Male 26 5.0 Microdeletion (9) -22 28 49 3
524 nm49 Male 27 4.0 Microdeletion (9) -110 31539 31648 3
518 sm63 Male 33 29.0 Microdeletion (9) -2 196 197 3
515 sm112 Male 38 10.0 Microdeletion (9) -50 101 107 3
522 nm50 Male 42 9.0 Microdeletion (9) -67 27824 27825 3
511 sm36 Male 43 8.0 Microdeletion (9) -3 45 82 3
523 sm90 Male 50 19.0 Microdeletion (9) -35 32 66 3
325 325 Male 50 13.0 Microdeletion (9) -18 39 56 5
333 325 Male 50 13.0 Microdeletion (9) -66 323 388 5
336 325 Male 50 13.0 Microdeletion (9) -6 309 314 5
3 17S Female 37 3.0 Microdeletion (9) -10 580 599 6
4 17S Female 37 3.0 Microdeletion (9) -66 323 388 6
5 17S Female 37 3.0 Microdeletion (9) -6 524 529 6
8 17S Female 37 3.0 Microdeletion (9) -10 41 50 6
759 1M0 Female 66 27.0 Microdeletion (9) -13 182 196 8
757 14M0 Female 70 33.0 Microdeletion (9) -8 511 518 8
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762 14M0 Female 70 33.0 Microdeletion (9) -3 162 164 8
763 14M0 Female 70 33.0 Microdeletion (9) -2 196 197 8
764 14M0 Female 70 33.0 Microdeletion (9) -19 229 247 8
765 3M0 Male 63 132.0 Microdeletion (9) -50 inc of 9b 14 8
767 2M0 Male 76 49.0 Microdeletion (9) -3 239 241 8
766 6M0 Male 85 28.0 Microdeletion (9) -31 inc of I1 8
55 16EO Female 75 18.0 Microdeletion (9) -13 E2-3 loss 341 353 9
58 24EO Male 78 26.0 Microdeletion (9) -2 369 370 9
61 24EO Male 78 26.0 Microdeletion (9) -584 E2-9 loss 93 I9+4 9
60 15EO Male 83 15.0 Microdeletion (9) -23 582 604 9
710 V127 Male 31 11.0 Microdeletion (9) -23 192 10
712 V135 Male 37 9.0 Microdeletion (9) -3 186 10
664 K25 Male 54 11.0 Microdeletion (9) -8 186 10
670 K25 Male 54 11.0 Microdeletion (9) -6 192 10
717 V143 Male 61 8.0 Microdeletion (9) -20 192 10
577 K34 Male 30 6.0 Microdeletion (9) -5 45 50 11
567 K37 Male 32 5.0 Microdeletion (9) -19 29 48 11
554 K30 Male 35 9.0 Microdeletion (9) -26 561 587 11
579 V138 Male 37 18.0 Microdeletion (9) -4 546 550 11
553 V151 Male 38 3.0 Microdeletion (9) -52 45 97 11
557 K29 Male 39 11.0 Microdeletion (9) -3 496 499 11
558 K36 Male 40 7.0 Microdeletion (9) -2 617 618 11
580 K28 Male 44 15.0 Microdeletion (9) -22 49 71 11
560 V145 Male 45 8.0 Microdeletion (9) -8 48 56 11
565 V145 Male 45 8.0 Microdeletion (9) -3 80 83 11
556 V141 Male 52 16.0 Microdeletion (9) -35 44 79 11
561 V132 Male 52 9.0 Microdeletion (9) -6 299 305 11
562 V136 Male 64 23.0 Microdeletion (9) -3 400 403 11
477 E Male 23 5.0 Microdeletion (9) -11 106 116 12
478 E Male 23 5.0 Microdeletion (9) -15 80 94 12
397 87ET Male 37 7.0 Microdeletion (9) -12 452 463 13
406 88FX Male 40 25.0 Microdeletion (9) -9 41 49 13
285 Male 60 Microdeletion (9) -25 279 303 14
147 BC67 Female 35 15.0 Microdeletion (9) -9 426 434 15
148 BC5 Male 50 14.0 Microdeletion (9) -10 434 443 15
354 437S Male 30 26.0 Microdeletion (9) -42 E2-3 loss 139 16
366 42S Male 56 6.0 Microdeletion (9) -36 I1 (5') + 24 I1:34  (1 16
368 42S Male 56 6.0 Microdeletion (9) -42 E2-3 loss 139 16
369 42S Male 56 6.0 Microdeletion (9) -17 574 590 16
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453 89MA Male 19 4.0 Microdeletion (9) 155 158 17
431 89MC Male 38 10.0 Microdeletion (9) -18 42 59 17
443 88EZ Male 39 14.0 Microdeletion (9) -3 195 197 17
435 89JI Male 46 7.0 Microdeletion (9) -8 147 154 17
442 88FH Male 48 8.0 Microdeletion (9) -15 548 562 17
97 nm3.1 Male 24 5.0 Duplication (10) E8 loss 2
519 sf38 Female 46 47.0 Duplication (10) 136 207 3
512 sm42 Male 43 9.0 Duplication (10) 132 17 3
783 3M0 Male 63 132.0 Duplication (10) 132 70 8
662 K31 Male 27 5.0 Duplication (10) 136 E2-3 207 10
589 V143 Male 27 7.0 Duplication (10) 132 196 11
586 K34 Male 30 6.0 Duplication (10) 149 144 11
585 K26 Male 33 5.0 Duplication (10) 132 223 11
496 E Male 23 5.0 Duplication (10) 136 482 12
386 87ET Male 37 7.0 Duplication (10) 132 609 13
417 89MG Male 42 4.0 Duplication (10) 136 404 17
419 89MG Male 42 4.0 Duplication (10) +C 15 17
438 89ME Male 44 8.0 Duplication (10) 132 487 17
310 900H Male 29 21.0 Loss (10) 142 58 59 1
76 sm29.1 Male 24 7.0 Loss (10) -A 182 182 2
92 sm3.1 Male 29 4.0 Loss (10) -C 142 2
72 nm26.1 Male 33 3.0 Loss (10) 440 440 2
75 nm1.4 Male 41 8.0 Loss (10) 354 354 2
546 nm44.1 Female 33 5.0 Loss (10) -G 207 3
543 sf45 Female 38 13.0 Loss (10) -G 207 3
530 sf39 Female 46 24.0 Loss (10) -A 342 3
544 nm33 Male 22 1.0 Loss (10) -G 207 3
500 sm81 Male 23 9.0 Loss (10) 131 537 3
532 nm32.1 Male 26 5.0 Loss (10) -A 133 3
538 sm66 Male 28 8.0 Loss (10) 131 305 3
541 sm48 Male 28 11.0 Loss (10) -G 34 3
502 nm19.1 Male 31 5.0 Loss (10) -C 213 3
516 sm99 Male 32 10.0 Loss (10) -G 562 3
531 sm106 Male 33 3.0 Loss (10) -G 384 3
499 nm40.1 Male 36 9.0 Loss (10) -G 190 3
498 sm88 Male 37 12.0 Loss (10) -G 207 3
536 sm100 Male 39 12.0 Loss (10) -A 155 3
505 sm116 Male 42 5.0 Loss (10) -C 526 3
533 sm37 Male 42 5.0 Loss (10) 3
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501 sm51 Male 45 17.0 Loss (10) -A 326 3
294 20A Male 25 Loss (10) -C 213 213 7
299 61H Male 35 Loss (10) -A 76 76 7
758 14M0 Female 70 33.0 Loss (10) -A E2-3 265 8
775 3M0 Male 63 132.0 Loss (10) 131 532 8
57 16EO Female 75 18.0 Loss (10) -A 523 9
63 16EO Female 75 18.0 Loss (10) -A E2-3 loss 326 9
56 7EO Male 67 67.0 Loss (10) -A 167 9
64 1EO Male 80 18.0 Loss (10) 263 9
665 V146 Male 56 8.0 Loss (10) -C E8 loss 550 10
673 V126 Male 61 22.0 Loss (10) -A 191 98 10
594 V127 Male 31 11.0 Loss (10) -A 552 11
596 V127 Male 31 11.0 Loss (10) -C 610 11
548 K26 Male 33 5.0 Loss (10) 131 318 11
595 V135 Male 37 9.0 Loss (10) -C 368 11
630 K28 Male 44 15.0 Loss (10) -C 503 11
628 K33 Male 52 20.0 Loss (10) 131 595 11
632 V147 Male 52 16.0 Loss (10) -G 589 11
633 V141 Male 52 16.0 Loss (10) 131 294 11
582 V126 Male 61 22.0 Loss (10) 131 536 11
489 E Male 23 5.0 Loss (10) -TA 583 584 12
387 87ES Male 31 6.0 Loss (10) -C 15 15 13
388 87EK Male 31 6.0 Loss (10) 46 46 13
401 88FX Male 40 25.0 Loss (10) -C 8 8 13
403 88FH Male 48 8.0 Loss (10) -C 15 15 13
272 Male 60 Loss (10) -G 207 207 14
278 Male 60 Loss (10) -G E2-3 loss 574 14
279 6S Male 60 6.0 Loss (10) -G 207 207 14
284 16S Male 60 10.0 Loss (10) -G 207 207 14
261 4S Male 72 5.0 Loss (10) -A 561 561 14
134 BC8 Female 25 15.0 Loss (10) -G 361 361 15
139 BC7 Male 29 17.0 Loss (10) -TA TA- 519 15
362 325 Male 50 13.0 Loss (10) 131 E2-3 or 2 196 196 16
463 89LO Male 31 1.0 Loss (10) -A 523 523 17
457 90MX Male 33 10.0 Loss (10) -G 207 207 17
459 90MX Male 33 10.0 Loss (10) 45 45 17
436 87DY Male 35 5.0 Loss (10) -G 599 599 17
425 88FG Male 39 4.0 Loss (10) -C 183 183 17
467 89MG Male 42 4.0 Loss (10) -G 346 346 17
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428 88FH Male 48 8.0 Loss (10) 131 614 614 17
309 900H Male 29 21.0 Insertion (11) 269 276 1
88 sm21.1 Male 21 5.0 Insertion (11) 2
86 nm9.1 Male 31 6.0 Insertion (11) 2
520 nm48 Male 26 5.0 Insertion (11) 38 425 462 3
359 42S Male 56 6.0 Insertion (11) 247 16
89 nf27.1 Female 25 2.0 Deletion/Insertion (12) TGG>A 117 2
528 sm35 Male 22 7.0 Deletion/Insertion (12) 3
526 sm71 Male 26 26.0 Deletion/Insertion (12) 3
527 sm27 Male 41 17.0 Deletion/Insertion (12) 3
343 325 Male 50 13.0 Deletion/Insertion (12) 5
344 325 Male 50 13.0 Deletion/Insertion (12) 5
721 14M0 Female 70 33.0 Deletion/Insertion (12) 8
722 14M0 Female 70 33.0 Deletion/Insertion (12) G>C E8 loss 211 8
723 14M0 Female 70 33.0 Deletion/Insertion (12) A>C E2-3 301 311 8
740 4M0 Male 55 78.0 Deletion/Insertion (12) 8
742 7M0 Male 62 34.0 Deletion/Insertion (12) 154 401 8
734 2M0 Male 76 49.0 Deletion/Insertion (12) A>C 400 637 8
743 2M0 Male 76 49.0 Deletion/Insertion (12) 11 18 8
591 V131 Male 46 4.0 Deletion/Insertion (12) 151 405 421 11
267 14S Male 64 4.0 Deletion/Insertion (12) 14
129 BC7 Male 29 17.0 Deletion/Insertion (12) 4 15
355 102S Male 51 40.0 Deletion/Insertion (12) E8 loss 16
465 87DY Male 35 5.0 Deletion/Insertion (12) 595 17
423 88FB Male 42 82.0 Deletion/Insertion (12) 17
183 sm63 Male 33 29.0 Tandem (13) CC>TT 463 4
182 nm43 Male 53 23.0 Tandem (13) GG>AA E3 and E2 135 4
671 K30 Male 35 9.0 Tandem (13) CC>TT E8 loss 550 10
616 K29 Male 36 6.0 Tandem (13) CC>TT 112 11
622 V143 Male 61 8.0 Tandem (13) GG>AA 399 11
488 E Male 23 5.0 Tandem (13) GA>AT 569 12
270 Male 60 Tandem (13) 137 623 14
469 90MX Male 33 10.0 Tandem (13) CC>AT 17
bCurry J, Karnaoukhova L, Guenette GC, Glickman BW.  (1999) Influence of sex, smoking and age on human HPRT mutation frequencies and spectra.  
Genetics.  152(3):1065-77.  PMID: 10388825
aFinette BA, Kendall H, Vacek PM.  (2002) Mutational spectral analysis at the HPRT locus in healthy children.  Mutat Res.  505(1-2):27-41.  PMID: 12175903
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ABSTRACT 
Microsatellites are nucleotide sequences of tandem repeats occurring throughout 
the genome, which have been widely used in genetic linkage analysis, studies of loss of 
heterozygosity, determination of lineage and clonality, and the measurement of genome 
instability or the emergence of drug resistance reflective of mismatch repair deficiency.  
Such analyses may involve the parallel evaluation of many microsatellite loci, which are 
often limited by sample DNA, are labor intensive, and require large data processing.  To 
overcome these challenges, we developed a cost-effective high-throughput approach of 
microsaellite analysis, in which the amplifications of microsatellites are performed in 
miniaturized, multiplexed PCR reactions adaptable to 384 well plates and accurate 
automated allele identification has been optimized with a collective reference dataset of 
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INTRODUCTION 
 
Microsatellites are nucleotide sequences of tandem repeat units ranging from 1 to 
6 nucleotides that occur throughout the genome.  Their polymorphisms, primarily 
exhibited as variations in length from the expansion or contraction of repeat units, reflect 
the tendency of DNA polymerase to slip during replication of repeat tracts.  Although 
polymorphic through evolution, microsatellites are generally stably inherited between 
closely related individuals (Ellegren 2004).  These attributes have led to their wide use in 
genetic linkage analysis, studies of loss of heterozygosity (LOH) in cancer, and 
determination of lineage and clonality (Rubben et al. 2004). 
On the other hand, microsatellite instability (MSI) in tumors, first observed in a 
proportion of sporadic colon cancers (Ionov et al. 1993; Thibodeau et al. 1993) and most 
colon cancers of hereditary nonpolyposis colon cancer (HNPCC) families (Aaltonen et al. 
1993), may indicate genetic instability as a result of mismatch repair (MMR) deficiency 
(Lengauer et al. 1998; Markowitz 2000).  The MMR system corrects post-replication 
base-base mismatches and insertion/deletion loops, and has also been implicated in the 
cytotoxicity of some DNA damaging agents (Li 2003; Stojic et al. 2004). Mismatch 
repair deficiency has been observed to exhibit a high mutation rate (Bhattacharyya et al. 
1994) and confer tolerance to methylating agents (Koi et al. 1994; Umar et al. 1997), 
cisplatin (Aebi et al. 1997; Fink et al. 1997), and 6-thioguanine or 6-mercaptopurine 
(Fink et al. 1998; Glaab et al. 1998). Since the findings of MSI in colon cancer, the 
measurement of microsatellite instability has been extended to other solid tumors 
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(Peltomaki 2003) and hematological malignancies (Gafanovich et al. 1999; Gartenhaus 
1997; Olipitz et al. 2002), as an indication of the potential contribution of mismatch 
repair deficiency in tumor development, transformation (Fulop et al. 2003; Ohyashiki et 
al. 1996; Wada et al. 1994) and drug resistance. 
Depending on the type of analysis, microsatellite markers are selected based on 
their chromosomal locations and frequency of heterozygosity.  In genetic linkage 
analysis, studies of LOH, and determination of lineage, polymorphic markers are utilized 
to distinguish and follow alleles on homologous chromosomes, while sensitive and 
specific measurements of microsatellite instability reflective of mismatch repair 
deficiency in colon cancer are achieved with quasimonomorphic mononucleotide 
markers, including Bat25, Bat26, NR22, and NR24 (Suraweera et al. 2002; Xicola et al. 
2007). 
In some cases, these studies may involve the parallel evaluation of many 
microsatellite loci that are often limited by sample DNA, can be labor intensive 
depending on the number of loci and samples being examined, and require the processing 
of numerous data.  To address these limitations, we demonstrate a cost effective, high-
throughput, and reproducible process of microsatellite analysis from PCR amplification 
to automated data processing using model studies of microsatellite instability and lineage 
determination.  Performed in miniaturized and multiplexed PCR format, our assay 
evaluates 11 microsatellite loci, consisting of the NCI recommended panel (Boland et al. 
1998; Umar et al. 2004) of mononucleotide markers, Bat25 and Bat26, and dinucleotide 
markers, D2S123, D5S2346, and D17S250, and 6 additional dinucleotide markers, 
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D3S1262, D3S3623, D6S262, D7S481, D9S171, and D18S61, that altogether samples 9 
chromosomes.  We have designed the assay to also simultaneously evaluate for LOH of 
mismatch repair components commonly associated with HNPCC by including 
polymorphic markers, with the exception of Bat26, that are in close proximity to MLH1 
(D3S3623), MSH2 (Bat26), MSH6 (D2S123), and PMS2 (D7S481) gene regions.  For 
other applications, markers may be replaced or added to the existing assay format with 
minimal optimization.  Following the separation of amplified products by capillary 
electrophoresis, accurate automated allele identification is performed with optimized 
peak detection algorithm and sizing method using the GeneMapperV4.0 software. 
 
RESULTS 
A quality high-throughput process of microsatellite analysis requires specific 
high-throughput PCR amplification of microsatellite regions and automated specific peak 
detection and precise sizing of amplified fragments.  In the following, we present 
optimized conditions for the amplification of 11 microsatellite loci in two miniaturized, 
multiplexed PCR reactions.  We also present the optimization of analysis methods and 
marker parameters of the GeneMapper V4.0 software to detect specific peaks of 
amplified products from background signals and precisely size microsatellite fragments 
in order to achieve reproducible automated allele identification. 
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Performance of Multiplex PCR 
In silico design and optimization to minimize hairpin and primer-dimer formation 
as well as cross dimerization among possible primer combinations were performed prior 
to in vitro testing.  Predicted compatible primer sets were tested and evaluated for 
optimal assay performance of low background signals, high fluorescence of specific PCR 
products that fall within the detectable dynamic range, and signal and size resolution 
among amplified products.  We found that multiplexing Bat25, Bat26, D3S3623, 
D5S346, D6S262, and D7S481 into one PCR reaction (Group I) and D2S123, D3S1262, 
D9S171, D17S250, and D18S61 into another (Group II) met these criteria.  The 
compatibility of primer sets in our experimental conditions is overall consistent with in 
silico predictions.  Figure 1a shows the electropherograms of Group I markers amplified 
with T-cell lysates in a 10µL PCR reaction.  Panel A displays the complete spectrum of 
an individual’s microsatellite profile for Group I markers with internal size standards 
represented as red peaks.  Bat 25 and D3S3623 are labeled with Fam (blue), Bat26 and 
D6S262 with Hex (green), and D5S346 and D7S481 with Ned (black).  Similarly labeled 
fragments are distally spaced in size by assay design to accommodate both population 
size distribution and possible microsatellite instability.  Background signals from 
nonspecific priming in multiplex PCR are kept to a minimum for each fluorescent tag.  
However, there is overlap in spectral emission of Hex into Fam that is most evident at 
D6S262.  These parameters are examined in detailed for each dye in Panels B (Fam), C 
(Hex), and D (Ned).  Red peaks in Panels B-D mark the size range for each microsatellite 
marker.  In all three panels, signals from nonspecific products for each dye are quite low 
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compared to specific signals of amplified microsatellites.  Bleed through of Hex into Fam 
is evident in Panel B as background microsatellite fragments labeled with Fam that have 
similar stutter patterns and size of Bat26 and D6S262.  However, this is not concerning 
for the genotyping of either Bat25 or D3S3623 since the nonspecific signal from Bat26 is 
extremely low compared to the specific signal of Bat25 and the expected fragment size 
range of D3S36S3 is approximately 40 nucleotides away from the background peaks 
from D6S262, which can be excluded from automated identification by the adjustment of 
marker and analysis method parameters in the GeneMapper software.  Alternatively, 
using narrower band filters for detecting Fam or exchanging labels to tag markers that are 
farther apart in size can minimize this spectral overlap.  Figure 1b shows the 
electropherograms of group II markers also amplified with cell lysates in a 10µL PCR 
reaction.  The complete spectrum of Group II markers is shown in Panel A, consisting of 
D18S61 labeled with Fam, D2S123 and D3S1262 labeled with Hex, and D9S171 and 
D17S250 labeled with Ned, and amplified products of individual dye are analyzed in 
Panels B (Fam), C (Hex), and D (Ned).  Similar to Group I, fragments labeled with the 
same fluorescent tags are distally spaced apart and background signals from nonspecific 
priming in multiplex PCR are minimized within the relevant marker size ranges.  The 
spectral overlap of Hex into Fam is again observed in Panel B as microsatellite fragments 
with the same stutter patterns and size as D3S1262 and D2S123.  Since these background 
peaks are present outside the size range of D18S61, they will not interfere with the 
genotyping of D18S61.  The nonspecific peak outside of the lower limit of D9S171 size 
range in Panel D can also be excluded from identification with specified marker and 
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analysis parameters.  Overall, PCR conditions for Groups I and II markers produce data 
with clear resolution of specific signals and sizes of similarly labeled amplified 
fragments, which are suitable for high-throughput microsatellite analysis. 
Specific Peak Detection and Precise Sizing 
Automated data processing was performed with the GeneMapper V4.0 software.  
A reference dataset of 5508 alleles from 27 subjects and 1 cancer cell line (Supplemental 
Table 1) was used to optimize parameters for specific peak detection, precise fragment 
sizing, and accurate allele identification of amplified microsatellites, which minimize the 
recognition of nonspecific artifacts of PCR amplifications and dye bleed through.  
Several peak detection algorithms and sizing methods were tested.  Superior genotyping 
quality was observed using the advanced peak detection algorithm in combination with 
the Local Southern sizing method (parameters listed in Table 2a), which determines the 
best-fit line fragment size for an unknown fragment from the four nearest sizing 
standards based on the reciprocal relationship between fragment length and mobility 
(Southern 1979; Applied Biosystems, Part Number 4366831 Rev. A 2005).  We also 
tested different sizing methods, including the 3rd order least squares and Global Southern 
methods, and did not observe comparable precision as the Local Southern method.  This 
is consistent with what Gosh and colleagues had observed with fragment sizing (Ghosh et 
al. 1997).  We further improved specific peak detection by increasing the minimum peak 
half width to 4pts for Group I markers to minimize the recognition of nonspecific spikes 
observed in some samples. 
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Along with peak detection and fragment sizing, parameters were also optimized 
for accurate allele calling of amplified microsatellites with unique nucleotide repeats.  
Specific allele identification was promoted by specifying the size range for each marker 
(Table 2b), using previously determined values of a population sampling from the GDB 
human genome database that have been adjusted for primer locations and product size in 
our assay conditions (Table 1), and also those determined from 27 additional subjects and 
1 cell line in our studies (Supplemental Table 1).  Nonspecific peaks outside the defined 
size range for each marker that may interfere with allele identification of similarly 
labeled marker, including bleed through of Hex into Fam, were additionally filtered out 
by specified range filters in the analysis method parameters (Table 2a).  Allele 
identification of quasimonomorphic microsatellites with mononucleotide repeats, 
including Bat25 and Bat26, was optimized to recognize the highest peaks among stutter 
peaks that have heights >95% of the maximum peak height or height of allele 1 by setting 
the mono cut-off value at 0.95 (Table 2a).  This setting reproducibly identified at most 
two alleles for Bat25 and Bat26 per PCR amplification of a sample without microsatellite 
instability in our dataset.   
Following the optimization of pertinent parameters, the reference dataset was also 
utilized to define bins for each marker, which are rounded off or specified integer values 
that represent different categories of fragment sizes of amplified products for a particular 
microsatellite, to enable automatic allele identification of detected peaks that fall within 
the bin settings.  The maximum offset of each bin was set at +0.5 base pairs to allow up 
to 1 nucleotide range of experimental variations for each fragment size.   
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Quality of High-Throughput Microsatellite Analysis 
 We next assessed the performance of the entire high-throughput process from 
PCR amplification to automated data analyses for potential sources of variations and 
process accuracy and reproducibility over the course of five months.  Subsets of the 
reference dataset including studies of microsatellite instability and lineage determination, 
which have been automatically analyzed with optimized parameters and bin settings, 
were utilized in these assessments since the observed outcome from those studies 
provided the appropriate controls for comparison.   
In those studies, PCR amplifications were performed in 10uL reactions with either 
purified DNA or cell lysates prepared from T-cell clones, which expressed varying 
growth rates and were cultured at different times.  The inclusion of different conditions 
captured the potential variation associated with sample preparation, including the 
contribution of background matrix from tissue culture and DNA isolation.  Along with 
every analysis of unknown samples, we included the amplification of a known control 
sample to distinguish process reproducibility from sample integrity as the source of 
variation.  Not included in our comparisons were PCR amplifications of samples that 
resulted in no signals or very low signals that do not display distinguishable marker peaks 
when our controls were performing.  These may be the result of interferences from 
sample matrix and/or low DNA content since the use of higher sample volumes resulted 
in the successful amplifications of some samples. 
The reproducibility of each day’s processing as well as over the course of 5 
months were assessed by examining the performance of control samples.  Tables 3a and 
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3b provide the sizing values for identified alleles of Group I and Group II markers, which 
have been amplified with cell lysates in 23 and 18 different runs, respectively, and 
analyzed with optimized parameters using the GeneMapperV4.0 software.  The sizing 
values of alleles for control samples, which reflect processing from PCR amplifications 
of microsatellite regions, fragment separation by capillary electrophoresis, specific peak 
detection to sizing of fragments, were very reproducible over the course of 5 months 
showing cumulative %CV ranging from 0.05% to 0.12% among identified alleles.  In 
addition, automatic allele identification with indicated bins was accurate in 360 out 364 
alleles analyzed for markers with dinucleotide repeat units.  Although peak detection and 
sizing may be accurate, problems with automatic allele calling of markers with 
dinucleotide repeats occur in cases where signals from nonspecific products generated 
during PCR amplifications have surpassed pre-set threshold values.  This was observed 
on two occasions for D5S346 (alleles highlighted in blue, Table 3a).  We also observed 
the most ambiguity with allele calling of mononucleotide markers, Bat25 and Bat26 (also 
in Table 4a).  The algorithm for automatic allele identification of markers with 
mononucleotide repeats reproducibly called peaks using the preset cut-off value of 95% 
of the maximum peak height or allele 1 among stutter peaks.  However, whether 
performed manually or automatically, the ambiguity in allele calling appears to reflect the 
variability in biochemistry of amplifying regions with mononucleotide repeats, and 
consistency appears to depend on pre-set criteria of tolerance for variations.  From our 
dataset, we accepted a deviation of + 1 nucleotide as normal for these markers. 
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Process accuracy and reproducibility were further examined in an analysis of 
4440 identified alleles of Groups I and II markers from the amplifications of 239 and 156 
T-cell clones from 13 and 12 subjects, respectively, in a microsatellite instability study.  
This dataset is unique in that different clones from the same subjects exhibited identical 
patterns of microsatellite profiles or microsatellite stability, providing the appropriate 
internal controls for measuring process deviations.  Tables 4a and 4b provide summaries 
of identified alleles for Groups I and II markers, respectively, organized in chronological 
order by dates of processing, subjects and respective number of clones analyzed, and the 
percent deviation from expected values.   Percent deviation from expected values 
connotes the percent of alleles that were miscalled, indicated by “*”. All discordant 
samples were manually analyzed to confirm that deviations were unrelated to 
microsatellite instability.  Misidentification can represent failure in any part of the 
process from sample preparation, PCR amplification, fragment separation, peak 
detection, fragment sizing, to automated allele calling.  The analysis of 1920 alleles of 
dinucleotide markers in Group I (Table 4a) showed percents deviation from expected 
values ranging from 0.0% to 4.69% for day to day processing and of 0.63% for all days.    
When discordant samples were analyzed manually, most deviations from expected allele 
calls were related to the presence of higher nonspecific signals or unequal amplifications 
of alleles.  On the day showing the highest percent deviation, three independent 
amplifications of control samples performed optimally, indicating that deviations were 
likely related to sample integrity.  There did not appear to be a trend of higher deviations 
among any of the markers.  As previously mentioned, mononucleotide markers Bat25 and 
  152 
Bat26 are more difficult to call whether performed manually or automatically even 
though their fragment sizing is very precise (Table 3a).  We accepted a deviation of + 1 
nucleotide as normal and did not calculate a percent deviation for these markers since all 
alleles were automatically called within this range.  The analysis of 1560 alleles for 
Group II dinucleotide markers (Table 4b) showed percents deviation from expected 
values ranging from 0.0% to 3.57% for day to day processing and of 0.90% for all days.  
Most of discordant samples showed deviations related to the presence of higher 
nonspecific signals and unequal amplifications of alleles as observed with Group I 
markers.  On the day showing the highest percent deviation, our control sample 
performed optimally, suggesting that sample integrity is the cause of poor PCR 
amplifications. There was also no apparent trend of higher deviations among any of the 
markers in Group II. 
 Thus far, we have demonstrated the accuracy and reproducibility of our high-
throughput process with control samples and clones from the same subjects in which 
deviations from expected patterns of microsatellites were analyzed.  The accuracy of our 
methods was also examined in a lineage determination study of a family of four members 
unknown to us.  Figure 2 shows the microsatellite profiles of Group I markers in four 
panels that we have determined as Child 1, Parent 1, Parent 2, and Child 2 based on the 
patterns of segregation of microsatellite alleles.  Alleles inherited from each parent have 
been appropriately color coded in each child’s microsatellite profiles.  As previously 
discussed with the exception of the ambiguity in identification of Bat25 and Bat26, all 
alleles of dinucleotide markers were accurately automatically identified in Child 1 and 
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Child 2 and can be traced back to Parent 1 and Parent 2.  Furthermore, the microsatellite 
profiles of Child 1 and Child 2 were identical, suggesting that the children are 
monozygotic twins.  The parents later confirmed these determinations. 
 
DISCUSSION  
 We have developed a reproducible high-throughput process of microsatellite 
analysis in which the amplifications of microsatellite regions are performed in 
miniaturized, multiplexed PCR format and automated allele identification have been 
optimized to overcome many challenges encountered in genetic studies of linkage 
analysis, LOH, lineage determination, or microsatellite instability.  Our microsatellite 
assay minimizes sample requirement by using approximately 2-4 ng of DNA in PCR 
amplifications of 11 microsatellite loci in two 10 uL reactions that be can adapted to a 
384-well high-throughput assay format.  Our optimized conditions produced clear 
resolution of specific signals and sizes of amplified microsatellites, allowing for 
reproducible peak detection and fragment sizing.  The current assay is amenable to the 
incorporation of more markers to increase throughput without compromising size 
resolution of additional amplified products. 
Using the Advanced Peak Detection Algorithm with specific optimized 
parameters in combination with the Local Southern Sizing Method, our control samples 
were precisely sized with %CV ranging from 0.05% to 0.12% for all markers in Groups I 
and II in 23 and 18 independent runs, respectively, over the course of five months.  These 
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values included the variation from sample preparation, PCR amplification, fragment 
separation, peak detection to fragment sizing.  For dinucleotide markers, these data also 
indicate that the addition of the GTGTCTT tail to our primer sets in conjunction with 
optimized extension time have successfully promoted consistent amplifications of 
fragment size using a basic PCR protocol.  The observed precision demonstrates the 
reproducibility of this process over time.   
From a collective reference dataset of 5508 alleles from 27 subjects and 1 cell 
line, we have defined bins or categories representing different fragment sizes for each 
marker to enable automatic allele identification in future studies with these markers.  This 
dataset is unique in that sufficient replicates of the same allele have been amplified using 
samples from different T-cell isolates that have been cultured and lysed at different times, 
thus testing a wide spectrum of variation during sample preparation.  
Allowing a bin offset of + 0.5 base pairs, the performance of the entire process 
showed percents deviation from expected values of 0.63% and 0.90% in 1920 and 1560 
alleles analyzed for Groups I and II dinucleotide markers, respectively.  Most 
misidentifications were of nonspecific signals above our preset threshold values or from 
the unequal amplifications of alleles, which were related to poor sample quality rather 
than process quality since control samples performed optimally on the same runs.  We 
actually expected a higher percent deviation since all samples from this dataset were 
amplified with crude lysates of T-cells.  In the analysis of control samples, similarly 
amplified with crude lysates, we had leaned towards a higher estimation of the percent 
deviation by counting both alleles as being miscalled for marker D5S346 when 
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background signals were also identified as alleles.  Automated allele identification of 
quasimonomorphic mononucleotide markers, Bat25 and Bat26, was highly reproducible 
using the algorithm of >95% cut-off value and an allowable +1 nucleotide deviation due 
to the biochemistry of amplifying these markers.  These data support the reproducibility 
and accuracy of this high-throughput process. 
In this investigation, we have documented our experience with the optimization of 
multiplex PCR conditions and automated allele identification, and have generated a 
unique body of data that provide a starting point for a cost-effective, high-throughput 
process of microsatellite analysis using the studied markers.  For specific applications, 
markers may be exchanged or added with some optimization to the existing assay format 
and analysis methods.  For microsatellite instability studies to test the functional 
deficiency of mismatch repair, the placement of polymorphic markers in proximity to 
mismatch repair components in this assay may provide additional information on LOH. 
 
MATERIALS AND METHODS 
Microsatellite Assay 
The amplifications of 11 microsatellite loci are performed in two multiplex PCR 
reactions, consisting of 6 and 5 sets of forward and reverse primers that are either labeled 
with fluorescent tags Hex, Fam or Ned or tailed with GTGTCTT nucleotides.  Since Taq 
polymerase can add a nucleotide to the 3’ end of DNA fragments, primarily adenosine, in 
a non-templated and primer-specific context (Clark 1988; Hu 1993; Smith et al. 1995), 
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errors in genotyping may occur when the fractions of adenylated products vary.  To 
achieve consistency, we have added the GTGTCTT tail to the 5’ ends of the unlabeled 
primers to promote the adenylation of majority of PCR products (Brownstein et al. 1996).  
To accommodate variations in microsatellite size among individuals (range listed in 
Table 1) and possible instability, the analyses of multiple loci within the same PCR 
reaction are made possible by designing primers, when labeled with similar fluorescent 
dyes, to prime products that are at least 40 nucleotides apart in size.  Finally, sample 
requirement is minimized by the miniaturization of PCR reactions in 10µL volume.  
DNA Samples 
DNA templates from both purified DNA as well as crude cell lysates have been 
utilized in PCR reactions.  Adequate fluorescence units have been achieved with 
amplifications of as low as 0.75ng of purified DNA and 0.5µL of lysates of 10,000 T-cell 
pellets.  Cell lysates are prepared by adding 10µL of lysis reagent containing 80% Qiagen 
EB buffer (10mM TrisHCl pH8.5), 0.5% Tween 20, 0.5% NP40, and 0.1mg/mL of 
proteinase K to cell pellets, followed by incubation at 56°C for 1 hour and heat 
inactivation at 96°C for 10 minutes.  
PCR Conditions 
PCR reactions are performed with 10mM TrisHCl pH 8.3, 50mM KCl, 1.5mM 
MgCl2, 0.25U or 0.025U/µL of Platinum (Invitrogen) or HotStart-It Taq polymerase 
(USB), primers at concentrations listed in Table 1, and DNA templates.  Reaction 
mixtures are heated to 94ºC for 2 minutes for enzyme activation and then proceed for 35 
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cycles of (94ºC for 30s, 55ºC for 30s, and 72ºC for 40s) with a final extension at 72ºC for 
10 minutes. 
Microsatellite Detection and Analysis 
Amplified products from PCR reactions 1 and 2 are diluted ½ with water.  1µL of 
diluted products are mixed with 10µL of formamide and 0.4µL of GeneScan 500 Rox 
size standards, ranging from 35 – 500 nucleotides, and heat denatured at 95ºC for 5 
minutes.  PCR products and internal standard mixtures are then electrophoresed using the 
ABI 3100 Avant Genetic Analyzer.  
Subsequently, automated allele identification is performed with the GeneMapper 
V4.0 software, in which markers and method parameters (Tables 2a and 2b, respectively) 
have been empirically optimized for specific peak detection and precise sizing of 
amplified products, using the Advanced Peak Detection Algorithm and Local Southern 
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FIGURES 
Figure Legends 
Figure 1a.  Electropherograms of Group I Markers 
Panel A) Complete spectrum of Group I markers labeled with specific fluorescent tags.  
D5S346 and D7S481 labeled with Ned, Bat26 and D6S262 labeled with Hex, and Bat25 
and D3S3623 labeled with Fam.  Similarly labeled fragments are distally spaced in size 
by assay design to accommodate population distribution and possible microsatellite 
instability.  Nonspecific signals are kept at a minimum; however, there is overlap in 
spectral emission of Hex into Fam, observed as similar stutter peaks with lower signals at 
Bat26 and D6S262 that are labeled as Fam. 
Panel B) Allele identification of Fam labeled fragments, Bat25 and D3S3623.  
Background peaks from the spectral overlap of Hex into Fam were excluded from 
identification due to either low nonspecific signals compared to specific signals as in 
Bat25 or by filtering out with specified marker and analysis method parameters as in 
D3S3623.  
Panel C) Allele identification of Hex labeled fragments, Bat26 and D6S262.   
Panel D) Allele identification of Ned labeled fragments, D5S346 and D7S481.   
Figure 1b.  Electropherograms of Group II Markers 
Panel A) Complete spectrum of Group II markers labeled with specific fluorescent tags.  
D9S171 and D17S250 labeled with Ned, D3S1262 and D2S123 labeled with Hex, and 
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D18S61 labeled with Fam.  Similar to Group I, the spectral overlap of Hex into Fam is 
observed at D3S1262 and D2S123. 
Panel B) Allele identification of Fam labeled fragment, D18S61.  Nonspecific stutters 
from the spectral overlap of Hex into Fam were excluded from identification by filtering 
out with specified marker and analysis method parameters.  
Panel C) Allele identification of Hex labeled fragments, D3S1262 and D2S123. 
Panel D) Allele identification of Ned labeled fragments, D9S171 and D17S250.  
Nonspecific peaks outside of marker size range were excluded from identification by 
filtering out with specified marker and analysis method parameters. 
Figure 2.  Microsatellite Profiles of Group I Markers of Family Members in Lineage 
Determination.  Relationships among family members were predicted based on the 
patterns of inheritance of microsatellite alleles.  Child 1 and 2 are monozygotic twins. 
Panel Child 1) Microsatellite profile of Child 1.  Automated identification accurately 
called inherited microsatellite alleles of dinucleotide markers, which can be traced back 
to the microsatellite profiles of Parent 1 and Parent 2. 
Panel Parent 1) Microsatellite profile of Parent 1.  Alleles have been automatically 
called with optimized methods. 
Panel Parent 2) Microsatellite profile of Parent 2.  Alleles have been automatically 
called with optimized methods. 
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Panel Child 2) Microsatellite profile of Child 2.  Automated identification accurately 
called inherited microsatellite alleles of dinucleotide markers, which can be traced back 




Table 1.  Microsatellite Markers Size Ranges and Primer Design and 
Concentrations in Multiplex PCR Reactions.  Summary of microsatellite markers, 
population size ranges for amplified products with specific primer sets, and primer 
sequences, labels, and concentrations used in multiplex PCR amplifications. 
Table 2a.  Analysis Method Parameters.  Optimized parameters for automated specific 
peak detection, precise sizing, and accurate allele identification. 
Table 2b.  Marker Parameters.  Defined size ranges of markers, which include the 
GDB human genome database population distribution and additional allele sizes observed 
in our studies, for optimal automatic allele identification. 
Table 3.  Process Reproducibility. 
Table 3a) Process Reproducibility with Group I Markers.  Summary of sizing values 
of identified alleles for each marker from the amplification of control samples in 23 
independent runs over the course of five months.  Averages, standard deviations, and % 
CVs have been calculated for each allele.  Process variation include sample preparation, 
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PCR amplification, fragment separation, peak detection, and fragment sizing.  Although 
sizing is very precise, automatic identification failed in samples highlighted in blue due to 
the presence of nonspecific signals that have surpassed preset threshold values. 
Table 3b) Process Reproducibility with Group II Markers.  Summary of sizing values 
of identified alleles for each marker from the amplification of control samples in 18 
independent runs over the course of one month.  Averages, standard deviations, and 
%CVs have been calculated for each allele.  Process variation include sample 
preparation, PCR amplification, fragment separation, peak detection, and fragment sizing. 
Table 4.  Process Accuracy 
Table 4a) Process Accuracy with Group I Markers.  Summary of results from 
automated allele identification of 1920 dinucleotide markers and 960 mononucleotide 
markers from 239 T-cell clones from different subjects organized by dates of processing. 
Table 4b) Process Accuracy with Group II Markers.  Summary of results from 
automated allele identification of 1560 dinucleotide markers from 156 T-cell clones from 
different subjects organized by dates of processing.   
Percent deviation from expected values connotes the percent of alleles that have been 
miscalled, indicated by an “*”.  Misidentification can represent failure in any part of the 
process from sample preparation, PCR amplification, fragment separation, peak 
detection, fragment sizing, to automated allele calling.  We manually analyzed all 
discordant samples and found failures to be related to either the interferences of 
nonspecific signals above threshold values or from the unequal amplification of alleles.  
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These failures were likely related to poor sample quality since control samples performed 
optimally in the same runs. 
Supplemental Table 1.  Summary of all samples and clones from 27 subjects and 1 cell 
line that have been amplified with optimized PCR conditions using Groups I and II 
microsatellite markers.  Raw data from these samples have been used to optimize marker 
and method parameters to achieve specific peak detection, precise fragment sizing, and 
accurate automated allele identification.  Sizing values and allele calls for 5508 alleles 
have been automatically analyzed with optimized parameters and bin settings, using the 
Advanced Peak Detection Algorithm in combination with the Local Southern Sizing 
Method.  Samples or clones with “*” represent those that have been miscalled by 
automated allele identification. 
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Marker Range of PCR 
Product Size 
(bases) 
Dye Primer Sequences (5’->3’) [Primer], 
uM 
1 BAT25 130 Fam FamTCGCCTCCAAGAATGTAAGT 0.25 
    gtgtcttTCTGCATTTTAACTATGGCTC 0.25 
1 BAT26 120 Hex HexTGACTACTTTTGACTTCAGCC 2.00 
    gtgtcttAACCATTCAACATTTTTAACCC 2.00 
1 D3S3623 207-223 Fam FamCCATGTTGGTTAAAGGCAAG 0.25 
    gtgtcttCTCTGAACTGAAGTGACCTCC 0.25 
1 D5S346 73-109 Ned NedTTCAGGGAATTGAGAGTTACAG 0.25 
    gtgtcttACTCACTCTAGTGATAAATCGGG 0.25 
1 D6S262 167-183 Hex HexATTCTTACTGCTGGAAAACCAT 0.50 
    gtgtcttGGAGCATAGTTACCCTTAAAATC 0.50 
1 D7S481 181-199 Ned NedTTCTCATTCTCACCCCCAT 0.50 
    gtgtcttATCCCCCACTGTCTCCAA 0.50 
2 D2S123 203-233 Hex gtgtcttAACAGGATGCCTGCCTTTA 1.00 
    HexGGACTTTCCACCTATGGGAC 1.00 
2 D3S1262 132-146 Hex HexCAGTTGTGAGCCACCATGTC 2.00 
    gtgtcttCAGTTTTTATGGACGGGGT 2.00 
2 D9S171 103-122 Ned NedGTGAACCTCATCTCTGTCTGCT 0.25 
    gtgtcttACTTTATTAACAATCAGTATTTTCC 0.25 
2 D17S250 188-203 Ned gtgtcttGTAAGCATAAAAAGGAAGAATCA 0.50 
    NedTTACAGGCATGAGCCACTC 0.50 
2 D18S61 150-176 Fam FamATTTCTAAGAGGACTCCCAAAC 0.50 
    gtgtcttGAAACTCAGGAGCATGGTTATG 0.50 
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Table 2b – Marker Parameters. 
 
Multiplex PCR Reaction 1 
Markers Min Size Max Size Marker Repeat 
BAT25 115 145 1 
BAT26 105 135 1 
D3S3623 200 230 2 
D5S346 70 115 2 
D6S262 160 190 2 
D7S481 175 205 2 
Multiplex PCR Reaction 2 
Markers Min Size Max Size Marker Repeat 
D2S123 200 240 2 
D3S1262 120 150 2 
D9S171 100 130 2 
D17S250 175 210 2 
D18S61 145 180 2 
Multiplex PCR 
Peak Detection Algorithm 
Size Calling Method 
Min Peak Half Width 
Multiplex PCR 
Mono Cut-off value 
Range Filter: From To From To 
Blue 146 194 181 250 
Green 136 159 151 199 
Yellow 116 174 131 174 










Peak Detector Tab 
Group I Group II 
Local Southern 
Advanced 
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Table 3a – Process Reproducibility with Group I Markers. 
Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2
Bins 127 128 122 219 225 92 94 176 182 187 193
Run Date
1 1 5/31/2005 127.1 122.0 219.1 225.4 91.9 94.2 176.5 182.3 187.6 193.4
2 2 6/6/2005 126.7 121.8 218.3 224.6 91.6 93.8 176.0 181.8 187.1 192.9
3 6/6/2005 126.6 121.6 218.2 224.7 91.6 93.8 176.0 181.8 187.1 192.7
3 4 6/8/2005 126.8 121.7 218.8 225.0 91.8 94.0 176.3 182.0 187.3 193.2
5 6/8/2005 126.9 121.8 218.9 225.1 91.8 94.0 176.3 182.1 187.4 193.2
4 6 6/15/2005 127.0 128.0 122.0 219.1 225.4 92.0 94.1 176.4 182.3 187.6 193.4
7 6/15/2005 126.9 128.0 121.9 219.0 225.3 91.9 94.1 176.4 182.2 187.4 193.3
5 8 6/16/2005 127.0 128.0 121.9 219.1 225.4 91.9 94.1 176.5 182.3 187.6 193.3
9 6/16/2005 126.9 127.9 121.8 218.7 224.9 91.7 94.0 176.2 182.1 187.4 193.2
10 6/16/2005 127.1 128.1 122.0 218.9 225.2 91.8 94.0 176.4 182.2 187.6 193.3
6 11 6/20/2005 126.9 121.8 218.5 224.8 91.7 93.9 176.2 182.0 187.3 193.0
7 12 6/30/2005 126.7 121.6 218.4 224.6 91.6 93.8 176.0 181.8 187.0 192.8
13 6/30/2005 126.7 121.6 218.4 224.6 91.7 93.9 176.1 181.9 187.2 192.9
8 14 7/6/2005 126.8 121.6 218.6 224.8 91.6 93.9 176.1 181.9 187.2 192.9
9 15 7/7/2005 126.7 121.7 218.5 224.8 91.6 93.8 176.1 181.9 187.2 192.9
16 7/7/2005 126.7 121.6 218.6 224.8 91.6 93.8 176.0 181.9 187.2 193.0
10 17 7/8/2005 126.8 121.7 218.4 224.6 91.7 93.9 176.1 181.8 187.2 192.9
18 7/8/2005 126.8 121.8 218.4 224.6 91.6 93.9 176.1 181.9 187.2 192.9
19 7/8/2005 127.0 121.8 218.7 224.9 91.8 94.0 176.3 182.1 187.4 193.1
11 20 7/11/2005 126.8 121.8 218.6 224.8 91.7 93.9 176.1 182.0 187.2 193.0
12 21 7/13/2005 126.9 121.9 218.9 225.1 91.8 94.1 176.3 182.1 187.5 193.2
13 22 7/15/2005 126.9 121.8 218.5 224.7 91.7 93.9 176.0 181.8 187.2 192.9
14 23 11/14/2005 126.8 121.6 218.5 224.8 91.6 93.8 176.1 181.9 187.2 192.9
Average 126.8 128.0 121.8 218.6 224.9 91.7 93.9 176.2 182.0 187.3 193.0
SD 0.12 0.06 0.12 0.27 0.27 0.11 0.12 0.17 0.17 0.18 0.19
%CV 0.09% 0.05% 0.10% 0.12% 0.12% 0.12% 0.12% 0.09% 0.10% 0.10% 0.10%
Run 
Count




Bat25 Bat26 D3S3623 D5S346 D6S262 D7S481
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Table 3b – Process Reproducibility with Group II Markers. 
 
Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2
Bins 195 202 154 219 136 142 113
Run Date
1 1 6/15/2005 195.5 201.9 153.9 218.5 135.8 142.0 113.1
2 6/15/2005 195.7 202.1 154.0 218.8 135.9 142.0 113.2
3 6/15/2005 195.7 201.9 154.0 218.7 135.7 142.0 113.2
2 4 6/16/2005 195.8 202.1 154.1 218.9 135.8 142.1 113.2
5 6/16/2005 195.7 202.1 154.0 218.9 135.8 142.0 113.2
6 6/16/2005 195.7 202.0 153.9 218.8 135.8 142.1 113.2
7 6/16/2005 195.8 202.1 154.0 218.8 135.8 142.0 113.2
3 8 6/20/2005 195.6 201.8 154.0 218.4 135.9 142.1 113.1
9 6/20/2005 195.6 201.8 154.0 218.6 135.9 142.1 113.2
4 10 6/30/2005 195.5 201.7 153.9 218.3 135.8 142.0 113.0
11 6/30/2005 195.4 201.7 153.9 218.2 135.7 142.0 112.9
5 12 7/5/2005 195.5 201.7 153.9 218.4 135.6 141.9 112.9
13 7/5/2005 195.5 201.8 153.8 218.5 135.6 141.8 112.9
6 14 7/6/2005 195.5 201.8 153.8 218.5 135.6 141.9 113.0
7 15 7/7/2005 195.5 201.8 153.8 218.5 135.6 141.9 112.9
8 16 7/8/2005 195.5 201.8 154.0 218.4 135.9 142.1 113.2
9 17 7/13/2005 195.7 202.1 154.1 218.9 135.9 142.2 113.3
10 18 7/14/2005 195.6 201.8 153.9 218.5 135.8 142.1 113.0
Average 195.6 201.9 153.9 218.6 135.8 142.0 113.1
SD 0.12 0.15 0.11 0.22 0.10 0.10 0.12





Reproducibility of Control Samples - Group II Markers
Microsatellite Markers
D17S250 D18S61 D2S123 D3S1262 D9S171
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Table 4a – Process Accuracy with Group I Markers. 
Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2
UC002B1 6/30/2005 4 128 122 219 225 103 105 182 201 32
m19 1 127 128 122 219 225 103 105 182 201 8
UC005B1 6/30/2005 2 126 127 123 225 227 92 103 172 182 199 203 16
m3 1 127 123 225 227 92 103 172 182 199 203 8
UC006B1 6/30/2005 3 127 122 219 223 92 105 179 184 193 201 24
UC009B1 6/30/2005 3 127 123 219 221 94 170 172 203 24
Subtotal Count 6/30/2005 14 112 0.00%
CD003B1_2 7/5/2005 32 127 122 219 92 105 182 185 197 201 256
m9 1 127 128 122 219 92 105 182 185 197 201 8
m5, m8 2 126 127 122 219 92 105 182 185 197 201 16
m40 1 127 121 122 219 92 105 182 185 197 201 8
Subtotal Count 7/5/2005 36 288 0.00%
CD006B1 7/6/2005 32 127 122 219 92 94 182 184 187 197 256
6 126 127 122 219 92 94 182 184 187 197 48
m15, m20 2 127 121 122 219 92 94 182 184 187 197 16
m25 1 127 122 219 * 92 94 182 184 187 197 8
Subtotal Count 7/6/2005 41 328 0.30%
CD006B1 7/7/2005 1 127 122 219 92 94 182 184 187 197
CD009B1 7/7/2005 5 127 123 219 221 94 170 172 203 40
m31 1 127 122 219 221 94 170 172 203 8
m51 1 127 128 123 219 221 94 170 172 203 8
11 127 122 123 219 221 94 170 172 203 88
CD010B1_2 7/7/2005 2 126 127 121 219 225 89 92 172 176 187 199 16
m18, m1 2 126 127 121 219 225 * 92 172 176 187 199 16
m15 1 126 127 121 219 225 89 92 * 176 187 199 8
Subtotal Count 7/7/2005 24 192 1.04%
CD013B1 7/8/2005 1 128 122 219 223 103 107 172 182 199 8
m5_1ul 1 128 122 219 * * 107 172 182 199 8
2 128 129 122 219 223 103 107 172 182 199 16
m10_0.4ul extra sample 128 129 122 * 223 103 107 172 182 199 8
3 129 122 219 103 107 172 182 199 24
Subtotal Count 7/8/2005 7 56 4.69%
Automated Allele Identification - Group I Markers
D5S346 D6S262 D7S481
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Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2
CD015B1 7/11/2005 8 126 122 221 92 101 184 186 187 197 64
m13 1 126 122 221 92 101 184 * 187 197 8
Subtotal Count 7/11/2005 9 72 1.39%
CD015B1 7/13/2005 24 126 122 221 92 101 184 186 187 197 192
4 126 127 122 221 92 101 184 186 187 197 32
m48 1 126 127 122 221 92* 101* 184 186 187 * 8
m50 1 126 127 122 123 221 92 101 184 186 187 197 8
m53, m56 2 127 122 221 92 101 184 186 187 197 16
CD009B1 7/13/2005 4 127 123 219 221 94 170 172 203 32
CD013B1 7/13/2005 1 128 129 122 219 103 107 172 182 199 8
Subtotal Count 7/13/2005 37 296 1.01%
CD003B1_2 7/15/2005 2 127 122 219 92 105 182 185 197 201
CD009B1 7/15/2005 6 127 123 219 221 94 170 172 203 48
m3, m44 2 127 122 123 219 221 94 170 172 203 16
m2 1 127 122 219 221 94 170 172 203 8
CD010B1_2 7/15/2005 5 127 121 219 225 89 92 172 176 187 199 40
Subtotal Count 7/15/2005 16 128 0.00%
CD010B1_2 7/18/2005 3 127 121 219 225 89 92 172 176 187 199 24
CD013B1 7/18/2005 10 128 129 122 219 103 107 172 182 199 80
m36 1 128 122 219 103 107 172 182 199 8
m17, m57 2 129 122 219 103 107 172 182 199 16
m58 1 129 122 123 219 103 107 172 182 199 8
CD014B1 7/18/2005 22 127 122 219 221 89 92 174 182 199 201 176
m22 1 127 122 219 221 89 92 174 182 199 * 8
m24 1 127 122 219 221 89 92 174 182 * 201 8
CD015B1 7/18/2005 2 126 122 221 92 101 184 186 187 197 16
Subtotal Count 7/18/2005 43 344 0.58%
CD005B1 11/14/2005 4 127 122 219 221 89 92 170 172 187 203 32
m5 1 127 122 123 219 221 89 92 170 172 187 203 8
CD008B1 11/14/2005 6 127 122 221 227 94 101 182 184 197 199 48
m2 1 127 128 122 221 227 94 101 182 184 197 199 8
Subtotal Count 11/14/2005 12 96 0.00%
Total Count All Days 239 1920 0.63%
Automated Allele Identification - Group I Markers
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Table 4b – Process Accuracy with Group II Markers. 
Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2
UC002B1 6/30/2005 5 193 200 152 168 216 219 136 138 113 50
UC005B1 6/30/2005 3 191 195 168 172 219 236 136 105 113 30
UC006B1 6/30/2005 3 191 204 166 172 219 132 142 113 115 30
UC009B1 6/30/2005 3 191 195 154 170 219 132 136 115 121 30
Subtotal Count 6/30/2005 14 140 0.00%
CD003B1_2 7/5/2005 32 181 202 164 172 223 236 136 113 320
Subtotal Count 7/5/2005 32 320 0.00%
CD006B1 7/6/2005 40 191 168 170 219 132 146 111 113 400
m51 1 191 168 170 219 132 146 * 113 10
Subtotal Count 7/6/2005 41 410 0.24%
CD009B1 7/7/2005 18 191 195 154 170 219 132 136 115 121 180
m103 1 * 195 154 170 219 132 136 115 121 10
m8 1 191 195 154 170 219 132 136 115 * 10
CD010B1_2 7/7/2005 8 195 197 168 170 221 236 136 105 119 80
Subtotal Count 7/7/2005 28 280 0.71%
CD009B1 7/13/2005 4 191 195 154 170 219 132 136 115 121 40
m37_1ul 1 191 * 154 * 219 132 136 115 121 10
CD013B1 7/13/2005 2 193 168 176 219 221 136 138 105 113 20
m5_1ul 1 193 168 * 219 221 136 * 105 113 10
CD015B1 7/13/2005 5 191 170 176 219 221 142 107 111 50
m12 1 191 170 176 219 221 142 * 107 111 10
Subtotal Count 7/13/2005 14 140 3.57%
CD015B1 7/14/2005 24 191 170 176 219 221 142 107 111 240
m31 1 * 170 176 219 221 142 107 111 10
m29 1 191 * 176 219 221 142 * 107 111 10
m58 1 191 170 176 219 221 142 * 107 111 10
Subtotal Count 7/14/2005 27 270 1.48%
Total Count All Days 156 1560 0.90%
# of 
Clone(s)




Automated Allele Identification - Group II Markers
Run DateSubject Microsatellite Markers
D17S250 D18S61 D2S123 D3S1262 D9S171
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
1 1 6/20/05 UC001B1WT1 BAT25 127 127.0 1265 9380 3489
1 6/20/05 UC001B1WT1 BAT26 122 121.9 645 5477 3422
1 6/20/05 UC001B1WT1 D3S3623 219 225 218.7 225.0 1032 798 8861 6879 4616 4689
1 6/20/05 UC001B1WT1 D5S346 94 94.1 1058 8760 3048
1 6/20/05 UC001B1WT1 D6S262 170 182 170.5 182.1 955 754 7746 5951 4025 4173
1 6/20/05 UC001B1WT1 D7S481 193 203 193.2 203.0 525 448 4557 3578 4314 4435
1 1 6/30/05 UC002B1M10 BAT25 128 128.0 2069 14692 3416
2 6/30/05 UC002B1M13 BAT25 128 127.9 3356 22927 3392
3 6/30/05 UC002B1M18 BAT25 128 127.9 3983 27636 3374
4 6/30/05 UC002B1M19 BAT25 127 128 126.9 127.9 3089 3230 21129 22839 3354 3367
5 6/30/05 UC002B1M15 BAT25 128 127.9 2680 19046 3387
1 1 6/30/05 UC002B1M10 BAT26 122 121.9 834 7061 3338
2 6/30/05 UC002B1M13 BAT26 122 121.8 1152 10490 3314
3 6/30/05 UC002B1M18 BAT26 122 121.8 1347 12492 3296
4 6/30/05 UC002B1M19 BAT26 122 121.8 1210 11217 3290
5 6/30/05 UC002B1M15 BAT26 122 121.8 1110 10722 3310
1 1 6/30/05 UC002B1M10 D3S3623 219 225 218.7 225.0 1972 1418 17181 12244 4504 4575
2 6/30/05 UC002B1M13 D3S3623 219 225 218.6 224.8 3247 2373 27308 20529 4477 4546
3 6/30/05 UC002B1M18 D3S3623 219 225 218.5 224.8 4747 3209 40702 27494 4453 4523
4 6/30/05 UC002B1M19 D3S3623 219 225 218.6 224.8 3857 2696 32835 22756 4443 4512
5 6/30/05 UC002B1M15 D3S3623 219 225 218.6 224.8 3186 2153 27366 18228 4468 4537
1 1 6/30/05 UC002B1M10 D5S346 103 105 102.7 104.8 1139 658 8820 5005 3085 3113
2 6/30/05 UC002B1M13 D5S346 103 105 102.7 104.7 1524 959 11588 6808 3062 3089
3 6/30/05 UC002B1M18 D5S346 103 105 102.6 104.7 1828 1115 13843 8038 3044 3072
4 6/30/05 UC002B1M19 D5S346 103 105 102.5 104.6 1555 905 12080 6525 3038 3066
5 6/30/05 UC002B1M15 D5S346 103 105 102.7 104.7 1404 875 10932 6222 3058 3085
1 1 6/30/05 UC002B1M15 D6S262 182 181.9 3645 29399 4038
2 6/30/05 UC002B1M10 D6S262 182 182.0 2409 19505 4072
3 6/30/05 UC002B1M13 D6S262 182 182.0 3971 33101 4046
4 6/30/05 UC002B1M18 D6S262 182 181.9 5329 42627 4024
5 6/30/05 UC002B1M19 D6S262 182 181.9 4451 35784 4015
1 1 6/30/05 UC002B1M15 D7S481 201 200.7 1421 12935 4268
2 6/30/05 UC002B1M10 D7S481 201 200.9 960 8721 4304
3 6/30/05 UC002B1M13 D7S481 201 200.7 1496 13725 4276
4 6/30/05 UC002B1M18 D7S481 201 200.7 2003 18085 4254
5 6/30/05 UC002B1M19 D7S481 201 200.7 1801 16079 4244
1 1 6/20/05 UC003B1WT1 BAT25 127 126.9 1170 8159 3468
1 6/20/05 UC003B1WT1 BAT26 122 121.8 565 4867 3401
1 6/20/05 UC003B1WT1 D3S3623 221 225 220.7 224.9 1861 1430 15404 11551 4611 4659
1 6/20/05 UC003B1WT1 D5S346 94 103 94.0 102.7 422 296 3203 2052 3029 3144
1 6/20/05 UC003B1WT1 D6S262 172 172.4 3171 27136 4026
1 6/20/05 UC003B1WT1 D7S481 187 195 187.3 195.1 785 599 7091 5370 4214 4311
1 1 6/30/05 UC005B1M18 BAT25 126 127 125.8 126.9 2651 2783 19352 20126 3321 3334
2 6/30/05 UC005B1M3 BAT25 127 126.8 2910 21789 3351
3 6/30/05 UC005B1M5 BAT25 126 127 125.7 126.8 2963 3093 21597 23465 3331 3344
1 1 6/30/05 UC005B1M18 BAT26 123 122.8 589 4864 3282
2 6/30/05 UC005B1M3 BAT26 123 122.7 777 6286 3299
3 6/30/05 UC005B1M5 BAT26 123 122.6 729 6486 3291
1 1 6/30/05 UC005B1M18 D3S3623 225 227 224.7 226.8 2957 1778 23983 13700 4491 4514
2 6/30/05 UC005B1M3 D3S3623 225 227 224.7 226.8 2719 1672 21709 12754 4511 4534
3 6/30/05 UC005B1M5 D3S3623 225 227 224.7 226.7 2978 1803 23775 13874 4499 4522
1 1 6/30/05 UC005B1M18 D5S346 92 103 91.7 102.6 1539 663 13041 5061 2879 3019
2 6/30/05 UC005B1M3 D5S346 92 103 91.7 102.6 1802 736 14988 5564 2895 3036
3 6/30/05 UC005B1M5 D5S346 92 103 91.6 102.5 1880 753 16220 6028 2889 3029
1 1 6/30/05 UC005B1M18 D6S262 172 182 172.2 181.8 2026 1199 16767 9312 3876 3994
2 6/30/05 UC005B1M3 D6S262 172 182 172.3 181.9 1928 1233 15244 9585 3895 4014
Supplemental Table 1: Group I Microsatellite Markers Bat25, Bat26, D3S3623, D5S346, D6S262, D7S481
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Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
3 6/30/05 UC005B1M5 D6S262 172 182 172.2 181.9 2106 1378 17204 10837 3886 4004
1 1 6/30/05 UC005B1M18 D7S481 199 203 198.7 202.8 671 484 5495 3849 4200 4247
2 6/30/05 UC005B1M3 D7S481 199 203 198.7 202.8 589 452 4715 3443 4219 4266
3 6/30/05 UC005B1M5 D7S481 199 203 198.7 202.7 695 527 5695 4028 4209 4255
1 1 6/30/05 UC006B1M5 BAT25 127 126.8 635 4914 3328
2 6/30/05 UC006B1M9 BAT25 127 126.8 5672 42412 3341
3 6/30/05 UC006B1M15 BAT25 127 126.8 1481 10842 3331
1 1 6/30/05 UC006B1M5 BAT26 122 121.7 228 1870 3263
2 6/30/05 UC006B1M9 BAT26 122 121.6 1297 11027 3276
3 6/30/05 UC006B1M15 BAT26 122 121.7 557 4846 3266
1 1 6/30/05 UC006B1M5 D3S3623 219 223 218.5 222.6 462 218 3736 1646 4412 4457
2 6/30/05 UC006B1M9 D3S3623 219 223 218.5 222.6 4394 3057 35535 24251 4430 4476
3 6/30/05 UC006B1M15 D3S3623 219 223 218.5 222.6 1292 895 10547 7040 4414 4460
1 1 6/30/05 UC006B1M5 D5S346 92 105 91.7 104.6 596 318 4950 2562 2874 3041
2 6/30/05 UC006B1M9 D5S346 92 105 91.6 104.7 3072 1072 25119 8516 2885 3054
3 6/30/05 UC006B1M15 D5S346 92 105 91.7 104.6 1930 878 15942 7144 2877 3044
1 1 6/30/05 UC006B1M5 D6S262 179 184 179.1 183.8 455 291 3682 2184 3951 4009
2 6/30/05 UC006B1M9 D6S262 179 184 179.1 183.8 3469 2074 30558 15476 3968 4026
3 6/30/05 UC006B1M15 D6S262 179 184 179.2 183.9 1675 845 15146 6371 3955 4013
1 1 6/30/05 UC006B1M5 D7S481 193 201 192.9 200.6 149 140 1257 1349 4120 4213
2 6/30/05 UC006B1M9 D7S481 193 201 193.0 200.6 814 656 7189 5823 4138 4231
3 6/30/05 UC006B1M15 D7S481 193 201 193.1 200.6 283 230 2554 2127 4125 4216
1 1 6/30/05 UC009B1M6 BAT25 127 126.9 4114 30655 3350
2 6/30/05 UC009B1M8 BAT25 127 126.8 3909 28809 3343
3 6/30/05 UC009B1M11 BAT25 127 126.9 3085 23039 3318
1 1 6/30/05 UC009B1M6 BAT26 123 122.7 1039 8744 3297
2 6/30/05 UC009B1M8 BAT26 123 122.7 1169 10033 3291
3 6/30/05 UC009B1M11 BAT26 123 122.7 790 6581 3266
1 1 6/30/05 UC009B1M6 D3S3623 219 221 218.5 220.6 4635 3069 36964 23611 4441 4464
2 6/30/05 UC009B1M8 D3S3623 219 221 218.5 220.6 4152 2697 33449 20694 4429 4452
3 6/30/05 UC009B1M11 D3S3623 219 221 218.4 220.5 3724 2360 29843 17743 4398 4421
1 1 6/30/05 UC009B1M6 D5S346 94 93.8 4153 33835 2921
2 6/30/05 UC009B1M8 D5S346 94 93.8 4437 36908 2916
3 6/30/05 UC009B1M11 D5S346 94 93.9 2993 24426 2893
1 1 6/30/05 UC009B1M6 D6S262 170 172 170.3 172.3 4129 2827 31429 20014 3869 3893
2 6/30/05 UC009B1M8 D6S262 170 172 170.3 172.2 4510 3009 34597 21637 3861 3884
3 6/30/05 UC009B1M11 D6S262 170 172 170.2 172.2 3516 2355 26242 17024 3833 3857
1 1 6/30/05 UC009B1M6 D7S481 203 202.8 1362 11605 4265
2 6/30/05 UC009B1M11 D7S481 203 202.7 1209 10443 4224
3 6/30/05 UC009B1M8 D7S481 203 202.8 1302 11337 4254
1 1 6/20/05 UC018B1WT6 BAT25 127 126.9 1686 12333 3457
1 6/20/05 UC018B1WT6 BAT26 122 121.9 728 6503 3392
1 6/20/05 UC018B1WT6 D3S3623 219 227 218.7 227.0 2520 1874 21136 15819 4575 4670
1 6/20/05 UC018B1WT6* D5S346* 92 94 91.7 94.0 746 514 5782 3489 2990 3020
1 6/20/05 UC018B1WT6 D6S262 172 186 172.4 185.9 2068 1287 16601 10300 4014 4184
1 6/20/05 UC018B1WT6 D7S481 195 201 195.1 200.8 804 707 6934 6398 4299 4370
1 1 7/5/05 CD3B1_2M9 BAT25 127 128 126.7 127.8 6102 5859 53465 41605 3374 3387
2 7/5/05 CD3B1_2M19 BAT25 127 126.7 3455 26623 3366
3 7/5/05 CD3B1_2M35 BAT25 127 126.7 4523 34771 3377
4 7/5/05 CD3B1_2M2 BAT25 127 126.8 2493 19386 3406
5 7/5/05 CD3B1_2M10 BAT25 127 126.7 5877 45731 3342
6 7/5/05 CD3B1_2M20 BAT25 127 126.7 1859 14322 3336
7 7/5/05 CD3B1_2M28 BAT25 127 126.7 4190 31789 3346
8 7/5/05 CD3B1_2M36 BAT25 127 126.7 3020 23764 3348
9 7/5/05 CD3B1_2M3 BAT25 127 126.8 3942 32224 3431
10 7/5/05 CD3B1_2M11 BAT25 127 126.7 3939 31363 3390
11 7/5/05 CD3B1_2M21 BAT25 127 126.7 1095 8963 3384
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Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
12 7/5/05 CD3B1_2M37 BAT25 127 126.7 3306 26074 3386
13 7/5/05 CD3B1_2M12 BAT25 127 126.7 6235 50533 3382
14 7/5/05 CD3B1_2M22 BAT25 127 126.7 5460 42388 3374
15 7/5/05 CD3B1_2M30 BAT25 127 126.8 1410 11197 3392
16 7/5/05 CD3B1_2M38 BAT25 127 126.8 2844 22038 3390
17 7/5/05 CD3B1_2M5 BAT25 126 127 125.7 126.7 5586 5835 47446 63024 3364 3377
18 7/5/05 CD3B1_2M13 BAT25 127 126.7 4071 31972 3378
19 7/5/05 CD3B1_2M23 BAT25 127 126.8 1675 13427 3360
20 7/5/05 CD3B1_2M31 BAT25 127 126.8 2950 22804 3397
21 7/5/05 CD3B1_2M39 BAT25 127 126.8 2813 22147 3366
22 7/5/05 CD3B1_2M6 BAT25 127 126.7 5156 40503 3346
23 7/5/05 CD3B1_2M14 BAT25 127 126.7 3067 23695 3341
24 7/5/05 CD3B1_2M24 BAT25 127 126.7 2074 16211 3330
25 7/5/05 CD3B1_2M32 BAT25 127 126.8 3279 25015 3367
26 7/5/05 CD3B1_2M40 BAT25 127 126.8 665 5072 3339
27 7/5/05 CD3B1_2M7 BAT25 127 126.8 5287 43581 3390
28 7/5/05 CD3B1_2M16 BAT25 127 126.7 2600 20288 3381
29 7/5/05 CD3B1_2M25 BAT25 127 126.7 890 7285 3376
30 7/5/05 CD3B1_2M33 BAT25 127 126.8 1609 12218 3410
31 7/5/05 CD3B1_2M41 BAT25 127 126.7 464 3875 3370
32 7/5/05 CD3B1_2M8 BAT25 126 127 125.7 126.7 5433 5674 43022 57907 3372 3385
33 7/5/05 CD3B1_2M17 BAT25 127 126.7 5694 43893 3378
34 7/5/05 CD3B1_2M26 BAT25 127 126.7 2337 18602 3376
35 7/5/05 CD3B1_2M34 BAT25 127 126.7 4576 35609 3411
36 7/5/05 CD3B1_2M42 BAT25 127 126.8 1664 12978 3376
2 37 7/15/05 CD003B1_2M4 BAT25 127 126.9 1433 11635 3583
38 7/15/05 CD003B1_2M27 BAT25 127 127.0 838 7386 3590
1 1 7/5/05 CD3B1_2M9 BAT26 122 121.7 2215 21948 3309
2 7/5/05 CD3B1_2M19 BAT26 122 121.7 1025 9744 3302
3 7/5/05 CD3B1_2M35 BAT26 122 121.7 1415 13673 3312
4 7/5/05 CD3B1_2M2 BAT26 122 121.7 954 9330 3339
5 7/5/05 CD3B1_2M10 BAT26 122 121.7 1938 19827 3278
6 7/5/05 CD3B1_2M20 BAT26 122 121.7 618 5762 3271
7 7/5/05 CD3B1_2M28 BAT26 122 121.7 1204 12806 3282
8 7/5/05 CD3B1_2M36 BAT26 122 121.7 1042 10421 3284
9 7/5/05 CD3B1_2M3 BAT26 122 121.7 1558 15423 3365
10 7/5/05 CD3B1_2M11 BAT26 122 121.6 1458 15798 3324
11 7/5/05 CD3B1_2M21 BAT26 122 121.7 253 2390 3319
12 7/5/05 CD3B1_2M37 BAT26 122 121.7 979 9511 3321
13 7/5/05 CD3B1_2M12 BAT26 122 121.6 2069 20632 3317
14 7/5/05 CD3B1_2M22 BAT26 122 121.7 1667 16206 3309
15 7/5/05 CD3B1_2M30 BAT26 122 121.7 602 5461 3326
16 7/5/05 CD3B1_2M38 BAT26 122 121.7 891 8573 3325
17 7/5/05 CD3B1_2M5 BAT26 122 121.7 3024 33985 3312
18 7/5/05 CD3B1_2M13 BAT26 122 121.7 889 8764 3313
19 7/5/05 CD3B1_2M23 BAT26 122 121.6 447 4339 3294
20 7/5/05 CD3B1_2M31 BAT26 122 121.7 1046 9808 3332
21 7/5/05 CD3B1_2M39 BAT26 122 121.7 968 8810 3301
22 7/5/05 CD3B1_2M6 BAT26 122 121.7 2067 21425 3282
23 7/5/05 CD3B1_2M14 BAT26 122 121.7 1109 11165 3277
24 7/5/05 CD3B1_2M24 BAT26 122 121.6 733 7128 3265
25 7/5/05 CD3B1_2M32 BAT26 122 121.7 1216 10953 3302
26 7/5/05 CD3B1_2M40 BAT26 121 122 120.7 121.7 269 277 2252 2300 3262 3275
27 7/5/05 CD3B1_2M7 BAT26 122 121.8 1667 17431 3326
28 7/5/05 CD3B1_2M16 BAT26 122 121.7 731 7017 3316
29 7/5/05 CD3B1_2M25 BAT26 122 121.7 309 2807 3312
30 7/5/05 CD3B1_2M33 BAT26 122 121.7 470 4336 3344
31 7/5/05 CD3B1_2M41 BAT26 122 121.7 331 3108 3306
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32 7/5/05 CD3B1_2M8 BAT26 122 121.8 3676 37770 3321
33 7/5/05 CD3B1_2M17 BAT26 122 121.7 2128 21016 3313
34 7/5/05 CD3B1_2M26 BAT26 122 121.7 929 9028 3311
35 7/5/05 CD3B1_2M34 BAT26 122 121.7 1515 14910 3346
36 7/5/05 CD3B1_2M42 BAT26 122 121.7 553 5115 3310
2 37 7/15/05 CD003B1_2M4 BAT26 122 121.9 688 5846 3516
38 7/15/05 CD003B1_2M27 BAT26 122 121.9 282 2319 3523
1 1 7/5/05 CD3B1_2M9 D3S3623 219 218.6 7519 68213 4481
2 7/5/05 CD3B1_2M19 D3S3623 219 218.5 2888 25548 4471
3 7/5/05 CD3B1_2M35 D3S3623 219 218.5 6977 61645 4484
4 7/5/05 CD3B1_2M2 D3S3623 219 218.6 3224 29763 4525
5 7/5/05 CD3B1_2M10 D3S3623 219 218.5 7499 81260 4441
6 7/5/05 CD3B1_2M20 D3S3623 219 218.5 2696 23128 4433
7 7/5/05 CD3B1_2M28 D3S3623 219 218.5 6963 60947 4445
8 7/5/05 CD3B1_2M36 D3S3623 219 218.5 4826 42123 4447
9 7/5/05 CD3B1_2M3 D3S3623 219 218.7 6194 59461 4556
10 7/5/05 CD3B1_2M11 D3S3623 219 218.4 7453 71550 4497
11 7/5/05 CD3B1_2M21 D3S3623 219 218.5 1323 11504 4490
12 7/5/05 CD3B1_2M37 D3S3623 219 218.5 6153 53952 4491
13 7/5/05 CD3B1_2M12 D3S3623 219 218.5 7680 87566 4493
14 7/5/05 CD3B1_2M22 D3S3623 219 218.6 7573 73315 4482
15 7/5/05 CD3B1_2M30 D3S3623 219 218.5 1455 12778 4502
16 7/5/05 CD3B1_2M38 D3S3623 219 218.5 5947 53357 4499
17 7/5/05 CD3B1_2M5 D3S3623 219 218.5 8644 120010 4486
18 7/5/05 CD3B1_2M13 D3S3623 219 218.5 5757 51031 4487
19 7/5/05 CD3B1_2M23 D3S3623 219 218.5 2891 25555 4462
20 7/5/05 CD3B1_2M31 D3S3623 219 218.5 4820 42320 4508
21 7/5/05 CD3B1_2M39 D3S3623 219 218.6 6061 53518 4469
22 7/5/05 CD3B1_2M6 D3S3623 219 218.5 7426 74145 4446
23 7/5/05 CD3B1_2M14 D3S3623 219 218.6 5141 45589 4442
24 7/5/05 CD3B1_2M24 D3S3623 219 218.4 3028 26205 4424
25 7/5/05 CD3B1_2M32 D3S3623 219 218.5 5385 47173 4471
26 7/5/05 CD3B1_2M40 D3S3623 219 218.6 1501 12791 4435
27 7/5/05 CD3B1_2M7 D3S3623 219 218.4 7354 85309 4498
28 7/5/05 CD3B1_2M16 D3S3623 219 218.5 3661 32296 4488
29 7/5/05 CD3B1_2M25 D3S3623 219 218.5 946 8170 4479
30 7/5/05 CD3B1_2M33 D3S3623 219 218.5 2824 24664 4520
31 7/5/05 CD3B1_2M41 D3S3623 219 218.4 1154 9831 4468
32 7/5/05 CD3B1_2M8 D3S3623 219 218.6 7965 104723 4499
33 7/5/05 CD3B1_2M17 D3S3623 219 218.5 7733 83173 4488
34 7/5/05 CD3B1_2M26 D3S3623 219 218.5 4952 43289 4483
35 7/5/05 CD3B1_2M34 D3S3623 219 218.6 6989 62182 4526
36 7/5/05 CD3B1_2M42 D3S3623 219 218.6 2741 23428 4480
2 37 7/15/05 CD003B1_2M4 D3S3623 219 218.8 1341 12425 4737
38 7/15/05 CD003B1_2M27 D3S3623 219 218.8 483 4446 4738
1 1 7/5/05 CD3B1_2M9 D5S346 92 105 91.7 104.7 5790 1816 47836 14559 2912 3083
2 7/5/05 CD3B1_2M19 D5S346 92 105 91.6 104.6 2624 1087 22104 8443 2905 3076
3 7/5/05 CD3B1_2M35 D5S346 92 105 91.6 104.6 3846 1633 32227 12785 2915 3086
4 7/5/05 CD3B1_2M2 D5S346 92 105 91.6 104.7 1922 993 16403 7833 2940 3112
5 7/5/05 CD3B1_2M10 D5S346 92 105 91.6 104.7 4373 2116 36065 16623 2884 3054
6 7/5/05 CD3B1_2M20 D5S346 92 105 91.6 104.6 1284 884 10576 6706 2878 3047
7 7/5/05 CD3B1_2M28 D5S346 92 105 91.6 104.6 3630 1630 29452 12553 2887 3056
8 7/5/05 CD3B1_2M36 D5S346 92 105 91.6 104.6 2850 1058 23561 8253 2889 3059
9 7/5/05 CD3B1_2M3 D5S346 92 105 91.7 104.7 3517 1483 30143 12056 2963 3136
10 7/5/05 CD3B1_2M11 D5S346 92 105 91.6 104.6 3604 1825 30658 14653 2927 3098
11 7/5/05 CD3B1_2M21 D5S346 92 105 91.5 104.6 192 198 1722 1516 2921 3093
12 7/5/05 CD3B1_2M37 D5S346 92 105 91.6 104.6 2495 1432 20807 11505 2924 3095
13 7/5/05 CD3B1_2M12 D5S346 92 105 91.6 104.7 5622 2498 47279 19942 2919 3091
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14 7/5/05 CD3B1_2M22 D5S346 92 105 91.7 104.6 3449 1973 28585 15702 2912 3082
15 7/5/05 CD3B1_2M30 D5S346 92 105 91.6 104.7 2208 1180 18172 9583 2928 3100
16 7/5/05 CD3B1_2M38 D5S346 92 105 91.7 104.7 2053 995 17582 7908 2927 3098
17 7/5/05 CD3B1_2M5 D5S346 92 105 91.7 104.7 6727 3340 56840 26513 2915 3086
18 7/5/05 CD3B1_2M13 D5S346 92 105 91.6 104.7 2612 1317 21684 10547 2915 3087
19 7/5/05 CD3B1_2M23 D5S346 92 105 91.6 104.6 1328 707 11470 5689 2899 3070
20 7/5/05 CD3B1_2M31 D5S346 92 105 91.6 104.7 2336 1159 19652 9251 2933 3105
21 7/5/05 CD3B1_2M39 D5S346 92 105 91.6 104.7 2644 1159 22528 9224 2905 3076
22 7/5/05 CD3B1_2M6 D5S346 92 105 91.6 104.6 4282 2087 35363 16319 2887 3057
23 7/5/05 CD3B1_2M14 D5S346 92 105 91.5 104.6 3700 1744 30847 13723 2882 3052
24 7/5/05 CD3B1_2M24 D5S346 92 105 91.6 104.6 1944 1182 16166 9156 2873 3042
25 7/5/05 CD3B1_2M32 D5S346 92 105 91.6 104.6 2675 1159 21938 8944 2906 3076
26 7/5/05 CD3B1_2M40 D5S346 92 105 91.6 104.6 757 243 6039 1836 2881 3050
27 7/5/05 CD3B1_2M7 D5S346 92 105 91.6 104.6 3337 1492 29415 11728 2927 3098
28 7/5/05 CD3B1_2M16 D5S346 92 105 91.7 104.6 1835 964 15465 7745 2919 3089
29 7/5/05 CD3B1_2M25 D5S346 92 105 91.6 104.6 459 433 4683 3682 2915 3086
30 7/5/05 CD3B1_2M33 D5S346 92 105 91.6 104.7 1109 664 9506 5401 2946 3118
31 7/5/05 CD3B1_2M41 D5S346 92 105 91.6 104.6 632 339 5249 3147 2911 3081
32 7/5/05 CD3B1_2M8 D5S346 92 105 91.6 104.6 5403 2755 44971 21892 2922 3093
33 7/5/05 CD3B1_2M17 D5S346 92 105 91.6 104.6 4346 2081 35725 16426 2915 3086
34 7/5/05 CD3B1_2M26 D5S346 92 105 91.6 104.6 1838 1038 14961 7989 2914 3085
35 7/5/05 CD3B1_2M34 D5S346 92 105 91.6 104.7 3520 1624 29593 13028 2946 3118
36 7/5/05 CD3B1_2M42 D5S346 92 105 91.6 104.6 1477 847 12025 6671 2914 3084
2 37 7/15/05 CD003B1_2M4 D5S346 92 105 91.8 104.8 797 403 6767 3136 3103 3280
38 7/15/05 CD003B1_2M27 D5S346 92 105 91.9 104.8 404 279 3488 2400 3111 3287
1 1 7/5/05 CD3B1_2M9 D6S262 182 185 182.0 184.9 2832 3323 26313 26376 4046 4082
2 7/5/05 CD3B1_2M19 D6S262 182 185 181.9 184.8 1360 2219 12068 17242 4037 4073
3 7/5/05 CD3B1_2M35 D6S262 182 185 181.8 184.8 2319 2766 20218 21656 4049 4086
4 7/5/05 CD3B1_2M2 D6S262 182 185 182.0 185.0 1089 1396 10351 11569 4085 4122
5 7/5/05 CD3B1_2M10 D6S262 182 185 181.9 184.9 3547 3849 31620 29751 4009 4046
6 7/5/05 CD3B1_2M20 D6S262 182 185 181.8 184.7 976 909 8372 6652 4002 4038
7 7/5/05 CD3B1_2M28 D6S262 182 185 181.9 184.9 2701 3066 23048 23714 4013 4050
8 7/5/05 CD3B1_2M36 D6S262 182 185 181.9 184.8 1657 1702 14288 12872 4015 4051
9 7/5/05 CD3B1_2M3 D6S262 182 185 181.9 184.9 1966 2374 18597 20160 4113 4151
10 7/5/05 CD3B1_2M11 D6S262 182 185 181.9 184.8 2575 2798 22856 21769 4062 4099
11 7/5/05 CD3B1_2M21 D6S262 182 185 181.8 184.8 297 528 2146 3966 4055 4092
12 7/5/05 CD3B1_2M37 D6S262 182 185 181.8 184.8 1665 1805 14636 13988 4057 4094
13 7/5/05 CD3B1_2M12 D6S262 182 185 181.9 184.9 3699 4111 32698 32165 4057 4094
14 7/5/05 CD3B1_2M22 D6S262 182 185 181.9 184.8 2682 3011 23599 23300 4046 4083
15 7/5/05 CD3B1_2M30 D6S262 182 185 181.9 184.8 862 1287 6995 10283 4066 4102
16 7/5/05 CD3B1_2M38 D6S262 182 185 181.9 184.9 1322 1637 12235 13061 4063 4100
17 7/5/05 CD3B1_2M5 D6S262 182 185 181.9 184.9 5467 5803 49998 49938 4050 4087
18 7/5/05 CD3B1_2M13 D6S262 182 185 181.9 184.9 1590 1877 13971 14736 4051 4088
19 7/5/05 CD3B1_2M23 D6S262 182 185 181.9 184.8 831 984 6798 7399 4029 4065
20 7/5/05 CD3B1_2M31 D6S262 182 185 181.9 184.8 1460 1862 12870 14449 4072 4108
21 7/5/05 CD3B1_2M39 D6S262 182 185 181.9 184.9 1837 2053 14694 15308 4035 4072
22 7/5/05 CD3B1_2M6 D6S262 182 185 181.9 184.8 3272 3899 30806 31600 4014 4050
23 7/5/05 CD3B1_2M14 D6S262 182 185 181.8 184.8 2152 2439 17452 19025 4009 4046
24 7/5/05 CD3B1_2M24 D6S262 182 185 181.9 184.8 926 1429 7277 10963 3994 4030
25 7/5/05 CD3B1_2M32 D6S262 182 185 181.9 184.8 1985 2510 16438 19119 4037 4073
26 7/5/05 CD3B1_2M40 D6S262 182 185 181.9 184.8 368 191 2546 1343 4004 4040
27 7/5/05 CD3B1_2M7 D6S262 182 185 181.9 184.8 2647 3149 25586 26239 4064 4100
28 7/5/05 CD3B1_2M16 D6S262 182 185 181.9 184.8 1503 1487 13139 11490 4053 4090
29 7/5/05 CD3B1_2M25 D6S262 182 185 181.9 184.9 423 319 3205 2274 4046 4083
30 7/5/05 CD3B1_2M33 D6S262 182 185 181.9 184.9 890 921 7142 7137 4084 4121
31 7/5/05 CD3B1_2M41 D6S262 182 185 181.9 184.9 414 477 3196 3368 4037 4074
32 7/5/05 CD3B1_2M8 D6S262 182 185 181.9 184.9 3660 4823 35468 40907 4061 4098
33 7/5/05 CD3B1_2M17 D6S262 182 185 181.9 184.9 3394 3240 29975 24938 4052 4089
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34 7/5/05 CD3B1_2M26 D6S262 182 185 181.8 184.8 1292 1266 11279 9748 4048 4085
35 7/5/05 CD3B1_2M34 D6S262 182 185 181.9 184.9 2313 2741 20747 21716 4087 4125
36 7/5/05 CD3B1_2M42 D6S262 182 185 182.0 184.9 697 908 5690 6667 4046 4083
2 37 7/15/05 CD003B1_2M4 D6S262 182 185 182.0 185.0 465 509 4626 3920 4283 4322
38 7/15/05 CD003B1_2M27 D6S262 182 185 182.1 185.1 204 225 1666 1713 4287 4326
1 1 7/5/05 CD3B1_2M9 D7S481 197 201 196.8 200.6 866 738 7774 6484 4231 4278
2 7/5/05 CD3B1_2M19 D7S481 197 201 196.8 200.7 417 273 3712 2351 4222 4270
3 7/5/05 CD3B1_2M35 D7S481 197 201 196.7 200.6 806 586 6992 4902 4234 4282
4 7/5/05 CD3B1_2M2 D7S481 197 201 196.8 200.8 476 368 4503 3403 4272 4321
5 7/5/05 CD3B1_2M10 D7S481 197 201 196.9 200.7 1150 982 10053 8539 4194 4241
6 7/5/05 CD3B1_2M20 D7S481 197 201 196.8 200.6 378 332 3314 2844 4186 4233
7 7/5/05 CD3B1_2M28 D7S481 197 201 196.8 200.6 715 617 6393 5400 4198 4244
8 7/5/05 CD3B1_2M36 D7S481 197 201 196.8 200.6 599 411 5361 3518 4199 4246
9 7/5/05 CD3B1_2M3 D7S481 197 201 196.8 200.7 920 728 9179 6908 4301 4350
10 7/5/05 CD3B1_2M11 D7S481 197 201 196.8 200.7 917 673 8331 5904 4248 4296
11 7/5/05 CD3B1_2M21 D7S481 197 201 196.8 200.6 398 179 3567 1499 4241 4288
12 7/5/05 CD3B1_2M37 D7S481 197 201 196.8 200.6 685 533 5994 4597 4242 4289
13 7/5/05 CD3B1_2M12 D7S481 197 201 196.8 200.7 1279 1000 11705 8936 4243 4291
14 7/5/05 CD3B1_2M22 D7S481 197 201 196.8 200.7 928 689 8393 6343 4232 4280
15 7/5/05 CD3B1_2M30 D7S481 197 201 196.8 200.6 360 259 3133 2346 4252 4299
16 7/5/05 CD3B1_2M38 D7S481 197 201 196.8 200.6 682 526 6300 4713 4249 4296
17 7/5/05 CD3B1_2M5 D7S481 197 201 196.8 200.7 2242 1780 21633 16576 4236 4284
18 7/5/05 CD3B1_2M13 D7S481 197 201 196.7 200.6 637 455 5866 4091 4236 4284
19 7/5/05 CD3B1_2M23 D7S481 197 201 196.8 200.6 549 431 4927 3921 4213 4260
20 7/5/05 CD3B1_2M31 D7S481 197 201 196.8 200.6 557 442 4901 3861 4258 4305
21 7/5/05 CD3B1_2M39 D7S481 197 201 196.8 200.6 632 489 5528 4072 4220 4267
22 7/5/05 CD3B1_2M6 D7S481 197 201 196.8 200.7 1607 1082 15256 10057 4198 4246
23 7/5/05 CD3B1_2M14 D7S481 197 201 196.8 200.6 657 546 6021 4986 4193 4240
24 7/5/05 CD3B1_2M24 D7S481 197 201 196.8 200.5 464 435 4200 3908 4178 4224
25 7/5/05 CD3B1_2M32 D7S481 197 201 196.8 200.6 761 555 6762 4800 4222 4269
26 7/5/05 CD3B1_2M40 D7S481 197 201 196.8 200.6 209 227 1656 2187 4188 4234
27 7/5/05 CD3B1_2M7 D7S481 197 201 196.9 200.7 1725 1075 16758 9825 4250 4297
28 7/5/05 CD3B1_2M16 D7S481 197 201 196.7 200.6 484 381 4183 3303 4238 4286
29 7/5/05 CD3B1_2M25 D7S481 197 201 196.8 200.6 283 253 2525 2106 4231 4278
30 7/5/05 CD3B1_2M33 D7S481 197 201 196.8 200.7 388 308 3310 2696 4270 4318
31 7/5/05 CD3B1_2M41 D7S481 197 201 196.8 200.6 306 173 2678 1519 4221 4268
32 7/5/05 CD3B1_2M8 D7S481 197 201 196.7 200.6 1932 1333 18836 12281 4247 4295
33 7/5/05 CD3B1_2M17 D7S481 197 201 196.8 200.7 1357 1070 12062 9392 4238 4286
34 7/5/05 CD3B1_2M26 D7S481 197 201 196.7 200.5 726 393 6813 3464 4233 4280
35 7/5/05 CD3B1_2M34 D7S481 197 201 196.8 200.7 946 705 8484 6204 4274 4322
36 7/5/05 CD3B1_2M42 D7S481 197 201 196.9 200.7 555 472 4693 4104 4231 4278
2 37 7/15/05 CD003B1_2M4 D7S481 197 201 196.9 200.9 344 368 3186 3596 4476 4526
38 7/15/05 CD003B1_2M27 D7S481 197 201 197.0 200.9 155 107 1385 1002 4479 4528
1 1 11/14/05 CD005B1M1 BAT25 127 126.7 4464 36399 3613
2 11/14/05 CD005B1M3 BAT25 127 126.8 4908 39330 3571
3 11/14/05 CD005B1M4 BAT25 127 126.8 5652 45929 3623
4 11/14/05 CD005B1M5 BAT25 127 126.8 5135 40184 3641
5 11/14/05 CD005B1M6 BAT25 127 126.7 1901 14887 3641
1 1 11/14/05 CD005B1M1 BAT26 122 121.6 1142 11109 3546
2 11/14/05 CD005B1M3 BAT26 122 121.7 1267 11464 3505
3 11/14/05 CD005B1M4 BAT26 122 121.7 1473 18149 3555
4 11/14/05 CD005B1M5 BAT26 122 123 121.7 122.6 1053 1038 10234 9114 3572 3584
5 11/14/05 CD005B1M6 BAT26 122 121.6 432 4034 3573
1 1 11/14/05 CD005B1M1 D3S3623 219 221 218.5 220.6 5206 3272 49122 29103 4753 4777
2 11/14/05 CD005B1M3 D3S3623 219 221 218.5 220.6 5339 3502 47888 29214 4699 4723
3 11/14/05 CD005B1M4 D3S3623 219 221 218.5 220.7 6127 3874 59701 34803 4765 4790
4 11/14/05 CD005B1M5 D3S3623 219 221 218.6 220.7 5612 3553 51246 30574 4800 4825
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5 11/14/05 CD005B1M6 D3S3623 219 221 218.7 220.7 2270 1222 21939 10710 4799 4823
1 1 11/14/05 CD005B1M1 D5S346 89 92 89.4 91.6 4847 3276 38404 23755 3107 3136
2 11/14/05 CD005B1M3 D5S346 89 92 89.4 91.6 4714 3305 35188 22887 3069 3099
3 11/14/05 CD005B1M4 D5S346 89 92 89.4 91.6 5050 3483 39547 25254 3114 3144
4 11/14/05 CD005B1M5 D5S346 89 92 89.5 91.7 4676 3332 36415 23973 3127 3157
5 11/14/05 CD005B1M6 D5S346 89 92 89.4 91.6 1491 1390 11503 10504 3128 3158
1 1 11/14/05 CD005B1M1 D6S262 170 172 170.2 172.2 5580 3893 53698 30679 4155 4181
2 11/14/05 CD005B1M3 D6S262 170 172 170.3 172.1 5627 4169 53869 31551 4109 4132
3 11/14/05 CD005B1M4 D6S262 170 172 170.3 172.2 5879 4066 54810 33604 4166 4191
4 11/14/05 CD005B1M5 D6S262 170 172 170.3 172.2 5238 3789 46654 29988 4192 4217
5 11/14/05 CD005B1M6 D6S262 170 172 170.3 172.2 1728 1289 15605 10515 4191 4217
1 1 11/14/05 CD005B1M1 D7S481 187 203 187.1 202.8 1478 1054 17154 11680 4373 4570
2 11/14/05 CD005B1M3 D7S481 187 203 187.1 202.6 1548 1125 17410 12220 4323 4516
3 11/14/05 CD005B1M4 D7S481 187 203 187.2 202.7 1945 1289 23342 14579 4384 4581
4 11/14/05 CD005B1M5 D7S481 187 203 187.2 202.8 1427 1007 16212 10915 4413 4613
5 11/14/05 CD005B1M6 D7S481 187 203 187.2 202.7 884 497 10298 5360 4412 4611
1 1 7/6/05 CD006B1_M2 BAT25 127 126.8 5074 39843 3458
2 7/6/05 CD006B1_M15 BAT25 127 126.7 4773 36909 3370
3 7/6/05 CD006B1_M27 BAT25 127 126.7 5760 43960 3336
4 7/6/05 CD006B1_M37 BAT25 127 126.7 4665 36540 3355
5 7/6/05 CD006B1_M48 BAT25 126 127 125.7 126.7 3430 3451 26520 26576 3369 3382
6 7/6/05 CD006B1_M73 BAT25 127 126.7 2198 16507 3400
7 7/6/05 CD006B1_M3 BAT25 127 126.9 3370 25994 3433
8 7/6/05 CD006B1_M16 BAT25 127 126.7 4315 32285 3345
9 7/6/05 CD006B1_M28 BAT25 127 126.7 1632 12946 3310
10 7/6/05 CD006B1_M39 BAT25 127 126.7 4453 34223 3332
11 7/6/05 CD006B1_M51 BAT25 126 127 125.7 126.7 2919 2791 22239 20267 3345 3358
12 7/6/05 CD006B1_M75 BAT25 127 126.7 1455 11367 3377
13 7/6/05 CD006B1_M4 BAT25 127 126.8 4001 32409 3448
14 7/6/05 CD006B1_M19 BAT25 127 126.7 4055 31561 3364
15 7/6/05 CD006B1_M29 BAT25 127 126.7 1865 14564 3328
16 7/6/05 CD006B1_M40 BAT25 127 126.7 2766 21896 3349
17 7/6/05 CD006B1_M52 BAT25 126 127 125.7 126.7 1177 1155 9409 9473 3361 3374
18 7/6/05 CD006B1_M82 BAT25 126 127 125.7 126.7 1410 1473 10808 11008 3356 3369
19 7/6/05 CD006B1_M5 BAT25 127 126.8 1906 15664 3462
20 7/6/05 CD006B1_M20 BAT25 127 126.8 5064 39598 3373
21 7/6/05 CD006B1_M31 BAT25 127 126.7 3521 27714 3340
22 7/6/05 CD006B1_M41 BAT25 127 126.8 4763 36838 3359
23 7/6/05 CD006B1_M53 BAT25 127 126.8 4402 33656 3383
24 7/6/05 CD006B1_M6 BAT25 127 126.7 4019 30955 3368
25 7/6/05 CD006B1_M23 BAT25 127 126.7 4219 33601 3352
26 7/6/05 CD006B1_M32 BAT25 127 126.8 3699 28597 3369
27 7/6/05 CD006B1_M54 BAT25 127 126.8 2331 17732 3397
28 7/6/05 CD006B1_M8 BAT25 127 126.7 3512 27101 3345
29 7/6/05 CD006B1_M24 BAT25 127 126.7 3433 26915 3327
30 7/6/05 CD006B1_M33 BAT25 127 126.7 2995 22859 3345
31 7/6/05 CD006B1_M45 BAT25 127 126.8 3358 25521 3354
32 7/6/05 CD006B1_M55 BAT25 127 126.7 3096 23883 3374
33 7/6/05 CD006B1_M9 BAT25 127 126.7 3810 30145 3364
34 7/6/05 CD006B1_M25 BAT25 127 126.7 4586 35535 3347
35 7/6/05 CD006B1_M35 BAT25 127 126.7 3550 27843 3363
36 7/6/05 CD006B1_M46 BAT25 127 126.7 3582 27405 3375
37 7/6/05 CD006B1_M65 BAT25 126 127 125.7 126.7 4018 4191 30549 32410 3376 3389
38 7/6/05 CD006B1_M26 BAT25 127 126.7 5326 41660 3355
39 7/6/05 CD006B1_M36 BAT25 126 127 125.7 126.7 3375 3465 25166 25960 3360 3373
40 7/6/05 CD006B1_M47 BAT25 127 126.7 3361 25704 3386
41 7/6/05 CD006B1_M67 BAT25 127 126.8 4823 35875 3399
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2 42 7/7/05 CD006B1_M43-REDO BAT25 127 126.7 2189 17457 3368
1 1 7/6/05 CD006B1_M2 BAT26 122 121.7 1920 17595 3392
2 7/6/05 CD006B1_M15 BAT26 121 122 120.8 121.7 1250 1296 11544 11169 3294 3305
3 7/6/05 CD006B1_M27 BAT26 122 121.6 1621 15660 3271
4 7/6/05 CD006B1_M37 BAT26 122 121.6 1324 12369 3290
5 7/6/05 CD006B1_M48 BAT26 122 121.6 1117 10353 3316
6 7/6/05 CD006B1_M73 BAT26 122 121.6 638 5323 3334
7 7/6/05 CD006B1_M3 BAT26 122 121.8 1430 12655 3367
8 7/6/05 CD006B1_M16 BAT26 122 121.6 1317 12805 3280
9 7/6/05 CD006B1_M28 BAT26 122 121.6 682 6414 3246
10 7/6/05 CD006B1_M39 BAT26 122 121.6 1443 13327 3267
11 7/6/05 CD006B1_M51 BAT26 122 121.6 913 8127 3293
12 7/6/05 CD006B1_M75 BAT26 122 121.6 597 4846 3312
13 7/6/05 CD006B1_M4 BAT26 122 121.8 1688 15142 3382
14 7/6/05 CD006B1_M19 BAT26 122 121.6 1371 13260 3299
15 7/6/05 CD006B1_M29 BAT26 122 121.7 791 7789 3265
16 7/6/05 CD006B1_M40 BAT26 122 121.6 1021 9941 3284
17 7/6/05 CD006B1_M52 BAT26 122 121.6 456 4177 3309
18 7/6/05 CD006B1_M82 BAT26 122 121.6 495 4135 3304
19 7/6/05 CD006B1_M5 BAT26 122 121.8 587 5146 3396
20 7/6/05 CD006B1_M20 BAT26 121 122 120.7 121.6 1391 1463 12582 12620 3295 3307
21 7/6/05 CD006B1_M31 BAT26 122 121.7 1145 10585 3276
22 7/6/05 CD006B1_M41 BAT26 122 121.7 1550 14269 3294
23 7/6/05 CD006B1_M53 BAT26 122 121.7 1444 13415 3318
24 7/6/05 CD006B1_M6 BAT26 122 121.7 1282 11865 3303
25 7/6/05 CD006B1_M23 BAT26 122 121.7 1211 11722 3287
26 7/6/05 CD006B1_M32 BAT26 122 121.7 1230 11494 3304
27 7/6/05 CD006B1_M54 BAT26 122 121.7 814 7497 3331
28 7/6/05 CD006B1_M8 BAT26 122 121.7 1326 12725 3280
29 7/6/05 CD006B1_M24 BAT26 122 121.6 1226 11899 3262
30 7/6/05 CD006B1_M33 BAT26 122 121.6 1126 10654 3280
31 7/6/05 CD006B1_M45 BAT26 122 121.7 1223 11687 3289
32 7/6/05 CD006B1_M55 BAT26 122 121.6 1062 9905 3309
33 7/6/05 CD006B1_M9 BAT26 122 121.7 1349 12953 3299
34 7/6/05 CD006B1_M25 BAT26 122 121.6 1620 15792 3282
35 7/6/05 CD006B1_M35 BAT26 122 121.6 1386 13491 3298
36 7/6/05 CD006B1_M46 BAT26 122 121.6 1272 12004 3310
37 7/6/05 CD006B1_M65 BAT26 122 121.7 1337 12982 3324
38 7/6/05 CD006B1_M26 BAT26 122 121.7 1717 15616 3291
39 7/6/05 CD006B1_M36 BAT26 122 121.6 1275 11339 3308
40 7/6/05 CD006B1_M47 BAT26 122 121.6 1128 9666 3320
41 7/6/05 CD006B1_M67 BAT26 122 121.7 1185 11066 3333
2 42 7/7/05 CD006B1_M43-REDO BAT26 122 121.7 665 5628 3303
1 1 7/6/05 CD006B1_M2 D3S3623 219 218.8 6929 68467 4586
2 7/6/05 CD006B1_M15 D3S3623 219 218.6 7553 70369 4476
3 7/6/05 CD006B1_M27 D3S3623 219 218.4 7716 77139 4435
4 7/6/05 CD006B1_M37 D3S3623 219 218.5 5503 49573 4459
5 7/6/05 CD006B1_M48 D3S3623 219 218.6 5322 48360 4493
6 7/6/05 CD006B1_M73 D3S3623 219 218.6 3663 32050 4513
7 7/6/05 CD006B1_M3 D3S3623 219 218.7 4823 44230 4555
8 7/6/05 CD006B1_M16 D3S3623 219 218.5 6216 55792 4445
9 7/6/05 CD006B1_M28 D3S3623 219 218.5 2586 22979 4401
10 7/6/05 CD006B1_M39 D3S3623 219 218.4 7235 64896 4430
11 7/6/05 CD006B1_M51 D3S3623 219 218.5 4279 38406 4462
12 7/6/05 CD006B1_M75 D3S3623 219 218.6 2520 22222 4486
13 7/6/05 CD006B1_M4 D3S3623 219 218.7 6042 55116 4571
14 7/6/05 CD006B1_M19 D3S3623 219 218.6 6853 61369 4462
15 7/6/05 CD006B1_M29 D3S3623 219 218.4 3386 30308 4420
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16 7/6/05 CD006B1_M40 D3S3623 219 218.5 4994 45906 4446
17 7/6/05 CD006B1_M52 D3S3623 219 218.6 2351 20135 4477
18 7/6/05 CD006B1_M82 D3S3623 219 218.5 2281 20118 4464
19 7/6/05 CD006B1_M5 D3S3623 219 218.8 2912 27084 4593
20 7/6/05 CD006B1_M20 D3S3623 219 218.6 7697 79401 4479
21 7/6/05 CD006B1_M31 D3S3623 219 218.5 7242 63971 4440
22 7/6/05 CD006B1_M41 D3S3623 219 218.6 7517 69225 4462
23 7/6/05 CD006B1_M53 D3S3623 219 218.6 7537 70897 4492
24 7/6/05 CD006B1_M6 D3S3623 219 218.6 6935 62061 4473
25 7/6/05 CD006B1_M23 D3S3623 219 218.5 7261 64610 4451
26 7/6/05 CD006B1_M32 D3S3623 219 218.6 6760 60977 4472
27 7/6/05 CD006B1_M54 D3S3623 219 218.5 4879 44590 4509
28 7/6/05 CD006B1_M8 D3S3623 219 218.5 5283 46965 4446
29 7/6/05 CD006B1_M24 D3S3623 219 218.6 6169 54733 4420
30 7/6/05 CD006B1_M33 D3S3623 219 218.5 4877 43677 4442
31 7/6/05 CD006B1_M45 D3S3623 219 218.6 5944 53145 4456
32 7/6/05 CD006B1_M55 D3S3623 219 218.6 5486 48995 4482
33 7/6/05 CD006B1_M9 D3S3623 219 218.6 6231 56090 4463
34 7/6/05 CD006B1_M25* D3S3623* 219 223 218.5 222.7 6107 1412 54407 11319 4440 4487
35 7/6/05 CD006B1_M35 D3S3623 219 218.5 5506 49575 4459
36 7/6/05 CD006B1_M46 D3S3623 219 218.5 5934 53163 4476
37 7/6/05 CD006B1_M65 D3S3623 219 218.6 6652 60507 4494
38 7/6/05 CD006B1_M26 D3S3623 219 218.6 7522 71306 4457
39 7/6/05 CD006B1_M36 D3S3623 219 218.5 5356 47327 4477
40 7/6/05 CD006B1_M47 D3S3623 219 218.6 5738 51323 4494
41 7/6/05 CD006B1_M67 D3S3623 219 218.6 6414 57625 4511
2 42 7/7/05 CD006B1_M43-REDO D3S3623 219 218.5 3867 34557 4474
1 1 7/6/05 CD006B1_M2 D5S346 92 94 91.7 93.9 3824 2545 30121 18558 2987 3017
2 7/6/05 CD006B1_M15 D5S346 92 94 91.6 93.8 4043 2668 31279 19336 2908 2937
3 7/6/05 CD006B1_M27 D5S346 92 94 91.6 93.9 4830 3076 36990 21852 2877 2906
4 7/6/05 CD006B1_M37 D5S346 92 94 91.6 93.8 3207 2014 25233 14644 2894 2923
5 7/6/05 CD006B1_M48 D5S346 92 94 91.6 93.9 3058 1751 24099 12787 2918 2948
6 7/6/05 CD006B1_M73 D5S346 92 94 91.6 93.9 1688 1087 13358 8189 2935 2965
7 7/6/05 CD006B1_M3 D5S346 92 94 91.7 94.0 2595 1565 19989 11310 2964 2994
8 7/6/05 CD006B1_M16 D5S346 92 94 91.6 93.8 3286 2268 24858 16104 2886 2914
9 7/6/05 CD006B1_M28 D5S346 92 94 91.6 93.8 1504 952 11339 6538 2854 2883
10 7/6/05 CD006B1_M39 D5S346 92 94 91.6 93.9 3677 2428 27879 17443 2874 2903
11 7/6/05 CD006B1_M51 D5S346 92 94 91.6 93.8 3138 1316 25141 9331 2897 2926
12 7/6/05 CD006B1_M75 D5S346 92 94 91.6 93.8 1397 969 10713 6993 2915 2944
13 7/6/05 CD006B1_M4 D5S346 92 94 91.7 93.9 3519 2348 27309 17318 2979 3008
14 7/6/05 CD006B1_M19 D5S346 92 94 91.6 93.8 3208 2167 24546 15295 2904 2933
15 7/6/05 CD006B1_M29 D5S346 92 94 91.6 93.8 1833 1134 14111 8121 2872 2900
16 7/6/05 CD006B1_M40 D5S346 92 94 91.6 93.8 3131 2221 24280 16222 2891 2919
17 7/6/05 CD006B1_M52 D5S346 92 94 91.6 93.7 1234 726 10199 5342 2913 2941
18 7/6/05 CD006B1_M82 D5S346 92 94 91.6 93.9 1110 736 8538 5273 2910 2939
19 7/6/05 CD006B1_M5 D5S346 92 94 91.7 93.9 1997 1436 15565 10762 2991 3020
20 7/6/05 CD006B1_M20 D5S346 92 94 91.6 93.9 4766 3067 36352 22176 2911 2940
21 7/6/05 CD006B1_M31 D5S346 92 94 91.6 93.9 2701 1918 20822 13998 2881 2910
22 7/6/05 CD006B1_M41 D5S346 92 94 91.6 93.9 3903 2673 30148 19108 2898 2927
23 7/6/05 CD006B1_M53 D5S346 92 94 91.6 93.8 4150 2547 32440 18692 2920 2949
24 7/6/05 CD006B1_M6 D5S346 92 94 91.6 93.8 2824 1892 21617 13549 2907 2935
25 7/6/05 CD006B1_M23 D5S346 92 94 91.6 93.9 3108 2056 23215 14546 2892 2921
26 7/6/05 CD006B1_M32 D5S346 92 94 91.6 93.9 3249 2070 25129 14996 2908 2937
27 7/6/05 CD006B1_M54 D5S346 92 94 91.6 93.9 1934 1429 14743 10274 2932 2961
28 7/6/05 CD006B1_M8 D5S346 92 94 91.5 93.8 3181 2156 24073 15062 2885 2914
29 7/6/05 CD006B1_M24 D5S346 92 94 91.6 93.8 3039 2000 23033 14347 2870 2898
30 7/6/05 CD006B1_M33 D5S346 92 94 91.5 93.8 2668 1654 20537 11718 2886 2915
31 7/6/05 CD006B1_M45 D5S346 92 94 91.6 93.8 3267 2134 25096 15214 2894 2922
184
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
32 7/6/05 CD006B1_M55 D5S346 92 94 91.6 93.8 3089 2027 24241 14447 2912 2941
33 7/6/05 CD006B1_M9 D5S346 92 94 91.6 93.9 3141 2108 24128 15034 2904 2933
34 7/6/05 CD006B1_M25 D5S346 92 94 91.5 93.7 4435 2882 33111 20702 2889 2917
35 7/6/05 CD006B1_M35 D5S346 92 94 91.6 93.8 3666 2379 27972 17028 2904 2933
36 7/6/05 CD006B1_M46 D5S346 92 94 91.6 93.8 3068 2126 23723 15413 2914 2943
37 7/6/05 CD006B1_M65 D5S346 92 94 91.6 93.8 3830 2374 29880 17451 2927 2955
38 7/6/05 CD006B1_M26 D5S346 92 94 91.6 93.8 4463 2997 34220 21614 2896 2924
39 7/6/05 CD006B1_M36 D5S346 92 94 91.6 93.9 2764 1790 21165 12832 2912 2941
40 7/6/05 CD006B1_M47 D5S346 92 94 91.6 93.8 3394 2241 26651 16473 2923 2952
41 7/6/05 CD006B1_M67 D5S346 92 94 91.6 93.8 3579 2244 28025 16404 2934 2963
2 42 7/7/05 CD006B1_M43-REDO D5S346 92 94 91.6 93.8 1848 1214 13961 8669 2907 2936
1 1 7/6/05 CD006B1_M2 D6S262 182 184 182.0 183.9 3916 2367 33904 18224 4143 4167
2 7/6/05 CD006B1_M15 D6S262 182 184 181.8 183.7 4095 2578 32768 19583 4041 4065
3 7/6/05 CD006B1_M27 D6S262 182 184 181.8 183.7 4909 3129 39815 22947 4003 4027
4 7/6/05 CD006B1_M37 D6S262 182 184 181.8 183.7 3097 1878 25551 14363 4025 4049
5 7/6/05 CD006B1_M48 D6S262 182 184 181.9 183.8 2733 1697 22438 12884 4056 4080
6 7/6/05 CD006B1_M73 D6S262 182 184 181.9 183.9 1739 1014 13905 7435 4076 4100
7 7/6/05 CD006B1_M3 D6S262 182 184 181.9 183.9 3055 1750 25591 13461 4114 4139
8 7/6/05 CD006B1_M16 D6S262 182 184 181.8 183.8 4053 2420 33245 18083 4012 4036
9 7/6/05 CD006B1_M28 D6S262 182 184 181.8 183.7 1618 953 12890 6990 3972 3996
10 7/6/05 CD006B1_M39 D6S262 182 184 181.8 183.7 4649 2807 38454 21274 3998 4022
11 7/6/05 CD006B1_M51 D6S262 182 184 181.9 183.8 2342 1624 19006 12342 4028 4052
12 7/6/05 CD006B1_M75 D6S262 182 184 181.9 183.8 1603 989 12443 7247 4050 4074
13 7/6/05 CD006B1_M4 D6S262 182 184 182.0 183.9 3669 2214 31268 16748 4130 4154
14 7/6/05 CD006B1_M19 D6S262 182 184 181.8 183.8 4182 2561 33539 19022 4030 4054
15 7/6/05 CD006B1_M29 D6S262 182 184 181.8 183.7 2050 1256 16906 9380 3991 4015
16 7/6/05 CD006B1_M40 D6S262 182 184 181.8 183.8 3198 2028 25694 14803 4015 4039
17 7/6/05 CD006B1_M52 D6S262 182 184 181.8 183.8 1373 876 11254 6866 4043 4067
18 7/6/05 CD006B1_M82 D6S262 182 184 182.0 183.8 1256 832 10200 5881 4035 4058
19 7/6/05 CD006B1_M5 D6S262 182 184 181.9 183.9 1785 1125 15206 8594 4148 4173
20 7/6/05 CD006B1_M20 D6S262 182 184 181.9 183.8 4836 2966 39675 21962 4044 4068
21 7/6/05 CD006B1_M31 D6S262 182 184 181.9 183.8 3399 2101 27666 15816 4008 4032
22 7/6/05 CD006B1_M41 D6S262 182 184 181.9 183.8 4562 2896 36981 21690 4028 4052
23 7/6/05 CD006B1_M53 D6S262 182 184 181.9 183.8 4355 2682 35334 19914 4056 4080
24 7/6/05 CD006B1_M6 D6S262 182 184 181.9 183.8 3132 1977 25494 15003 4039 4063
25 7/6/05 CD006B1_M23 D6S262 182 184 181.9 183.8 3750 2384 30253 17708 4019 4043
26 7/6/05 CD006B1_M32 D6S262 182 184 182.0 183.9 3449 2132 28332 15913 4039 4063
27 7/6/05 CD006B1_M54 D6S262 182 184 181.9 183.8 2352 1426 19173 10969 4072 4096
28 7/6/05 CD006B1_M8 D6S262 182 184 181.8 183.8 3361 1966 27693 14629 4013 4037
29 7/6/05 CD006B1_M24 D6S262 182 184 181.8 183.8 3632 2212 29291 16498 3990 4014
30 7/6/05 CD006B1_M33 D6S262 182 184 181.8 183.8 2941 1880 23907 14067 4011 4035
31 7/6/05 CD006B1_M45 D6S262 182 184 181.8 183.8 3595 2171 29597 16552 4022 4046
32 7/6/05 CD006B1_M55 D6S262 182 184 182.0 183.9 3257 2012 26704 15193 4047 4071
33 7/6/05 CD006B1_M9 D6S262 182 184 181.9 183.7 3580 2137 29438 16059 4031 4054
34 7/6/05 CD006B1_M25 D6S262 182 184 181.8 183.8 4799 2948 38620 21528 4011 4035
35 7/6/05 CD006B1_M35 D6S262 182 184 181.9 183.8 3665 2176 29485 16112 4029 4053
36 7/6/05 CD006B1_M46 D6S262 182 184 181.8 183.8 3658 2193 30386 16567 4043 4067
37 7/6/05 CD006B1_M65 D6S262 182 184 181.8 183.8 4049 2485 32576 18717 4060 4084
38 7/6/05 CD006B1_M26 D6S262 182 184 181.9 183.8 4497 2867 36901 20892 4024 4048
39 7/6/05 CD006B1_M36 D6S262 182 184 181.8 183.9 2779 1771 22681 13319 4043 4068
40 7/6/05 CD006B1_M47 D6S262 182 184 181.9 183.8 3386 1947 27851 14642 4058 4082
41 7/6/05 CD006B1_M67 D6S262 182 184 181.9 183.9 3502 2073 28826 15653 4074 4098
2 42 7/7/05 CD006B1_M43-REDO D6S262 182 184 181.9 183.8 2305 1461 18649 10829 4040 4064
1 1 7/6/05 CD006B1_M2 D7S481 187 197 187.3 197.0 1082 797 11246 7956 4210 4332
2 7/6/05 CD006B1_M15 D7S481 187 197 187.2 196.8 907 741 8810 6724 4108 4227
3 7/6/05 CD006B1_M27 D7S481 187 197 187.1 196.7 1031 791 9873 7268 4069 4187
4 7/6/05 CD006B1_M37 D7S481 187 197 187.1 196.7 676 506 6525 4626 4091 4210
5 7/6/05 CD006B1_M48 D7S481 187 197 187.3 196.9 729 592 6997 5532 4123 4243
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6 7/6/05 CD006B1_M73 D7S481 187 197 187.2 196.8 391 307 3444 2788 4142 4262
7 7/6/05 CD006B1_M3 D7S481 187 197 187.3 197.0 755 631 7428 5772 4182 4303
8 7/6/05 CD006B1_M16 D7S481 187 197 187.2 196.7 864 627 8270 5780 4078 4196
9 7/6/05 CD006B1_M28 D7S481 187 197 187.2 196.7 504 470 4651 4140 4038 4155
10 7/6/05 CD006B1_M39 D7S481 187 197 187.1 196.7 893 693 8671 6364 4064 4182
11 7/6/05 CD006B1_M51 D7S481 187 197 187.2 196.8 614 706 5862 6318 4094 4213
12 7/6/05 CD006B1_M75 D7S481 187 197 187.2 196.8 403 290 3644 2586 4117 4236
13 7/6/05 CD006B1_M4 D7S481 187 197 187.3 196.9 858 634 8589 6171 4197 4318
14 7/6/05 CD006B1_M19 D7S481 187 197 187.2 196.8 949 749 9101 6773 4096 4214
15 7/6/05 CD006B1_M29 D7S481 187 197 187.1 196.7 653 499 5912 4657 4057 4174
16 7/6/05 CD006B1_M40 D7S481 187 197 187.2 196.7 697 497 6641 4581 4081 4198
17 7/6/05 CD006B1_M52 D7S481 187 197 187.2 196.7 433 390 3989 3556 4109 4227
18 7/6/05 CD006B1_M82 D7S481 187 197 187.2 196.8 278 211 2657 1922 4099 4217
19 7/6/05 CD006B1_M5 D7S481 187 197 187.3 196.9 312 253 3059 2396 4216 4338
20 7/6/05 CD006B1_M20 D7S481 187 197 187.2 196.8 1109 897 10796 8494 4110 4229
21 7/6/05 CD006B1_M31 D7S481 187 197 187.1 196.8 905 682 8607 6250 4073 4192
22 7/6/05 CD006B1_M41 D7S481 187 197 187.2 196.8 1009 802 9599 7356 4094 4213
23 7/6/05 CD006B1_M53 D7S481 187 197 187.1 196.8 946 830 9152 7492 4122 4242
24 7/6/05 CD006B1_M6 D7S481 187 197 187.2 196.8 869 657 8158 6084 4105 4224
25 7/6/05 CD006B1_M23 D7S481 187 197 187.2 196.8 807 734 7722 6841 4085 4203
26 7/6/05 CD006B1_M32 D7S481 187 197 187.2 196.8 793 673 7621 6028 4104 4223
27 7/6/05 CD006B1_M54 D7S481 187 197 187.2 196.8 571 418 5327 3836 4139 4259
28 7/6/05 CD006B1_M8 D7S481 187 197 187.2 196.8 749 596 7114 5490 4079 4198
29 7/6/05 CD006B1_M24 D7S481 187 197 187.1 196.7 851 606 7908 5601 4055 4173
30 7/6/05 CD006B1_M33 D7S481 187 197 187.2 196.8 670 570 6316 5098 4077 4195
31 7/6/05 CD006B1_M45 D7S481 187 197 187.2 196.8 754 596 7197 5593 4089 4207
32 7/6/05 CD006B1_M55 D7S481 187 197 187.3 196.8 734 543 6825 4982 4113 4232
33 7/6/05 CD006B1_M9 D7S481 187 197 187.1 196.8 1004 726 9704 6708 4096 4215
34 7/6/05 CD006B1_M25 D7S481 187 197 187.2 196.7 1131 844 10761 7774 4077 4194
35 7/6/05 CD006B1_M35 D7S481 187 197 187.2 196.8 844 641 8067 5841 4095 4213
36 7/6/05 CD006B1_M46 D7S481 187 197 187.2 196.8 867 638 8619 6045 4110 4228
37 7/6/05 CD006B1_M65 D7S481 187 197 187.2 196.8 920 726 8739 6622 4126 4245
38 7/6/05 CD006B1_M26 D7S481 187 197 187.2 196.8 1105 836 10627 7687 4090 4208
39 7/6/05 CD006B1_M36 D7S481 187 197 187.2 196.8 798 604 7635 5383 4109 4229
40 7/6/05 CD006B1_M47 D7S481 187 197 187.1 196.8 692 526 6628 4831 4124 4244
41 7/6/05 CD006B1_M67 D7S481 187 197 187.2 196.8 752 537 7234 5071 4140 4260
2 42 7/7/05 CD006B1_M43-REDO D7S481 187 197 187.1 196.8 481 401 4510 3437 4105 4225
1 1 11/14/05 CD007B1M2 BAT25 128 127.8 3021 21674 3614
1 11/14/05 CD007B1M2 BAT26 122 121.7 1624 16952 3533
1 11/14/05 CD007B1M2 D3S3623 225 227 224.8 226.8 3794 2351 34573 19950 4817 4841
1 11/14/05 CD007B1M2 D5S346 94 93.8 6563 57316 3152
1 11/14/05 CD007B1M2 D6S262 172 172.1 6331 72428 4168
1 11/14/05 CD007B1M2 D7S481 201 203 200.6 202.7 1193 820 11630 7144 4535 4560
1 1 11/14/05 CD008B1M1 BAT25 127 126.8 3823 30949 3653
2 11/14/05 CD008B1M2 BAT25 127 128 126.8 127.8 5984 5856 57763 49142 3619 3633
3 11/14/05 CD008B1M3 BAT25 127 126.7 4739 39715 3619
4 11/14/05 CD008B1M5 BAT25 127 126.8 5261 40897 3580
5 11/14/05 CD008B1M6 BAT25 127 126.8 4784 37917 3630
6 11/14/05 CD008B1M7 BAT25 127 126.8 4656 36481 3650
7 11/14/05 CD008B1M8 BAT25 127 126.8 4667 38632 3648
1 1 11/14/05 CD008B1M1 BAT26 122 121.6 987 9685 3584
2 11/14/05 CD008B1M2 BAT26 122 121.8 2174 22167 3552
3 11/14/05 CD008B1M3 BAT26 122 121.7 1592 17626 3552
4 11/14/05 CD008B1M5 BAT26 122 121.6 1882 19945 3512
5 11/14/05 CD008B1M6 BAT26 122 121.7 1526 15856 3562
6 11/14/05 CD008B1M7 BAT26 122 121.7 1416 13629 3581
7 11/14/05 CD008B1M8 BAT26 122 121.7 1474 15709 3579
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1 1 11/14/05 CD008B1M1 D3S3623 221 227 220.7 227.1 2477 2903 25988 30943 4837 4913
2 11/14/05 CD008B1M2 D3S3623 221 227 220.7 227.0 6891 7139 66879 69722 4791 4865
3 11/14/05 CD008B1M3 D3S3623 221 227 220.6 226.9 3559 3551 36998 37304 4787 4861
4 11/14/05 CD008B1M5 D3S3623 221 227 220.7 227.0 3998 4028 38652 38954 4737 4810
5 11/14/05 CD008B1M6 D3S3623 221 227 220.7 227.0 3410 3570 36299 37878 4802 4876
6 11/14/05 CD008B1M7 D3S3623 221 227 220.7 227.0 3443 3279 33385 32136 4838 4913
7 11/14/05 CD008B1M8 D3S3623 221 227 220.7 227.0 3199 3311 34146 35330 4831 4906
1 1 11/14/05 CD008B1M1 D5S346 94 101 93.9 100.6 2088 1424 18260 12313 3199 3289
2 11/14/05 CD008B1M2 D5S346 94 101 93.8 100.5 4605 2915 40267 24678 3169 3258
3 11/14/05 CD008B1M3 D5S346 94 101 93.9 100.5 3661 2465 32989 20546 3171 3259
4 11/14/05 CD008B1M5 D5S346 94 101 93.8 100.5 3699 2299 30990 18957 3135 3223
5 11/14/05 CD008B1M6 D5S346 94 101 93.8 100.5 2863 1906 25283 15944 3180 3269
6 11/14/05 CD008B1M7 D5S346 94 101 93.8 100.5 2793 1486 24715 12460 3194 3284
7 11/14/05 CD008B1M8 D5S346 94 101 93.9 100.6 3025 1962 26997 16986 3194 3284
1 1 11/14/05 CD008B1M1 D6S262 182 184 182.0 183.9 2585 1700 23808 14298 4356 4381
2 11/14/05 CD008B1M2 D6S262 182 184 181.9 183.8 5884 5101 55453 40021 4316 4340
3 11/14/05 CD008B1M3 D6S262 182 184 181.9 183.8 4198 2554 38703 20381 4313 4338
4 11/14/05 CD008B1M5 D6S262 182 184 181.9 183.8 4624 2539 40771 19431 4267 4291
5 11/14/05 CD008B1M6 D6S262 182 184 181.9 183.8 3466 1913 32714 15659 4327 4351
6 11/14/05 CD008B1M7 D6S262 182 184 181.9 183.8 3200 1765 28826 13728 4355 4380
7 11/14/05 CD008B1M8 D6S262 182 184 181.9 183.8 3346 1950 31100 15845 4350 4375
1 1 11/14/05 CD008B1M1 D7S481 197 199 196.8 198.8 997 567 10364 5434 4550 4576
2 11/14/05 CD008B1M2 D7S481 197 199 196.8 198.7 1870 1406 18469 12633 4508 4532
3 11/14/05 CD008B1M3 D7S481 197 199 196.7 198.6 1398 981 14603 9496 4504 4529
4 11/14/05 CD008B1M5 D7S481 197 199 196.7 198.7 1783 1194 17235 10557 4456 4481
5 11/14/05 CD008B1M6 D7S481 197 199 196.7 198.7 1602 1044 16417 9886 4518 4543
6 11/14/05 CD008B1M7 D7S481 197 199 196.9 198.7 1617 1046 15988 9746 4551 4575
7 11/14/05 CD008B1M8 D7S481 197 199 196.7 198.6 1536 997 15646 9629 4544 4569
1 1 7/7/05 CD009B1_M27 BAT25 127 126.8 844 7217 3503
2 7/7/05 CD009B1_M70 BAT25 127 126.7 6201 48682 3333
3 7/7/05 CD009B1_M30 BAT25 127 126.8 2677 21716 3482
4 7/7/05 CD009B1_M82 BAT25 127 126.7 5791 44021 3309
5 7/7/05 CD009B1_M31 BAT25 127 126.8 2602 21083 3473
6 7/7/05 CD009B1_M42 BAT25 127 126.8 5815 45919 3384
7 7/7/05 CD009B1_M103 BAT25 127 126.7 1962 15459 3344
8 7/7/05 CD009B1_M33 BAT25 127 126.7 5386 42717 3385
9 7/7/05 CD009B1_M43 BAT25 127 126.7 5233 40078 3354
10 7/7/05 CD009B1_M108 BAT25 127 126.7 6264 52875 3362
11 7/7/05 CD009B1_M34 BAT25 127 126.7 4866 38259 3362
12 7/7/05 CD009B1_M117 BAT25 127 126.7 4937 37497 3341
13 7/7/05 CD009B1_M46 BAT25 127 126.7 2682 20467 3330
14 7/7/05 CD009B1_M11 BAT25 127 126.7 3589 27687 3358
15 7/7/05 CD009B1_M51 BAT25 127 128 126.7 127.7 6311 6151 57787 49330 3365 3378
16 7/7/05 CD009B1_M6 BAT25 127 126.7 2493 19983 3386
17 7/7/05 CD009B1_M8 BAT25 127 126.8 5025 40154 3381
18 7/7/05 CD009B1_M22 BAT25 127 126.7 4578 36505 3339
2 19 7/13/05 CD009B1M5_1uL BAT25 127 126.9 2165 16993 3470
20 7/13/05 CD009B1M9_1uL BAT25 127 126.8 3971 30120 3446
21 7/13/05 CD009B1M37_1uL BAT25 127 126.8 3172 24753 3429
22 7/13/05 CD009B1M12_1uL BAT25 127 126.9 2769 21722 3461
3 23 7/15/05 CD009B1M32 BAT25 127 126.8 3672 28263 3363
24 7/15/05 CD009B1M35 BAT25 127 126.7 846 7364 3371
25 7/15/05 CD009B1M2 BAT25 127 126.9 3609 29244 3597
26 7/15/05 CD009B1M3 BAT25 127 126.9 4593 36240 3436
27 7/15/05 CD009B1M4 BAT25 127 126.8 2008 15795 3416
28 7/15/05 CD009B1M41 BAT25 127 126.8 3388 26779 3452
29 7/15/05 CD009B1M14 BAT25 127 126.7 899 7754 3427
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30 7/15/05 CD009B1M44 BAT25 127 126.8 2372 20053 3462
31 7/15/05 CD009B1M16 BAT25 127 126.8 5589 42070 3428
1 1 7/7/05 CD009B1_M27 BAT26 122 123 121.7 122.7 178 186 1338 1202 3436 3449
2 7/7/05 CD009B1_M70 BAT26 123 122.5 986 8729 3279
3 7/7/05 CD009B1_M30 BAT26 122 123 121.7 122.7 527 536 4125 4128 3415 3428
4 7/7/05 CD009B1_M82 BAT26 123 122.6 1286 11876 3257
5 7/7/05 CD009B1_M31 BAT26 122 121.7 572 4434 3406
6 7/7/05 CD009B1_M42 BAT26 122 123 121.8 122.6 1057 1006 8711 8018 3319 3330
7 7/7/05 CD009B1_M103 BAT26 122 123 121.6 122.5 423 433 3434 3287 3279 3291
8 7/7/05 CD009B1_M33 BAT26 122 123 121.6 122.6 795 812 6747 7021 3320 3332
9 7/7/05 CD009B1_M43 BAT26 122 123 121.6 122.5 835 857 7492 7385 3289 3301
10 7/7/05 CD009B1_M108 BAT26 122 123 121.6 122.6 633 615 5410 4913 3297 3309
11 7/7/05 CD009B1_M34 BAT26 123 122.6 933 7770 3309
12 7/7/05 CD009B1_M117 BAT26 123 122.5 930 7642 3288
13 7/7/05 CD009B1_M46 BAT26 122 123 121.5 122.6 585 589 5114 4758 3265 3278
14 7/7/05 CD009B1_M11 BAT26 122 123 121.6 122.5 569 588 4860 4779 3293 3305
15 7/7/05 CD009B1_M51 BAT26 123 122.5 1507 13141 3311
16 7/7/05 CD009B1_M6 BAT26 122 123 121.6 122.5 490 471 4037 3903 3320 3332
17 7/7/05 CD009B1_M8 BAT26 122 123 121.7 122.6 896 858 7273 7270 3316 3327
18 7/7/05 CD009B1_M22 BAT26 123 122.6 839 7283 3287
2 19 7/13/05 CD009B1M5_1uL BAT26 123 122.8 630 5568 3417
20 7/13/05 CD009B1M9_1uL BAT26 123 122.6 1556 14461 3392
21 7/13/05 CD009B1M37_1uL BAT26 123 122.7 978 9635 3375
22 7/13/05 CD009B1M12_1uL BAT26 123 122.7 1011 9539 3407
3 23 7/15/05 CD009B1M32 BAT26 123 122.6 1198 11101 3310
24 7/15/05 CD009B1M35 BAT26 123 122.6 316 3176 3319
25 7/15/05 CD009B1M2 BAT26 122 121.9 984 7701 3530
26 7/15/05 CD009B1M3 BAT26 122 123 121.7 122.7 986 1032 9355 9333 3370 3382
27 7/15/05 CD009B1M4 BAT26 123 122.7 680 5862 3363
28 7/15/05 CD009B1M41 BAT26 123 122.6 1281 11671 3398
29 7/15/05 CD009B1M14 BAT26 123 122.5 213 2083 3373
30 7/15/05 CD009B1M44 BAT26 122 123 121.7 122.6 723 728 6456 6181 3396 3408
31 7/15/05 CD009B1M16 BAT26 123 122.7 1400 12574 3375
1 1 7/7/05 CD009B1_M27 D3S3623 219 218.8 359 3366 4644
2 7/7/05 CD009B1_M70 D3S3623 219 221 218.5 220.5 5007 3311 40660 25279 4430 4453
3 7/7/05 CD009B1_M30 D3S3623 219 221 218.8 220.9 1701 1216 14946 9966 4619 4644
4 7/7/05 CD009B1_M82 D3S3623 219 221 218.4 220.5 4974 3453 40553 26334 4401 4424
5 7/7/05 CD009B1_M31 D3S3623 219 221 218.8 220.9 1436 860 12839 7058 4602 4626
6 7/7/05 CD009B1_M42 D3S3623 219 221 218.6 220.6 5317 3408 44851 26992 4494 4517
7 7/7/05 CD009B1_M103 D3S3623 219 221 218.5 220.6 2321 1164 19664 9253 4445 4469
8 7/7/05 CD009B1_M33 D3S3623 219 221 218.6 220.6 4644 3172 39107 25118 4494 4517
9 7/7/05 CD009B1_M43 D3S3623 219 221 218.4 220.6 5239 3769 43349 29711 4453 4477
10 7/7/05 CD009B1_M108 D3S3623 219 221 218.5 220.6 2143 1067 17809 8390 4467 4491
11 7/7/05 CD009B1_M34 D3S3623 219 221 218.5 220.6 3998 2708 32988 20815 4466 4490
12 7/7/05 CD009B1_M117 D3S3623 219 221 218.5 220.6 3844 2543 31684 19801 4441 4464
13 7/7/05 CD009B1_M46 D3S3623 219 221 218.5 220.6 811 652 6619 5141 4416 4439
14 7/7/05 CD009B1_M11 D3S3623 219 221 218.5 220.6 2745 1953 23083 15647 4459 4483
15 7/7/05 CD009B1_M51 D3S3623 219 221 218.6 220.6 7004 4619 57883 36688 4469 4492
16 7/7/05 CD009B1_M6 D3S3623 219 221 218.6 220.8 2195 1318 18513 10570 4493 4517
17 7/7/05 CD009B1_M8 D3S3623 219 221 218.5 220.7 4512 2995 37385 23450 4475 4499
18 7/7/05 CD009B1_M22 D3S3623 219 221 218.5 220.6 4182 2807 33983 21365 4428 4451
2 19 7/13/05 CD009B1M5_1uL D3S3623 219 221 218.7 220.7 1222 863 10246 7185 4587 4610
20 7/13/05 CD009B1M9_1uL D3S3623 219 221 218.5 220.6 423 283 3456 2277 4558 4582
21 7/13/05 CD009B1M37_1uL D3S3623 219 221 218.5 220.6 233 173 1963 1479 4539 4563
22 7/13/05 CD009B1M12_1uL D3S3623 219 221 218.6 220.6 799 560 6818 4461 4573 4596
3 23 7/15/05 CD009B1M32 D3S3623 219 221 218.4 220.5 1128 728 9154 5499 4459 4483
24 7/15/05 CD009B1M35 D3S3623 219 221 218.5 220.4 112 77 931 553 4464 4486
25 7/15/05 CD009B1M2 D3S3623 219 221 218.9 220.9 2166 1432 19144 12057 4752 4776
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26 7/15/05 CD009B1M3 D3S3623 219 221 218.5 220.5 1471 888 12142 7182 4545 4568
27 7/15/05 CD009B1M4 D3S3623 219 221 218.5 220.6 495 321 4207 2555 4523 4546
28 7/15/05 CD009B1M41 D3S3623 219 221 218.5 220.6 529 370 4255 2883 4570 4594
29 7/15/05 CD009B1M14 D3S3623 219 221 218.5 220.6 124 65 1176 514 4529 4552
30 7/15/05 CD009B1M44 D3S3623 219 221 218.6 220.6 227 149 1967 1194 4576 4599
31 7/15/05 CD009B1M16 D3S3623 219 221 218.4 220.5 1498 980 12081 7494 4533 4556
1 1 7/7/05 CD009B1_M27 D5S346 94 94.0 1302 11211 3058
2 7/7/05 CD009B1_M70 D5S346 94 93.8 5852 48204 2902
3 7/7/05 CD009B1_M30 D5S346 94 93.9 3103 26709 3038
4 7/7/05 CD009B1_M82 D5S346 94 93.8 6693 54251 2882
5 7/7/05 CD009B1_M31 D5S346 94 94.0 2162 18723 3032
6 7/7/05 CD009B1_M42 D5S346 94 93.8 6130 51459 2949
7 7/7/05 CD009B1_M103 D5S346 94 93.8 1345 10903 2913
8 7/7/05 CD009B1_M33 D5S346 94 93.8 4798 40548 2951
9 7/7/05 CD009B1_M43 D5S346 94 93.8 5257 43284 2923
10 7/7/05 CD009B1_M108 D5S346 94 93.8 3194 26713 2930
11 7/7/05 CD009B1_M34 D5S346 94 93.8 5732 48239 2929
12 7/7/05 CD009B1_M117 D5S346 94 93.8 5504 45469 2911
13 7/7/05 CD009B1_M46 D5S346 94 93.7 3286 27055 2903
14 7/7/05 CD009B1_M11 D5S346 94 93.8 3123 25417 2927
15 7/7/05 CD009B1_M51 D5S346 94 94.0 6920 70986 2935
16 7/7/05 CD009B1_M6 D5S346 94 93.8 2724 23744 2952
17 7/7/05 CD009B1_M8 D5S346 94 93.9 5203 43944 2950
18 7/7/05 CD009B1_M22 D5S346 94 93.8 5274 44500 2912
2 19 7/13/05 CD009B1M5_1uL D5S346 94 94.0 2750 22987 3031
20 7/13/05 CD009B1M9_1uL D5S346 94 93.9 7218 62868 3009
21 7/13/05 CD009B1M37_1uL D5S346 94 93.9 7182 64739 2993
22 7/13/05 CD009B1M12_1uL D5S346 94 94.0 3266 28608 3023
3 23 7/15/05 CD009B1M32 D5S346 94 93.9 5199 42040 2933
24 7/15/05 CD009B1M35 D5S346 94 93.9 1375 12048 2942
25 7/15/05 CD009B1M2 D5S346 94 94.1 4694 40415 3146
26 7/15/05 CD009B1M4 D5S346 94 93.9 2773 23119 2982
27 7/15/05 CD009B1M41 D5S346 94 93.9 5013 42947 3014
28 7/15/05 CD009B1M14 D5S346 94 93.8 831 7070 2994
29 7/15/05 CD009B1M44 D5S346 94 93.9 4485 39657 3025
30 7/15/05 CD009B1M16 D5S346 94 93.9 6029 49360 2994
31 7/15/05 CD009B1M3 D5S346 94 93.9 4609 39052 3000
1 1 7/7/05 CD009B1_M27 D6S262 170 172 170.5 172.4 390 203 3305 1385 4047 4071
2 7/7/05 CD009B1_M70 D6S262 170 172 170.2 172.1 4458 3054 34446 22007 3855 3879
3 7/7/05 CD009B1_M30 D6S262 170 172 170.3 172.4 1873 1311 15871 9987 4023 4049
4 7/7/05 CD009B1_M82 D6S262 170 172 170.2 172.1 4959 3478 38627 24669 3830 3853
5 7/7/05 CD009B1_M31 D6S262 170 172 170.4 172.3 1336 702 11464 5217 4011 4035
6 7/7/05 CD009B1_M42 D6S262 170 172 170.2 172.1 4258 3028 34362 22373 3912 3936
7 7/7/05 CD009B1_M103 D6S262 170 172 170.2 172.2 1209 606 9537 4219 3868 3892
8 7/7/05 CD009B1_M33 D6S262 170 172 170.2 172.2 3073 2137 24867 15972 3913 3937
9 7/7/05 CD009B1_M43 D6S262 170 172 170.2 172.2 3746 2474 29229 17826 3878 3902
10 7/7/05 CD009B1_M108 D6S262 170 172 170.2 172.2 1526 988 12270 7038 3889 3913
11 7/7/05 CD009B1_M34 D6S262 170 172 170.2 172.2 3803 2613 29598 18413 3888 3912
12 7/7/05 CD009B1_M117 D6S262 170 172 170.2 172.2 4039 2928 31898 21234 3865 3889
13 7/7/05 CD009B1_M46 D6S262 170 172 170.2 172.3 1059 857 8344 6231 3847 3872
15 7/7/05 CD009B1_M51 D6S262 170 172 170.3 172.2 6262 4456 51434 32207 3891 3915
14 7/7/05 CD009B1_M11 D6S262 170 172 170.3 172.2 2229 1266 17917 9396 3883 3906
16 7/7/05 CD009B1_M6 D6S262 170 172 170.3 172.2 1638 1115 13170 8300 3913 3937
17 7/7/05 CD009B1_M8 D6S262 170 172 170.3 172.2 3250 2055 25913 14978 3903 3927
18 7/7/05 CD009B1_M22 D6S262 170 172 170.3 172.2 3518 2380 26996 16887 3858 3882
2 19 7/13/05 CD009B1M5_1uL D6S262 170 172 170.3 172.3 1500 1048 11978 8107 4002 4027
20 7/13/05 CD009B1M9_1uL D6S262 170 172 170.3 172.3 1786 1184 13710 8518 3976 4001
21 7/13/05 CD009B1M12_1uL D6S262 170 172 170.3 172.3 1461 1042 11839 8354 3991 4015
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22 7/13/05 CD009B1M37_1uL D6S262 170 172 170.3 172.2 987 662 7734 4775 3958 3982
3 23 7/15/05 CD009B1M32 D6S262 170 172 170.3 172.2 2164 1469 16479 10319 3885 3909
24 7/15/05 CD009B1M35 D6S262 170 172 170.2 172.2 197 145 1536 1035 3892 3916
25 7/15/05 CD009B1M2 D6S262 170 172 170.5 172.5 2633 1850 22312 14828 4147 4172
26 7/15/05 CD009B1M4 D6S262 170 172 170.3 172.2 848 487 6812 3505 3943 3967
27 7/15/05 CD009B1M41 D6S262 170 172 170.3 172.3 1297 948 10114 6670 3985 4010
28 7/15/05 CD009B1M14 D6S262 170 172 170.2 172.1 179 135 1319 1002 3952 3976
29 7/15/05 CD009B1M44 D6S262 170 172 170.3 172.3 692 470 5386 3411 3992 4017
30 7/15/05 CD009B1M16 D6S262 170 172 170.3 172.3 2297 1451 17589 10173 3955 3979
31 7/15/05 CD009B1M3 D6S262 170 172 170.3 172.2 1713 1160 12983 8439 3964 3988
1 1 7/7/05 CD009B1_M27 D7S481 203 203.1 186 1809 4462
2 7/7/05 CD009B1_M70 D7S481 203 202.7 1331 11767 4253
3 7/7/05 CD009B1_M30 D7S481 203 203.0 536 4788 4437
4 7/7/05 CD009B1_M82 D7S481 203 202.6 1547 13464 4225
5 7/7/05 CD009B1_M31 D7S481 203 203.1 684 6358 4421
6 7/7/05 CD009B1_M42 D7S481 203 202.7 1872 17032 4315
7 7/7/05 CD009B1_M103 D7S481 203 202.8 856 7564 4268
8 7/7/05 CD009B1_M33 D7S481 203 202.7 1734 16276 4315
9 7/7/05 CD009B1_M43 D7S481 203 202.8 1745 15679 4277
10 7/7/05 CD009B1_M108 D7S481 203 202.7 531 4751 4289
11 7/7/05 CD009B1_M34 D7S481 203 202.8 1427 12746 4289
12 7/7/05 CD009B1_M117 D7S481 203 202.8 1265 11441 4264
13 7/7/05 CD009B1_M46 D7S481 203 202.7 263 2243 4241
15 7/7/05 CD009B1_M51 D7S481 203 202.8 1946 17974 4291
14 7/7/05 CD009B1_M11 D7S481 203 202.8 981 8773 4282
16 7/7/05 CD009B1_M6 D7S481 203 202.8 970 8815 4315
17 7/7/05 CD009B1_M8 D7S481 203 202.7 1896 17181 4299
18 7/7/05 CD009B1_M22 D7S481 203 202.8 1561 13782 4253
2 19 7/13/05 CD009B1M9_1uL D7S481 203 202.8 172 1388 4379
20 7/13/05 CD009B1M12_1uL D7S481 203 202.7 203 1852 4393
21 7/13/05 CD009B1M37_1uL D7S481 203 202.6 99 752 4359
22 7/13/05 CD009B1M5_1uL D7S481 203 202.9 379 3315 4407
3 23 7/15/05 CD009B1M32 D7S481 203 202.8 486 4316 4283
24 7/15/05 CD009B1M35 D7S481 203 202.7 61 593 4287
25 7/15/05 CD009B1M2 D7S481 203 203.1 637 6281 4566
26 7/15/05 CD009B1M4 D7S481 203 202.7 397 3511 4344
27 7/15/05 CD009B1M41 D7S481 203 202.8 379 3546 4390
28 7/15/05 CD009B1M14 D7S481 203 202.7 138 1223 4351
29 7/15/05 CD009B1M44 D7S481 203 202.8 190 1765 4396
30 7/15/05 CD009B1M16 D7S481 203 202.7 590 5299 4355
31 7/15/05 CD009B1M3 D7S481 203 202.7 703 6401 4366
1 1 7/7/05 CD010B1_2M15 BAT25 126 127 125.7 126.7 969 1010 7987 8192 3364 3377
2 7/7/05 CD010B1_2M18 BAT25 126 127 125.7 126.8 910 907 7508 7216 3342 3356
3 7/7/05 CD010B1_2M20 BAT25 126 127 125.7 126.8 1634 1718 12391 13537 3379 3393
4 7/7/05 CD010B1_2M1 BAT25 126 127 125.6 126.6 896 941 7436 7687 3325 3338
5 7/7/05 CD010B1_2M58 BAT25 126 127 125.7 126.7 873 843 7189 6548 3324 3337
2 6 7/15/05 CD010B1_2M16 BAT25 127 126.9 1312 10693 3425
7 7/15/05 CD010B1_2M28 BAT25 127 126.8 1537 11978 3405
8 7/15/05 CD010B1_2M33 BAT25 127 126.8 562 4586 3451
9 7/15/05 CD010B1_2M10 BAT25 127 126.9 2757 22738 3463
10 7/15/05 CD010B1_2M48 BAT25 127 126.9 2362 17967 3446
3 11 7/18/05 CD010B1_2M52 BAT25 127 126.9 1385 9920 3567
12 7/18/05 CD010B1_2M53 BAT25 127 126.9 1842 13280 3557
13 7/18/05 CD010B1_2M56 BAT25 127 126.9 3766 28556 3528
1 1 7/7/05 CD010B1_2M15 BAT26 121 120.7 272 2514 3299
2 7/7/05 CD010B1_2M18 BAT26 121 120.7 358 3177 3278
3 7/7/05 CD010B1_2M20 BAT26 121 120.7 466 4082 3314
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4 7/7/05 CD010B1_2M1 BAT26 121 120.6 272 2565 3261
5 7/7/05 CD010B1_2M58 BAT26 121 120.6 326 2846 3260
2 6 7/15/05 CD010B1_2M16 BAT26 121 120.8 293 2733 3347
7 7/15/05 CD010B1_2M28 BAT26 121 120.7 653 6105 3327
8 7/15/05 CD010B1_2M33 BAT26 121 120.8 182 1574 3372
9 7/15/05 CD010B1_2M10 BAT26 121 120.9 852 7806 3385
10 7/15/05 CD010B1_2M48 BAT26 121 120.9 717 6152 3368
3 11 7/18/05 CD010B1_2M52 BAT26 121 120.9 558 5271 3488
12 7/18/05 CD010B1_2M53 BAT26 121 120.8 777 7388 3477
13 7/18/05 CD010B1_2M56 BAT26 121 120.9 1420 14685 3449
1 1 7/7/05 CD010B1_2M15 D3S3623 219 225 218.5 224.8 217 136 1912 1218 4486 4557
2 7/7/05 CD010B1_2M18 D3S3623 219 225 218.4 224.7 398 467 3361 4083 4450 4520
3 7/7/05 CD010B1_2M20 D3S3623 219 225 218.6 224.7 656 314 5826 2662 4507 4577
4 7/7/05 CD010B1_2M1 D3S3623 219 225 218.5 224.7 523 471 4481 3935 4429 4498
5 7/7/05 CD010B1_2M58 D3S3623 219 225 218.5 224.7 409 314 3371 2620 4424 4493
2 6 7/15/05 CD010B1_2M16 D3S3623 219 225 218.5 224.7 428 329 3705 2752 4534 4605
7 7/15/05 CD010B1_2M28 D3S3623 219 225 218.4 224.7 309 240 2632 1977 4510 4581
8 7/15/05 CD010B1_2M33 D3S3623 219 225 218.5 224.7 207 162 1723 1405 4572 4644
9 7/15/05 CD010B1_2M10 D3S3623 219 225 218.6 224.8 1080 771 9949 6685 4581 4652
10 7/15/05 CD010B1_2M48 D3S3623 219 225 218.4 224.7 1739 1284 15275 10907 4563 4635
3 11 7/18/05 CD010B1_2M52 D3S3623 219 225 218.5 224.7 786 520 6654 4563 4704 4776
12 7/18/05 CD010B1_2M53 D3S3623 219 225 218.5 224.7 967 743 8619 6505 4691 4763
13 7/18/05 CD010B1_2M56 D3S3623 219 225 218.6 224.8 1778 1326 15880 11543 4657 4729
1 1 7/7/05 CD010B1_2M15 D5S346 89 92 89.5 91.7 315 304 2353 2255 2885 2914
2 7/7/05 CD010B1_2M18* D5S346* 92 91.6 583 4145 2897
3 7/7/05 CD010B1_2M20 D5S346 89 92 89.4 91.6 1388 1011 10614 7642 2899 2928
4 7/7/05 CD010B1_2M1* D5S346* 89 92 89.4 91.6 604 603 4459 4357 2854 2883
5 7/7/05 CD010B1_2M58 D5S346 89 92 89.4 91.5 1287 814 9778 5834 2853 2881
2 6 7/15/05 CD010B1_2M16 D5S346 89 92 89.4 91.6 1632 1167 12343 8415 2931 2960
7 7/15/05 CD010B1_2M28 D5S346 89 92 89.4 91.6 1437 1089 11292 8066 2913 2942
8 7/15/05 CD010B1_2M33 D5S346 89 92 89.5 91.7 571 422 4425 3185 2953 2983
9 7/15/05 CD010B1_2M10 D5S346 89 92 89.5 91.7 2275 1631 17657 12038 2966 2995
10 7/15/05 CD010B1_2M48 D5S346 89 92 89.4 91.7 1901 1438 14798 10718 2949 2979
3 11 7/18/05 CD010B1_2M52 D5S346 89 92 89.5 91.7 1288 804 10258 5989 3062 3092
12 7/18/05 CD010B1_2M53 D5S346 89 92 89.5 91.7 1905 1449 15072 10887 3054 3083
13 7/18/05 CD010B1_2M56 D5S346 89 92 89.5 91.7 4104 3100 31729 22915 3027 3057
1 1 7/7/05 CD010B1_2M15* D6S262* 176 176.1 605 5298 3978
2 7/7/05 CD010B1_2M18 D6S262 172 176 172.2 176.1 464 682 3747 5922 3901 3949
3 7/7/05 CD010B1_2M20 D6S262 172 176 172.2 176.1 726 414 6019 3571 3947 3995
4 7/7/05 CD010B1_2M1 D6S262 172 176 172.2 176.1 515 420 4962 3699 3882 3930
5 7/7/05 CD010B1_2M58 D6S262 172 176 172.2 176.0 277 298 2009 2421 3879 3926
2 6 7/15/05 CD010B1_2M16 D6S262 172 176 172.2 176.1 877 715 6932 5721 3977 4026
7 7/15/05 CD010B1_2M28 D6S262 172 176 172.2 176.1 652 535 5330 4339 3955 4004
8 7/15/05 CD010B1_2M33 D6S262 172 176 172.3 176.1 335 281 2507 2205 4010 4058
9 7/15/05 CD010B1_2M10 D6S262 172 176 172.3 176.1 1187 878 9779 7855 4020 4068
10 7/15/05 CD010B1_2M48 D6S262 172 176 172.2 176.1 1876 1510 15116 12219 4002 4051
3 11 7/18/05 CD010B1_2M52 D6S262 172 176 172.3 176.2 880 710 7398 6285 4133 4183
12 7/18/05 CD010B1_2M53 D6S262 172 176 172.2 176.1 1543 1226 12525 11127 4122 4171
13 7/18/05 CD010B1_2M56 D6S262 172 176 172.2 176.2 2828 2271 24805 20462 4090 4140
1 1 7/7/05 CD010B1_2M15 D7S481 187 199 187.1 198.7 256 75 2430 685 4116 4261
2 7/7/05 CD010B1_2M18 D7S481 187 199 187.2 198.6 326 262 3008 2398 4086 4227
3 7/7/05 CD010B1_2M20 D7S481 187 199 187.2 198.6 166 154 1461 1187 4135 4279
4 7/7/05 CD010B1_2M1 D7S481 187 199 187.2 198.7 289 122 2592 1197 4066 4207
5 7/7/05 CD010B1_2M58 D7S481 187 199 187.0 198.5 142 60 1302 539 4061 4201
2 6 7/15/05 CD010B1_2M16 D7S481 187 199 187.2 198.8 112 74 909 699 4164 4309
7 7/15/05 CD010B1_2M28 D7S481 187 199 187.2 198.7 240 133 2190 1168 4142 4285
8 7/15/05 CD010B1_2M33 D7S481 187 199 187.2 198.7 93 59 819 499 4198 4343
9 7/15/05 CD010B1_2M10 D7S481 187 199 187.2 198.7 545 336 5135 3038 4208 4352
191
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
10 7/15/05 CD010B1_2M48 D7S481 187 199 187.2 198.7 649 453 5698 4010 4191 4335
3 11 7/18/05 CD010B1_2M52 D7S481 187 199 187.3 198.8 383 208 3620 1899 4325 4472
12 7/18/05 CD010B1_2M53 D7S481 187 199 187.2 198.7 332 248 3165 2352 4313 4459
13 7/18/05 CD010B1_2M56 D7S481 187 199 187.3 198.7 663 447 6323 4248 4281 4426
1 1 11/14/05 CD0011B1M1 BAT25 127 128 126.9 127.8 3284 3372 27314 27324 3663 3676
1 11/14/05 CD0011B1M1 BAT26 122 121.7 1233 14245 3593
1 11/14/05 CD0011B1M1 D3S3623 225 224.8 5174 58129 4897
1 11/14/05 CD0011B1M1 D5S346 94 96 93.9 96.1 3029 1917 24189 13721 3207 3237
1 11/14/05 CD0011B1M1 D6S262 174 184 174.2 183.9 2967 2085 33699 22574 4265 4392
1 11/14/05 CD0011B1M1 D7S481 203 202.7 1237 15439 4635
1 1 7/8/05 CD0013B1M5_1UL BAT25 128 127.9 1633 10997 3449
2 7/8/05 0013B1M10_.4UL BAT25 128 129 127.9 128.9 908 933 6219 6120 3450 3463
3 7/8/05 0013B1M10_1UL BAT25 128 129 127.8 128.8 2462 2578 17053 17597 3425 3438
4 7/8/05 0013B1M18_1UL BAT25 129 128.9 4375 32354 3463
5 7/8/05 CD013B1_M1 BAT25 129 129.0 2500 19011 3477
6 7/8/05 CD013B1_M4 BAT25 129 129.1 2565 19664 3485
7 7/8/05 CD013B1_M24 BAT25 128 127.9 1993 15286 3428
8 7/8/05 CD013B1_M35 BAT25 128 129 128.0 129.0 686 711 4841 4734 3454 3467
2 9 7/13/05 CD013B1M15_1uL BAT25 128 129 127.8 128.8 2006 2090 14673 15721 3433 3446
3 10 7/18/05 CD013B1M41 BAT25 128 129 127.8 128.9 1406 1383 10189 9296 3537 3551
11 7/18/05 CD013B1M55 BAT25 128 129 127.8 128.9 1139 1137 8334 8030 3519 3533
12 7/18/05 CD013B1M17 BAT25 129 128.9 2001 15400 3507
13 7/18/05 CD013B1M30 BAT25 128 129 127.9 128.9 1389 1402 10120 10016 3533 3546
14 7/18/05 CD013B1M57 BAT25 129 128.9 1313 8869 3566
15 7/18/05 CD013B1M46 BAT25 128 129 127.9 128.9 2570 2578 18124 17918 3538 3551
16 7/18/05 CD013B1M58 BAT25 129 128.9 1400 8964 3551
17 7/18/05 CD013B1M20 BAT25 128 129 127.9 128.9 1799 1796 14276 13972 3464 3477
18 7/18/05 CD013B1M33 BAT25 128 129 127.9 128.9 2987 3069 22152 24025 3486 3499
19 7/18/05 CD013B1M47 BAT25 128 129 127.9 128.9 1817 1865 13173 13637 3511 3524
20 7/18/05 CD013B1M21 BAT25 128 129 128.0 129.0 5093 5232 38142 38742 3480 3493
21 7/18/05 CD013B1M34 BAT25 128 129 127.9 129.0 2804 2716 20453 18878 3514 3528
22 7/18/05 CD013B1M36 BAT25 128 127.9 1193 8442 3548
23 7/18/05 CD013B1M49 BAT25 128 129 127.9 129.0 2573 2612 17847 18229 3558 3572
1 1 7/8/05 CD0013B1M5_1UL BAT26 122 121.7 908 8099 3370
2 7/8/05 0013B1M10_.4UL BAT26 122 121.8 415 3880 3371
3 7/8/05 0013B1M10_1UL BAT26 122 121.7 1160 10311 3346
4 7/8/05 0013B1M18_1UL BAT26 122 121.8 1463 14393 3371
5 7/8/05 CD013B1_M1 BAT26 122 122.0 775 7084 3386
6 7/8/05 CD013B1_M4 BAT26 122 122.0 887 7973 3393
7 7/8/05 CD013B1_M24 BAT26 122 121.9 717 6751 3349
8 7/8/05 CD013B1_M35 BAT26 122 121.9 308 2583 3375
2 9 7/13/05 CD013B1M15_1uL BAT26 122 121.7 838 8003 3355
3 10 7/18/05 CD013B1M41 BAT26 122 121.7 767 6449 3457
11 7/18/05 CD013B1M55 BAT26 122 121.7 630 5723 3439
12 7/18/05 CD013B1M17 BAT26 122 121.8 692 6489 3415
13 7/18/05 CD013B1M30 BAT26 122 121.9 582 5337 3453
14 7/18/05 CD013B1M57 BAT26 122 121.8 612 5150 3472
15 7/18/05 CD013B1M46 BAT26 122 121.8 1547 13152 3458
16 7/18/05 CD013B1M58 BAT26 122 123 121.8 122.7 582 554 4800 4068 3457 3470
17 7/18/05 CD013B1M20 BAT26 122 121.7 835 8525 3384
18 7/18/05 CD013B1M33 BAT26 122 121.8 1424 12932 3407
19 7/18/05 CD013B1M47 BAT26 122 121.8 790 7491 3431
20 7/18/05 CD013B1M21 BAT26 122 121.9 2303 21818 3401
21 7/18/05 CD013B1M34 BAT26 122 121.9 1447 12311 3435
22 7/18/05 CD013B1M36 BAT26 122 121.8 598 5242 3468
23 7/18/05 CD013B1M49 BAT26 122 121.8 1366 12306 3478
1 1 7/8/05 CD0013B1M5_1UL* D3S3623* 219 218.4 1030 8668 4546
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2 7/8/05 0013B1M10_.4UL* D3S3623* 223 222.7 621 5477 4597
3 7/8/05 0013B1M10_1UL D3S3623 219 223 218.5 222.6 1416 993 11993 8350 4518 4565
4 7/8/05 0013B1M18_1UL D3S3623 219 223 218.5 222.7 2532 1954 21432 16374 4548 4596
5 7/8/05 CD013B1_M1 D3S3623 219 223 218.7 223.0 1266 1001 10763 8069 4569 4618
6 7/8/05 CD013B1_M4 D3S3623 219 223 218.8 223.1 1740 1378 14966 11695 4584 4633
7 7/8/05 CD013B1_M24 D3S3623 219 223 218.7 222.8 796 690 6675 5866 4537 4585
8 7/8/05 CD013B1_M35 D3S3623 219 223 218.7 223.0 600 382 4999 3207 4560 4609
2 9 7/13/05 CD013B1M15_1uL D3S3623 219 223 218.4 222.7 1169 837 9682 6760 4522 4570
3 10 7/18/05 CD013B1M41 D3S3623 219 223 218.4 222.6 353 225 2987 1839 4657 4706
11 7/18/05 CD013B1M55 D3S3623 219 223 218.4 222.6 408 400 3462 3391 4630 4679
12 7/18/05 CD013B1M17 D3S3623 219 223 218.6 222.7 1424 1055 12218 8638 4602 4650
13 7/18/05 CD013B1M30 D3S3623 219 223 218.4 222.6 738 644 6186 5329 4653 4702
14 7/18/05 CD013B1M57 D3S3623 219 223 218.4 222.6 200 191 1629 1679 4678 4728
15 7/18/05 CD013B1M46 D3S3623 219 223 218.4 222.6 359 277 2995 2195 4656 4705
16 7/18/05 CD013B1M58 D3S3623 219 223 218.3 222.5 706 564 5962 4493 4659 4708
17 7/18/05 CD013B1M20 D3S3623 219 223 218.6 222.7 327 251 2960 2115 4563 4610
18 7/18/05 CD013B1M33 D3S3623 219 223 218.4 222.6 655 484 5559 3925 4593 4642
19 7/18/05 CD013B1M47 D3S3623 219 223 218.4 222.5 880 745 7402 6251 4620 4667
20 7/18/05 CD013B1M21 D3S3623 219 223 218.5 222.7 1060 749 9011 6250 4586 4635
21 7/18/05 CD013B1M34 D3S3623 219 223 218.5 222.6 490 345 4229 2785 4633 4681
22 7/18/05 CD013B1M36 D3S3623 219 223 218.4 222.6 759 678 6423 5632 4670 4720
23 7/18/05 CD013B1M49 D3S3623 219 223 218.4 222.5 552 379 4694 2956 4682 4730
1 1 7/8/05 CD0013B1M5_1UL* D5S346* 103 107 102.6 106.7 646 760 5170 6032 3114 3170
2 7/8/05 0013B1M10_.4UL D5S346 103 107 102.6 106.7 497 338 4060 2721 3114 3170
3 7/8/05 0013B1M10_1UL D5S346 103 107 102.6 106.7 2007 1419 16125 11572 3091 3147
4 7/8/05 0013B1M18_1UL D5S346 103 107 102.6 106.7 2909 2284 23503 18058 3115 3171
5 7/8/05 CD013B1_M1 D5S346 103 107 102.8 106.8 1536 1127 12290 8945 3128 3184
6 7/8/05 CD013B1_M4 D5S346 103 107 102.7 106.9 1359 1007 10453 7736 3134 3191
7 7/8/05 CD013B1_M24 D5S346 103 107 102.7 106.9 1335 856 10460 6656 3092 3149
8 7/8/05 CD013B1_M35 D5S346 103 107 102.8 106.9 401 338 3104 2647 3118 3174
2 9 7/13/05 CD013B1M15_1uL D5S346 103 107 102.6 106.7 1346 1001 11297 8141 3101 3157
3 10 7/18/05 CD013B1M41 D5S346 103 107 102.6 106.7 1527 932 12234 7491 3196 3254
11 7/18/05 CD013B1M55 D5S346 103 107 102.5 106.7 930 581 7941 4679 3180 3238
12 7/18/05 CD013B1M17 D5S346 103 107 102.6 106.7 1034 813 8414 6514 3156 3213
13 7/18/05 CD013B1M30 D5S346 103 107 102.7 106.8 917 657 7463 5409 3192 3249
14 7/18/05 CD013B1M57 D5S346 103 107 102.6 106.8 1019 867 8552 7237 3210 3268
15 7/18/05 CD013B1M46 D5S346 103 107 102.6 106.7 2704 1808 21915 14344 3197 3254
16 7/18/05 CD013B1M58 D5S346 103 107 102.6 106.7 1145 905 9373 7338 3196 3253
17 7/18/05 CD013B1M20 D5S346 103 107 102.5 106.7 1390 962 11942 7659 3128 3185
18 7/18/05 CD013B1M33 D5S346 103 107 102.6 106.8 1633 1205 14070 9851 3149 3206
19 7/18/05 CD013B1M47 D5S346 103 107 102.5 106.7 919 732 7847 6019 3172 3229
20 7/18/05 CD013B1M21 D5S346 103 107 102.7 106.8 2903 2014 23623 16097 3143 3200
21 7/18/05 CD013B1M34 D5S346 103 107 102.6 106.7 2117 1534 17418 12533 3174 3231
22 7/18/05 CD013B1M36 D5S346 103 107 102.6 106.7 743 547 6119 4306 3206 3263
23 7/18/05 CD013B1M49 D5S346 103 107 102.6 106.7 2381 1802 19946 14715 3215 3273
1 1 7/8/05 CD0013B1M5_1UL D6S262 172 182 172.3 181.9 293 786 2309 6203 3989 4110
2 7/8/05 0013B1M10_.4UL D6S262 172 182 172.3 181.9 416 125 3343 904 3991 4112
3 7/8/05 0013B1M10_1UL D6S262 172 182 172.3 182.0 1705 1159 13871 9303 3963 4084
4 7/8/05 0013B1M18_1UL D6S262 172 182 172.2 182.0 3033 1921 26120 16225 3990 4112
5 7/8/05 CD013B1_M1 D6S262 172 182 172.4 182.1 3306 2068 30345 18785 4008 4130
6 7/8/05 CD013B1_M4 D6S262 172 182 172.4 182.1 3803 2558 35753 23418 4018 4141
7 7/8/05 CD013B1_M24 D6S262 172 182 172.4 182.1 2603 1802 23798 15944 3973 4096
8 7/8/05 CD013B1_M35 D6S262 172 182 172.3 182.0 1356 705 11771 5869 3998 4120
2 9 7/13/05 CD013B1M15_1uL D6S262 172 182 172.3 182.0 1241 849 10779 7199 3970 4090
3 10 7/18/05 CD013B1M41 D6S262 172 182 172.3 182.0 261 181 2032 1259 4088 4212
11 7/18/05 CD013B1M55 D6S262 172 182 172.2 181.9 521 260 4328 2069 4066 4188
12 7/18/05 CD013B1M17 D6S262 172 182 172.3 181.9 1271 717 10712 6071 4039 4161
13 7/18/05 CD013B1M30 D6S262 172 182 172.3 181.9 932 547 7549 4363 4084 4207
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14 7/18/05 CD013B1M57 D6S262 172 182 172.3 181.9 301 169 2522 1335 4107 4230
15 7/18/05 CD013B1M46 D6S262 172 182 172.2 181.9 1050 560 8297 4205 4088 4212
16 7/18/05 CD013B1M58 D6S262 172 182 172.2 181.9 1062 722 8409 5577 4089 4213
17 7/18/05 CD013B1M20 D6S262 172 182 172.3 182.0 804 573 6833 4521 4004 4125
18 7/18/05 CD013B1M33 D6S262 172 182 172.2 181.8 1258 707 10728 5691 4031 4153
19 7/18/05 CD013B1M47 D6S262 172 182 172.3 181.9 985 695 8122 5724 4057 4179
20 7/18/05 CD013B1M21 D6S262 172 182 172.3 181.9 1652 1033 13388 8130 4024 4146
21 7/18/05 CD013B1M34 D6S262 172 182 172.2 182.0 858 477 7088 3678 4064 4188
22 7/18/05 CD013B1M36 D6S262 172 182 172.3 182.0 613 365 4908 2823 4100 4225
23 7/18/05 CD013B1M49 D6S262 172 182 172.2 181.9 764 391 6203 2958 4111 4235
1 1 7/8/05 CD0013B1M5_1UL D7S481 199 198.7 253 2140 4320
2 7/8/05 0013B1M10_.4UL D7S481 199 198.7 179 1601 4322
3 7/8/05 0013B1M10_1UL D7S481 199 198.7 336 2691 4292
4 7/8/05 0013B1M18_1UL D7S481 199 198.7 425 3863 4321
5 7/8/05 CD013B1_M1 D7S481 199 198.9 338 3200 4341
7 7/8/05 CD013B1_M4 D7S481 199 199.0 517 5125 4354
8 7/8/05 CD013B1_M24 D7S481 199 198.9 311 2971 4308
9 7/8/05 CD013B1_M35 D7S481 199 198.9 139 1286 4332
2 10 7/13/05 CD013B1M15_1uL D7S481 199 198.6 255 2152 4297
3 11 7/18/05 CD013B1M41 D7S481 199 198.7 74 619 4426
12 7/18/05 CD013B1M55 D7S481 199 198.8 203 1880 4402
13 7/18/05 CD013B1M17 D7S481 199 198.8 340 2881 4373
14 7/18/05 CD013B1M30 D7S481 199 198.7 88 768 4422
15 7/18/05 CD013B1M57 D7S481 199 198.8 150 1289 4446
16 7/18/05 CD013B1M46 D7S481 199 198.7 161 1381 4424
17 7/18/05 CD013B1M58 D7S481 199 198.7 139 1152 4428
18 7/18/05 CD013B1M20 D7S481 199 198.7 166 1439 4335
19 7/18/05 CD013B1M33 D7S481 199 198.6 224 2081 4364
20 7/18/05 CD013B1M47 D7S481 199 198.7 362 3187 4390
21 7/18/05 CD013B1M21 D7S481 199 198.8 312 2858 4358
22 7/18/05 CD013B1M34 D7S481 199 198.7 221 1884 4401
23 7/18/05 CD013B1M36 D7S481 199 198.8 538 4579 4439
24 7/18/05 CD013B1M49 D7S481 199 198.7 151 1320 4450
1 1 7/18/05 CD014B1M3 BAT25 127 126.9 1495 10895 3568
2 7/18/05 CD014B1M11 BAT25 127 126.9 3672 28001 3368
3 7/18/05 CD014B1M19 BAT25 127 126.9 1222 9216 3407
4 7/18/05 CD014B1M12 BAT25 127 126.9 916 6925 3363
5 7/18/05 CD014B1M5 BAT25 127 126.9 568 4660 3527
6 7/18/05 CD014B1M13 BAT25 127 126.8 1246 9993 3398
7 7/18/05 CD014B1M7 BAT25 127 126.9 1286 9519 3541
8 7/18/05 CD014B1M8 BAT25 127 126.9 1226 9115 3526
9 7/18/05 CD014B1M2 BAT25 127 126.8 2927 21571 3525
10 7/18/05 CD014B1M10 BAT25 127 126.9 3284 24161 3528
11 7/18/05 CD014B1M18 BAT25 127 127.0 1107 9401 3438
12 7/18/05 CD014B1M20 BAT25 127 126.9 2845 21415 3386
13 7/18/05 CD014B1M21 BAT25 127 126.9 2621 20657 3391
14 7/18/05 CD014B1M22 BAT25 127 126.9 638 5294 3408
15 7/18/05 CD014B1M23 BAT25 127 126.9 1895 14522 3405
16 7/18/05 CD014B1M24 BAT25 127 126.9 703 5708 3384
17 7/18/05 CD014B1M25 BAT25 127 126.8 1014 8286 3398
18 7/18/05 CD014B1M30 BAT25 127 126.9 2064 15835 3412
19 7/18/05 CD014B1M31 BAT25 127 126.9 2387 18050 3401
20 7/18/05 CD014B1M32 BAT25 127 126.9 582 4521 3380
21 7/18/05 CD014B1M37 BAT25 127 126.9 1017 8255 3393
22 7/18/05 CD014B1M44 BAT25 127 126.9 1598 12403 3406
23 7/18/05 CD014B1M46 BAT25 127 126.8 905 7061 3400
24 7/18/05 CD014B1M48 BAT25 127 126.9 801 6369 3380
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1 1 7/18/05 CD014B1M3 BAT26 122 121.8 595 5113 3501
2 7/18/05 CD014B1M11 BAT26 122 121.9 1198 10906 3304
3 7/18/05 CD014B1M19 BAT26 122 121.7 330 2782 3341
4 7/18/05 CD014B1M12 BAT26 122 121.8 281 2394 3298
5 7/18/05 CD014B1M5 BAT26 122 121.8 262 2245 3460
6 7/18/05 CD014B1M13 BAT26 122 121.7 663 6314 3333
7 7/18/05 CD014B1M7 BAT26 122 121.8 410 3399 3474
8 7/18/05 CD014B1M8 BAT26 122 121.9 440 3584 3460
9 7/18/05 CD014B1M2 BAT26 122 121.8 1335 10701 3459
10 7/18/05 CD014B1M10 BAT26 122 121.9 1211 9297 3462
11 7/18/05 CD014B1M18 BAT26 122 121.9 374 3641 3372
12 7/18/05 CD014B1M20 BAT26 122 121.8 1170 11236 3321
13 7/18/05 CD014B1M21 BAT26 122 121.8 973 9170 3326
14 7/18/05 CD014B1M22 BAT26 122 121.9 232 1898 3344
15 7/18/05 CD014B1M23 BAT26 122 121.8 724 6617 3340
16 7/18/05 CD014B1M24 BAT26 122 121.9 304 2594 3320
17 7/18/05 CD014B1M25 BAT26 122 121.7 346 3100 3332
18 7/18/05 CD014B1M30 BAT26 122 121.8 620 5482 3347
19 7/18/05 CD014B1M31 BAT26 122 121.8 703 6398 3336
20 7/18/05 CD014B1M32 BAT26 122 121.8 216 1841 3315
21 7/18/05 CD014B1M37 BAT26 122 121.8 293 2576 3328
22 7/18/05 CD014B1M44 BAT26 122 121.8 498 4432 3341
23 7/18/05 CD014B1M46 BAT26 122 121.8 293 2554 3335
24 7/18/05 CD014B1M48 BAT26 122 121.7 312 2770 3315
1 1 7/18/05 CD014B1M3 D3S3623 219 221 218.4 220.5 972 506 7879 3872 4710 4734
2 7/18/05 CD014B1M11 D3S3623 219 221 218.5 220.6 1029 667 8270 5105 4459 4482
3 7/18/05 CD014B1M19 D3S3623 219 221 218.5 220.6 756 495 5852 3811 4508 4532
4 7/18/05 CD014B1M12 D3S3623 219 221 218.6 220.6 548 335 4119 2484 4455 4477
5 7/18/05 CD014B1M5 D3S3623 219 221 218.4 220.6 358 319 3110 2850 4655 4680
6 7/18/05 CD014B1M13 D3S3623 219 221 218.4 220.5 387 227 3358 1775 4496 4519
7 7/18/05 CD014B1M7 D3S3623 219 221 218.3 220.5 852 498 7049 3910 4679 4704
8 7/18/05 CD014B1M8 D3S3623 219 221 218.3 220.4 1196 849 9676 6832 4660 4685
9 7/18/05 CD014B1M2 D3S3623 219 221 218.4 220.5 306 232 2505 1775 4662 4686
10 7/18/05 CD014B1M10 D3S3623 219 221 218.4 220.5 959 688 8045 5179 4664 4689
11 7/18/05 CD014B1M18 D3S3623 219 221 218.6 220.7 508 435 4559 3631 4552 4576
12 7/18/05 CD014B1M20 D3S3623 219 221 218.4 220.4 277 193 2161 1424 4482 4505
13 7/18/05 CD014B1M21 D3S3623 219 221 218.5 220.5 399 234 3211 1803 4486 4509
14 7/18/05 CD014B1M22 D3S3623 219 221 218.4 220.5 221 147 1844 1189 4511 4535
15 7/18/05 CD014B1M23 D3S3623 219 221 218.5 220.6 292 169 2227 1267 4510 4533
16 7/18/05 CD014B1M24 D3S3623 219 221 218.6 220.6 248 142 1910 1122 4484 4507
17 7/18/05 CD014B1M25 D3S3623 219 221 218.5 220.6 672 440 5454 3445 4497 4521
18 7/18/05 CD014B1M30 D3S3623 219 221 218.6 220.7 912 342 7530 2656 4519 4543
19 7/18/05 CD014B1M31 D3S3623 219 221 218.5 220.6 913 624 7271 4864 4501 4524
20 7/18/05 CD014B1M32 D3S3623 219 221 218.4 220.5 415 264 3329 2104 4474 4497
21 7/18/05 CD014B1M37 D3S3623 219 221 218.4 220.6 523 335 4382 2653 4488 4512
22 7/18/05 CD014B1M44 D3S3623 219 221 218.6 220.7 832 531 6813 4284 4509 4533
23 7/18/05 CD014B1M46 D3S3623 219 221 218.5 220.6 418 258 3350 2000 4502 4525
24 7/18/05 CD014B1M48 D3S3623 219 221 218.5 220.5 444 289 3435 2132 4476 4499
1 1 7/18/05 CD014B1M3 D5S346 89 92 89.5 91.7 1441 922 11904 7142 3060 3090
2 7/18/05 CD014B1M11 D5S346 89 92 89.5 91.7 3470 2529 25638 18165 2882 2911
3 7/18/05 CD014B1M19 D5S346 89 92 89.5 91.7 1206 894 8994 6580 2916 2945
4 7/18/05 CD014B1M12 D5S346 89 92 89.5 91.8 916 705 6799 4852 2877 2906
5 7/18/05 CD014B1M5 D5S346 89 92 89.5 91.7 524 240 4347 1819 3024 3054
6 7/18/05 CD014B1M13 D5S346 89 92 89.5 91.6 1299 940 10237 7479 2910 2938
7 7/18/05 CD014B1M7 D5S346 89 92 89.5 91.7 925 644 7455 4821 3034 3064
8 7/18/05 CD014B1M8 D5S346 89 92 89.5 91.7 887 683 7123 5340 3022 3051
9 7/18/05 CD014B1M2 D5S346 89 92 89.5 91.7 3509 2488 27574 18746 3021 3050
10 7/18/05 CD014B1M10 D5S346 89 92 89.5 91.7 2702 2053 21433 15589 3023 3053
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11 7/18/05 CD014B1M18 D5S346 89 92 89.5 91.8 955 644 7551 4978 2942 2972
12 7/18/05 CD014B1M20 D5S346 89 92 89.5 91.7 4138 3002 31596 22101 2897 2926
13 7/18/05 CD014B1M21 D5S346 89 92 89.5 91.7 3271 2408 25169 17937 2903 2932
14 7/18/05 CD014B1M22 D5S346 89 92 89.5 91.7 930 709 6863 5101 2918 2947
15 7/18/05 CD014B1M23 D5S346 89 92 89.6 91.8 2344 1752 18162 13278 2914 2943
16 7/18/05 CD014B1M24 D5S346 89 92 89.5 91.7 1112 732 8420 5440 2895 2924
17 7/18/05 CD014B1M25 D5S346 89 92 89.5 91.6 1038 766 7812 5754 2909 2937
18 7/18/05 CD014B1M30 D5S346 89 92 89.6 91.8 1590 1117 12165 8350 2920 2949
19 7/18/05 CD014B1M31 D5S346 89 92 89.5 91.7 1913 1555 14476 11693 2911 2940
20 7/18/05 CD014B1M32 D5S346 89 92 89.5 91.7 549 359 4189 2651 2893 2921
21 7/18/05 CD014B1M37 D5S346 89 92 89.5 91.7 1117 840 8618 6245 2905 2933
22 7/18/05 CD014B1M44 D5S346 89 92 89.5 91.7 1701 1299 12916 9530 2916 2945
23 7/18/05 CD014B1M46 D5S346 89 92 89.4 91.7 778 585 5938 4290 2910 2939
24 7/18/05 CD014B1M48 D5S346 89 92 89.5 91.7 868 672 6507 4785 2892 2921
1 1 7/18/05 CD014B1M3 D6S262 174 182 174.3 182.0 466 333 4101 2547 4162 4262
2 7/18/05 CD014B1M11 D6S262 174 182 174.2 181.9 1206 845 9728 6296 3936 4031
3 7/18/05 CD014B1M19 D6S262 174 182 174.2 182.0 798 589 6667 4568 3980 4076
4 7/18/05 CD014B1M12 D6S262 174 182 174.2 182.0 675 519 5486 3818 3931 4027
5 7/18/05 CD014B1M5 D6S262 174 182 174.2 182.0 423 226 3688 1895 4114 4213
6 7/18/05 CD014B1M13 D6S262 174 182 174.2 182.0 408 301 3592 2261 3970 4066
7 7/18/05 CD014B1M7 D6S262 174 182 174.1 181.8 693 412 5693 3193 4133 4232
8 7/18/05 CD014B1M8 D6S262 174 182 174.2 181.9 889 612 7126 4729 4116 4215
9 7/18/05 CD014B1M2 D6S262 174 182 174.2 181.9 597 312 5298 2494 4116 4215
10 7/18/05 CD014B1M10 D6S262 174 182 174.2 181.9 930 669 7835 5219 4119 4218
11 7/18/05 CD014B1M18 D6S262 174 182 174.3 182.0 443 291 4195 2444 4018 4115
12 7/18/05 CD014B1M20 D6S262 174 182 174.2 181.8 751 462 6256 3693 3957 4051
13 7/18/05 CD014B1M21 D6S262 174 182 174.3 182.0 720 478 6358 3773 3961 4056
14 7/18/05 CD014B1M22 D6S262 174 182 174.3 182.0 385 220 3291 1687 3983 4079
15 7/18/05 CD014B1M23 D6S262 174 182 174.3 182.0 404 272 3353 2176 3980 4076
16 7/18/05 CD014B1M24 D6S262 174 182 174.3 182.0 306 198 2646 1506 3956 4052
17 7/18/05 CD014B1M25 D6S262 174 182 174.3 181.9 614 473 5272 3714 3971 4066
18 7/18/05 CD014B1M30 D6S262 174 182 174.3 182.0 578 407 4721 3194 3988 4084
19 7/18/05 CD014B1M31 D6S262 174 182 174.2 181.9 917 493 7596 3948 3973 4069
20 7/18/05 CD014B1M32 D6S262 174 182 174.2 182.0 356 100 2788 748 3950 4046
21 7/18/05 CD014B1M37 D6S262 174 182 174.3 182.0 626 451 5392 3667 3964 4059
22 7/18/05 CD014B1M44 D6S262 174 182 174.2 182.0 819 611 6836 4605 3980 4076
23 7/18/05 CD014B1M46 D6S262 174 182 174.2 181.9 334 324 2944 2379 3974 4069
24 7/18/05 CD014B1M48 D6S262 174 182 174.1 181.9 447 322 3694 2374 3950 4046
1 1 7/18/05 CD014B1M3 D7S481 199 201 198.8 200.7 435 260 3628 2084 4477 4501
2 7/18/05 CD014B1M11 D7S481 199 201 198.8 200.7 338 202 2619 1680 4237 4260
3 7/18/05 CD014B1M19 D7S481 199 201 198.8 200.8 173 125 1361 984 4284 4308
4 7/18/05 CD014B1M12 D7S481 199 201 198.8 200.7 127 81 963 773 4232 4255
5 7/18/05 CD014B1M5 D7S481 199 201 198.7 200.7 218 68 1761 522 4425 4449
6 7/18/05 CD014B1M13 D7S481 199 201 198.8 200.7 150 131 1277 1097 4273 4296
7 7/18/05 CD014B1M7 D7S481 199 201 198.7 200.7 305 189 2510 1582 4448 4472
8 7/18/05 CD014B1M8 D7S481 199 201 198.8 200.6 284 197 2390 1627 4430 4453
9 7/18/05 CD014B1M2 D7S481 199 201 198.7 200.8 86 67 721 699 4429 4455
10 7/18/05 CD014B1M10 D7S481 199 201 198.7 200.7 293 194 2351 1495 4433 4457
11 7/18/05 CD014B1M18 D7S481 199 201 198.7 200.8 141 140 1311 1416 4324 4349
12 7/18/05 CD014B1M20 D7S481 199 201 198.7 200.6 117 72 974 674 4259 4282
13 7/18/05 CD014B1M21 D7S481 199 201 198.8 200.7 130 97 1109 806 4263 4286
14 7/18/05 CD014B1M22* D7S481* 199 201 198.8 200.8 59 45 481 404 4287 4311
15 7/18/05 CD014B1M23 D7S481 199 201 198.7 200.7 118 110 968 902 4284 4308
16 7/18/05 CD014B1M24* D7S481* 199 201 198.9 200.8 154 164 1288 1459 4260 4283
17 7/18/05 CD014B1M25 D7S481 199 201 198.8 200.9 141 95 1138 796 4274 4299
18 7/18/05 CD014B1M30 D7S481 199 201 198.8 200.7 293 99 2341 724 4293 4316
19 7/18/05 CD014B1M31 D7S481 199 201 198.8 200.7 339 245 2722 1992 4277 4300
20 7/18/05 CD014B1M32 D7S481 199 201 198.8 200.6 160 94 1330 825 4252 4274
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21 7/18/05 CD014B1M37 D7S481 199 201 198.8 200.6 104 73 905 632 4266 4288
22 7/18/05 CD014B1M44 D7S481 199 201 198.9 200.8 167 113 1397 1029 4285 4308
23 7/18/05 CD014B1M46 D7S481 199 201 198.8 200.8 102 74 780 683 4278 4302
24 7/18/05 CD014B1M48 D7S481 199 201 198.8 200.8 115 86 801 682 4253 4277
1 1 7/11/05 CD015B1_M12 BAT25 126 125.8 1343 10334 3374
2 7/11/05 CD015B1_M1 BAT25 126 125.8 2969 22856 3355
3 7/11/05 CD015B1_M13 BAT25 126 125.8 417 3369 3345
4 7/11/05 CD015B1_M2 BAT25 126 125.8 1772 14948 3394
5 7/11/05 CD015B1_M14 BAT25 126 125.9 1455 11516 3386
6 7/11/05 CD015B1_M3 BAT25 126 125.8 1205 9832 3404
7 7/11/05 CD015B1_M5 BAT25 126 125.9 879 6684 3352
8 7/11/05 CD015B1_M9 BAT25 126 125.8 1023 8264 3394
9 7/11/05 CD015B1_M10 BAT25 126 125.9 3224 24941 3402
2 10 7/13/05 CD015B1_M17 BAT25 126 127 125.8 126.8 948 942 6931 6717 3390 3403
11 7/13/05 CD015B1_M30 BAT25 126 127 125.9 126.9 2898 2789 22847 21826 3477 3490
12 7/13/05 CD015B1_M42 BAT25 126 125.9 2591 20219 3496
13 7/13/05 CD015B1_M54 BAT25 126 125.8 1107 8615 3513
14 7/13/05 CD015B1_M66 BAT25 126 125.9 2987 24704 3582
15 7/13/05 CD015B1_M19 BAT25 126 127 125.8 126.9 578 600 4391 4532 3367 3381
16 7/13/05 CD015B1_M31 BAT25 126 125.9 1375 10659 3455
17 7/13/05 CD015B1_M44 BAT25 126 125.8 2274 17565 3474
18 7/13/05 CD015B1_M67 BAT25 126 125.9 683 5603 3557
19 7/13/05 CD015B1_M32 BAT25 126 125.8 2793 22803 3470
20 7/13/05 CD015B1_M46 BAT25 126 125.8 2153 17033 3489
21 7/13/05 CD015B1_M56 BAT25 127 126.9 416 3630 3517
22 7/13/05 CD015B1_M70 BAT25 126 125.9 2023 15852 3570
23 7/13/05 CD015B1_M21 BAT25 126 125.8 1558 11934 3402
24 7/13/05 CD015B1_M34 BAT25 126 125.9 794 6309 3484
25 7/13/05 CD015B1_M48 BAT25 126 127 125.9 126.9 731 745 5860 5994 3503 3517
26 7/13/05 CD015B1_M57 BAT25 126 125.9 2630 20065 3519
27 7/13/05 CD015B1_M72 BAT25 126 125.9 3653 29262 3582
28 7/13/05 CD015B1_M23 BAT25 126 125.8 1080 8418 3464
29 7/13/05 CD015B1_M36 BAT25 126 125.9 3297 25567 3498
30 7/13/05 CD015B1_M58 BAT25 126 125.9 3540 27114 3536
31 7/13/05 CD015B1_M73 BAT25 126 125.9 2159 17310 3608
32 7/13/05 CD015B1_M26 BAT25 126 127 125.8 126.9 1374 1315 10392 10352 3442 3455
33 7/13/05 CD015B1_M50 BAT25 126 127 125.8 126.9 4105 4139 31616 32520 3470 3484
34 7/13/05 CD015B1_M38 BAT25 126 125.8 2301 18850 3490
35 7/13/05 CD015B1_M51 BAT25 126 125.8 2252 18170 3486
36 7/13/05 CD015B1_M64 BAT25 126 125.9 1739 13614 3525
37 7/13/05 CD015B1_M15 BAT25 126 125.9 2306 17888 3415
38 7/13/05 CD015B1_M29 BAT25 126 125.8 3358 26355 3469
39 7/13/05 CD015B1_M39 BAT25 126 126.0 3867 29459 3506
40 7/13/05 CD015B1_M53 BAT25 127 126.9 278 2787 3517
41 7/13/05 CD015B1_M65 BAT25 126 125.9 1246 9726 3538
3 42 7/18/05 CD015B1M20 BAT25 126 125.9 1295 10003 3378
43 7/18/05 CD015B1M28 BAT25 126 125.8 1031 7862 3392
1 1 7/11/05 CD015B1_M12 BAT26 122 121.7 487 4444 3322
2 7/11/05 CD015B1_M1 BAT26 122 121.8 931 9321 3304
3 7/11/05 CD015B1_M13 BAT26 122 121.8 205 1731 3293
4 7/11/05 CD015B1_M2 BAT26 122 121.8 516 5463 3343
5 7/11/05 CD015B1_M14 BAT26 122 121.7 553 4947 3333
6 7/11/05 CD015B1_M3 BAT26 122 121.8 688 6796 3352
7 7/11/05 CD015B1_M5 BAT26 122 121.9 442 4091 3301
8 7/11/05 CD015B1_M9 BAT26 122 122.0 234 2211 3344
9 7/11/05 CD015B1_M10 BAT26 122 121.8 1324 12482 3349
2 10 7/13/05 CD015B1_M17 BAT26 122 121.7 400 3541 3337
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11 7/13/05 CD015B1_M30 BAT26 122 121.9 1094 10769 3424
12 7/13/05 CD015B1_M42 BAT26 122 121.8 799 8175 3442
13 7/13/05 CD015B1_M54 BAT26 122 121.8 468 4652 3460
14 7/13/05 CD015B1_M66 BAT26 122 121.9 1008 9666 3528
15 7/13/05 CD015B1_M19 BAT26 122 121.8 306 2529 3316
16 7/13/05 CD015B1_M31 BAT26 122 121.8 487 4652 3402
17 7/13/05 CD015B1_M44 BAT26 122 121.8 953 9612 3421
18 7/13/05 CD015B1_M67 BAT26 122 121.8 386 3715 3503
19 7/13/05 CD015B1_M32 BAT26 122 121.7 1196 11830 3417
20 7/13/05 CD015B1_M46 BAT26 122 121.8 925 8788 3436
21 7/13/05 CD015B1_M56 BAT26 122 121.8 134 1131 3451
22 7/13/05 CD015B1_M70 BAT26 122 121.8 827 7683 3516
23 7/13/05 CD015B1_M21 BAT26 122 121.8 659 5678 3350
24 7/13/05 CD015B1_M34 BAT26 122 121.8 735 6672 3431
25 7/13/05 CD015B1_M48 BAT26 122 121.8 520 4634 3450
26 7/13/05 CD015B1_M57 BAT26 122 121.8 977 8865 3465
27 7/13/05 CD015B1_M72 BAT26 122 121.8 1401 12528 3528
28 7/13/05 CD015B1_M23 BAT26 122 121.9 354 3485 3412
29 7/13/05 CD015B1_M36 BAT26 122 121.8 1218 11569 3445
30 7/13/05 CD015B1_M58 BAT26 122 121.8 1184 11751 3482
31 7/13/05 CD015B1_M73 BAT26 122 121.9 722 6639 3554
32 7/13/05 CD015B1_M26 BAT26 122 121.8 648 5933 3390
33 7/13/05 CD015B1_M50 BAT26 122 123 121.9 122.7 1431 1368 13317 11351 3418 3429
34 7/13/05 CD015B1_M38 BAT26 122 121.8 950 9013 3437
35 7/13/05 CD015B1_M51 BAT26 122 121.8 862 8275 3433
36 7/13/05 CD015B1_M64 BAT26 122 121.8 562 5399 3472
37 7/13/05 CD015B1_M15 BAT26 122 121.8 1148 11129 3362
38 7/13/05 CD015B1_M29 BAT26 122 121.8 1314 12100 3417
39 7/13/05 CD015B1_M39 BAT26 122 121.9 1436 13852 3453
40 7/13/05 CD015B1_M53 BAT26 122 121.8 202 1634 3450
41 7/13/05 CD015B1_M65 BAT26 122 121.8 702 6872 3484
3 42 7/18/05 CD015B1M20 BAT26 122 121.8 363 3289 3326
43 7/18/05 CD015B1M28 BAT26 122 121.8 398 3378 3340
1 1 7/11/05 CD015B1_M12 D3S3623 221 220.6 2025 17330 4517
2 7/11/05 CD015B1_M1 D3S3623 221 220.6 2453 20976 4490
3 7/11/05 CD015B1_M13 D3S3623 221 220.6 1123 9230 4478
4 7/11/05 CD015B1_M2 D3S3623 221 220.6 2725 24736 4539
5 7/11/05 CD015B1_M14 D3S3623 221 220.7 2851 25065 4527
6 7/11/05 CD015B1_M3 D3S3623 221 220.7 1547 13767 4556
7 7/11/05 CD015B1_M5 D3S3623 221 220.5 2427 20702 4486
8 7/11/05 CD015B1_M9 D3S3623 221 220.5 2292 20457 4538
9 7/11/05 CD015B1_M10 D3S3623 221 220.6 6394 55962 4551
2 10 7/13/05 CD015B1_M17 D3S3623 221 220.5 2761 23888 4532
11 7/13/05 CD015B1_M30 D3S3623 221 220.7 5316 47505 4641
12 7/13/05 CD015B1_M42 D3S3623 221 220.7 4148 37568 4665
13 7/13/05 CD015B1_M54 D3S3623 221 220.6 1842 16738 4687
14 7/13/05 CD015B1_M66 D3S3623 221 220.8 6163 57103 4773
15 7/13/05 CD015B1_M19 D3S3623 221 220.5 1042 8759 4502
16 7/13/05 CD015B1_M31 D3S3623 221 220.7 2569 22542 4612
17 7/13/05 CD015B1_M44 D3S3623 221 220.6 4791 42242 4635
18 7/13/05 CD015B1_M67 D3S3623 221 220.8 1050 9484 4742
19 7/13/05 CD015B1_M32 D3S3623 221 220.6 6549 58654 4626
20 7/13/05 CD015B1_M46 D3S3623 221 220.7 3703 33313 4650
21 7/13/05 CD015B1_M56 D3S3623 221 220.6 485 4471 4669
22 7/13/05 CD015B1_M70 D3S3623 221 220.8 4199 38407 4752
23 7/13/05 CD015B1_M21 D3S3623 221 220.6 3939 34184 4547
24 7/13/05 CD015B1_M34 D3S3623 221 220.7 2088 18640 4649
25 7/13/05 CD015B1_M48 D3S3623 221 220.7 1352 12256 4672
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26 7/13/05 CD015B1_M57 D3S3623 221 220.7 4183 37597 4694
27 7/13/05 CD015B1_M72 D3S3623 221 220.9 6506 60928 4774
28 7/13/05 CD015B1_M23 D3S3623 221 220.7 2173 19555 4624
29 7/13/05 CD015B1_M36 D3S3623 221 220.6 6228 56489 4666
30 7/13/05 CD015B1_M58 D3S3623 221 220.7 5447 50737 4715
31 7/13/05 CD015B1_M73 D3S3623 221 220.9 4097 38894 4808
32 7/13/05 CD015B1_M26 D3S3623 221 220.6 1668 14502 4596
33 7/13/05 CD015B1_M50 D3S3623 221 220.6 2070 18258 4629
34 7/13/05 CD015B1_M38 D3S3623 221 220.6 3839 34543 4651
35 7/13/05 CD015B1_M51 D3S3623 221 220.6 3880 34957 4645
36 7/13/05 CD015B1_M64 D3S3623 221 220.6 2410 21764 4695
37 7/13/05 CD015B1_M15 D3S3623 221 220.6 6338 55100 4558
38 7/13/05 CD015B1_M29 D3S3623 221 220.7 5617 48888 4631
39 7/13/05 CD015B1_M39 D3S3623 221 220.7 6702 59958 4676
40 7/13/05 CD015B1_M53 D3S3623 221 220.7 876 7704 4671
41 7/13/05 CD015B1_M65 D3S3623 221 220.8 2141 19504 4717
3 42 7/18/05 CD015B1M20 D3S3623 221 220.6 772 6752 4511
43 7/18/05 CD015B1M28 D3S3623 221 220.7 324 2820 4533
1 1 7/11/05 CD015B1_M12 D5S346 92 101 91.7 100.5 541 491 4424 3902 2925 3039
2 7/11/05 CD015B1_M1 D5S346 92 101 91.7 100.5 1996 1326 16097 10702 2909 3022
3 7/11/05 CD015B1_M13 D5S346 92 101 91.7 100.5 387 559 3214 4439 2900 3013
4 7/11/05 CD015B1_M2 D5S346 92 101 91.7 100.6 1534 872 13888 7338 2944 3059
5 7/11/05 CD015B1_M14 D5S346 92 101 91.7 100.6 1375 855 12258 7139 2936 3051
6 7/11/05 CD015B1_M3 D5S346 92 101 91.7 100.5 856 206 7220 1601 2953 3067
7 7/11/05 CD015B1_M5 D5S346 92 101 91.6 100.5 759 578 6327 4769 2905 3019
8 7/11/05 CD015B1_M9 D5S346 92 101 91.7 100.6 663 348 5856 2949 2944 3059
9 7/11/05 CD015B1_M10 D5S346 92 101 91.7 100.6 2800 1762 23665 14059 2950 3065
2 10 7/13/05 CD015B1_M17 D5S346 92 101 91.7 100.5 997 670 8704 5523 2940 3054
11 7/13/05 CD015B1_M30 D5S346 92 101 91.7 100.6 3076 1805 26789 14992 3019 3135
12 7/13/05 CD015B1_M42 D5S346 92 101 91.8 100.6 1828 1037 15517 8624 3036 3153
13 7/13/05 CD015B1_M54 D5S346 92 101 91.7 100.6 588 656 5289 5492 3051 3169
14 7/13/05 CD015B1_M66 D5S346 92 101 91.8 100.6 2375 1339 21171 11274 3114 3233
15 7/13/05 CD015B1_M19 D5S346 92 101 91.6 100.4 570 442 4725 3619 2921 3034
16 7/13/05 CD015B1_M31 D5S346 92 101 91.6 100.5 965 481 8175 4072 2999 3115
17 7/13/05 CD015B1_M44 D5S346 92 101 91.7 100.6 2198 1307 18713 10694 3016 3133
18 7/13/05 CD015B1_M67 D5S346 92 101 91.8 100.6 371 233 3088 2032 3092 3210
19 7/13/05 CD015B1_M32 D5S346 92 101 91.7 100.6 2734 1516 24124 13163 3015 3131
20 7/13/05 CD015B1_M46 D5S346 92 101 91.7 100.6 2010 1116 17898 9656 3032 3148
21 7/13/05 CD015B1_M56 D5S346 92 101 91.7 100.6 192 132 1764 1102 3045 3163
22 7/13/05 CD015B1_M70 D5S346 92 101 91.8 100.6 1487 1011 13131 8580 3105 3223
23 7/13/05 CD015B1_M21 D5S346 92 101 91.6 100.5 1613 740 13416 5968 2951 3066
24 7/13/05 CD015B1_M34 D5S346 92 101 91.7 100.6 835 779 7757 6619 3027 3143
25 7/13/05 CD015B1_M48* D5S346* 92 101 91.8 100.6 521 328 4455 2609 3044 3161
26 7/13/05 CD015B1_M57 D5S346 92 101 91.7 100.6 2991 1740 25631 14816 3057 3174
27 7/13/05 CD015B1_M72 D5S346 92 101 91.8 100.7 3106 1742 27322 14912 3115 3234
28 7/13/05 CD015B1_M23 D5S346 92 101 91.7 100.6 550 344 5012 2905 3008 3124
29 7/13/05 CD015B1_M36 D5S346 92 101 91.7 100.6 2798 1702 23843 14075 3038 3155
30 7/13/05 CD015B1_M58 D5S346 92 101 91.8 100.6 2251 1276 19989 10739 3072 3190
31 7/13/05 CD015B1_M73 D5S346 92 101 91.8 100.7 1559 776 13616 6684 3137 3257
32 7/13/05 CD015B1_M26 D5S346 92 101 91.7 100.5 1565 678 12342 5418 2988 3103
33 7/13/05 CD015B1_M50 D5S346 92 101 91.7 100.6 4224 1336 35165 11052 3014 3130
34 7/13/05 CD015B1_M38 D5S346 92 101 91.7 100.5 1885 1067 16917 9323 3033 3149
35 7/13/05 CD015B1_M51 D5S346 92 101 91.7 100.5 1961 1044 17457 8915 3030 3145
36 7/13/05 CD015B1_M64 D5S346 92 101 91.7 100.6 1202 520 10558 4256 3064 3182
37 7/13/05 CD015B1_M15 D5S346 92 101 91.7 100.5 1804 1324 15257 10780 2964 3078
38 7/13/05 CD015B1_M29 D5S346 92 101 91.7 100.6 3494 2084 30019 17016 3013 3129
39 7/13/05 CD015B1_M39 D5S346 92 101 91.8 100.6 3546 2042 30616 17044 3046 3163
40 7/13/05 CD015B1_M53 D5S346 92 101 91.7 100.6 214 212 1842 1559 3043 3161
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41 7/13/05 CD015B1_M65 D5S346 92 101 91.8 100.6 1138 936 9983 7998 3075 3193
3 42 7/18/05 CD015B1M20 D5S346 92 101 91.8 100.6 933 546 8367 4648 2932 3045
43 7/18/05 CD015B1M28 D5S346 92 101 91.8 100.6 1011 513 8481 4125 2944 3058
1 1 7/11/05 CD015B1_M12 D6S262 184 186 184.0 185.8 1244 601 10296 4559 4084 4107
2 7/11/05 CD015B1_M1 D6S262 184 186 183.8 185.8 1900 994 15345 7811 4059 4083
3 7/11/05 CD015B1_M13* D6S262* 184 183.9 436 3319 4048
4 7/11/05 CD015B1_M2 D6S262 184 186 183.8 185.8 1713 723 14467 5828 4104 4129
5 7/11/05 CD015B1_M14 D6S262 184 186 183.9 185.9 1705 1032 13428 7786 4093 4118
6 7/11/05 CD015B1_M3 D6S262 184 186 183.9 185.8 628 354 5009 2786 4118 4142
7 7/11/05 CD015B1_M5 D6S262 184 186 183.9 185.8 1321 758 10456 5491 4056 4080
8 7/11/05 CD015B1_M9 D6S262 184 186 183.9 185.8 802 392 6765 3100 4104 4128
9 7/11/05 CD015B1_M10 D6S262 184 186 183.9 185.8 3277 2050 26435 15239 4115 4139
2 10 7/13/05 CD015B1_M17 D6S262 184 186 183.8 185.8 759 385 6044 2836 4098 4123
11 7/13/05 CD015B1_M30 D6S262 184 186 184.0 185.9 3161 1959 25578 15079 4199 4223
12 7/13/05 CD015B1_M42 D6S262 184 186 183.9 185.8 2035 1227 17288 9713 4221 4245
13 7/13/05 CD015B1_M54 D6S262 184 186 183.9 185.9 1204 581 10372 4576 4241 4266
14 7/13/05 CD015B1_M66 D6S262 184 186 184.0 185.9 2823 1708 23968 13737 4320 4345
15 7/13/05 CD015B1_M19 D6S262 184 186 183.8 185.8 733 422 5912 3129 4072 4096
16 7/13/05 CD015B1_M31 D6S262 184 186 183.8 185.8 1419 783 11816 5853 4172 4197
17 7/13/05 CD015B1_M44 D6S262 184 186 183.9 185.8 2754 1550 22548 12257 4194 4218
18 7/13/05 CD015B1_M67 D6S262 184 186 183.9 185.9 311 146 2690 1134 4291 4317
19 7/13/05 CD015B1_M32 D6S262 184 186 183.8 185.8 3585 2240 28956 17084 4187 4212
20 7/13/05 CD015B1_M46 D6S262 184 186 183.9 185.9 2442 1456 20253 11094 4209 4234
21 7/13/05 CD015B1_M56 D6S262 184 186 183.9 185.8 744 696 5884 5784 4226 4251
22 7/13/05 CD015B1_M70 D6S262 184 186 184.0 186.0 1902 1087 15736 8784 4303 4328
23 7/13/05 CD015B1_M21 D6S262 184 186 183.8 185.8 1555 758 12756 5694 4112 4136
24 7/13/05 CD015B1_M34 D6S262 184 186 183.9 185.8 906 477 7690 3721 4206 4230
25 7/13/05 CD015B1_M48 D6S262 184 186 183.9 185.8 563 318 4536 2187 4228 4253
26 7/13/05 CD015B1_M57 D6S262 184 186 183.9 185.9 2338 1642 19564 12939 4247 4272
27 7/13/05 CD015B1_M72 D6S262 184 186 184.0 185.9 3639 2301 31031 18339 4320 4345
28 7/13/05 CD015B1_M23 D6S262 184 186 183.9 185.9 1079 432 9312 3353 4183 4208
29 7/13/05 CD015B1_M36 D6S262 184 186 184.0 185.9 2887 1619 24197 12292 4223 4247
30 7/13/05 CD015B1_M58 D6S262 184 186 183.9 185.9 2673 1670 22839 13110 4267 4292
31 7/13/05 CD015B1_M73 D6S262 184 186 184.0 185.9 2010 1188 17867 9736 4352 4377
32 7/13/05 CD015B1_M26 D6S262 184 186 183.9 185.8 954 348 7865 2651 4158 4182
33 7/13/05 CD015B1_M50 D6S262 184 186 184.0 185.8 2011 1117 16460 8768 4190 4213
34 7/13/05 CD015B1_M38 D6S262 184 186 183.8 185.8 2602 1532 21447 11855 4210 4235
35 7/13/05 CD015B1_M51 D6S262 184 186 183.9 185.8 2502 1498 20837 11485 4205 4229
36 7/13/05 CD015B1_M64 D6S262 184 186 183.9 185.8 1653 1082 13795 8727 4251 4275
37 7/13/05 CD015B1_M15 D6S262 184 186 183.9 185.8 2758 1847 22217 13889 4124 4148
38 7/13/05 CD015B1_M29 D6S262 184 186 183.9 185.8 3531 2176 29014 16431 4189 4214
39 7/13/05 CD015B1_M39 D6S262 184 186 183.9 185.9 4160 2552 34550 19562 4231 4256
40 7/13/05 CD015B1_M53 D6S262 184 186 183.9 185.8 178 98 1415 657 4227 4251
41 7/13/05 CD015B1_M65 D6S262 184 186 184.0 185.9 1251 623 10684 4742 4268 4293
3 42 7/18/05 CD015B1M20 D6S262 184 186 183.9 185.7 756 460 5993 3468 4081 4104
43 7/18/05 CD015B1M28 D6S262 184 186 183.9 185.8 369 279 2896 2002 4099 4123
1 1 7/11/05 CD015B1_M12 D7S481 187 197 187.3 196.9 408 329 3595 2810 4125 4245
2 7/11/05 CD015B1_M1 D7S481 187 197 187.1 196.8 513 378 4673 3273 4100 4219
3 7/11/05 CD015B1_M13 D7S481 187 197 187.2 196.8 234 127 2072 1229 4089 4207
4 7/11/05 CD015B1_M2 D7S481 187 197 187.3 196.8 395 649 3556 6224 4147 4265
5 7/11/05 CD015B1_M14 D7S481 187 197 187.2 196.9 564 438 4963 4051 4135 4255
6 7/11/05 CD015B1_M3 D7S481 187 197 187.2 196.9 383 574 3553 5224 4160 4281
7 7/11/05 CD015B1_M5 D7S481 187 197 187.3 196.8 527 406 4751 3578 4098 4216
8 7/11/05 CD015B1_M9 D7S481 187 197 187.2 196.8 689 305 6308 2789 4146 4265
9 7/11/05 CD015B1_M10 D7S481 187 197 187.3 196.9 1065 756 9869 6713 4157 4277
2 10 7/13/05 CD015B1_M17 D7S481 187 197 187.2 196.8 476 281 4317 2434 4140 4259
11 7/13/05 CD015B1_M30 D7S481 187 197 187.3 196.8 711 576 6748 5465 4241 4362
12 7/13/05 CD015B1_M42 D7S481 187 197 187.3 196.9 630 610 5907 5637 4264 4386
200
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
13 7/13/05 CD015B1_M54 D7S481 187 197 187.3 196.9 414 421 3799 3857 4285 4407
14 7/13/05 CD015B1_M66 D7S481 187 197 187.4 196.9 676 541 6502 5225 4364 4488
15 7/13/05 CD015B1_M19 D7S481 187 197 187.2 196.7 311 208 2782 1772 4113 4231
16 7/13/05 CD015B1_M31 D7S481 187 197 187.3 196.9 394 384 3501 3398 4215 4336
17 7/13/05 CD015B1_M44 D7S481 187 197 187.3 196.8 707 457 6420 4195 4237 4358
18 7/13/05 CD015B1_M67 D7S481 187 197 187.3 197.0 575 587 5457 5396 4335 4459
19 7/13/05 CD015B1_M32 D7S481 187 197 187.3 196.8 1062 825 9900 7508 4230 4350
20 7/13/05 CD015B1_M46 D7S481 187 197 187.3 196.9 608 440 5854 4026 4252 4373
21 7/13/05 CD015B1_M56 D7S481 187 197 187.2 196.9 272 182 2649 1785 4269 4392
22 7/13/05 CD015B1_M70 D7S481 187 197 187.4 197.0 582 451 5565 4253 4347 4470
23 7/13/05 CD015B1_M21 D7S481 187 197 187.2 196.8 690 389 6260 3408 4154 4273
24 7/13/05 CD015B1_M34 D7S481 187 197 187.3 196.9 383 153 3304 1461 4249 4371
25 7/13/05 CD015B1_M48* D7S481* 187 197 187.3 196.9 734 130 6910 1227 4271 4393
26 7/13/05 CD015B1_M57 D7S481 187 197 187.3 196.9 611 451 5830 3913 4291 4413
27 7/13/05 CD015B1_M72 D7S481 187 197 187.5 197.0 899 783 8691 7375 4365 4489
28 7/13/05 CD015B1_M23 D7S481 187 197 187.3 196.9 536 319 4952 2893 4226 4347
29 7/13/05 CD015B1_M36 D7S481 187 197 187.4 196.9 894 676 8466 6392 4266 4388
30 7/13/05 CD015B1_M58 D7S481 187 197 187.3 197.0 804 632 7915 5900 4310 4434
31 7/13/05 CD015B1_M73 D7S481 187 197 187.4 196.9 845 659 8297 6366 4396 4521
32 7/13/05 CD015B1_M26 D7S481 187 197 187.3 196.8 355 273 3177 2471 4200 4320
33 7/13/05 CD015B1_M50 D7S481 187 197 187.3 197.0 427 272 3851 2466 4232 4354
34 7/13/05 CD015B1_M38 D7S481 187 197 187.2 196.8 744 568 6827 5129 4253 4374
35 7/13/05 CD015B1_M51 D7S481 187 197 187.3 196.8 513 460 4890 4259 4248 4368
36 7/13/05 CD015B1_M64 D7S481 187 197 187.2 196.9 534 340 4955 3095 4293 4416
37 7/13/05 CD015B1_M15 D7S481 187 197 187.2 196.8 841 920 7602 8267 4166 4285
38 7/13/05 CD015B1_M29 D7S481 187 197 187.3 196.8 856 619 7965 5673 4233 4353
39 7/13/05 CD015B1_M39 D7S481 187 197 187.3 196.9 995 771 9322 7148 4274 4396
40 7/13/05 CD015B1_M53 D7S481 187 197 187.3 196.9 145 201 1254 1773 4270 4392
41 7/13/05 CD015B1_M65 D7S481 187 197 187.4 197.0 500 492 4531 4434 4312 4435
3 42 7/18/05 CD015B1M20 D7S481 187 197 187.2 196.8 205 145 1845 1263 4122 4240
43 7/18/05 CD015B1M28 D7S481 187 197 187.2 196.9 127 96 1057 827 4141 4260
1 1 11/14/05 CD0016B1M1 BAT25 128 127.8 4171 31042 3624
1 11/14/05 CD0016B1M1 BAT26 122 121.7 1593 16572 3542
1 11/14/05 CD0016B1M1 D3S3623 219 221 218.6 220.7 4873 3141 43810 27096 4757 4782
1 11/14/05 CD0016B1M1 D5S346 103 105 102.6 104.7 2572 1664 20188 11602 3279 3308
1 11/14/05 CD0016B1M1 D6S262 172 182 172.2 181.9 4175 2786 40554 26544 4181 4306
1 11/14/05 CD0016B1M1 D7S481 187 203 187.2 202.7 1463 973 15695 10232 4375 4572
1 1 5/31/05 G1WT7 BAT25 127 127.1 1469 10830 3649
2 2 6/6/05 G1WT.5 BAT25 127 126.7 663 5152 3369
3 6/6/05 G1WT.25 BAT25 127 126.6 263 2799 3379
3 4 6/8/05 G1WT.5_1-2 BAT25 127 126.8 2249 21059 3548
5 6/8/05 G1WT.25_1-2 BAT25 127 126.9 1314 10249 3557
4 6 6/15/05 .2N1.5M.025T_1-2 BAT25 127 128 127.0 128.0 1919 1989 14389 15304 3567 3581
7 6/15/05 .2N1.5M.05T_1-3 BAT25 127 128 126.9 128.0 1918 1957 14664 14354 3506 3520
5 8 6/16/05 .2N1.5M.025T_1-2 BAT25 127 128 127.0 128.0 1987 2018 14730 15253 3670 3684
9 6/16/05 .8N6M.1T_1-4 BAT25 127 128 126.9 127.9 1432 1470 10112 10151 3560 3574
10 6/16/05 .2N1.5M.05T_1-2 BAT25 127 128 127.1 128.1 2304 2310 17886 17580 3638 3652
6 11 6/20/05 0.25uM BAT25 127 126.9 727 5247 3445
7 12 6/30/05 CTRL6-19-05 BAT25 127 126.7 985 6884 3268
13 6/30/05 CTRL BAT25 127 126.7 2381 17490 3311
8 14 7/5/05 CTRL_61905 BAT25 127 126.7 747 5655 3337
9 15 7/6/05 CTRL BAT25 127 126.8 1129 8755 3381
10 16 7/7/05 CRTL BAT25 127 126.7 2118 16416 3371
17 7/7/05 CRTL BAT25 127 126.7 2010 15591 3397
11 18 7/8/05 CTRL_.4UL BAT25 127 126.8 2275 17311 3436
19 7/8/05 CTRL_1UL BAT25 127 126.8 1545 11774 3413
20 7/8/05 CTRL BAT25 127 127.0 1872 14395 3419
201
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
12 21 7/11/05 CTRL BAT25 127 126.8 4069 33614 3407
13 22 7/13/05 CTRL BAT25 127 126.9 5731 46618 3685
14 23 7/15/05 CTRL BAT25 127 126.9 3589 27723 3454
15 24 11/14/05 10K_CTRL BAT25 127 126.8 4616 37024 3610
1 1 5/31/05 G1WT7 BAT26 122 122.0 245 2028 3580
2 2 6/6/05 G1WT.5 BAT26 122 121.8 161 1348 3306
3 6/6/05 G1WT.25 BAT26 122 121.6 143 1546 3315
3 4 6/8/05 G1WT.5_1-2 BAT26 122 121.7 539 5668 3480
5 6/8/05 G1WT.25_1-2 BAT26 122 121.8 730 5854 3489
4 6 6/15/05 .2N1.5M.025T_1-2 BAT26 122 122.0 411 3426 3500
7 6/15/05 .2N1.5M.05T_1-3 BAT26 122 121.9 585 4755 3440
5 8 6/16/05 .2N1.5M.025T_1-2 BAT26 122 121.9 456 3855 3600
9 6/16/05 .8N6M.1T_1-4 BAT26 122 121.8 380 3153 3491
10 6/16/05 .2N1.5M.05T_1-2 BAT26 122 122.0 761 6455 3569
6 11 6/20/05 0.25uM BAT26 122 121.8 257 2204 3379
7 12 6/30/05 CTRL6-19-05 BAT26 122 121.6 330 2700 3204
13 6/30/05 CTRL BAT26 122 121.6 623 5510 3247
8 14 7/5/05 CTRL_61905 BAT26 122 121.6 289 2438 3273
9 15 7/6/05 CTRL BAT26 122 121.6 403 3090 3315
10 16 7/7/05 CRTL BAT26 122 121.7 676 5949 3306
17 7/7/05 CRTL BAT26 122 121.6 591 5268 3331
11 18 7/8/05 CTRL_.4UL BAT26 122 121.7 764 6679 3370
19 7/8/05 CTRL_1UL BAT26 122 121.8 623 5338 3348
20 7/8/05 CTRL BAT26 122 121.8 478 4714 3353
12 21 7/11/05 CTRL BAT26 122 121.8 1138 11605 3342
13 22 7/13/05 CTRL BAT26 122 121.9 1887 16461 3616
14 23 7/15/05 CTRL BAT26 122 121.8 781 7002 3388
15 24 11/14/05 10K_CTRL BAT26 122 121.6 1458 15395 3542
1 1 5/31/05 G1WT7 D3S3623 219 225 219.1 225.4 1752 1406 16055 12464 4813 4887
2 2 6/6/05 G1WT.5 D3S3623 219 225 218.3 224.6 703 507 5941 4435 4460 4530
3 6/6/05 G1WT.25 D3S3623 219 225 218.2 224.7 256 218 3454 3067 4479 4552
3 4 6/8/05 G1WT.5_1-2 D3S3623 219 225 218.8 225.0 2025 1515 25725 19273 4692 4765
5 6/8/05 G1WT.25_1-2 D3S3623 219 225 218.9 225.1 1614 1302 14966 11782 4704 4776
4 6 6/15/05 .2N1.5M.025T_1-2 D3S3623 219 225 219.1 225.4 408 278 3611 2318 4717 4791
7 6/15/05 .2N1.5M.05T_1-3 D3S3623 219 225 219.0 225.3 591 507 4970 4316 4638 4709
5 8 6/16/05 .2N1.5M.025T_1-2 D3S3623 219 225 219.1 225.4 447 258 3959 2445 4856 4932
9 6/16/05 .8N6M.1T_1-4 D3S3623 219 225 218.7 224.9 900 592 7937 5417 4739 4814
10 6/16/05 .2N1.5M.05T_1-2 D3S3623 219 225 218.9 225.2 679 619 6468 5533 4813 4889
6 11 6/20/05 0.25uM D3S3623 219 225 218.5 224.8 680 558 5708 4572 4560 4632
7 12 6/30/05 CTRL6-19-05 D3S3623 219 225 218.4 224.6 838 674 7007 5714 4340 4409
13 6/30/05 CTRL D3S3623 219 225 218.4 224.6 1818 1380 15146 11489 4387 4455
8 14 7/5/05 CTRL_61905 D3S3623 219 225 218.5 224.7 626 489 5055 4100 4429 4498
9 15 7/6/05 CTRL D3S3623 219 225 218.6 224.8 859 575 7291 4927 4481 4551
10 16 7/7/05 CRTL D3S3623 219 225 218.5 224.8 1569 1058 13786 9131 4476 4547
17 7/7/05 CRTL D3S3623 219 225 218.6 224.8 1609 1068 13738 9194 4509 4580
11 18 7/8/05 CTRL_.4UL D3S3623 219 225 218.4 224.6 1648 1128 14113 9679 4548 4619
19 7/8/05 CTRL_1UL D3S3623 219 225 218.4 224.6 1219 1015 10539 8477 4519 4589
20 7/8/05 CTRL D3S3623 219 225 218.7 224.9 1230 920 10660 7973 4532 4603
12 21 7/11/05 CTRL D3S3623 219 225 218.6 224.8 2670 1733 23518 15295 4519 4590
13 22 7/13/05 CTRL D3S3623 219 225 218.9 225.1 3657 2300 34439 21880 4863 4938
14 23 7/15/05 CTRL D3S3623 219 225 218.5 224.7 2300 1516 19393 13017 4570 4641
15 24 11/14/05 10K_CTRL D3S3623 219 225 218.5 224.8 4249 3346 40681 31627 4751 4824
1 1 5/31/05 G1WT7 D5S346 92 94 91.9 94.2 1824 1360 14359 9900 3163 3193
2 2 6/6/05 G1WT.5 D5S346 92 94 91.6 93.8 1186 804 9197 5930 2912 2940
3 6/6/05 G1WT.25 D5S346 92 94 91.6 93.8 403 270 3788 2431 2919 2947
3 4 6/8/05 G1WT.5_1-2 D5S346 92 94 91.8 94.0 4136 2713 35028 21329 3071 3101
5 6/8/05 G1WT.25_1-2 D5S346 92 94 91.8 94.0 1745 1199 13486 8868 3079 3109
4 6 6/15/05 .2N1.5M.025T_1-2 D5S346 92 94 92.0 94.1 1808 1096 14291 7996 3089 3118
202
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7 6/15/05 .2N1.5M.05T_1-3 D5S346 92 94 91.9 94.1 1623 1033 12860 7754 3035 3064
5 8 6/16/05 .2N1.5M.025T_1-2 D5S346 92 94 91.9 94.1 1984 1177 16548 9036 3178 3208
9 6/16/05 .8N6M.1T_1-4* D5S346* 92 94 91.7 94.0 1125 622 10169 4778 3073 3104
10 6/16/05 .2N1.5M.05T_1-2 D5S346 92 94 91.8 94.0 2085 1281 17194 9708 3149 3179
6 11 6/20/05 0.25uM D5S346 92 94 91.7 93.9 576 355 5128 2431 2978 3007
7 12 6/30/05 CTRL6-19-05* D5S346* 92 94 91.6 93.8 716 430 6340 2954 2819 2847
13 6/30/05 CTRL D5S346 92 94 91.7 93.9 1757 1120 13701 8418 2860 2888
8 14 7/5/05 CTRL_61905* D5S346* 92 94 91.6 93.8 588 344 5008 2452 2880 2909
9 15 7/6/05 CTRL D5S346 92 94 91.6 93.9 866 526 6555 3711 2920 2949
10 16 7/7/05 CRTL D5S346 92 94 91.6 93.8 1459 870 11505 6426 2910 2938
17 7/7/05 CRTL D5S346 92 94 91.6 93.8 1347 826 10549 5921 2933 2962
11 18 7/8/05 CTRL_.4UL D5S346 92 94 91.7 93.9 2165 1520 16970 11338 2970 2999
19 7/8/05 CTRL_1UL D5S346 92 94 91.6 93.9 1958 1301 15299 9417 2950 2979
20 7/8/05 CTRL D5S346 92 94 91.8 94.0 1719 1214 13007 8721 2954 2983
12 21 7/11/05 CTRL D5S346 92 94 91.7 93.9 2960 1973 23957 15129 2944 2973
13 22 7/13/05 CTRL D5S346 92 94 91.8 94.1 4008 2669 33131 21154 3194 3225
14 23 7/15/05 CTRL D5S346 92 94 91.7 93.9 2275 1456 17591 10976 2987 3016
15 24 11/14/05 10K_CTRL D5S346 92 94 91.6 93.8 3463 2450 27117 17460 3133 3163
1 1 5/31/05 G1WT7 D6S262 176 182 176.5 182.3 346 263 2871 2075 4279 4355
2 2 6/6/05 G1WT.5 D6S262 176 182 176.0 181.8 438 300 3393 2380 3961 4032
3 6/6/05 G1WT.25 D6S262 176 182 176.0 181.8 296 223 3819 2831 3977 4048
3 4 6/8/05 G1WT.5_1-2 D6S262 176 182 176.3 182.0 1145 795 13509 8896 4168 4242
5 6/8/05 G1WT.25_1-2 D6S262 176 182 176.3 182.1 1591 1219 15317 11115 4178 4253
4 6 6/15/05 .2N1.5M.025T_1-2 D6S262 176 182 176.4 182.3 837 581 6881 4633 4189 4265
7 6/15/05 .2N1.5M.05T_1-3 D6S262 176 182 176.4 182.2 1061 802 8759 6277 4119 4193
5 8 6/16/05 .2N1.5M.025T_1-2 D6S262 176 182 176.5 182.3 859 577 7836 5144 4312 4389
9 6/16/05 .8N6M.1T_1-4 D6S262 176 182 176.2 182.1 587 412 5217 3584 4197 4275
10 6/16/05 .2N1.5M.05T_1-2 D6S262 176 182 176.4 182.2 1276 908 11245 8021 4274 4351
6 11 6/20/05 0.25uM D6S262 176 182 176.2 182.0 538 363 4486 2712 4049 4122
7 12 6/30/05 CTRL6-19-05 D6S262 176 182 176.0 181.8 645 428 5407 3169 3849 3919
13 6/30/05 CTRL D6S262 176 182 176.1 181.9 1498 1294 12349 10220 3895 3965
8 14 7/5/05 CTRL_61905 D6S262 176 182 176.1 181.8 528 358 4544 2667 3929 4000
9 15 7/6/05 CTRL D6S262 176 182 176.1 181.9 815 600 6843 4836 3977 4049
10 16 7/7/05 CRTL D6S262 176 182 176.1 181.9 1361 1013 11316 7981 3970 4042
17 7/7/05 CRTL D6S262 176 182 176.0 181.9 1248 955 10699 7606 3999 4072
11 18 7/8/05 CTRL_.4UL D6S262 176 182 176.1 181.8 1512 1223 12362 9814 4039 4111
19 7/8/05 CTRL_1UL D6S262 176 182 176.1 181.9 1323 1039 10662 8310 4013 4085
20 7/8/05 CTRL D6S262 176 182 176.3 182.1 2745 2232 23608 18880 4022 4095
12 21 7/11/05 CTRL D6S262 176 182 176.1 182.0 2788 1493 26082 14002 4009 4082
13 22 7/13/05 CTRL D6S262 176 182 176.3 182.1 4046 2217 38496 20814 4322 4399
14 23 7/15/05 CTRL D6S262 176 182 176.0 181.8 1794 1531 15557 12905 4058 4131
15 24 11/14/05 10K_CTRL D6S262 176 182 176.1 181.9 3600 2678 35279 24676 4228 4302
1 1 5/31/05 G1WT7 D7S481 187 193 187.6 193.4 421 417 3767 3794 4425 4500
2 2 6/6/05 G1WT.5 D7S481 187 193 187.1 192.9 230 191 2054 1535 4097 4168
3 6/6/05 G1WT.25 D7S481 187 193 187.1 192.7 156 139 2053 1811 4114 4184
3 4 6/8/05 G1WT.5_1-2 D7S481 187 193 187.3 193.2 699 503 8559 6200 4310 4386
5 6/8/05 G1WT.25_1-2 D7S481 187 193 187.4 193.2 920 780 9241 7703 4322 4396
4 6 6/15/05 .2N1.5M.025T_1-2 D7S481 187 193 187.6 193.4 212 177 1911 1707 4334 4409
7 6/15/05 .2N1.5M.05T_1-3 D7S481 187 193 187.4 193.3 438 322 3821 2824 4260 4334
5 8 6/16/05 .2N1.5M.025T_1-2 D7S481 187 193 187.6 193.3 226 190 2192 1818 4460 4537
9 6/16/05 .8N6M.1T_1-4 D7S481 187 193 187.4 193.2 254 230 2357 2269 4345 4422
10 6/16/05 .2N1.5M.05T_1-2 D7S481 187 193 187.6 193.3 522 379 5081 3487 4422 4498
6 11 6/20/05 0.25uM D7S481 187 193 187.3 193.0 338 237 2819 1962 4188 4260
7 12 6/30/05 CTRL6-19-05 D7S481 187 193 187.0 192.8 376 276 3339 2382 3982 4051
13 6/30/05 CTRL D7S481 187 193 187.2 192.9 738 657 6308 5623 4029 4098
8 14 7/5/05 CTRL_61905 D7S481 187 193 187.1 192.9 325 231 2757 1937 4065 4136
9 15 7/6/05 CTRL D7S481 187 193 187.2 192.9 348 289 3220 2490 4114 4185
10 16 7/7/05 CRTL D7S481 187 193 187.2 192.9 620 483 5649 4425 4108 4179
203
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17 7/7/05 CRTL D7S481 187 193 187.2 193.0 615 480 5584 4370 4139 4211
11 18 7/8/05 CTRL_.4UL D7S481 187 193 187.2 192.9 627 564 5437 4934 4178 4250
19 7/8/05 CTRL_1UL D7S481 187 193 187.2 192.9 478 374 4130 3259 4151 4222
20 7/8/05 CTRL D7S481 187 193 187.4 193.1 829 706 8324 6878 4161 4233
12 21 7/11/05 CTRL D7S481 187 193 187.2 193.0 660 622 6739 6677 4148 4220
13 22 7/13/05 CTRL D7S481 187 193 187.5 193.2 998 927 9684 9236 4470 4546
14 23 7/15/05 CTRL D7S481 187 193 187.2 192.9 845 740 7381 6701 4198 4270
15 24 11/14/05 10K_CTRL D7S481 187 193 187.2 192.9 1877 1505 20115 16043 4370 4444
1 1 5/31/05 G1MF7_10 BAT25 126 126.1 2508 18819 3623
2 5/31/05 G1MF7_15 BAT25 126 126.0 2072 15553 3633
3 5/31/05 G1MF7_20 BAT25 126 126.1 3760 28514 3648
4 5/31/05 G1MF7_25 BAT25 126 125.9 1246 9276 3526
5 5/31/05 G1MF10 BAT25 126 126.0 820 6444 3516
6 5/31/05 G1MF15 BAT25 126 126.0 1013 7578 3532
2 7 6/6/05 G1MF10 BAT25 126 125.8 752 7783 3369
8 6/6/05 G1MF.5 BAT25 126 125.7 1758 12869 3366
3 9 6/8/05 G1MF.5_1-9 BAT25 126 125.9 2334 17630 3516
10 6/8/05 G1MF.25_1-6 BAT25 126 125.9 1584 12078 3554
4 11 7/14/05 MF BAT25 126 125.9 3137 24882 3498
1 1 5/31/05 G1MF7_10 BAT26 121 121.1 409 2912 3556
2 5/31/05 G1MF7_15 BAT26 121 121.0 383 2731 3565
3 5/31/05 G1MF7_20 BAT26 121 121.1 605 4426 3579
4 5/31/05 G1MF7_25 BAT26 121 120.9 196 1287 3460
5 5/31/05 G1MF10 BAT26 121 120.9 165 1121 3449
6 5/31/05 G1MF15 BAT26 121 120.9 175 1247 3465
2 7 6/6/05 G1MF10 BAT26 121 120.8 115 981 3305
8 6/6/05 G1MF.5 BAT26 121 120.7 281 2128 3301
3 9 6/8/05 G1MF.5_1-9 BAT26 121 120.9 439 3206 3450
10 6/8/05 G1MF.25_1-6 BAT26 121 120.9 663 4526 3487
4 11 7/14/05 MF BAT26 121 120.9 871 7016 3432
1 1 5/31/05 G1MF7_10 D3S3623 219 225 219.0 225.4 1657 1315 14507 11512 4798 4874
2 5/31/05 G1MF7_15 D3S3623 219 225 219.0 225.4 1801 1297 16236 11306 4810 4885
3 5/31/05 G1MF7_20 D3S3623 219 225 219.1 225.4 3130 2188 28361 19382 4833 4908
4 5/31/05 G1MF7_25 D3S3623 219 225 218.8 225.1 1617 1224 14366 10229 4677 4750
5 5/31/05 G1MF10 D3S3623 219 225 218.8 225.2 1227 978 10863 8501 4664 4738
6 5/31/05 G1MF15 D3S3623 219 225 218.9 225.1 1248 945 11003 8162 4684 4756
2 7 6/6/05 G1MF10 D3S3623 219 225 218.2 224.6 591 399 7475 5118 4480 4552
8 6/6/05 G1MF.5 D3S3623 219 225 218.4 224.7 2088 1435 17354 11841 4478 4548
3 9 6/8/05 G1MF.5_1-9 D3S3623 219 225 218.8 225.2 2598 1799 23822 16278 4672 4746
10 6/8/05 G1MF.25_1-6 D3S3623 219 225 218.8 225.2 1868 1385 16530 12128 4722 4797
4 11 7/14/05 MF D3S3623 219 225 218.6 224.9 5926 4360 54764 40174 4644 4717
1 1 5/31/05 G1MF7_10 D5S346 92 109 91.9 109.1 2489 945 21574 7696 3152 3389
2 5/31/05 G1MF7_15 D5S346 92 109 91.9 109.1 2369 986 20694 8462 3161 3399
3 5/31/05 G1MF7_20 D5S346 92 109 92.0 109.1 3779 1531 33213 12955 3174 3412
4 5/31/05 G1MF7_25 D5S346 92 109 91.9 108.9 1355 723 11464 5590 3065 3297
5 5/31/05 G1MF10 D5S346 92 109 91.8 109.0 1197 685 10001 5557 3055 3287
6 5/31/05 G1MF15 D5S346 92 109 91.9 109.0 1352 698 11787 5797 3071 3303
2 7 6/6/05 G1MF10 D5S346 92 109 91.7 108.8 1106 529 10713 5264 2921 3147
8 6/6/05 G1MF.5 D5S346 92 109 91.6 108.8 2191 1021 18005 8096 2919 3145
3 9 6/8/05 G1MF.5_1-9 D5S346 92 109 91.7 108.9 3388 1531 29452 12437 3053 3287
10 6/8/05 G1MF.25_1-6 D5S346 92 109 91.8 109.0 1552 695 12847 5669 3087 3323
4 11 7/14/05 MF D5S346 92 109 91.7 108.9 2156 1205 18432 9819 3038 3270
1 1 5/31/05 G1MF7_10 D6S262 172 186 172.7 186.2 1023 596 8276 4781 4215 4392
2 5/31/05 G1MF7_15 D6S262 172 186 172.6 186.1 885 533 7453 4327 4226 4403
3 5/31/05 G1MF7_20 D6S262 172 186 172.6 186.1 1428 864 11986 7265 4244 4422
4 5/31/05 G1MF7_25 D6S262 172 186 172.5 185.9 344 249 2594 1879 4106 4279
5 5/31/05 G1MF10 D6S262 172 186 172.4 186.0 322 212 2562 1675 4094 4267
204
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
6 5/31/05 G1MF15 D6S262 172 186 172.5 186.0 427 262 3441 2136 4112 4286
2 7 6/6/05 G1MF10 D6S262 172 186 172.2 185.6 350 203 4023 2430 3931 4097
8 6/6/05 G1MF.5 D6S262 172 186 172.2 185.7 1047 691 8362 5234 3927 4094
3 9 6/8/05 G1MF.5_1-9 D6S262 172 186 172.4 185.9 1488 923 12773 8060 4098 4272
10 6/8/05 G1MF.25_1-6 D6S262 172 186 172.4 185.9 1909 1087 16904 9259 4142 4318
4 11 7/14/05 MF D6S262 172 186 172.4 185.8 2873 2044 27778 18709 4076 4248
1 1 5/31/05 G1MF7_10 D7S481 187 197 187.6 197.3 410 278 3735 2539 4411 4537
2 5/31/05 G1MF7_15 D7S481 187 197 187.5 197.2 470 319 4133 2774 4422 4548
3 5/31/05 G1MF7_20 D7S481 187 197 187.6 197.3 704 507 6447 4631 4442 4569
4 5/31/05 G1MF7_25 D7S481 187 197 187.4 197.0 402 320 3554 2680 4298 4421
5 5/31/05 G1MF10 D7S481 187 197 187.4 197.0 347 252 2999 2129 4285 4408
6 5/31/05 G1MF15 D7S481 187 197 187.4 197.0 353 257 3058 2133 4304 4426
2 7 6/6/05 G1MF10 D7S481 187 197 187.2 196.7 163 126 1902 1467 4116 4234
8 6/6/05 G1MF.5 D7S481 187 197 187.1 196.8 499 351 4403 2964 4112 4231
3 9 6/8/05 G1MF.5_1-9 D7S481 187 197 187.5 197.0 721 506 6733 4656 4292 4415
10 6/8/05 G1MF.25_1-6 D7S481 187 197 187.4 197.1 964 658 9009 6166 4337 4463
4 11 7/14/05 MF D7S481 187 197 187.2 196.9 3234 2262 31635 22110 4266 4389
1 1 06-06-05-GS G1BF53WT3 BAT25 126 127 125.9 127.0 2193 2137 17698 16849 3569 3583
1 06-06-05-GS G1BF53M3 BAT25 127 126.9 2576 19203 3582
1 06-06-05-GS G1BF53M4 BAT25 127 126.8 2946 27563 3456
1 06-06-05-GS G1BF53WT3 BAT26 121 120.9 494 4304 3502
1 06-06-05-GS G1BF53M3 BAT26 122 121.9 438 3386 3515
1 06-06-05-GS G1BF53M4 BAT26 122 123 121.7 122.6 344 354 3344 2950 3390 3402
1 06-06-05-GS G1BF53WT3 D3S3623 219 221 218.8 220.9 3789 2203 41714 22853 4730 4755
1 06-06-05-GS G1BF53M3 D3S3623 217 225 216.8 225.1 2683 1824 25228 17296 4707 4804
1 06-06-05-GS G1BF53M4 D3S3623 217 225 216.4 224.8 1787 1441 21623 18060 4548 4643
1 06-06-05-GS G1BF53WT3 D5S346 103 107 102.7 106.9 1864 1455 16847 12468 3251 3309
1 06-06-05-GS G1BF53M3 D5S346 92 96 91.8 96.3 2680 1848 22754 15188 3103 3163
1 06-06-05-GS G1BF53M4 D5S346 92 96 91.6 96.1 3291 2115 30336 19237 2988 3047
1 06-06-05-GS G1BF53WT3 D6S262 180 182 180.2 182.1 1209 744 12097 6402 4255 4280
1 06-06-05-GS G1BF53M3 D6S262 179 184 179.2 184.0 1239 863 11463 7680 4243 4305
1 06-06-05-GS G1BF53M4 D6S262 179 184 179.0 183.8 1124 686 13157 7257 4098 4158
1 06-06-05-GS G1BF53WT3 D7S481 193 203 193.1 203.0 511 419 5834 4665 4422 4546
1 06-06-05-GS G1BF53M3 D7S481 187 193 187.3 193.2 681 509 6780 4948 4347 4423
1 06-06-05-GS G1BF53M4 D7S481 187 193 187.1 193.0 447 481 5293 5620 4199 4273
1 06-06-05-GS G1CS72M1 BAT25 126 125.7 3013 23265 3401
1 06-06-05-GS G1CS72M2 BAT25 126 125.7 1394 12614 3415
1 06-06-05-GS G1CS72M6 BAT25 126 125.7 4354 34967 3405
1 06-06-05-GS G1CS72M1 BAT26 111 110.6 310 3428 3204
1 06-06-05-GS G1CS72M2 BAT26 122 121.7 371 4595 3363
1 06-06-05-GS G1CS72M6 BAT26 111 110.7 712 8122 3208
1 06-06-05-GS G1CS72M1 D3S3623 217 225 216.3 224.8 1624 1392 15161 12467 4494 4589
1 06-06-05-GS G1CS72M2 D3S3623 219 225 218.3 224.6 1413 775 20128 10873 4539 4611
1 06-06-05-GS G1CS72M6 D3S3623 217 225 216.3 224.8 3423 2539 31410 23503 4498 4594
1 06-06-05-GS G1CS72M1 D5S346 92 107 91.6 106.7 2679 1246 22220 9958 2952 3151
1 06-06-05-GS G1CS72M2 D5S346 94 111 93.9 110.8 2611 1265 25210 12663 2992 3219
1 06-06-05-GS G1CS72M6 D5S346 92 107 91.7 106.7 4104 2256 33277 17984 2956 3155
1 06-06-05-GS G1CS72M1 D6S262 179 186 179.0 185.7 883 578 7497 4639 4050 4133
1 06-06-05-GS G1CS72M2 D6S262 172 178 172.2 178.0 793 472 9728 5592 3983 4056
1 06-06-05-GS G1CS72M6 D6S262 179 186 179.0 185.7 1967 1192 18097 9535 4054 4137
1 06-06-05-GS G1CS72M1 D7S481 187 201 187.2 200.5 400 291 3831 2723 4151 4316
1 06-06-05-GS G1CS72M2 D7S481 195 203 194.9 202.6 369 243 5017 3343 4268 4361
1 06-06-05-GS G1CS72M6 D7S481 187 201 187.2 200.6 987 624 9591 5880 4155 4321
1 06-06-05-GS G1BF113WT1 BAT25 126 125.8 776 6347 3437
1 06-06-05-GS G1BF113WT2 BAT25 126 127 125.7 126.7 1910 1894 17994 18286 3416 3430
1 06-06-05-GS G1BF113M1 BAT25 126 127 125.7 126.8 4378 4175 34175 30643 3420 3433
1 06-06-05-GS G1BF113M4 BAT25 127 126.7 4521 48283 3438
205
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
1 06-06-05-GS G1BF113WT1 BAT26 121 120.7 121 965 3371
1 06-06-05-GS G1BF113WT2 BAT26 122 121.7 460 4919 3364
1 06-06-05-GS G1BF113M1 BAT26 122 121.6 911 10154 3367
1 06-06-05-GS G1BF113M4 BAT26 122 121.7 729 8622 3372
1 06-06-05-GS G1BF113WT1 D3S3623 219 225 218.6 224.7 415 284 3836 2577 4563 4633
1 06-06-05-GS G1BF113WT2 D3S3623 219 225 218.4 224.7 1574 1172 20050 14984 4541 4613
1 06-06-05-GS G1BF113M1 D3S3623 219 225 218.4 224.7 3996 2967 36639 27394 4541 4612
1 06-06-05-GS G1BF113M4 D3S3623 219 227 218.3 226.8 3065 1920 42012 26985 4551 4647
1 06-06-05-GS G1BF113WT1 D5S346 92 107 91.7 106.8 1465 680 12392 5517 2985 3185
1 06-06-05-GS G1BF113WT2 D5S346 92 107 91.6 106.7 3147 1455 30562 13953 2963 3164
1 06-06-05-GS G1BF113M1 D5S346 92 107 91.6 106.6 6445 2889 56137 23459 2969 3168
1 06-06-05-GS G1BF113M4 D5S346 94 103 93.8 102.5 5405 3327 53673 33533 3000 3115
1 06-06-05-GS G1BF113WT1 D6S262 182 181.9 405 3646 4125
1 06-06-05-GS G1BF113WT2 D6S262 182 181.9 1347 15225 4106
1 06-06-05-GS G1BF113M1 D6S262 182 181.9 3989 33761 4106
1 06-06-05-GS G1BF113M4 D6S262 178 182 178.0 181.9 1565 1125 18248 12587 4067 4115
1 06-06-05-GS G1BF113WT1 D7S481 187 193 187.2 193.0 148 136 1431 1282 4192 4264
1 06-06-05-GS G1BF113WT2 D7S481 187 193 187.2 193.0 434 349 5360 4266 4172 4245
1 06-06-05-GS G1BF113M1 D7S481 187 193 187.2 192.9 1042 887 9823 8361 4172 4244
1 06-06-05-GS G1BF113M4 D7S481 187 201 187.1 200.5 835 567 11044 7489 4181 4348
1 06-06-05-GS G1CS143WT6 BAT25 127 126.7 3774 31397 3391
1 06-06-05-GS G1CS143MC BAT25 126 125.7 1809 16989 3391
1 06-06-05-GS G1CS143M6 BAT25 126 125.7 4293 32345 3381
1 06-06-05-GS G1CS143M3 BAT25 127 126.8 3871 40379 3405
1 06-06-05-GS G1CS143WT6 BAT26 122 121.6 448 4786 3325
1 06-06-05-GS G1CS143MC BAT26 122 123 121.6 122.6 209 216 1946 2053 3338 3350
1 06-06-05-GS G1CS143M3 BAT26 122 121.7 737 8747 3340
1 06-06-05-GS G1CS143M6 BAT26 122 123 121.6 122.6 429 422 4129 3588 3329 3341
1 06-06-05-GS G1CS143WT6 D3S3623 219 218.4 7260 66542 4488
1 06-06-05-GS G1CS143MC D3S3623 225 227 224.7 226.6 1265 708 15791 7550 4581 4603
1 06-06-05-GS G1CS143M3 D3S3623 219 218.4 6213 88672 4512
1 06-06-05-GS G1CS143M6 D3S3623 225 227 224.7 226.7 4463 2649 38782 22036 4562 4585
1 06-06-05-GS G1CS143WT6 D5S346 89 96 89.4 96.1 3487 2696 29139 21611 2902 2988
1 06-06-05-GS G1CS143MC D5S346 92 107 91.6 106.7 3928 1341 37447 12831 2941 3140
1 06-06-05-GS G1CS143M3 D5S346 89 96 89.4 96.0 6532 4325 65985 44584 2912 2999
1 06-06-05-GS G1CS143M6 D5S346 92 107 91.6 106.7 4420 2045 36965 16676 2934 3132
1 06-06-05-GS G1CS143WT6 D6S262 170 184 170.3 183.9 1580 1027 13175 8506 3914 4082
1 06-06-05-GS G1CS143MC D6S262 176 182 176.0 181.8 699 506 9052 6157 4004 4076
1 06-06-05-GS G1CS143M3 D6S262 170 184 170.3 183.8 1797 1024 22824 13040 3933 4102
1 06-06-05-GS G1CS143M6 D6S262 176 182 176.1 181.9 1763 1192 15130 9434 3990 4062
1 06-06-05-GS G1CS143WT6 D7S481 199 198.7 1269 11460 4265
1 06-06-05-GS G1CS143MC D7S481 193 203 192.9 202.6 213 142 2754 1847 4214 4331
1 06-06-05-GS G1CS143M3 D7S481 199 198.6 1064 14361 4286
1 06-06-05-GS G1CS143M6 D7S481 193 203 192.9 202.8 839 660 7875 5893 4197 4316
1 1 11/14/05 S3_1_10 BAT25 127 126.9 5153 40079 3777
2 11/14/05 S2_1_10 BAT25 126 125.9 3801 29159 3802
3 11/14/05 S4_1_10 BAT25 126 125.9 3892 31671 3801
4 11/14/05 S1_1_10 BAT25 126 127 125.9 126.9 126.9 3823 3704 27815 25857 3805
1 1 11/14/05 S3_1_10 BAT26 122 121.8 505 4011 3706
2 11/14/05 S2_1_10 BAT26 122 121.8 546 4679 3745
3 11/14/05 S4_1_10 BAT26 122 121.8 501 4326 3744
4 11/14/05 S1_1_10 BAT26 122 121.8 403 3472 3748
1 1 11/14/05 S3_1_10 D3S3623 219 218.6 7145 95578 4955
2 11/14/05 S2_1_10 D3S3623 225 227 225.2 227.3 227.3 4141 2413 41293 21651 5085
3 11/14/05 S4_1_10 D3S3623 219 227 219.0 227.4 227.4 3532 2248 40741 25463 5010
4 11/14/05 S1_1_10 D3S3623 219 227 218.9 227.3 227.3 3825 2747 38828 27496 5015
1 1 11/14/05 S3_1_10 D5S346 89 92 89.6 91.8 91.8 2494 1922 19783 14171 3253
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2 11/14/05 S2_1_10 D5S346 94 103 93.9 102.7 102.7 2038 993 17895 8418 3349
3 11/14/05 S4_1_10 D5S346 89 94 89.5 94.0 94.0 1569 1611 13213 14324 3286
4 11/14/05 S1_1_10 D5S346 89 94 89.6 94.0 94.0 2084 1805 17930 15816 3290
1 1 11/14/05 S3_1_10 D6S262 180 184 180.1 184.0 184.0 4164 2576 36930 22370 4467
2 11/14/05 S2_1_10 D6S262 174 180 174.3 180.2 180.2 3116 2177 30132 22549 4435
3 11/14/05 S4_1_10 D6S262 174 184 174.3 184.0 184.0 2434 1916 27645 20702 4435
4 11/14/05 S1_1_10 D6S262 174 184 174.4 184.0 184.0 2880 2315 26103 22775 4440
1 1 11/14/05 S3_1_10 D7S481 193 203 193.1 203.0 203.0 475 395 5543 4458 4640
2 11/14/05 S2_1_10 D7S481 201 203 200.9 203.0 203.0 446 293 4878 2796 4791
3 11/14/05 S4_1_10 D7S481 193 203 193.2 203.0 203.0 258 175 3290 2179 4689
4 11/14/05 S1_1_10 D7S481 193 203 193.2 203.0 203.0 262 224 2955 2462 4694
Sample Type # of Patients # of Marker # of Alleles
UC 7 102 204
CD 12 1374 2748
Control Sample 1 144 288
Cell Line 1 66 132
Other Samples 4 84 168
Lineage Study 4 24 48
TOTAL 29 1794 3588
207
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
1 1 6/20/05 UC001B1WT1 D17S250 189 191 189.5 191.5 1689 1019 13318 7456 4241 4266
1 6/20/05 UC001B1WT1 D18S61 154 170 154.1 170.0 376 280 3194 2068 3797 3994
1 6/20/05 UC001B1WT1 D2S123 219 236 218.6 235.9 244 307 1909 2666 4587 4786
1 6/20/05 UC001B1WT1 D3S1262 136 140 135.9 140.0 1851 1291 19620 13422 3581 3632
1 6/20/05 UC001B1WT1 D9S171 113 113.2 2359 19779 3286
1 1 6/30/05 UC002B1M10 D17S250 193 200 193.6 199.7 1204 916 10108 7561 4236 4312
2 6/30/05 UC002B1M13 D17S250 193 200 193.6 199.7 1806 1342 14460 10949 4154 4229
3 6/30/05 UC002B1M15 D17S250 193 200 193.5 199.7 3115 2303 25171 18102 4194 4270
4 6/30/05 UC002B1M18 D17S250 193 200 193.4 199.6 2027 1533 16046 11864 4130 4205
5 6/30/05 UC002B1M19 D17S250 193 200 193.6 199.7 3063 2280 25301 18243 4169 4244
1 1 6/30/05 UC002B1M10 D18S61 152 168 152.0 168.0 866 444 7236 3596 3720 3916
2 6/30/05 UC002B1M13 D18S61 152 168 151.8 168.0 786 468 6288 3765 3646 3840
3 6/30/05 UC002B1M15 D18S61 152 168 151.9 168.0 1080 590 8856 4988 3682 3877
4 6/30/05 UC002B1M18 D18S61 152 168 151.8 167.9 770 441 6188 3647 3625 3818
5 6/30/05 UC002B1M19 D18S61 152 168 151.9 168.0 1081 610 8919 5001 3660 3853
1 1 6/30/05 UC002B1M10 D2S123 216 219 216.4 218.6 1229 708 10016 5320 4502 4527
2 6/30/05 UC002B1M13 D2S123 216 219 216.2 218.5 1784 1127 14189 7931 4414 4439
3 6/30/05 UC002B1M15 D2S123 216 219 216.3 218.6 2100 1324 16859 9591 4458 4483
4 6/30/05 UC002B1M18 D2S123 216 219 216.2 218.3 1682 1046 13259 7480 4390 4414
5 6/30/05 UC002B1M19 D2S123 216 219 216.3 218.4 2328 1457 18930 10656 4431 4455
1 1 6/30/05 UC002B1M10 D3S1262 136 138 135.9 137.8 1682 1261 16891 12360 3532 3556
2 6/30/05 UC002B1M13 D3S1262 136 138 135.8 137.9 2630 2106 26474 20647 3461 3486
3 6/30/05 UC002B1M15 D3S1262 136 138 135.8 137.8 3237 2519 34117 26249 3496 3520
4 6/30/05 UC002B1M18 D3S1262 136 138 135.8 137.8 2281 1761 23082 17704 3441 3465
5 6/30/05 UC002B1M19 D3S1262 136 138 135.7 137.8 3336 2588 34083 25385 3473 3498
1 1 6/30/05 UC002B1M10 D9S171 113 113.1 2447 20492 3239
2 6/30/05 UC002B1M13 D9S171 113 113.1 3497 27711 3173
3 6/30/05 UC002B1M15 D9S171 113 113.1 4357 35396 3205
4 6/30/05 UC002B1M18 D9S171 113 113.1 2707 21879 3154
5 6/30/05 UC002B1M19 D9S171 113 113.0 4302 35061 3184
1 1 6/20/05 UC003B1WT1 D17S250 191 202 191.5 202.0 1407 954 11723 7741 4283 4413
1 6/20/05 UC003B1WT1 D18S61 152 172 152.0 171.9 838 437 6712 3454 3786 4034
1 6/20/05 UC003B1WT1 D2S123 219 236 218.7 236.1 658 590 5386 5154 4605 4806
1 6/20/05 UC003B1WT1 D3S1262 132 142 132.0 142.2 2097 1870 21692 19773 3544 3670
1 6/20/05 UC003B1WT1 D9S171 113 113.2 2744 23895 3298
1 1 6/30/05 UC005B1M18 D17S250 191 195 191.4 195.5 1458 740 11828 5669 4077 4126
2 6/30/05 UC005B1M3 D17S250 191 195 191.4 195.5 1299 960 10024 7220 4095 4145
3 6/30/05 UC005B1M5 D17S250 191 195 191.4 195.5 1712 1230 13922 9368 4132 4182
1 1 6/30/05 UC005B1M18 D18S61 168 172 167.9 171.7 331 190 2604 1410 3791 3838
2 6/30/05 UC005B1M3 D18S61 168 172 167.9 171.8 311 219 2424 1572 3809 3856
3 6/30/05 UC005B1M5 D18S61 168 172 168.0 171.9 630 447 5028 3410 3843 3891
1 1 6/30/05 UC005B1M18 D2S123 219 236 218.4 235.8 990 689 8531 5836 4385 4577
2 6/30/05 UC005B1M3 D2S123 219 236 218.4 235.7 650 643 5211 5324 4404 4596
3 6/30/05 UC005B1M5 D2S123 219 236 218.5 235.9 873 885 7346 7476 4443 4637
1 1 6/30/05 UC005B1M18 D3S1262 136 135.7 2281 23772 3415
2 6/30/05 UC005B1M3 D3S1262 136 135.8 2714 26552 3433
3 6/30/05 UC005B1M5 D3S1262 136 135.8 3457 35388 3464
1 1 6/30/05 UC005B1M18 D9S171 105 113 105.4 113.0 984 920 7637 7044 3030 3130
2 6/30/05 UC005B1M3 D9S171 105 113 105.5 113.1 1277 907 10294 7415 3046 3146
3 6/30/05 UC005B1M5 D9S171 105 113 105.5 113.1 1797 1211 15010 10420 3075 3176
1 1 6/30/05 UC006B1M5 D17S250 191 204 191.4 204.0 713 432 5762 3369 4111 4261
2 6/30/05 UC006B1M9 D17S250 191 204 191.4 204.1 1552 1016 12412 7747 4086 4235
Supplemental Table 1.  Group II Microsatellite Markers D2S123, D3S1262, D9S171, D17S250, D18S61
208
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
3 6/30/05 UC006B1M15 D17S250 191 204 191.4 204.0 878 551 7056 4284 4120 4270
1 1 6/30/05 UC006B1M5 D18S61 166 172 165.9 171.8 327 282 2655 2272 3798 3870
2 6/30/05 UC006B1M9 D18S61 166 172 166.0 171.8 520 425 4351 3228 3776 3847
3 6/30/05 UC006B1M15 D18S61 166 172 165.9 171.8 428 336 3416 2576 3807 3879
1 1 6/30/05 UC006B1M5 D2S123 219 218.4 3105 26905 4421
2 6/30/05 UC006B1M9 D2S123 219 218.4 2407 20047 4394
3 6/30/05 UC006B1M15 D2S123 219 218.5 2840 23885 4431
1 1 6/30/05 UC006B1M5 D3S1262 132 142 131.8 142.0 805 779 8684 8074 3396 3518
2 6/30/05 UC006B1M9 D3S1262 132 142 131.8 142.0 1858 1565 18311 15386 3375 3497
3 6/30/05 UC006B1M15 D3S1262 132 142 131.7 142.0 1074 993 11318 10185 3404 3527
1 1 6/30/05 UC006B1M5 D9S171 113 115 113.0 114.9 2364 1359 18830 9245 3157 3182
2 6/30/05 UC006B1M9 D9S171 113 115 113.0 115.0 1777 1171 13963 7814 3138 3163
3 6/30/05 UC006B1M15 D9S171 113 115 113.1 115.0 1604 1042 12395 7325 3166 3191
1 1 6/30/05 UC009B1M6 D17S250 191 195 191.3 195.4 1417 1048 11007 8105 4093 4143
2 6/30/05 UC009B1M8 D17S250 191 195 191.5 195.5 2668 1971 21575 15539 4131 4181
3 6/30/05 UC009B1M11 D17S250 191 195 191.3 195.4 1601 1116 12753 8435 4056 4106
1 1 6/30/05 UC009B1M6 D18S61 154 170 154.0 169.8 468 283 3746 2122 3640 3831
2 6/30/05 UC009B1M8 D18S61 154 170 154.0 169.9 980 622 7994 4975 3673 3866
3 6/30/05 UC009B1M11 D18S61 154 170 153.9 169.8 620 379 4855 2751 3606 3796
1 1 6/30/05 UC009B1M6 D2S123 219 218.3 1208 10008 4402
2 6/30/05 UC009B1M8 D2S123 219 218.4 2415 20186 4442
3 6/30/05 UC009B1M11 D2S123 219 218.3 1534 12778 4362
1 1 6/30/05 UC009B1M6 D3S1262 132 136 131.9 135.8 1440 1343 13189 12323 3383 3431
2 6/30/05 UC009B1M8 D3S1262 132 136 131.9 135.8 2714 2716 26119 25643 3414 3463
3 6/30/05 UC009B1M11 D3S1262 132 136 131.8 135.8 1568 1480 14870 13780 3351 3399
1 1 6/30/05 UC009B1M6 D9S171 115 121 115.0 120.9 747 657 5666 5105 3170 3245
2 6/30/05 UC009B1M8 D9S171 115 121 115.1 120.9 1592 1342 12065 10469 3200 3275
3 6/30/05 UC009B1M11 D9S171 115 121 115.0 120.8 803 754 6022 5586 3140 3214
1 1 6/20/05 UC018B1WT6 D17S250 187 189 187.3 189.4 680 477 5054 3451 4178 4204
1 6/20/05 UC018B1WT6 D18S61 154 176 154.0 175.7 198 153 1581 1149 3764 4033
1 6/20/05 UC018B1WT6 D2S123 236 235.9 433 3691 4745
1 6/20/05 UC018B1WT6 D3S1262 136 138 135.9 137.9 1041 544 10256 5047 3550 3575
1 6/20/05 UC018B1WT6 D9S171 113 113.2 942 7847 3257
1 1 7/5/05 CD3B1_2M9 D17S250 181 202 181.0 201.6 1694 726 14356 5888 3994 4246
2 7/5/05 CD3B1_2M27 D17S250 181 202 181.0 201.7 734 334 6403 2861 4017 4271
3 7/5/05 CD3B1_2M35 D17S250 181 202 181.1 201.8 1502 703 12335 5992 4001 4255
4 7/5/05 CD3B1_2M2 D17S250 181 202 181.0 201.7 1736 763 14353 6296 3989 4242
5 7/5/05 CD3B1_2M10 D17S250 181 202 181.0 201.7 1251 594 10152 4874 3961 4212
6 7/5/05 CD3B1_2M20 D17S250 181 202 181.0 201.7 790 380 6452 3316 3982 4235
7 7/5/05 CD3B1_2M28 D17S250 181 202 181.0 201.7 1198 631 9790 4908 3986 4239
8 7/5/05 CD3B1_2M36 D17S250 181 202 181.1 201.7 856 421 6978 3355 3975 4226
9 7/5/05 CD3B1_2M3 D17S250 181 202 181.0 201.7 1920 908 16079 7443 4021 4274
10 7/5/05 CD3B1_2M11 D17S250 181 202 180.9 201.7 1006 463 8178 3966 3988 4241
11 7/5/05 CD3B1_2M21 D17S250 181 202 181.1 201.7 625 315 5102 2534 4003 4255
12 7/5/05 CD3B1_2M37 D17S250 181 202 181.0 201.7 863 436 7177 3487 3993 4244
13 7/5/05 CD3B1_2M12 D17S250 181 202 181.0 201.8 1641 830 13329 6734 4003 4257
14 7/5/05 CD3B1_2M22 D17S250 181 202 181.0 201.7 1493 771 12519 6381 4015 4269
15 7/5/05 CD3B1_2M30 D17S250 181 202 181.1 201.9 858 395 6998 3302 4018 4273
16 7/5/05 CD3B1_2M38 D17S250 181 202 181.1 201.8 958 380 7893 3141 4006 4260
17 7/5/05 CD3B1_2M5 D17S250 181 202 181.0 201.8 1815 896 15303 7527 4015 4270
18 7/5/05 CD3B1_2M13 D17S250 181 202 181.0 201.7 969 434 7893 3591 3996 4249
19 7/5/05 CD3B1_2M23 D17S250 181 202 181.1 201.8 1016 536 8701 4378 4009 4263
20 7/5/05 CD3B1_2M31 D17S250 181 202 181.1 201.7 1022 554 8576 4505 4002 4255
209
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
21 7/5/05 CD3B1_2M39 D17S250 181 202 181.0 201.7 1187 518 9832 4348 3994 4247
22 7/5/05 CD3B1_2M6 D17S250 181 202 181.1 201.7 1326 653 10746 5359 3985 4237
23 7/5/05 CD3B1_2M14 D17S250 181 202 181.0 201.7 1301 646 10594 4953 3966 4218
24 7/5/05 CD3B1_2M32 D17S250 181 202 181.0 201.7 1114 509 9017 4052 3971 4223
25 7/5/05 CD3B1_2M7 D17S250 181 202 181.0 201.7 1087 455 8967 3830 4012 4265
26 7/5/05 CD3B1_2M16 D17S250 181 202 181.1 201.7 833 455 6960 3716 3988 4239
27 7/5/05 CD3B1_2M33 D17S250 181 202 181.0 201.6 745 367 6118 3016 3989 4241
28 7/5/05 CD3B1_2M8 D17S250 181 202 181.1 201.8 1599 807 12957 6598 4023 4277
29 7/5/05 CD3B1_2M17 D17S250 181 202 181.1 201.7 1599 801 13177 6393 4000 4253
30 7/5/05 CD3B1_2M26 D17S250 181 202 181.1 201.8 1281 472 10453 3744 4012 4266
31 7/5/05 CD3B1_2M34 D17S250 181 202 181.1 201.8 1883 839 15605 6824 4003 4257
32 7/5/05 CD3B1_2M42 D17S250 181 202 181.0 201.7 1469 499 11988 4111 3995 4248
1 1 7/5/05 CD3B1_2M9 D18S61 164 172 163.8 171.6 484 418 3981 3341 3781 3877
2 7/5/05 CD3B1_2M27 D18S61 164 172 163.9 171.7 231 136 1828 1063 3804 3901
3 7/5/05 CD3B1_2M35 D18S61 164 172 163.9 171.8 378 286 3149 2311 3788 3886
4 7/5/05 CD3B1_2M2 D18S61 164 172 163.9 171.6 536 433 4693 3364 3778 3874
5 7/5/05 CD3B1_2M10 D18S61 164 172 163.8 171.7 427 343 3496 2638 3750 3846
6 7/5/05 CD3B1_2M20 D18S61 164 172 163.9 171.7 286 204 2326 1520 3770 3866
7 7/5/05 CD3B1_2M28 D18S61 164 172 163.8 171.6 416 296 3421 2351 3774 3871
8 7/5/05 CD3B1_2M36 D18S61 164 172 163.8 171.7 422 450 3400 3489 3762 3859
9 7/5/05 CD3B1_2M3 D18S61 164 172 163.9 171.7 546 398 4627 3070 3809 3906
10 7/5/05 CD3B1_2M11 D18S61 164 172 163.8 171.6 347 274 2759 2162 3777 3873
11 7/5/05 CD3B1_2M21 D18S61 164 172 163.9 171.8 170 205 1442 1764 3791 3888
12 7/5/05 CD3B1_2M37 D18S61 164 172 163.8 171.6 406 308 3181 2408 3781 3877
13 7/5/05 CD3B1_2M12 D18S61 164 172 163.9 171.6 521 346 4179 2729 3791 3887
14 7/5/05 CD3B1_2M22 D18S61 164 172 163.9 171.7 534 458 4237 3489 3802 3899
15 7/5/05 CD3B1_2M30 D18S61 164 172 163.9 171.8 414 233 3341 2006 3804 3902
16 7/5/05 CD3B1_2M38 D18S61 164 172 163.9 171.7 455 392 3608 3146 3793 3890
17 7/5/05 CD3B1_2M5 D18S61 164 172 163.9 171.7 503 372 4065 2881 3802 3899
18 7/5/05 CD3B1_2M13 D18S61 164 172 163.9 171.6 552 409 4482 3336 3784 3880
19 7/5/05 CD3B1_2M23 D18S61 164 172 163.9 171.7 361 254 2884 1937 3796 3893
20 7/5/05 CD3B1_2M31 D18S61 164 172 163.8 171.7 266 206 2282 1587 3788 3886
21 7/5/05 CD3B1_2M39 D18S61 164 172 163.9 171.6 439 341 3425 2627 3782 3878
22 7/5/05 CD3B1_2M6 D18S61 164 172 163.9 171.7 468 297 3827 2334 3773 3869
23 7/5/05 CD3B1_2M14 D18S61 164 172 163.8 171.6 344 262 2725 2052 3755 3851
24 7/5/05 CD3B1_2M32 D18S61 164 172 163.9 171.7 312 202 2464 1551 3760 3856
25 7/5/05 CD3B1_2M7 D18S61 164 172 163.9 171.6 223 176 2007 1392 3801 3896
26 7/5/05 CD3B1_2M16 D18S61 164 172 163.8 171.6 207 283 1689 2121 3776 3872
27 7/5/05 CD3B1_2M33 D18S61 164 172 163.9 171.6 384 258 3178 1982 3779 3874
28 7/5/05 CD3B1_2M8 D18S61 164 172 163.9 171.8 514 371 3969 2907 3810 3907
29 7/5/05 CD3B1_2M17 D18S61 164 172 164.0 171.7 549 479 4469 3765 3788 3884
30 7/5/05 CD3B1_2M26 D18S61 164 172 163.9 171.7 314 178 2604 1424 3799 3896
31 7/5/05 CD3B1_2M34 D18S61 164 172 163.9 171.7 558 418 4524 3362 3790 3887
32 7/5/05 CD3B1_2M42 D18S61 164 172 163.8 171.7 309 230 2636 1835 3782 3880
1 1 7/5/05 CD3B1_2M9 D2S123 223 236 222.8 235.8 723 715 6367 6299 4483 4629
2 7/5/05 CD3B1_2M27 D2S123 223 236 222.8 236.0 302 265 2696 2161 4508 4656
3 7/5/05 CD3B1_2M35 D2S123 223 236 222.7 235.9 555 518 4759 4468 4490 4638
4 7/5/05 CD3B1_2M2 D2S123 223 236 222.7 235.9 882 846 7948 7288 4477 4624
5 7/5/05 CD3B1_2M10 D2S123 223 236 222.7 235.8 670 589 5678 4974 4446 4592
6 7/5/05 CD3B1_2M20 D2S123 223 236 222.8 235.8 386 324 3173 2610 4471 4617
7 7/5/05 CD3B1_2M28 D2S123 223 236 222.7 235.9 727 634 6452 5624 4474 4621
8 7/5/05 CD3B1_2M36 D2S123 223 236 222.8 235.9 705 572 5779 5013 4462 4608
9 7/5/05 CD3B1_2M3 D2S123 223 236 222.7 235.8 658 635 5654 5342 4510 4657
10 7/5/05 CD3B1_2M11 D2S123 223 236 222.7 235.8 462 484 4219 4221 4475 4621
210
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
11 7/5/05 CD3B1_2M21 D2S123 223 236 222.7 235.8 278 410 2534 3465 4490 4636
12 7/5/05 CD3B1_2M37 D2S123 223 236 222.8 235.8 708 724 5916 6026 4479 4624
13 7/5/05 CD3B1_2M12 D2S123 223 236 222.8 235.8 608 557 5188 4752 4493 4639
14 7/5/05 CD3B1_2M22 D2S123 223 236 222.7 235.8 782 695 6698 6006 4506 4653
15 7/5/05 CD3B1_2M30 D2S123 223 236 222.9 236.0 586 520 5238 4696 4509 4656
16 7/5/05 CD3B1_2M38 D2S123 223 236 222.8 235.9 891 909 7860 7784 4496 4643
17 7/5/05 CD3B1_2M5 D2S123 223 236 222.8 235.8 622 566 5351 5024 4506 4652
18 7/5/05 CD3B1_2M13 D2S123 223 236 222.7 235.8 962 901 8785 8302 4484 4631
19 7/5/05 CD3B1_2M23 D2S123 223 236 222.8 236.0 595 403 5171 3500 4499 4647
20 7/5/05 CD3B1_2M31 D2S123 223 236 222.8 235.9 395 387 3559 3344 4492 4638
21 7/5/05 CD3B1_2M39 D2S123 223 236 222.8 235.9 518 473 4384 4288 4484 4630
22 7/5/05 CD3B1_2M6 D2S123 223 236 222.8 235.9 585 551 5185 4954 4472 4618
23 7/5/05 CD3B1_2M14 D2S123 223 236 222.7 235.7 471 476 4018 3952 4452 4597
24 7/5/05 CD3B1_2M32 D2S123 223 236 222.7 235.8 458 408 3710 3496 4457 4603
25 7/5/05 CD3B1_2M7 D2S123 223 236 222.7 235.8 478 459 3903 4005 4500 4645
26 7/5/05 CD3B1_2M16 D2S123 223 236 222.7 235.7 667 486 5673 4125 4473 4618
27 7/5/05 CD3B1_2M33 D2S123 223 236 222.8 235.8 618 530 5312 4552 4477 4622
28 7/5/05 CD3B1_2M8 D2S123 223 236 222.8 235.9 571 545 5043 4727 4513 4660
29 7/5/05 CD3B1_2M17 D2S123 223 236 222.8 235.9 752 699 6523 5983 4489 4636
30 7/5/05 CD3B1_2M26 D2S123 223 236 222.8 236.0 333 413 2661 3536 4502 4650
31 7/5/05 CD3B1_2M34 D2S123 223 236 222.8 235.9 655 572 5546 4958 4493 4640
32 7/5/05 CD3B1_2M42 D2S123 223 236 222.8 235.8 463 385 4098 3443 4484 4630
1 1 7/5/05 CD3B1_2M9 D3S1262 136 135.7 2750 26459 3450
2 7/5/05 CD3B1_2M27 D3S1262 136 135.7 529 4720 3471
3 7/5/05 CD3B1_2M35 D3S1262 136 135.7 5026 46811 3456
4 7/5/05 CD3B1_2M2 D3S1262 136 135.6 2910 30258 3446
5 7/5/05 CD3B1_2M10 D3S1262 136 135.7 3435 32565 3421
6 7/5/05 CD3B1_2M20 D3S1262 136 135.7 718 6654 3439
7 7/5/05 CD3B1_2M28 D3S1262 136 135.7 2899 27304 3443
8 7/5/05 CD3B1_2M36 D3S1262 136 135.7 1260 11663 3432
9 7/5/05 CD3B1_2M3 D3S1262 136 135.7 4777 48842 3477
10 7/5/05 CD3B1_2M11 D3S1262 136 135.6 2260 20847 3447
11 7/5/05 CD3B1_2M21 D3S1262 136 135.7 948 9056 3460
12 7/5/05 CD3B1_2M37 D3S1262 136 135.7 1482 13849 3451
13 7/5/05 CD3B1_2M12 D3S1262 136 135.7 4916 47561 3459
14 7/5/05 CD3B1_2M22 D3S1262 136 135.7 3546 34431 3469
15 7/5/05 CD3B1_2M30 D3S1262 136 135.7 951 9076 3472
16 7/5/05 CD3B1_2M38 D3S1262 136 135.7 1402 13789 3461
17 7/5/05 CD3B1_2M5 D3S1262 136 135.7 4621 46309 3470
18 7/5/05 CD3B1_2M13 D3S1262 136 135.7 2363 22732 3452
19 7/5/05 CD3B1_2M23 D3S1262 136 135.7 734 6972 3464
20 7/5/05 CD3B1_2M31 D3S1262 136 135.7 2507 23597 3457
21 7/5/05 CD3B1_2M39 D3S1262 136 135.7 2577 24553 3450
22 7/5/05 CD3B1_2M6 D3S1262 136 135.7 2992 28976 3442
23 7/5/05 CD3B1_2M14 D3S1262 136 135.7 3645 34080 3426
24 7/5/05 CD3B1_2M32 D3S1262 136 135.7 2794 25848 3429
25 7/5/05 CD3B1_2M7 D3S1262 136 135.7 1044 10239 3470
26 7/5/05 CD3B1_2M16 D3S1262 136 135.7 671 5944 3446
27 7/5/05 CD3B1_2M33 D3S1262 136 135.7 1686 15801 3448
28 7/5/05 CD3B1_2M8 D3S1262 136 135.7 2467 23790 3477
29 7/5/05 CD3B1_2M17 D3S1262 136 135.7 2694 25583 3456
30 7/5/05 CD3B1_2M26 D3S1262 136 135.7 924 8542 3466
31 7/5/05 CD3B1_2M34 D3S1262 136 135.7 4076 38758 3458
32 7/5/05 CD3B1_2M42 D3S1262 136 135.7 565 5336 3451
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1 1 7/5/05 CD3B1_2M9 D9S171 113 112.9 2115 17422 3160
2 7/5/05 CD3B1_2M27 D9S171 113 113.0 701 5689 3180
3 7/5/05 CD3B1_2M35 D9S171 113 113.0 2445 19793 3166
4 7/5/05 CD3B1_2M2 D9S171 113 112.9 2020 16127 3157
5 7/5/05 CD3B1_2M10 D9S171 113 113.0 2100 16834 3133
6 7/5/05 CD3B1_2M20 D9S171 113 112.9 751 6226 3150
7 7/5/05 CD3B1_2M28 D9S171 113 112.9 1899 15453 3154
8 7/5/05 CD3B1_2M36 D9S171 113 113.0 1166 9264 3144
9 7/5/05 CD3B1_2M3 D9S171 113 112.9 2222 18037 3186
10 7/5/05 CD3B1_2M11 D9S171 113 112.9 1507 12451 3158
11 7/5/05 CD3B1_2M21 D9S171 113 112.9 653 5248 3170
12 7/5/05 CD3B1_2M37 D9S171 113 112.9 1237 9828 3162
13 7/5/05 CD3B1_2M12 D9S171 113 112.9 2498 20224 3168
14 7/5/05 CD3B1_2M22 D9S171 113 113.0 2242 18199 3178
15 7/5/05 CD3B1_2M30 D9S171 113 112.9 1116 8672 3181
16 7/5/05 CD3B1_2M38 D9S171 113 112.9 1310 10817 3170
17 7/5/05 CD3B1_2M5 D9S171 113 112.9 2320 19022 3179
18 7/5/05 CD3B1_2M13 D9S171 113 112.9 3118 25528 3162
19 7/5/05 CD3B1_2M23 D9S171 113 112.9 853 7024 3173
20 7/5/05 CD3B1_2M31 D9S171 113 112.9 1424 11925 3166
21 7/5/05 CD3B1_2M39 D9S171 113 113.0 1619 13313 3161
22 7/5/05 CD3B1_2M6 D9S171 113 112.9 1907 15415 3153
23 7/5/05 CD3B1_2M14 D9S171 113 113.0 1719 13675 3138
24 7/5/05 CD3B1_2M32 D9S171 113 112.9 1454 11420 3141
25 7/5/05 CD3B1_2M7 D9S171 113 112.9 1000 8270 3180
26 7/5/05 CD3B1_2M16 D9S171 113 112.9 839 7082 3157
27 7/5/05 CD3B1_2M33 D9S171 113 112.9 1453 11971 3159
28 7/5/05 CD3B1_2M8 D9S171 113 112.9 1475 11922 3186
29 7/5/05 CD3B1_2M17 D9S171 113 113.0 2059 17248 3166
30 7/5/05 CD3B1_2M26 D9S171 113 113.0 699 5733 3176
31 7/5/05 CD3B1_2M34 D9S171 113 112.9 2150 17420 3168
32 7/5/05 CD3B1_2M42 D9S171 113 112.9 722 5730 3161
1 1 7/6/05 CD006B1_M2 D17S250 191 191.3 3693 32218 4208
2 7/6/05 CD006B1_M15 D17S250 191 191.3 3922 32949 4146
3 7/6/05 CD006B1_M27 D17S250 191 191.4 2317 19965 4230
4 7/6/05 CD006B1_M37 D17S250 191 191.4 1731 14769 4174
5 7/6/05 CD006B1_M48 D17S250 191 191.3 1391 11433 4174
6 7/6/05 CD006B1_M3 D17S250 191 191.4 3606 31358 4179
7 7/6/05 CD006B1_M28 D17S250 191 191.4 1309 11037 4208
8 7/6/05 CD006B1_M39 D17S250 191 191.3 1777 14874 4149
9 7/6/05 CD006B1_M51 D17S250 191 191.4 1122 8897 4149
10 7/6/05 CD006B1_M4 D17S250 191 191.4 3585 31324 4189
11 7/6/05 CD006B1_M29 D17S250 191 191.4 1314 11218 4216
12 7/6/05 CD006B1_M40 D17S250 191 191.3 1390 12048 4158
13 7/6/05 CD006B1_M52 D17S250 191 191.3 1021 8714 4129
14 7/6/05 CD006B1_M5 D17S250 191 191.4 3985 34972 4203
15 7/6/05 CD006B1_M20 D17S250 191 191.4 3510 30220 4152
16 7/6/05 CD006B1_M31 D17S250 191 191.5 1674 14383 4231
17 7/6/05 CD006B1_M41 D17S250 191 191.4 2108 17706 4175
18 7/6/05 CD006B1_M53 D17S250 191 191.4 1722 14686 4187
19 7/6/05 CD006B1_M73 D17S250 191 191.4 2239 18975 4197
20 7/6/05 CD006B1_M6 D17S250 191 191.4 3000 25759 4169
21 7/6/05 CD006B1_M23 D17S250 191 191.4 2460 20942 4157
212
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22 7/6/05 CD006B1_M32 D17S250 191 191.3 1622 13736 4183
23 7/6/05 CD006B1_M43 D17S250 191 191.3 1648 13768 4161
24 7/6/05 CD006B1_M54 D17S250 191 191.4 1233 10287 4180
25 7/6/05 CD006B1_M75 D17S250 191 191.3 1529 13034 4208
26 7/6/05 CD006B1_M8 D17S250 191 191.3 3101 26287 4145
27 7/6/05 CD006B1_M24 D17S250 191 191.3 2207 18521 4132
28 7/6/05 CD006B1_M33 D17S250 191 191.4 1055 9031 4162
29 7/6/05 CD006B1_M45 D17S250 191 191.4 1671 14135 4138
30 7/6/05 CD006B1_M55 D17S250 191 191.3 1464 12191 4156
31 7/6/05 CD006B1_M82 D17S250 191 191.3 1316 11191 4184
32 7/6/05 CD006B1_M9 D17S250 191 191.3 2700 22975 4155
33 7/6/05 CD006B1_M25 D17S250 191 191.4 1672 13943 4141
34 7/6/05 CD006B1_M35 D17S250 191 191.4 2249 18744 4167
35 7/6/05 CD006B1_M46 D17S250 191 191.3 2159 18093 4118
36 7/6/05 CD006B1_M65 D17S250 191 191.4 1311 11061 4139
37 7/6/05 CD006B1_M14 D17S250 191 191.3 3517 30219 4167
38 7/6/05 CD006B1_M26 D17S250 191 191.4 2983 25238 4159
39 7/6/05 CD006B1_M36 D17S250 191 191.4 1724 14839 4186
40 7/6/05 CD006B1_M47 D17S250 191 191.4 2013 16828 4164
41 7/6/05 CD006B1_M67 D17S250 191 191.4 1591 13784 4181
1 1 7/6/05 CD006B1_M2 D18S61 168 170 167.9 169.8 1823 1176 14688 8587 3912 3936
2 7/6/05 CD006B1_M15 D18S61 168 170 167.8 169.8 1788 1157 14283 8764 3853 3878
3 7/6/05 CD006B1_M27 D18S61 168 170 167.9 169.8 1187 691 9253 5010 3933 3957
4 7/6/05 CD006B1_M37 D18S61 168 170 167.9 169.8 1162 779 9087 5796 3880 3904
5 7/6/05 CD006B1_M48 D18S61 168 170 167.8 169.7 807 486 6345 3545 3880 3904
6 7/6/05 CD006B1_M3 D18S61 168 170 167.8 169.8 1544 954 12038 7190 3884 3909
7 7/6/05 CD006B1_M28 D18S61 168 170 167.8 169.7 703 415 5619 3036 3911 3935
8 7/6/05 CD006B1_M39 D18S61 168 170 167.8 169.6 812 578 6480 4123 3857 3880
9 7/6/05 CD006B1_M51 D18S61 168 170 167.8 169.7 747 343 5780 2491 3856 3880
10 7/6/05 CD006B1_M4 D18S61 168 170 167.8 169.8 1625 942 13027 6921 3895 3920
11 7/6/05 CD006B1_M29 D18S61 168 170 167.8 169.7 569 381 4619 2881 3921 3945
12 7/6/05 CD006B1_M40 D18S61 168 170 167.7 169.7 750 501 5921 3735 3866 3890
13 7/6/05 CD006B1_M52 D18S61 168 170 167.8 169.7 527 290 4176 2113 3840 3863
14 7/6/05 CD006B1_M5 D18S61 168 170 167.8 169.8 1812 1157 14567 8540 3907 3932
15 7/6/05 CD006B1_M20 D18S61 168 170 167.8 169.8 1729 1105 13657 7927 3858 3883
16 7/6/05 CD006B1_M31 D18S61 168 170 167.8 169.8 1100 681 8623 5179 3933 3958
17 7/6/05 CD006B1_M41 D18S61 168 170 167.9 169.8 1176 788 9325 5803 3881 3905
18 7/6/05 CD006B1_M53 D18S61 168 170 167.9 169.8 952 569 7501 4212 3892 3916
19 7/6/05 CD006B1_M73 D18S61 168 170 167.8 169.8 1355 793 10670 6013 3901 3926
20 7/6/05 CD006B1_M6 D18S61 168 170 167.8 169.8 1661 1117 13268 8302 3874 3899
21 7/6/05 CD006B1_M23 D18S61 168 170 167.8 169.8 1242 831 9781 6023 3863 3888
22 7/6/05 CD006B1_M32 D18S61 168 170 167.7 169.7 1050 658 8132 4999 3888 3913
23 7/6/05 CD006B1_M43 D18S61 168 170 167.7 169.7 854 561 6604 4100 3867 3892
24 7/6/05 CD006B1_M54 D18S61 168 170 167.8 169.7 853 529 6775 3794 3885 3909
25 7/6/05 CD006B1_M75 D18S61 168 170 167.8 169.8 704 435 5498 3168 3912 3937
26 7/6/05 CD006B1_M8 D18S61 168 170 167.7 169.6 1486 886 11873 6431 3852 3876
27 7/6/05 CD006B1_M24 D18S61 168 170 167.8 169.7 1033 704 8078 5005 3840 3864
28 7/6/05 CD006B1_M33 D18S61 168 170 167.8 169.7 513 358 3954 2491 3868 3892
29 7/6/05 CD006B1_M45 D18S61 168 170 167.7 169.7 759 462 5906 3467 3845 3869
30 7/6/05 CD006B1_M55 D18S61 168 170 167.8 169.8 875 550 6785 4081 3862 3887
31 7/6/05 CD006B1_M82 D18S61 168 170 167.7 169.7 897 621 7062 4668 3888 3913
32 7/6/05 CD006B1_M9 D18S61 168 170 167.7 169.8 982 657 7728 4653 3863 3888
33 7/6/05 CD006B1_M25 D18S61 168 170 167.8 169.7 682 458 5307 3222 3849 3873
34 7/6/05 CD006B1_M35 D18S61 168 170 167.8 169.7 840 545 6372 3835 3875 3899
213
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
35 7/6/05 CD006B1_M46 D18S61 168 170 167.7 169.6 862 582 6495 4135 3829 3852
36 7/6/05 CD006B1_M65 D18S61 168 170 167.9 169.7 654 409 5217 2888 3849 3872
37 7/6/05 CD006B1_M14 D18S61 168 170 167.9 169.8 1774 1137 14190 8486 3874 3898
38 7/6/05 CD006B1_M26 D18S61 168 170 167.8 169.8 1567 1037 12414 7495 3864 3889
39 7/6/05 CD006B1_M36 D18S61 168 170 167.8 169.7 914 531 7198 3982 3891 3915
40 7/6/05 CD006B1_M47 D18S61 168 170 167.8 169.8 928 587 7106 4286 3870 3895
41 7/6/05 CD006B1_M67 D18S61 168 170 167.8 169.7 1278 753 10428 5636 3886 3910
1 1 7/6/05 CD006B1_M2 D2S123 219 218.5 2307 22294 4527
2 7/6/05 CD006B1_M15 D2S123 219 218.4 2857 27006 4461
3 7/6/05 CD006B1_M27 D2S123 219 218.6 1804 16067 4550
4 7/6/05 CD006B1_M37 D2S123 219 218.5 1083 9826 4490
5 7/6/05 CD006B1_M48 D2S123 219 218.4 1218 10682 4490
6 7/6/05 CD006B1_M3 D2S123 219 218.5 2579 24887 4497
7 7/6/05 CD006B1_M28 D2S123 219 218.5 1115 10419 4527
8 7/6/05 CD006B1_M39 D2S123 219 218.5 1504 13712 4465
9 7/6/05 CD006B1_M51 D2S123 219 218.4 1181 10218 4464
10 7/6/05 CD006B1_M4 D2S123 219 218.5 2668 25699 4505
11 7/6/05 CD006B1_M29 D2S123 219 218.6 852 7688 4533
12 7/6/05 CD006B1_M40 D2S123 219 218.5 1088 9900 4472
13 7/6/05 CD006B1_M52 D2S123 219 218.4 718 6115 4439
14 7/6/05 CD006B1_M5 D2S123 219 218.6 3419 33921 4522
15 7/6/05 CD006B1_M20 D2S123 219 218.5 2573 24488 4467
16 7/6/05 CD006B1_M31 D2S123 219 218.7 1475 14053 4551
17 7/6/05 CD006B1_M41 D2S123 219 218.5 1948 18614 4491
18 7/6/05 CD006B1_M53 D2S123 219 218.5 1684 15214 4505
19 7/6/05 CD006B1_M73 D2S123 219 218.5 2261 20358 4515
20 7/6/05 CD006B1_M6 D2S123 219 218.4 2427 23133 4484
21 7/6/05 CD006B1_M23 D2S123 219 218.5 2083 19796 4473
22 7/6/05 CD006B1_M32 D2S123 219 218.5 1403 13218 4500
23 7/6/05 CD006B1_M43 D2S123 219 218.4 1467 13098 4477
24 7/6/05 CD006B1_M54 D2S123 219 218.5 1291 11456 4497
25 7/6/05 CD006B1_M75 D2S123 219 218.5 1018 9438 4527
26 7/6/05 CD006B1_M8 D2S123 219 218.4 2368 22900 4460
27 7/6/05 CD006B1_M24 D2S123 219 218.4 1775 16301 4447
28 7/6/05 CD006B1_M33 D2S123 219 218.4 991 8689 4477
29 7/6/05 CD006B1_M45 D2S123 219 218.4 1538 13529 4453
30 7/6/05 CD006B1_M55 D2S123 219 218.5 1451 12417 4473
31 7/6/05 CD006B1_M82 D2S123 219 218.5 1544 14375 4503
32 7/6/05 CD006B1_M9 D2S123 219 218.4 1976 19025 4469
33 7/6/05 CD006B1_M25 D2S123 219 218.5 1238 11460 4455
34 7/6/05 CD006B1_M35 D2S123 219 218.5 1555 13814 4482
35 7/6/05 CD006B1_M46 D2S123 219 218.5 1696 14661 4429
36 7/6/05 CD006B1_M65 D2S123 219 218.5 1235 10919 4451
37 7/6/05 CD006B1_M14 D2S123 219 218.4 1947 18189 4483
38 7/6/05 CD006B1_M26 D2S123 219 218.5 2361 21908 4475
39 7/6/05 CD006B1_M36 D2S123 219 218.6 1210 11099 4503
40 7/6/05 CD006B1_M47 D2S123 219 218.5 1423 12836 4480
41 7/6/05 CD006B1_M67 D2S123 219 218.5 2049 18504 4498
1 1 7/6/05 CD006B1_M2 D3S1262 132 146 131.7 146.1 1920 1451 25366 16812 3474 3649
2 7/6/05 CD006B1_M15 D3S1262 132 146 131.7 146.1 1918 1521 24002 16970 3421 3594
3 7/6/05 CD006B1_M27 D3S1262 132 146 131.7 146.3 1526 1174 17318 11742 3494 3670
4 7/6/05 CD006B1_M37 D3S1262 132 146 131.7 146.2 942 771 10224 7390 3446 3620
5 7/6/05 CD006B1_M48 D3S1262 132 146 131.6 146.2 975 606 9704 5880 3446 3620
6 7/6/05 CD006B1_M3 D3S1262 132 146 131.7 146.2 1754 1429 23418 17192 3448 3623
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7 7/6/05 CD006B1_M28 D3S1262 132 146 131.8 146.2 863 606 9528 6039 3474 3648
8 7/6/05 CD006B1_M39 D3S1262 132 146 131.6 146.1 1100 974 11720 9363 3424 3597
9 7/6/05 CD006B1_M51 D3S1262 132 136 131.6 135.6 1163 1068 11441 10226 3423 3473
10 7/6/05 CD006B1_M4 D3S1262 132 146 131.6 146.2 2019 1651 26247 19218 3461 3635
11 7/6/05 CD006B1_M29 D3S1262 132 146 131.7 146.2 672 585 7598 5896 3485 3660
12 7/6/05 CD006B1_M40 D3S1262 132 146 131.8 146.2 908 710 9864 6866 3436 3608
13 7/6/05 CD006B1_M52 D3S1262 132 146 131.7 146.1 556 364 5680 3570 3412 3583
14 7/6/05 CD006B1_M5 D3S1262 132 146 131.8 146.2 2497 2020 32681 24354 3471 3645
15 7/6/05 CD006B1_M20 D3S1262 132 146 131.7 146.1 2007 1631 24573 17939 3426 3599
16 7/6/05 CD006B1_M31 D3S1262 132 146 131.7 146.2 1168 873 12329 8592 3495 3670
17 7/6/05 CD006B1_M41 D3S1262 132 146 131.7 146.2 1666 1302 17942 13087 3447 3621
18 7/6/05 CD006B1_M53 D3S1262 132 146 131.8 146.2 1324 896 13903 8744 3456 3630
19 7/6/05 CD006B1_M73 D3S1262 132 146 131.8 146.2 1234 976 13602 9635 3466 3640
20 7/6/05 CD006B1_M6 D3S1262 132 146 131.6 146.1 1448 1092 18559 12375 3441 3615
21 7/6/05 CD006B1_M23 D3S1262 132 146 131.7 146.2 1598 1227 18520 12895 3430 3603
22 7/6/05 CD006B1_M32 D3S1262 132 146 131.7 146.2 1141 840 12440 8416 3454 3628
23 7/6/05 CD006B1_M43 D3S1262 132 146 131.7 146.2 1219 943 13142 9145 3435 3608
24 7/6/05 CD006B1_M54 D3S1262 132 146 131.6 146.2 610 492 6443 4890 3450 3624
25 7/6/05 CD006B1_M75 D3S1262 132 146 131.7 146.2 787 609 8138 5688 3475 3650
26 7/6/05 CD006B1_M8 D3S1262 132 146 131.6 146.2 1787 1568 22694 17851 3420 3594
27 7/6/05 CD006B1_M24 D3S1262 132 146 131.7 146.2 1248 1004 14076 10527 3408 3582
28 7/6/05 CD006B1_M33 D3S1262 132 146 131.7 146.2 843 647 8781 6375 3435 3608
29 7/6/05 CD006B1_M45 D3S1262 132 146 131.7 146.2 1265 908 12921 8764 3414 3587
30 7/6/05 CD006B1_M55 D3S1262 132 146 131.6 146.2 905 737 9601 6995 3428 3603
31 7/6/05 CD006B1_M82 D3S1262 132 146 131.7 146.2 681 472 7204 4720 3452 3627
32 7/6/05 CD006B1_M9 D3S1262 132 146 131.7 146.1 1470 1254 18884 14810 3432 3604
33 7/6/05 CD006B1_M25 D3S1262 132 146 131.7 146.1 1021 791 11488 7743 3420 3592
34 7/6/05 CD006B1_M35 D3S1262 132 146 131.6 146.1 1498 1245 16649 12579 3443 3616
35 7/6/05 CD006B1_M46 D3S1262 132 146 131.7 146.2 1580 1256 17302 12206 3403 3574
36 7/6/05 CD006B1_M65 D3S1262 132 146 131.6 146.1 1065 701 10921 6806 3419 3591
37 7/6/05 CD006B1_M14 D3S1262 132 146 131.6 146.1 1446 1150 18347 13149 3440 3614
38 7/6/05 CD006B1_M26 D3S1262 132 146 131.6 146.1 1791 1355 20214 14014 3431 3605
39 7/6/05 CD006B1_M36 D3S1262 132 146 131.6 146.2 990 653 10387 6398 3456 3631
40 7/6/05 CD006B1_M47 D3S1262 132 146 131.6 146.1 1603 1164 16300 11090 3437 3611
41 7/6/05 CD006B1_M67 D3S1262 132 146 131.7 146.2 516 563 5428 5473 3450 3625
1 1 7/6/05 CD006B1_M2 D9S171 111 113 111.1 113.0 1541 1180 12348 8944 3204 3230
2 7/6/05 CD006B1_M15 D9S171 111 113 111.0 112.9 1543 1135 12277 9577 3154 3179
3 7/6/05 CD006B1_M27 D9S171 111 113 111.1 113.0 1083 762 8634 5943 3223 3249
4 7/6/05 CD006B1_M37 D9S171 111 113 111.1 113.0 637 458 5099 3953 3178 3203
5 7/6/05 CD006B1_M48 D9S171 111 113 111.0 112.9 631 606 5013 4986 3178 3203
6 7/6/05 CD006B1_M3 D9S171 111 113 111.0 113.0 1342 944 10708 7729 3179 3205
7 7/6/05 CD006B1_M28 D9S171 111 113 111.0 113.0 653 495 5263 3919 3203 3229
8 7/6/05 CD006B1_M39 D9S171 111 113 111.1 112.9 871 606 6766 4578 3158 3182
9 7/6/05 CD006B1_M51* D9S171* 113 112.9 746 6088 3181
10 7/6/05 CD006B1_M4 D9S171 111 113 111.0 112.9 1582 1186 12693 8783 3193 3218
11 7/6/05 CD006B1_M29 D9S171 111 113 111.1 112.9 492 359 4049 2851 3216 3241
12 7/6/05 CD006B1_M40 D9S171 111 113 111.1 113.0 636 481 4867 3592 3169 3194
13 7/6/05 CD006B1_M52 D9S171 111 113 111.0 112.9 426 383 3401 3022 3147 3172
14 7/6/05 CD006B1_M5 D9S171 111 113 111.1 113.0 2090 1566 16440 11943 3201 3227
15 7/6/05 CD006B1_M20 D9S171 111 113 111.0 112.9 1459 1057 11382 8072 3159 3184
16 7/6/05 CD006B1_M31 D9S171 111 113 111.1 112.9 843 596 6804 4659 3224 3249
17 7/6/05 CD006B1_M41 D9S171 111 113 111.1 113.0 1293 966 10090 7934 3179 3205
18 7/6/05 CD006B1_M53 D9S171 111 113 111.1 112.9 1059 852 8657 6695 3186 3211
19 7/6/05 CD006B1_M73 D9S171 111 113 111.1 113.0 998 726 8033 5902 3196 3222
215
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20 7/6/05 CD006B1_M6 D9S171 111 113 111.0 112.9 1354 966 10968 8289 3173 3198
21 7/6/05 CD006B1_M23 D9S171 111 113 111.0 112.9 1293 917 10037 6967 3162 3187
22 7/6/05 CD006B1_M32 D9S171 111 113 111.1 112.9 934 665 7413 5277 3186 3211
23 7/6/05 CD006B1_M43 D9S171 111 113 111.0 112.9 960 646 7483 4867 3167 3192
24 7/6/05 CD006B1_M54 D9S171 111 113 111.1 112.9 629 418 5190 3288 3182 3207
25 7/6/05 CD006B1_M75 D9S171 111 113 111.0 113.0 494 362 3910 2923 3205 3231
26 7/6/05 CD006B1_M8 D9S171 111 113 111.0 112.9 1467 1021 11403 7725 3154 3179
27 7/6/05 CD006B1_M24 D9S171 111 113 111.1 113.0 964 715 7703 5489 3142 3167
28 7/6/05 CD006B1_M33 D9S171 111 113 111.0 113.0 603 500 4828 3814 3167 3194
29 7/6/05 CD006B1_M45 D9S171 111 113 111.0 113.0 901 698 7003 5297 3147 3173
30 7/6/05 CD006B1_M55 D9S171 111 113 111.0 112.9 792 599 6107 4581 3161 3186
31 7/6/05 CD006B1_M82 D9S171 111 113 111.0 113.0 564 430 4595 3563 3183 3209
32 7/6/05 CD006B1_M9 D9S171 111 113 111.1 113.0 1563 1096 12207 7819 3166 3191
33 7/6/05 CD006B1_M25 D9S171 111 113 111.1 113.0 815 567 6470 4172 3154 3179
34 7/6/05 CD006B1_M35 D9S171 111 113 111.0 112.9 1068 756 8824 5682 3176 3202
35 7/6/05 CD006B1_M46 D9S171 111 113 111.0 112.9 1248 887 9681 6489 3138 3163
36 7/6/05 CD006B1_M65 D9S171 111 113 111.0 112.9 841 669 6446 5193 3154 3179
37 7/6/05 CD006B1_M14 D9S171 111 113 111.1 112.9 1714 1081 13934 7806 3173 3198
38 7/6/05 CD006B1_M26 D9S171 111 113 111.1 112.9 1556 1141 12302 8759 3164 3189
39 7/6/05 CD006B1_M36 D9S171 111 113 111.0 113.0 853 666 6837 5283 3188 3214
40 7/6/05 CD006B1_M47 D9S171 111 113 111.0 112.9 1132 768 9169 5849 3169 3194
41 7/6/05 CD006B1_M67 D9S171 111 113 111.1 113.0 897 701 7373 5601 3182 3208
1 1 7/7/05 CD009B1_M1 D17S250 191 195 191.3 195.5 221 193 1918 1661 4149 4200
2 7/7/05 CD009B1_M11 D17S250 191 195 191.3 195.4 1078 709 9130 5703 4159 4210
3 7/7/05 CD009B1_M27 D17S250 191 195 191.4 195.5 362 267 3010 2065 4176 4227
4 7/7/05 CD009B1_M70 D17S250 191 195 191.4 195.5 1087 863 9317 6891 4172 4223
5 7/7/05 CD009B1_M30 D17S250 191 195 191.3 195.4 542 402 4401 3292 4146 4197
6 7/7/05 CD009B1_M82 D17S250 191 195 191.4 195.5 978 621 8132 5111 4141 4192
7 7/7/05 CD009B1_M15 D17S250 191 195 191.4 195.5 1452 1228 12143 9916 4173 4224
8 7/7/05 CD009B1_M42 D17S250 191 195 191.4 195.5 1499 1200 12476 10034 4207 4259
9 7/7/05 CD009B1_M103* D17S250* 195 195.5 582 4969 4235
10 7/7/05 CD009B1_M16 D17S250 191 195 191.3 195.5 222 238 1766 1871 4160 4212
11 7/7/05 CD009B1_M33 D17S250 191 195 191.4 195.5 1189 954 10201 7943 4199 4250
12 7/7/05 CD009B1_M43 D17S250 191 195 191.4 195.5 1129 880 9341 7248 4170 4221
13 7/7/05 CD009B1_M108 D17S250 191 195 191.3 195.5 1305 1021 10877 8459 4174 4226
14 7/7/05 CD009B1_M6 D17S250 191 195 191.4 195.4 811 589 6589 4735 4121 4171
15 7/7/05 CD009B1_M34 D17S250 191 195 191.4 195.4 974 746 8064 6078 4167 4217
16 7/7/05 CD009B1_M117 D17S250 191 195 191.3 195.4 526 415 4288 3272 4140 4191
17 7/7/05 CD009B1_M8 D17S250 191 195 191.3 195.4 1110 923 9298 7310 4111 4161
18 7/7/05 CD009B1_M22 D17S250 191 195 191.3 195.4 1060 845 8833 6602 4116 4166
19 7/7/05 CD009B1_M46 D17S250 191 195 191.3 195.4 536 230 4571 1852 4127 4178
20 7/7/05 CD009B1_M51 D17S250 191 195 191.3 195.5 1339 1046 11505 8795 4179 4231
2 21 7/13/05 CD009B1M5_1uL D17S250 191 195 191.6 195.7 412 292 3793 2761 4533 4588
22 7/13/05 CD009B1M12_1uL D17S250 191 195 191.6 195.7 712 509 6574 4523 4568 4623
23 7/13/05 CD009B1M9_1uL D17S250 191 195 191.6 195.7 284 170 2589 1491 4546 4600
24 7/13/05 CD009B1M37_1uL* D17S250* 191 191.6 322 2919 4554
25 7/13/05 CD009B1M84_1uL D17S250 191 195 191.7 195.8 507 282 4744 2456 4569 4624
1 1 7/7/05 CD009B1_M1 D18S61 154 170 153.7 169.7 1629 715 14620 6294 3685 3881
2 7/7/05 CD009B1_M11 D18S61 154 170 153.8 169.8 2231 1446 19498 13190 3695 3891
3 7/7/05 CD009B1_M27 D18S61 154 170 153.8 169.8 1337 685 11507 5917 3710 3906
4 7/7/05 CD009B1_M70 D18S61 154 170 153.8 169.8 2393 1482 20375 12968 3707 3903
5 7/7/05 CD009B1_M30 D18S61 154 170 153.8 169.8 1217 676 10704 5692 3682 3878
6 7/7/05 CD009B1_M82 D18S61 154 170 153.8 169.8 2919 1522 25551 13078 3678 3874
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7 7/7/05 CD009B1_M15 D18S61 154 170 153.8 169.9 3031 1891 25220 16601 3707 3904
8 7/7/05 CD009B1_M42 D18S61 154 170 153.8 169.8 3569 2151 31725 18739 3738 3936
9 7/7/05 CD009B1_M103 D18S61 154 170 153.8 169.8 1021 591 9190 4921 3717 3914
10 7/7/05 CD009B1_M16 D18S61 154 170 153.7 169.7 250 727 1957 6303 3696 3892
11 7/7/05 CD009B1_M33 D18S61 154 170 153.8 169.8 2580 1700 21947 15009 3730 3928
12 7/7/05 CD009B1_M43 D18S61 154 170 153.8 169.8 2555 1543 22456 13297 3705 3901
13 7/7/05 CD009B1_M108 D18S61 154 170 153.8 169.8 2899 1902 24523 16534 3709 3905
14 7/7/05 CD009B1_M6 D18S61 154 170 153.7 169.7 1290 930 11235 8038 3659 3854
15 7/7/05 CD009B1_M34 D18S61 154 170 153.8 169.8 1981 1330 17754 11383 3701 3897
16 7/7/05 CD009B1_M117 D18S61 154 170 153.8 169.8 1316 1043 11266 8713 3678 3874
17 7/7/05 CD009B1_M8 D18S61 154 170 153.8 169.7 2419 1725 21486 14442 3655 3847
18 7/7/05 CD009B1_M22 D18S61 154 170 153.8 169.8 2466 1610 22033 13772 3659 3852
19 7/7/05 CD009B1_M46 D18S61 154 170 153.7 169.8 286 231 2468 1978 3669 3863
20 7/7/05 CD009B1_M51 D18S61 154 170 153.8 169.8 3809 2152 34033 18646 3713 3910
2 21 7/13/05 CD009B1M5_1uL D18S61 154 170 154.2 170.1 1223 695 11270 6207 4039 4248
22 7/13/05 CD009B1M12_1uL D18S61 154 170 154.1 170.1 1719 834 16457 7673 4070 4280
23 7/13/05 CD009B1M9_1uL D18S61 154 170 154.1 170.1 313 217 2658 1862 4052 4261
24 7/13/05 CD009B1M37_1uL* D18S61* 154 154.1 936 8584 4058
25 7/13/05 CD009B1M84_1uL D18S61 154 170 154.1 170.1 709 458 6535 3936 4072 4282
1 1 7/7/05 CD009B1_M1 D2S123 219 218.4 625 5550 4463
2 7/7/05 CD009B1_M11 D2S123 219 218.4 1559 14165 4474
3 7/7/05 CD009B1_M27 D2S123 219 218.5 521 4730 4492
4 7/7/05 CD009B1_M70 D2S123 219 218.5 2330 20798 4488
5 7/7/05 CD009B1_M30 D2S123 219 218.5 835 7483 4462
6 7/7/05 CD009B1_M82 D2S123 219 218.4 1563 14324 4455
7 7/7/05 CD009B1_M15 D2S123 219 218.6 2508 22586 4490
8 7/7/05 CD009B1_M42 D2S123 219 218.6 1787 16946 4526
9 7/7/05 CD009B1_M103 D2S123 219 218.6 391 3706 4501
10 7/7/05 CD009B1_M16 D2S123 219 218.5 246 2120 4476
11 7/7/05 CD009B1_M33 D2S123 219 218.6 1924 18584 4517
12 7/7/05 CD009B1_M43 D2S123 219 218.4 1496 14037 4485
13 7/7/05 CD009B1_M108 D2S123 219 218.5 2419 21448 4491
14 7/7/05 CD009B1_M6 D2S123 219 218.5 1025 9342 4435
15 7/7/05 CD009B1_M34 D2S123 219 218.5 1525 14348 4483
16 7/7/05 CD009B1_M117 D2S123 219 218.4 1030 9149 4455
17 7/7/05 CD009B1_M8 D2S123 219 218.4 2131 19588 4421
18 7/7/05 CD009B1_M22 D2S123 219 218.4 1570 14867 4426
19 7/7/05 CD009B1_M46 D2S123 219 218.4 372 3251 4439
20 7/7/05 CD009B1_M51 D2S123 219 218.5 2576 24630 4496
2 21 7/13/05 CD009B1M5_1uL D2S123 219 218.8 652 6254 4870
22 7/13/05 CD009B1M12_1uL D2S123 219 218.9 1000 9781 4908
23 7/13/05 CD009B1M9_1uL D2S123 219 218.7 203 1945 4881
24 7/13/05 CD009B1M37_1uL D2S123 219 218.8 215 2015 4892
25 7/13/05 CD009B1M84_1uL D2S123 219 218.8 522 4998 4907
1 1 7/7/05 CD009B1_M1 D3S1262 132 136 131.6 135.6 351 442 3892 4915 3424 3474
2 7/7/05 CD009B1_M11 D3S1262 132 136 131.6 135.6 1433 1631 15521 17669 3433 3483
3 7/7/05 CD009B1_M27 D3S1262 132 136 131.6 135.6 1701 1970 17444 21103 3447 3497
4 7/7/05 CD009B1_M70 D3S1262 132 136 131.6 135.6 2723 2744 28771 29513 3444 3494
5 7/7/05 CD009B1_M30 D3S1262 132 136 131.7 135.6 998 1177 11065 12977 3421 3470
6 7/7/05 CD009B1_M82 D3S1262 132 136 131.6 135.5 1242 1445 13472 15678 3417 3466
7 7/7/05 CD009B1_M15 D3S1262 132 136 131.7 135.7 2710 2933 29887 32532 3445 3495
8 7/7/05 CD009B1_M42 D3S1262 132 136 131.7 135.6 2007 2185 23235 24570 3474 3524
9 7/7/05 CD009B1_M103 D3S1262 132 136 131.6 135.5 138 170 1459 1891 3454 3503
10 7/7/05 CD009B1_M16 D3S1262 132 136 131.7 135.7 425 339 4452 3553 3435 3485
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11 7/7/05 CD009B1_M33 D3S1262 132 136 131.6 135.6 2077 2296 22767 25300 3466 3516
12 7/7/05 CD009B1_M43 D3S1262 132 136 131.6 135.6 1669 1823 17524 19204 3442 3492
13 7/7/05 CD009B1_M108 D3S1262 132 136 131.6 135.5 2863 2977 30913 31454 3447 3496
14 7/7/05 CD009B1_M6 D3S1262 132 136 131.6 135.7 1285 1471 13264 15723 3400 3450
15 7/7/05 CD009B1_M34 D3S1262 132 136 131.6 135.7 1723 1795 18584 19729 3438 3489
16 7/7/05 CD009B1_M117 D3S1262 132 136 131.6 135.6 585 579 6192 6243 3417 3467
17 7/7/05 CD009B1_M8 D3S1262 132 136 131.7 135.6 2263 2316 24961 24618 3397 3446
18 7/7/05 CD009B1_M22 D3S1262 132 136 131.6 135.6 1923 2094 20368 22318 3400 3449
19 7/7/05 CD009B1_M46 D3S1262 132 136 131.6 135.7 244 287 2511 3012 3410 3460
20 7/7/05 CD009B1_M51 D3S1262 132 136 131.6 135.6 2308 2432 26646 27487 3450 3500
2 21 7/13/05 CD009B1M5_1uL D3S1262 132 136 132.0 135.9 1663 1655 20630 20785 3760 3812
22 7/13/05 CD009B1M12_1uL D3S1262 132 136 131.9 135.8 1538 1916 19296 24544 3789 3842
23 7/13/05 CD009B1M9_1uL D3S1262 132 136 131.8 135.8 445 420 5478 5103 3773 3826
24 7/13/05 CD009B1M37_1uL D3S1262 132 136 132.0 135.8 562 335 6890 4276 3777 3829
25 7/13/05 CD009B1M84_1uL D3S1262 132 136 131.9 135.8 1112 903 14260 11577 3792 3845
1 1 7/7/05 CD009B1_M1 D9S171 115 121 114.8 120.6 552 454 4434 3747 3208 3284
2 7/7/05 CD009B1_M11 D9S171 115 121 114.8 120.6 1094 815 8789 6453 3216 3292
3 7/7/05 CD009B1_M27 D9S171 115 121 114.8 120.6 1858 1369 15578 11113 3229 3306
4 7/7/05 CD009B1_M70 D9S171 115 121 114.8 120.7 1818 1489 14994 12215 3227 3304
5 7/7/05 CD009B1_M30 D9S171 115 121 114.8 120.6 561 565 4371 4422 3204 3280
6 7/7/05 CD009B1_M82 D9S171 115 121 114.7 120.6 859 714 7071 5492 3201 3277
7 7/7/05 CD009B1_M15 D9S171 115 121 114.8 120.7 1978 1624 16319 12977 3227 3304
8 7/7/05 CD009B1_M42 D9S171 115 121 114.9 120.7 1477 1181 11872 9753 3256 3333
9 7/7/05 CD009B1_M103 D9S171 121 125 120.7 125.5 348 405 2996 5163 3313 3375
10 7/7/05 CD009B1_M16 D9S171 115 121 114.9 120.7 342 186 2711 1577 3218 3294
11 7/7/05 CD009B1_M33 D9S171 115 121 114.8 120.7 1532 1261 12541 10300 3248 3325
12 7/7/05 CD009B1_M43 D9S171 115 121 114.9 120.7 1140 889 9417 7230 3226 3302
13 7/7/05 CD009B1_M108 D9S171 115 121 114.9 120.6 2034 1702 16630 13677 3230 3306
14 7/7/05 CD009B1_M6 D9S171 115 121 114.8 120.6 784 733 6254 6019 3185 3260
15 7/7/05 CD009B1_M34 D9S171 115 121 114.8 120.6 1154 977 9652 7973 3221 3297
16 7/7/05 CD009B1_M117 D9S171 115 121 114.8 120.6 486 437 3970 3502 3202 3277
17 7/7/05 CD009B1_M8* D9S171* 115 121 114.8 120.6 1538 1280 12503 10086 3183 3258
18 7/7/05 CD009B1_M22 D9S171 115 121 114.9 120.7 1262 989 10408 7852 3187 3262
19 7/7/05 CD009B1_M46 D9S171 115 121 114.8 120.6 171 163 1321 1224 3196 3271
20 7/7/05 CD009B1_M51 D9S171 115 121 114.8 120.6 1856 1485 15184 11962 3232 3309
2 21 7/13/05 CD009B1M5_1uL D9S171 115 121 115.2 121.0 946 766 8111 6368 3530 3611
22 7/13/05 CD009B1M12_1uL D9S171 115 121 115.1 120.9 1425 1018 12239 8418 3558 3639
23 7/13/05 CD009B1M9_1uL D9S171 115 121 115.1 120.9 538 369 4870 2888 3543 3624
24 7/13/05 CD009B1M37_1uL D9S171 115 121 115.2 121.0 200 570 1747 5045 3547 3627
25 7/13/05 CD009B1M84_1uL D9S171 115 121 115.1 120.9 614 388 5531 3270 3561 3642
1 1 7/7/05 CD010B1_2M34 D17S250 195 197 195.5 197.5 599 313 4928 2450 4231 4256
2 7/7/05 CD010B1_2M16 D17S250 195 197 195.4 197.5 545 334 4331 2553 4194 4220
3 7/7/05 CD010B1_2M38 D17S250 195 197 195.5 197.5 562 440 4728 3244 4196 4221
4 7/7/05 CD010B1_2M18 D17S250 195 197 195.5 197.5 255 173 2010 1235 4190 4214
5 7/7/05 CD010B1_2M20 D17S250 195 197 195.5 197.5 566 356 4891 2783 4241 4266
6 7/7/05 CD010B1_2M53 D17S250 195 197 195.4 197.5 249 113 2048 854 4237 4263
7 7/7/05 CD010B1_2M29 D17S250 195 197 195.5 197.5 506 431 4073 3388 4194 4219
8 7/7/05 CD010B1_2M58 D17S250 195 197 195.4 197.5 555 188 4766 1389 4196 4221
1 1 7/7/05 CD010B1_2M34 D18S61 168 170 167.8 169.8 1399 600 11484 4403 3885 3910
2 7/7/05 CD010B1_2M16 D18S61 168 170 167.7 169.7 1305 812 10419 6052 3851 3875
3 7/7/05 CD010B1_2M38 D18S61 168 170 167.7 169.7 1507 864 12435 6702 3852 3876
4 7/7/05 CD010B1_2M18 D18S61 168 170 167.8 169.7 726 485 5620 3416 3849 3873
5 7/7/05 CD010B1_2M20 D18S61 168 170 167.8 169.7 1335 612 10994 4483 3894 3918
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6 7/7/05 CD010B1_2M53 D18S61 168 170 167.7 169.7 855 588 6760 4526 3891 3916
7 7/7/05 CD010B1_2M29 D18S61 168 170 167.6 169.7 551 351 4391 2545 3850 3875
8 7/7/05 CD010B1_2M58 D18S61 168 170 167.7 169.6 606 476 4987 3691 3854 3878
1 1 7/7/05 CD010B1_2M34 D2S123 221 236 220.7 236.0 344 280 2960 2427 4521 4693
2 7/7/05 CD010B1_2M16 D2S123 221 236 220.6 235.9 611 591 5635 5348 4482 4654
3 7/7/05 CD010B1_2M38 D2S123 221 236 220.6 235.9 665 687 5919 6212 4484 4655
4 7/7/05 CD010B1_2M18 D2S123 221 236 220.6 235.8 352 293 3128 2656 4475 4644
5 7/7/05 CD010B1_2M20 D2S123 221 236 220.7 236.0 393 407 3582 3623 4532 4705
6 7/7/05 CD010B1_2M53 D2S123 221 236 220.7 236.0 112 118 1062 1021 4528 4700
7 7/7/05 CD010B1_2M29 D2S123 221 236 220.7 236.0 341 273 3129 2515 4483 4654
8 7/7/05 CD010B1_2M58 D2S123 221 236 220.7 235.9 325 316 2994 2898 4483 4652
1 1 7/7/05 CD010B1_2M34 D3S1262 136 135.6 1087 12334 3501
2 7/7/05 CD010B1_2M16 D3S1262 136 135.6 2524 29348 3469
3 7/7/05 CD010B1_2M38 D3S1262 136 135.6 1564 17713 3470
4 7/7/05 CD010B1_2M18 D3S1262 136 135.7 2177 25095 3470
5 7/7/05 CD010B1_2M20 D3S1262 136 135.6 1109 13347 3508
6 7/7/05 CD010B1_2M53 D3S1262 136 135.6 253 2794 3507
7 7/7/05 CD010B1_2M29 D3S1262 136 135.6 823 9416 3469
8 7/7/05 CD010B1_2M58 D3S1262 136 135.5 1242 15352 3474
1 1 7/7/05 CD010B1_2M34 D9S171 105 119 105.3 118.7 647 467 5539 3761 3105 3284
2 7/7/05 CD010B1_2M16 D9S171 105 119 105.2 118.8 1465 810 12158 6575 3076 3255
3 7/7/05 CD010B1_2M38 D9S171 105 119 105.2 118.7 1402 863 11648 6956 3077 3255
4 7/7/05 CD010B1_2M18 D9S171 105 119 105.3 118.7 1394 786 11495 6232 3079 3256
5 7/7/05 CD010B1_2M20 D9S171 105 119 105.3 118.7 847 533 6925 4285 3112 3291
6 7/7/05 CD010B1_2M53 D9S171 105 119 105.2 118.7 417 331 3582 2684 3110 3290
7 7/7/05 CD010B1_2M29 D9S171 105 119 105.3 118.7 514 354 4248 2778 3076 3254
8 7/7/05 CD010B1_2M58 D9S171 105 119 105.3 118.7 1051 664 8777 5534 3084 3261
1 1 7/13/05 CD013B1M15_1uL D17S250 193 193.7 949 8992 4607
2 7/13/05 CD013B1M18_1uL D17S250 193 193.8 796 7672 4618
3 7/13/05 CD013B1M5_1uL D17S250 193 193.7 787 7361 4618
1 1 7/13/05 CD013B1M15_1uL D18S61 168 176 168.0 175.9 833 607 7548 5586 4264 4369
2 7/13/05 CD013B1M18_1uL D18S61 168 176 168.2 175.9 600 541 5445 5144 4276 4379
3 7/13/05 CD013B1M5_1uL* D18S61* 168 174 168.1 174.0 661 281 5743 2524 4274 4353
1 1 7/13/05 CD013B1M15_1uL D2S123 219 221 218.9 221.0 605 377 5535 3199 4919 4945
2 7/13/05 CD013B1M18_1uL D2S123 219 221 218.9 221.1 453 303 4168 2579 4929 4955
3 7/13/05 CD013B1M5_1uL D2S123 219 221 218.9 221.1 457 347 4491 3169 4931 4958
1 1 7/13/05 CD013B1M15_1uL D3S1262 136 138 135.9 137.9 2539 1190 32457 14175 3853 3880
2 7/13/05 CD013B1M18_1uL D3S1262 136 138 135.8 137.9 1743 1009 22722 12139 3864 3891
3 7/13/05 CD013B1M5_1uL* D3S1262* 136 135.9 1397 18412 3861
1 1 7/13/05 CD013B1M15_1uL D9S171 105 113 105.7 113.2 1886 1379 16787 12262 3431 3540
2 7/13/05 CD013B1M18_1uL D9S171 105 113 105.6 113.3 1264 848 11673 8121 3444 3554
3 7/13/05 CD013B1M5_1uL D9S171 105 113 105.7 113.3 900 749 7867 7084 3438 3548
1 1 7/13/05 CD015B1_M5 D17S250 191 191.5 1269 11224 4468
2 7/13/05 CD015B1_M10 D17S250 191 191.6 3307 31036 4504
3 7/13/05 CD015B1_M12 D17S250 191 191.6 933 8737 4524
4 7/13/05 CD015B1_M1 D17S250 191 191.5 2169 19627 4419
5 7/13/05 CD015B1_M13 D17S250 191 191.6 587 5436 4491
6 7/13/05 CD015B1_M14 D17S250 191 191.5 2389 22372 4503
2 7 7/14/05 CD015B1_M26 D17S250 191 191.4 3430 29589 4263
8 7/14/05 CD015B1_M50 D17S250 191 191.4 840 7165 4275
9 7/14/05 CD015B1_M28 D17S250 191 191.3 2983 25207 4238
10 7/14/05 CD015B1_M38 D17S250 191 191.3 4086 34748 4248
11 7/14/05 CD015B1_M51 D17S250 191 191.4 1967 16509 4251
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12 7/14/05 CD015B1_M64 D17S250 191 191.4 890 7376 4280
13 7/14/05 CD015B1_M15 D17S250 191 191.5 4997 44813 4298
14 7/14/05 CD015B1_M29 D17S250 191 191.3 581 4980 4242
15 7/14/05 CD015B1_M39 D17S250 191 191.3 3018 25666 4254
16 7/14/05 CD015B1_M53 D17S250 191 191.4 1366 11995 4255
17 7/14/05 CD015B1_M17 D17S250 191 191.6 3585 31984 4310
18 7/14/05 CD015B1_M30 D17S250 191 191.3 4314 37015 4257
19 7/14/05 CD015B1_M42 D17S250 191 191.4 839 7288 4261
20 7/14/05 CD015B1_M66 D17S250 191 191.5 2805 24551 4294
21 7/14/05 CD015B1_M31* D17S250* 191 191.5 1107 9600 4292
22 7/14/05 CD015B1_M44 D17S250 191 191.4 3059 26354 4307
23 7/14/05 CD015B1_M32 D17S250 191 191.4 4407 37453 4267
24 7/14/05 CD015B1_M46 D17S250 191 191.4 2723 23624 4283
25 7/14/05 CD015B1_M56 D17S250 191 191.4 536 4714 4298
26 7/14/05 CD015B1_M70 D17S250 191 191.4 1061 9099 4291
27 7/14/05 CD015B1_M21 D17S250 191 191.4 1158 9905 4270
28 7/14/05 CD015B1_M57 D17S250 191 191.4 1546 13330 4302
29 7/14/05 CD015B1_M72 D17S250 191 191.5 1669 14532 4295
30 7/14/05 CD015B1_M23 D17S250 191 191.5 2117 18651 4281
31 7/14/05 CD015B1_M36 D17S250 191 191.5 5018 43318 4282
32 7/14/05 CD015B1_M58 D17S250 191 191.4 2638 23095 4313
33 7/14/05 CD015B1_M73 D17S250 191 191.4 1583 13870 4308
1 1 7/13/05 CD015B1_M5 D18S61 170 176 170.0 175.8 781 619 6997 5260 4185 4262
2 7/13/05 CD015B1_M10 D18S61 170 176 170.0 175.8 2917 2281 26696 20917 4219 4296
3 7/13/05 CD015B1_M12 D18S61 170 176 170.1 175.9 1549 553 13862 4878 4238 4315
4 7/13/05 CD015B1_M1 D18S61 170 176 170.0 175.8 1002 760 8827 7104 4139 4215
5 7/13/05 CD015B1_M13 D18S61 170 176 170.0 175.8 489 420 4266 3903 4207 4283
6 7/13/05 CD015B1_M14 D18S61 170 176 169.9 175.8 2076 1373 19270 12688 4219 4296
2 7 7/14/05 CD015B1_M26 D18S61 170 176 169.8 175.7 2529 1730 22716 15723 3990 4064
8 7/14/05 CD015B1_M50 D18S61 170 176 169.8 175.6 935 741 8029 6277 4002 4076
9 7/14/05 CD015B1_M28 D18S61 170 176 169.7 175.5 2453 1878 21815 16819 3967 4040
10 7/14/05 CD015B1_M38 D18S61 170 176 169.8 175.7 3477 2401 31047 21612 3977 4051
11 7/14/05 CD015B1_M51 D18S61 170 176 169.8 175.6 1662 1295 14236 11014 3979 4052
12 7/14/05 CD015B1_M64 D18S61 170 176 169.8 175.6 558 709 4601 6239 4007 4080
13 7/14/05 CD015B1_M15 D18S61 170 176 169.9 175.7 3376 2620 31493 24908 4025 4099
14 7/14/05 CD015B1_M29* D18S61* 168 176 167.8 175.6 240 166 2046 1813 3948 4045
15 7/14/05 CD015B1_M39 D18S61 170 176 169.8 175.6 2964 1738 26288 14969 3984 4057
16 7/14/05 CD015B1_M53 D18S61 170 176 169.8 175.7 896 530 7648 4633 3984 4058
17 7/14/05 CD015B1_M17 D18S61 170 176 169.9 175.8 1108 2533 9188 23277 4035 4110
18 7/14/05 CD015B1_M30 D18S61 170 176 169.8 175.6 3655 2760 31965 24601 3986 4059
19 7/14/05 CD015B1_M42 D18S61 170 176 169.8 175.6 1148 784 9842 7047 3990 4063
20 7/14/05 CD015B1_M66 D18S61 170 176 169.8 175.7 3146 2611 27589 22879 4020 4094
21 7/14/05 CD015B1_M31 D18S61 170 176 169.9 175.7 2390 1799 21500 16227 4017 4091
22 7/14/05 CD015B1_M44 D18S61 170 176 169.8 175.7 3335 2388 29395 21373 4032 4107
23 7/14/05 CD015B1_M32 D18S61 170 176 169.8 175.7 3557 2759 32543 25169 3994 4068
24 7/14/05 CD015B1_M46 D18S61 170 176 169.8 175.7 2139 1667 18667 14600 4010 4084
25 7/14/05 CD015B1_M56 D18S61 170 176 169.9 175.7 228 345 1872 3129 4024 4098
26 7/14/05 CD015B1_M70 D18S61 170 176 169.9 175.6 1171 983 10152 8585 4018 4091
27 7/14/05 CD015B1_M21 D18S61 170 176 169.8 175.6 1268 590 11568 5591 3999 4072
28 7/14/05 CD015B1_M57 D18S61 170 176 169.9 175.7 1140 1093 9603 9773 4029 4103
29 7/14/05 CD015B1_M72 D18S61 170 176 169.9 175.7 1699 1163 14546 10076 4022 4096
30 7/14/05 CD015B1_M23 D18S61 170 176 169.9 175.8 2126 3202 18391 29303 4008 4082
31 7/14/05 CD015B1_M36 D18S61 170 176 169.8 175.7 4426 3268 40132 29516 4008 4082
32 7/14/05 CD015B1_M58 D18S61 170 176 169.8 175.7 2257 1656 20204 15028 4038 4113
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33 7/14/05 CD015B1_M73 D18S61 170 176 169.9 175.7 2324 1640 20594 14370 4035 4109
1 1 7/13/05 CD015B1_M5 D2S123 219 221 218.6 220.8 613 325 5514 2734 4800 4826
2 7/13/05 CD015B1_M10 D2S123 219 221 218.8 221.0 1701 1207 15912 10658 4839 4866
3 7/13/05 CD015B1_M12 D2S123 219 221 218.7 221.0 1124 541 10559 4759 4860 4887
4 7/13/05 CD015B1_M1 D2S123 219 221 218.6 220.8 970 877 8843 7853 4749 4775
5 7/13/05 CD015B1_M13 D2S123 219 221 218.8 221.0 598 400 5672 3690 4826 4852
6 7/13/05 CD015B1_M14 D2S123 219 221 218.8 220.9 1298 818 12312 7011 4837 4863
2 7 7/14/05 CD015B1_M26 D2S123 219 221 218.4 220.6 1549 857 13955 7435 4582 4607
8 7/14/05 CD015B1_M50 D2S123 219 221 218.4 220.6 593 400 5019 3203 4596 4621
9 7/14/05 CD015B1_M28 D2S123 219 221 218.4 220.6 2254 1482 19566 11815 4556 4581
10 7/14/05 CD015B1_M38 D2S123 219 221 218.4 220.5 2422 1591 21401 13541 4567 4591
11 7/14/05 CD015B1_M51 D2S123 219 221 218.4 220.6 1434 876 12492 7135 4570 4595
12 7/14/05 CD015B1_M64 D2S123 219 221 218.4 220.6 1189 757 10430 6399 4601 4626
13 7/14/05 CD015B1_M15 D2S123 219 221 218.5 220.7 2994 1990 27992 18041 4619 4644
14 7/14/05 CD015B1_M29 D2S123 219 221 218.3 220.5 526 197 4875 1665 4559 4583
15 7/14/05 CD015B1_M39 D2S123 219 221 218.4 220.5 1831 1161 15659 9603 4571 4596
16 7/14/05 CD015B1_M53 D2S123 219 221 218.4 220.6 400 244 3573 2092 4573 4598
17 7/14/05 CD015B1_M17 D2S123 219 221 218.6 220.8 1139 713 10271 6244 4632 4657
18 7/14/05 CD015B1_M30 D2S123 219 221 218.4 220.5 2215 1493 19649 12215 4576 4600
19 7/14/05 CD015B1_M42 D2S123 219 221 218.5 220.6 1147 769 10251 6447 4580 4604
20 7/14/05 CD015B1_M66 D2S123 219 221 218.5 220.6 2525 1731 22694 14621 4615 4639
21 7/14/05 CD015B1_M31 D2S123 219 221 218.5 220.6 2640 1626 23763 13897 4614 4639
22 7/14/05 CD015B1_M44 D2S123 219 221 218.5 220.6 2379 1672 20382 13945 4630 4655
23 7/14/05 CD015B1_M32 D2S123 219 221 218.4 220.6 2612 1760 23150 14667 4588 4613
24 7/14/05 CD015B1_M46 D2S123 219 221 218.4 220.7 1741 1117 15172 9268 4604 4630
25 7/14/05 CD015B1_M56 D2S123 219 221 218.4 220.6 360 306 3137 2620 4620 4645
26 7/14/05 CD015B1_M70 D2S123 219 221 218.4 220.6 1103 846 9840 7326 4613 4638
27 7/14/05 CD015B1_M21 D2S123 219 221 218.4 220.6 834 459 7215 3640 4588 4613
28 7/14/05 CD015B1_M57 D2S123 219 221 218.4 220.6 922 739 8324 6350 4622 4647
29 7/14/05 CD015B1_M72 D2S123 219 221 218.4 220.6 1265 771 11236 6638 4614 4640
30 7/14/05 CD015B1_M23 D2S123 219 221 218.5 220.6 1463 1203 13662 10978 4601 4626
31 7/14/05 CD015B1_M36 D2S123 219 221 218.5 220.7 2845 2011 25569 16945 4603 4628
32 7/14/05 CD015B1_M58 D2S123 219 221 218.4 220.7 1859 1222 16718 10217 4635 4661
33 7/14/05 CD015B1_M73 D2S123 219 221 218.5 220.6 1788 1361 16135 11866 4630 4655
1 1 7/13/05 CD015B1_M5 D3S1262 142 142.1 1072 11661 3834
2 7/13/05 CD015B1_M10 D3S1262 142 142.1 3380 43919 3865
3 7/13/05 CD015B1_M12* D3S1262* 136 142 135.9 142.0 281 451 3534 6056 3803 3881
4 7/13/05 CD015B1_M1 D3S1262 142 142.0 2140 27129 3790
5 7/13/05 CD015B1_M13 D3S1262 142 142.1 831 10314 3854
6 7/13/05 CD015B1_M14 D3S1262 142 142.1 2540 33598 3866
2 7 7/14/05 CD015B1_M26 D3S1262 142 142.0 2266 27331 3653
8 7/14/05 CD015B1_M50 D3S1262 142 142.0 2435 28238 3663
9 7/14/05 CD015B1_M28 D3S1262 142 141.9 6011 70910 3631
10 7/14/05 CD015B1_M38 D3S1262 142 141.9 4367 55049 3640
11 7/14/05 CD015B1_M51 D3S1262 142 142.0 2327 25840 3642
12 7/14/05 CD015B1_M64 D3S1262 142 142.0 681 8071 3667
13 7/14/05 CD015B1_M15 D3S1262 142 141.8 2025 27779 3685
14 7/14/05 CD015B1_M29* D3S1262* 136 142 135.6 141.9 178 425 2061 5167 3562 3637
15 7/14/05 CD015B1_M39 D3S1262 142 141.9 4062 48488 3648
16 7/14/05 CD015B1_M53 D3S1262 142 141.9 473 5462 3648
17 7/14/05 CD015B1_M17 D3S1262 142 142.1 812 10040 3695
18 7/14/05 CD015B1_M30 D3S1262 142 142.0 6576 79295 3649
19 7/14/05 CD015B1_M42 D3S1262 142 142.0 678 8217 3653
20 7/14/05 CD015B1_M66 D3S1262 142 141.9 2830 35744 3680
221
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
21 7/14/05 CD015B1_M31 D3S1262 142 142.0 1563 19658 3676
22 7/14/05 CD015B1_M44 D3S1262 142 142.0 3039 37140 3691
23 7/14/05 CD015B1_M32 D3S1262 142 141.9 5654 72107 3654
24 7/14/05 CD015B1_M46 D3S1262 142 142.0 3641 43727 3670
25 7/14/05 CD015B1_M56 D3S1262 142 142.0 89 1015 3683
26 7/14/05 CD015B1_M70 D3S1262 142 142.0 629 7140 3677
27 7/14/05 CD015B1_M21 D3S1262 142 142.0 572 7278 3662
28 7/14/05 CD015B1_M57 D3S1262 142 142.0 795 9425 3690
29 7/14/05 CD015B1_M72 D3S1262 142 141.9 1221 14152 3683
30 7/14/05 CD015B1_M23 D3S1262 142 142.0 998 12280 3670
31 7/14/05 CD015B1_M36 D3S1262 142 142.0 4932 62571 3669
32 7/14/05 CD015B1_M58* D3S1262* 142 141.9 2479 32413 3697
33 7/14/05 CD015B1_M73 D3S1262 142 142.0 1045 12667 3694
1 1 7/13/05 CD015B1_M5 D9S171 107 111 107.5 111.2 545 642 4486 5237 3369 3422
2 7/13/05 CD015B1_M10 D9S171 107 111 107.4 111.3 2893 2082 25223 17288 3397 3452
3 7/13/05 CD015B1_M12 D9S171 107 111 107.5 111.4 672 353 5669 3013 3411 3467
4 7/13/05 CD015B1_M1 D9S171 107 111 107.4 111.3 3048 1776 25711 14297 3329 3383
5 7/13/05 CD015B1_M13 D9S171 107 111 107.4 111.2 489 886 3977 8263 3386 3440
6 7/13/05 CD015B1_M14 D9S171 107 111 107.5 111.3 1944 1623 16411 13362 3400 3454
2 7 7/14/05 CD015B1_M26 D9S171 107 111 107.3 111.1 4275 2401 33633 18774 3204 3256
8 7/14/05 CD015B1_M50 D9S171 107 111 107.3 111.2 3257 1960 24971 14773 3213 3265
9 7/14/05 CD015B1_M28 D9S171 107 111 107.2 111.1 4531 3475 35936 26412 3184 3236
10 7/14/05 CD015B1_M38 D9S171 107 111 107.3 111.0 4273 2856 33194 21249 3193 3244
11 7/14/05 CD015B1_M51 D9S171 107 111 107.3 111.1 2020 1574 15972 12310 3193 3245
12 7/14/05 CD015B1_M64 D9S171 107 111 107.3 111.2 967 566 7609 5167 3217 3269
13 7/14/05 CD015B1_M15 D9S171 107 111 107.3 111.1 2272 2215 19270 18458 3236 3288
14 7/14/05 CD015B1_M29 D9S171 107 111 107.4 111.1 250 115 2195 961 3193 3244
15 7/14/05 CD015B1_M39 D9S171 107 111 107.3 111.1 2898 2238 23148 17668 3202 3253
16 7/14/05 CD015B1_M53 D9S171 107 111 107.3 111.1 505 326 4113 2556 3201 3253
17 7/14/05 CD015B1_M17 D9S171 107 111 107.4 111.2 816 1224 6532 10443 3243 3295
18 7/14/05 CD015B1_M30 D9S171 107 111 107.3 111.2 5190 3820 41172 28759 3201 3253
19 7/14/05 CD015B1_M42 D9S171 107 111 107.4 111.1 834 864 6636 7148 3206 3257
20 7/14/05 CD015B1_M66 D9S171 107 111 107.3 111.2 3819 2758 30891 21389 3230 3282
21 7/14/05 CD015B1_M31 D9S171 107 111 107.3 111.1 3006 2247 24538 17940 3224 3276
22 7/14/05 CD015B1_M44 D9S171 107 111 107.3 111.1 3541 2625 28898 20907 3238 3290
23 7/14/05 CD015B1_M32 D9S171 107 111 107.3 111.1 4399 3623 34502 27783 3204 3256
24 7/14/05 CD015B1_M46 D9S171 107 111 107.3 111.1 3035 2616 24130 20319 3219 3271
25 7/14/05 CD015B1_M56 D9S171 107 111 107.4 111.1 201 204 1618 1663 3232 3283
26 7/14/05 CD015B1_M70 D9S171 107 111 107.3 111.1 883 884 6825 6778 3226 3278
27 7/14/05 CD015B1_M21 D9S171 107 111 107.3 111.1 691 597 5131 4491 3213 3265
28 7/14/05 CD015B1_M57 D9S171 107 111 107.3 111.1 922 759 7335 5963 3239 3291
29 7/14/05 CD015B1_M72 D9S171 107 111 107.3 111.1 1681 1322 13872 10636 3234 3286
30 7/14/05 CD015B1_M23 D9S171 107 111 107.3 111.1 1670 2182 12885 17999 3220 3271
31 7/14/05 CD015B1_M36 D9S171 107 111 107.3 111.1 4468 3612 35854 27927 3218 3270
32 7/14/05 CD015B1_M58 D9S171 107 111 107.3 111.2 2782 2248 22714 17723 3245 3298
33 7/14/05 CD015B1_M73 D9S171 107 111 107.3 111.1 1767 1126 14348 9129 3242 3294
1 1 6/15/05 B_1-3 D17S250 195 202 195.5 201.9 1161 892 9136 6865 4286 4362
2 6/15/05 C_1-3 D17S250 195 202 195.7 202.1 1152 947 9440 7639 4384 4463
3 6/15/05 C10uL_1-3 D17S250 195 202 195.7 201.9 461 408 3588 3076 4326 4403
2 4 6/16/05 0.25_10uL_1-2 D17S250 195 202 195.8 202.1 1361 968 14718 10210 4945 5036
5 6/16/05 0.5_10uL_1-2 D17S250 195 202 195.7 202.1 1173 931 12299 9925 4965 5057
6 6/16/05 0.5_10uL_1-2b D17S250 195 202 195.7 202.0 1269 1043 13503 10811 4925 5015
7 6/16/05 0.5_15uL_1-2 D17S250 195 202 195.8 202.1 772 673 7998 7134 4931 5021
222
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
3 8 6/20/05 0.25uM D17S250 195 202 195.6 201.8 394 297 3363 2359 4269 4344
9 6/20/05 CTRL D17S250 195 202 195.6 201.8 544 447 4676 3757 4293 4369
4 10 6/30/05 CTRL D17S250 195 202 195.5 201.7 1399 1070 11016 8528 4139 4213
11 6/30/05 CTRL6-19-05 D17S250 195 202 195.4 201.7 481 323 3949 2545 4050 4124
5 12 7/5/05 CTRL D17S250 195 202 195.5 201.7 1027 843 8377 6869 4154 4228
13 7/5/05 CTRL_61905 D17S250 195 202 195.5 201.8 697 483 5947 4004 4182 4258
6 14 7/6/05 CTRL D17S250 195 202 195.5 201.8 1044 738 8984 6263 4256 4333
7 15 7/7/05 CRTL D17S250 195 202 195.5 201.8 2559 1733 22726 14915 4249 4325
8 16 7/8/05 CTRL D17S250 195 202 195.5 201.8 1153 815 9403 6427 4261 4338
9 17 7/13/05 CTRL D17S250 195 202 195.7 202.1 914 770 8508 7196 4621 4703
10 18 7/14/05 CTLRL D17S250 195 202 195.6 201.8 645 549 5538 4672 4367 4444
1 1 6/15/05 B_1-3 D18S61 154 153.9 5334 47180 3774
2 6/15/05 C_1-3 D18S61 154 154.0 7163 71006 3850
3 6/15/05 C10uL_1-3 D18S61 154 154.0 2490 25397 3798
2 4 6/16/05 0.25_10uL_1-2 D18S61 154 154.1 7094 71893 4333
5 6/16/05 0.5_10uL_1-2 D18S61 154 154.0 7369 105395 4350
6 6/16/05 0.5_10uL_1-2b D18S61 154 153.9 6916 103191 4313
7 6/16/05 0.5_15uL_1-2 D18S61 154 154.0 7169 85540 4320
3 8 6/20/05 0.25uM D18S61 154 154.0 976 8667 3751
9 6/20/05 CTRL D18S61 154 154.0 645 5107 3775
4 10 6/30/05 CTRL D18S61 154 153.9 1598 13018 3636
11 6/30/05 CTRL6-19-05 D18S61 154 153.9 1227 10377 3554
5 12 7/5/05 CTRL D18S61 154 153.9 450 3420 3644
13 7/5/05 CTRL_61905 D18S61 154 153.8 1933 15951 3670
6 14 7/6/05 CTRL D18S61 154 153.8 1961 15979 3736
7 15 7/7/05 CRTL D18S61 154 153.8 4494 40369 3729
8 16 7/8/05 CTRL D18S61 154 154.0 4298 36536 3744
9 17 7/13/05 CTRL D18S61 154 154.1 6251 59854 4068
10 18 7/14/05 CTLRL D18S61 154 153.9 4361 38240 3838
1 1 6/15/05 B_1-3 D2S123 219 218.5 857 6875 4548
2 6/15/05 C_1-3 D2S123 219 218.8 3378 30504 4656
3 6/15/05 C10uL_1-3 D2S123 219 218.7 1720 15426 4594
2 4 6/16/05 0.25_10uL_1-2 D2S123 219 218.9 3926 41715 5262
5 6/16/05 0.5_10uL_1-2 D2S123 219 218.9 2779 29096 5284
6 6/16/05 0.5_10uL_1-2b D2S123 219 218.8 4023 43296 5241
7 6/16/05 0.5_15uL_1-2 D2S123 219 218.8 2134 22167 5245
3 8 6/20/05 0.25uM D2S123 219 218.4 470 3660 4533
9 6/20/05 CTRL D2S123 219 218.6 487 3938 4560
4 10 6/30/05 CTRL D2S123 219 218.3 1835 14966 4397
11 6/30/05 CTRL6-19-05 D2S123 219 218.2 578 4470 4305
5 12 7/5/05 CTRL D2S123 219 218.4 491 4340 4415
13 7/5/05 CTRL_61905 D2S123 219 218.5 753 6440 4445
6 14 7/6/05 CTRL D2S123 219 218.5 1307 12152 4524
7 15 7/7/05 CRTL D2S123 219 218.5 3013 29054 4516
8 16 7/8/05 CTRL D2S123 219 218.4 1645 14772 4527
9 17 7/13/05 CTRL D2S123 219 218.9 1238 12563 4906
10 18 7/14/05 CTLRL D2S123 219 218.5 802 7531 4637
1 1 6/15/05 B_1-3 D3S1262 136 142 135.8 142.0 881 666 8898 6554 3563 3637
2 6/15/05 C_1-3 D3S1262 136 142 135.9 142.0 800 624 8193 6472 3632 3708
3 6/15/05 C10uL_1-3 D3S1262 136 142 135.7 142.0 541 379 5569 4065 3582 3658
2 4 6/16/05 0.25_10uL_1-2 D3S1262 136 142 135.8 142.1 1889 1340 26047 18868 4083 4171
5 6/16/05 0.5_10uL_1-2 D3S1262 136 142 135.8 142.0 1302 1028 17911 14040 4099 4187
6 6/16/05 0.5_10uL_1-2b D3S1262 136 142 135.8 142.1 1880 1391 27314 19925 4065 4153
7 6/16/05 0.5_15uL_1-2 D3S1262 136 142 135.8 142.0 980 727 12845 9451 4073 4159
223
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3 8 6/20/05 0.25uM D3S1262 136 142 135.9 142.1 887 689 9195 7122 3538 3613
9 6/20/05 CTRL D3S1262 136 142 135.9 142.1 1092 869 11154 9103 3561 3636
4 10 6/30/05 CTRL D3S1262 136 142 135.8 142.0 1360 1095 13689 11124 3428 3501
11 6/30/05 CTRL6-19-05 D3S1262 136 142 135.7 142.0 1110 899 10854 8516 3349 3421
5 12 7/5/05 CTRL D3S1262 136 142 135.6 141.9 647 504 5690 4437 3434 3508
13 7/5/05 CTRL_61905 D3S1262 136 142 135.6 141.8 1532 1193 15337 11912 3459 3533
6 14 7/6/05 CTRL D3S1262 136 142 135.6 141.9 954 744 9919 7535 3522 3597
7 15 7/7/05 CRTL D3S1262 136 142 135.6 141.9 1854 1366 23933 17839 3515 3590
8 16 7/8/05 CTRL D3S1262 136 142 135.9 142.1 1591 1360 17461 15172 3531 3605
9 17 7/13/05 CTRL D3S1262 136 142 135.9 142.2 955 850 11781 10444 3840 3920
10 18 7/14/05 CTLRL D3S1262 136 142 135.8 142.1 728 642 7681 6893 3621 3698
1 1 6/15/05 B_1-3 D9S171 113 113.1 1043 8493 3272
2 6/15/05 C_1-3 D9S171 113 113.2 3721 29591 3333
3 6/15/05 C10uL_1-3 D9S171 113 113.2 2512 20177 3288
2 4 6/16/05 0.25_10uL_1-2 D9S171 113 113.2 3288 33567 3742
5 6/16/05 0.5_10uL_1-2 D9S171 113 113.2 1882 18846 3757
6 6/16/05 0.5_10uL_1-2b D9S171 113 113.2 2534 26283 3726
7 6/16/05 0.5_15uL_1-2 D9S171 113 113.2 1298 13107 3733
3 8 6/20/05 0.25uM D9S171 113 113.1 727 6757 3245
9 6/20/05 CTRL D9S171 113 113.2 1254 11121 3267
4 10 6/30/05 CTRL D9S171 113 113.0 2364 19779 3142
11 6/30/05 CTRL6-19-05 D9S171 113 112.9 859 8023 3067
5 12 7/5/05 CTRL D9S171 113 112.9 559 4560 3146
13 7/5/05 CTRL_61905 D9S171 113 112.9 1200 11337 3169
6 14 7/6/05 CTRL D9S171 113 113.0 991 8841 3228
7 15 7/7/05 CRTL D9S171 113 112.9 2470 21982 3221
8 16 7/8/05 CTRL D9S171 113 113.2 4085 32862 3238
9 17 7/13/05 CTRL D9S171 113 113.3 1826 16493 3529
10 18 7/14/05 CTLRL D9S171 113 113.0 1309 11242 3321
1 1 5/31/05 G2MF10_.5 D17S250 189 193 189.5 193.6 197 162 1607 1230 4336 4389
2 5/31/05 G2MF15_.5 D17S250 189 193 189.6 193.7 349 259 2890 2100 4347 4400
3 5/31/05 G2MF7_.5 D17S250 189 193 189.6 193.7 223 172 1783 1417 4341 4394
4 5/31/05 G2MF7_1 D17S250 189 193 189.6 193.6 546 436 4372 3581 4332 4384
2 5 6/6/05 G2MF10 D17S250 189 193 189.2 193.3 386 289 2985 2241 4074 4124
3 6 7/14/05 MF D17S250 189 193 189.3 193.5 1790 1452 14969 11902 4269 4322
1 1 5/31/05 G2MF10_.5 D18S61 168 168.0 157 1281 4060
2 5/31/05 G2MF15_.5 D18S61 168 168.1 220 1741 4069
3 5/31/05 G2MF7_.5 D18S61 168 168.1 167 1325 4065
4 5/31/05 G2MF7_1 D18S61 168 168.1 492 3763 4056
2 5 6/6/05 G2MF10 D18S61 168 167.7 177 1334 3812
3 6 7/14/05 MF D18S61 168 167.8 4583 41796 3996
1 1 5/31/05 G2MF10_.5 D2S123 219 218.7 1085 9569 4688
2 5/31/05 G2MF15_.5 D2S123 219 218.7 1353 11804 4700
3 5/31/05 G2MF7_.5 D2S123 219 218.8 999 8485 4694
4 5/31/05 G2MF7_1 D2S123 219 218.7 229 1886 4684
2 5 6/6/05 G2MF10 D2S123 219 218.3 908 7341 4408
3 6 7/14/05 MF D2S123 219 218.5 2044 19339 4617
1 1 5/31/05 G2MF10_.5 D3S1262 136 135.9 839 7937 3665
2 5/31/05 G2MF15_.5 D3S1262 136 135.9 1165 10561 3672
3 5/31/05 G2MF7_.5 D3S1262 136 136.0 858 7881 3668
4 5/31/05 G2MF7_1 D3S1262 136 135.9 1487 13898 3661
2 5 6/6/05 G2MF10* D3S1262* 132 136 131.7 135.7 601 1191 5143 10713 3388 3437
3 6 7/14/05 MF D3S1262 136 135.8 4123 51534 3605
224
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1 1 5/31/05 G2MF10_.5 D9S171 113 113.2 1171 9759 3365
2 5/31/05 G2MF15_.5 D9S171 113 113.2 1631 13773 3371
3 5/31/05 G2MF7_.5 D9S171 113 113.3 1132 9454 3367
4 5/31/05 G2MF7_1 D9S171 113 113.2 2095 17474 3360
2 5 6/6/05 G2MF10 D9S171 113 113.0 2738 21897 3151
3 6 7/14/05 MF D9S171 113 113.1 2914 24313 3308
1 1 06-06-05-GS G2BF53M3 D17S250 191 193 191.6 193.7 1112 740 9918 6210 4437 4464
1 06-06-05-GS G2BF53M4 D17S250 191 193 191.3 193.4 1108 792 8799 6202 4196 4221
1 06-06-05-GS G2BF53M3 D18S61 154 170 154.0 170.0 375 233 3233 1708 3948 4154
1 06-06-05-GS G2BF53M4 D18S61 154 170 153.9 169.9 230 125 1959 894 3733 3929
1 06-06-05-GS G2BF53M3 D2S123 216 219(1) 216.6 218.9 2447 1791 22901 15771 4743 4770
1 06-06-05-GS G2BF53M4 D2S123 216 219(1) 216.3 218.5 2070 1391 18083 11339 4486 4511
1 06-06-05-GS G2BF53M3 D3S1262 136 138 135.8 137.8 811 419 10603 5149 3725 3751
1 06-06-05-GS G2BF53M4 D3S1262 136 138 135.7 137.7 893 520 10186 5809 3520 3545
1 06-06-05-GS G2BF53M3 D9S171 111 115 111.3 115.1 3851 2388 32777 18505 3393 3447
1 06-06-05-GS G2BF53M4 D9S171 111 115 111.1 114.9 4635 3654 37150 27899 3203 3254
1 06-06-05-GS G2CS72M2 D17S250 191 195 191.4 195.5 718 484 5800 3630 4155 4205
1 06-06-05-GS G2CS72M6 D17S250 193 197 193.4 197.5 1700 1341 13658 10326 4242 4293
1 06-06-05-GS G2CS72M2 D18S61 170 169.8 1645 14161 3888
1 06-06-05-GS G2CS72M6 D18S61 166 168 165.8 167.9 562 317 4756 2325 3896 3922
1 06-06-05-GS G2CS72M2 D2S123 219(1) 218.4 2127 20343 4467
1 06-06-05-GS G2CS72M6 D2S123 214 219(1) 214.0 218.4 2309 1724 21396 14865 4483 4533
1 06-06-05-GS G2CS72M2 D3S1262 132 136 131.8 135.7 516 641 6157 7925 3435 3483
1 06-06-05-GS G2CS72M6 D3S1262 138 144 137.6 144.0 1088 902 13807 11047 3560 3635
1 06-06-05-GS G2CS72M2 D9S171 115 119 114.9 118.8 2595 2011 19998 15215 3219 3270
1 06-06-05-GS G2CS72M6 D9S171 107 119 107.2 118.7 6473 3959 62622 31414 3163 3318
1 06-06-05-GS G2BF113WT2 D17S250 195 207 195.5 206.1 483 340 4136 2992 4232 4357
1 06-06-05-GS G2BF113M1 D17S250 195 207 195.5 206.2 1085 795 8986 6512 4290 4418
1 06-06-05-GS G2BF113M4 D17S250 197 204 197.5 204.0 970 747 8118 5933 4263 4339
1 06-06-05-GS G2BF113WT2 D18S61 172 171.7 1617 13934 3937
1 06-06-05-GS G2BF113M1 D18S61 172 171.7 3232 29008 3991
1 06-06-05-GS G2BF113M4 D18S61 168 167.7 427 3585 3894
1 06-06-05-GS G2BF113WT2 D2S123 216 219(1) 216.1 218.4 1711 1093 15179 9300 4470 4495
1 06-06-05-GS G2BF113M1 D2S123 216 219(1) 216.2 218.4 2911 1874 26028 15366 4532 4557
1 06-06-05-GS G2BF113M4 D2S123 219(1) 236 218.4 235.9 1769 1452 16955 13384 4501 4697
1 06-06-05-GS G2BF113WT2 D3S1262 132 140 131.8 139.7 658 691 8101 8146 3457 3555
1 06-06-05-GS G2BF113M1 D3S1262 132 140 131.8 139.7 1330 1368 18124 16666 3504 3603
1 06-06-05-GS G2BF113M4 D3S1262 136 135.7 2643 33442 3512
1 06-06-05-GS G2BF113WT2 D9S171 113 119 113.0 118.8 3600 2404 29897 19206 3215 3291
1 06-06-05-GS G2BF113M1 D9S171 113 119 113.1 118.8 6484 5265 61633 42907 3260 3336
1 06-06-05-GS G2BF113M4 D9S171 113 121 112.9 120.7 6127 4357 49902 34470 3221 3323
1 06-06-05-GS G2CS143M3 D17S250 189 193 189.3 193.4 1384 1070 10944 8376 4101 4151
1 06-06-05-GS G2CS143M6 D17S250 191 193 191.4 193.3 2019 1299 16113 10055 4189 4213
1 06-06-05-GS G2CS143M3 D18S61 168 174 167.8 173.7 286 270 2219 2271 3837 3909
1 06-06-05-GS G2CS143M6 D18S61 168 172 167.8 171.6 450 290 3657 2267 3895 3943
1 06-06-05-GS G2CS143M3 D2S123 219(1) 223 218.3 222.7 2041 1632 17825 13562 4436 4485
1 06-06-05-GS G2CS143M6 D2S123 219(1) 218.3 4147 38350 4503
1 06-06-05-GS G2CS143M3 D3S1262 132 131.6 3886 46801 3409
1 06-06-05-GS G2CS143M6 D3S1262 134 138 133.6 137.7 828 703 10444 8440 3486 3537
1 06-06-05-GS G2CS143M3 D9S171 107 113 107.4 112.9 6580 6537 63820 53190 3097 3170
1 06-06-05-GS G2CS143M6 D9S171 105 105.1 6104 68435 3114
225
Day Count Run Date Sample Name Marker Allele 1 Allele 2 Size 1 Size 2 Height 1 Height 2 Peak Area 1 Peak Area 2 Data Point 1 Data Point 2
Sample Type # of Patients # of Markers # of Alleles
UC 7 85 850
CD 6 710 7100
Control Sample 1 90 900
Cell Line 1 30 300
Other Samples 4 45 450
TOTAL 19 960 9600
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CHAPTER 4:  SUMMARY AND FUTURE DIRECTIONS 
 
 
For this dissertation, I have investigated the genotoxicity and selection for 
mismatch repair deficient mutants as potential in vivo mechanisms of carcinogenicity 
associated with thiopurine treatment in subjects with inflammatory bowel disease.  Our 
data showed a dose-dependent increase in the frequency of somatic mutations at the 
HPRT locus in both children and adults, and specifically an increase in the proportion of 
G:C to A:T transitions that is consistent with in vitro observations of the mutagenicity of 
thiopurines, as previously discussed in Chapter 1.  Since we are measuring mutation 
events at the HPRT locus, we expected that thiopurine selection for HPRT mutants would 
confound the absolute frequency of somatic mutations, as this reflects the ratio of mutants 
over the total population of cells.  However, the significant dose-dependent correlation 
with both the increase in mutation frequency and specific spectra shift support that these 
agents are mutagenic in vivo. 
We also observed an increase in the prevalence of in vivo clonal proliferation in 
association with thiopurine treatment likely from both increased cell proliferation and 
survival of HPRT mutants that have undergone cell division in the presence of the 
underlying chronic inflammation and as a result of cytotoxicity from thiopurine therapy.  
Non-thiopurine and thiopurine treated subjects displayed distinct patterns of clonal 
expansion. Untreated subjects showed only post-β rearrangement intra-/post-thymic 
proliferations of thymocytes-TCRβ or mature T-cells, which may be a result of basal and 
antigen-driven proliferation. On the other hand, treated subjects displayed clonal 
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proliferations involving early precursors or committed progenitors and thymocyte-TCRβ 
or mature T-cells, suggesting the occurrence of normal thymopoiesis and/or repopulation 
by thymopoiesis and basal peripheral expansion, homeostatic proliferation, and/or 
expansion of diseasing-participating T-cells, respectively.  Five of 22 children who were 
treated with thiopurine showed a higher frequency of “hypermutable” post-β 
rearrangement intra-/post-thymic clonal expansions in which several independent HPRT 
mutation events were acquired from a common ancestral clone that has divided to give 
rise to respective progenies, when compared to 1 of 27 treated adults who showed this 
pattern.  In addition, in all hypermutable patterns from treated children, one of involved 
mutants was also a part of another post-β rearrangement intra-/post-thymic expansion, 
suggesting the high proliferative rate of these mutants. 
From the patterns of clonal expansions, we also traced the occurrence of G:C to 
A:T transitions in different cell lineages (Appendix B).  Approximately 11.1% of clonal 
expansions from untreated subjects showed G:C to A:T transitions unrelated to thiopurine 
treatment.  Among treated children, 50.0% of clonal expansions involving early 
precursors or committed progenitors, 41.9% involving post-β rearrangement thymocytes-
TCRβ or mature T-cells, and 80% involving “hyper-mutable” post-β rearrangement 
thymocytes-TCRβ or mature T-cells showed G:C to A:T mutations.  In treated adults 
50.0% of clonal expansions involving early precursors or committed progenitors and 
24.2% involving post-β rearrangement thymocytes-TCRβ or mature T-cells displayed 
G:C to A:T mutations.  Some of the observed G:C to A:T transitions among thiopurine 
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treated subjects may have arisen from events unrelated to thiopurine exposure, however, 
the overall higher occurrence of these mutations in treated subjects suggest that some are 
a result of thiopurine induction.  
 This is the first study in humans to demonstrate the in vivo mutagenicity of 
thiopurines. Our observations also indicate the potential risks to precursor cells and 
tissues with high proliferative rate, including proliferating cells within the bone marrow, 
disease-participating immune cells, and tissues undergoing repeated cycles of 
regeneration from chronic damage.  Increased cell proliferation may enhance the 
mutagenicity of thiopurine by allowing for the incorporation of 6-thioguanine 
nucleotides, as observed in different patterns of clonal proliferation. Treated children 
appear to harbor a subpopulation of hyper-mutable T-cells that is at increased 
susceptibility to the mutagenicity of thiopurines, which showed the highest frequency of 
G:C to A:T mutations.  This subpopulation may comprise of T-cells that have a higher 
propensity to progress to lymphoma that predominates in transplant children compared to 
adults, among whom a higher incidence of squamous cell carcinoma is observed.  
  The in vivo mechanism of mutagenicity of thiopurines and the contribution of 
selection may be further elucidated by several approaches.  We propose that mutation 
induction associated with thiopurine treatment likely occurs by several potential 
mechanisms following its incorporation into DNA.  Incorporated 6-thioguanine 
nucleotides can either directly mispair with thymine, become methylated then mispair 
with thymine, or interact with UVA forming replication blocking photoproducts, 2-
aminopurine-6-sulfonate that is bypassed with the insertion of thymine by Y family 
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polymerases to result in G:C to A:T transitions.  A closer correlation between these 
potential mutagenic mechanisms and the observed increase in G:C to A:T transitions 
among TP subjects may be achieved by measuring the levels of 6-thioguanine nucleotide 
incorporation in DNA of T-cells from these subjects.  The levels of incorporated 6-
thioguanine nucleotides will provide a better estimate of “dose or available substrates” 
for mutation induction that would bypass differences in drug metabolism among 
individuals.  We can then additionally correlate the levels of methylated 6-thioguanine 
and 2-aminopurine-6-sulfonate with thiopurine mutagenicity.   
 To evaluate for the contribution of in vivo selection in the observed HPRT 
MutFreq, thiopurine mutagenicity can be measured using other selectable markers.  
Several alternative methods for measuring in vivo mutation events have been discussed in 
Chapter 1, however, each of those methods has its own weaknesses, and the mutation 
database for respective reporter genes is also limited unlike the HPRT mutation database.  
Prior to comparing the effects of exposure at other loci, the establishment of normal 
values for Mf and mutation spectra for each age group of healthy subjects would be 
required.  
 
We have also begun to evaluate the possible selection for mismatch repair 
deficient mutants among treated subjects using high-throughput microsatellite analysis as 
described in Appendix C.  Subjects exhibiting high HPRT mutant frequencies were 
hypothesized to harbor a subpopulation of T-cells with mismatch repair deficiency that 
resulted in the acquisition of HPRT mutations.  The initial study of 248 HPRT mutant T-
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cell clones from 13 subjects, at different ages and who were receiving different total dose 
of thiopurine treatment, did not show microsatellite instability.  This may indicate that the 
sequential events of loss of mismatch repair function followed by the acquisition of an 
HPRT mutation in mutant clones are rare occurrences.  On the other hand, we may not 
have evaluated enough patients to include the possible genetic diversity that may give 
rise to these events.  
Alternatively, we have proposed to examine the CD45RO T-cell subpopulation, 
comprising of memory and effector T-cells, for the possible selection of mismatch repair 
deficient mutants.  This subpopulation of T-cells is likely to have divided or are dividing 
following T-cell activation, which renders them to be subjected to the selective pressure 
of thiopurine treatment and to have a higher probability of harboring unrepaired 
replication errors in cells with mismatch repair deficiency.  This approach complements 
the investigation of HPRT mutants in that we would also examine the non-mutant 
subpopulation since selection for mismatch repair deficiency requires that cells initially 
have intact HPRT enzymes in order for the activation of thiopurines to elicit mismatch 
repair signaling following its incorporation into DNA.   
HNPCC patients have also been included in the evaluation of microsatellite 
instability of both HPRT mutants and the CD45RO T-cell subpopulation to examine the 
background frequency of cells harboring mismatch repair deficiency in individuals who 
are heterozygous for the wildtype allele of mismatch repair component genes.  These 
subjects differ from the IBD group in that they do not have an underlying immunological 
disease and are not receiving thiopurine treatment.  The initial evaluation of four of these 
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subjects using the T-cell cloning assay showed elevated mutant frequencies in two 
subjects who inherited mutations in the MSH2 gene.  At this time it is unclear whether 
the observed elevation is related to clonal expansion, haploinsufficiency in association 
with specific mutations of the MMR component gene, or a result of loss of 
heterozygosity of the remaining wildtype allele in a subpopulation of T-cells with 





  233 
COMPREHENSIVE BIBLIOGRAPHY 
Applied Biosystems, Part Number 4366831 Rev. A 2005. 
Aaltonen, L.A., P. Peltomaki, F.S. Leach, P. Sistonen, L. Pylkkanen, J.P. Mecklin, H. 
Jarvinen, S.M. Powell, J. Jen, S.R. Hamilton, and et al. 1993. Clues to the 
pathogenesis of familial colorectal cancer. Science 260: 812-816. 
Abramson, L.S., R.J. Albertini, L.M. Pachman, and B.A. Finette. 1999. Association 
among somatic HPRT mutant frequency, peripheral blood T-lymphocyte 
clonality, and serologic parameters of disease activity in children with juvenile 
onset dermatomyositis. Clin Immunol. 91: 61-67. 
Aebi, S., D. Fink, R. Gordon, H.K. Kim, H. Zheng, J.L. Fink, and S.B. Howell. 1997. 
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin 
Cancer Res. 3: 1763-1767. 
Albertini, R.J., K.L. Castle, and W.R. Borcherding. 1982. T-cell cloning to detect the 
mutant 6-thioguanine-resistant lymphocytes present in human peripheral blood. 
Proc Natl Acad Sci. 79: 6617-6621. 
Albertini, R.J. and R.B. Hayes. 1997. Somatic cell mutations in cancer epidemiology. 
IARC Sci Publ. 142: 159-184. 
Albertini, R.J., J.A. Nicklas, and J.P. O'Neill. 1993. Somatic cell gene mutations in 
humans: biomarkers for genotoxicity. Environ Health Perspect 101 Suppl 3: 193-
201. 
Albertini, R.J., J.P. O'Neill, J.A. Nicklas, N.H. Heintz, and P.C. Kelleher. 1985. 
Alterations of the hprt gene in human in vivo-derived 6-thioguanine-resistant T 
lymphocytes. Nature. 316: 369-371. 
Al-khaldi, A. and R.C. Robbins. 2006. New directions in cardiac transplantation. Annu 
Rev Med. 57: 455-471. 
Allan, P.W. and L.L. Bennett, Jr. 1971. 6-Methylthioguanylic acid, a metabolite of 6-
thioguanine. Biochem Pharmacol. 20: 847-852. 
Altindag, O., M. Karakoc, A. Kocyigit, H. Celik, and N. Soran. 2007. Increased DNA 
damage and oxidative stress in patients with rheumatoid arthritis. Clin Biochem. 
40: 167-171. 
Andreone, P.A., M.T. Olivari, B. Elick, C.E. Arentzen, R.K. Sibley, R.M. Bolman, R.L. 
Simmons, and W.S. Ring. 1986. Reduction of infectious complications following 
heart transplantation with triple-drug immunotherapy. J Heart Transplant. 5: 13-
19. 
Ansari, A.A., A. Mayne, J.B. Sundstrom, M.B. Gravanis, K. Kanter, K.W. Sell, F. 
Villinger, C.O. Siu, and A. Herskowitz. 1995. Frequency of hypoxanthine 
guanine phosphoribosyltransferase (HPRT-) T cells in the peripheral blood of 
cardiac transplant recipients. A noninvasive technique for the diagnosis of 
allograft rejection. Circulation. 92: 862-874. 
Antonarakis, S.E., M. Krawczak, and D.N. Cooper. 2000. Disease-causing mutations in 
the human genome. Eur J Pediatr. 159 Suppl 3: S173-178. 
  234 
Apelt, F., J. Kolin-Gerresheim, and M. Bauchinger. 1981. Azathioprine, a clastogen in 
human somatic cells? Analysis of chromosome damage and SCE in lymphocytes 
after exposure in vivo and in vitro. Mutat Res. 88: 61-72. 
Askling, J., L. Brandt, A. Lapidus, P. Karlen, M. Bjorkholm, R. Lofberg, and A. Ekbom. 
2005. Risk of haematopoietic cancer in patients with inflammatory bowel disease. 
Gut. 54: 617-622. 
Asten, P., J. Barrett, and D. Symmons. 1999. Risk of developing certain malignancies is 
related to duration of immunosuppressive drug exposure in patients with 
rheumatic diseases. J Rheumatol. 26: 1705-1714. 
Balis FM, Holcenberg JS, Zimm S, Tubergen D, Collins JM, Murphy RF, Gilchrist GS, 
Hammond D, Poplack DG. 1987. The effect of methotrexate on the bioavailability 
of oral 6-mercaptopurine. Clin Pharmacol Ther 41: 384-7. 
Baumgart, D.C. 2008. What's new in inflammatory bowel disease in 2008? World J 
Gastroenterol. 14: 329-330. 
Bhattacharyya, N.P., A. Skandalis, A. Ganesh, J. Groden, and M. Meuth. 1994. Mutator 
phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci. 91: 
6319-6323. 
Bhandoola, A., H.V. Boehmer, H.T. Petrie, and J.C. Zuniga-Pflucker. 2007. Commitment 
and developmental potential of extrathymic and intrathymic T-cell precursors: 
plenty to choose from.  Immunity. 26: 678-689. 
Bokkerink, J.P., E.H. Stet, R.A. De Abreu, F.J. Damen, T.W. Hulscher, M.A. Bakker, 
and J.A. van Baal. 1993. 6-Mercaptopurine: cytotoxicity and biochemical 
pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol. 45: 
1455-1463. 
Boland, C.R., S.N. Thibodeau, S.R. Hamilton, D. Sidransky, J.R. Eshleman, R.W. Burt, 
S.J. Meltzer, M.A. Rodriguez-Bigas, R. Fodde, G.N. Ranzani, and S. Srivastava. 
1998. A National Cancer Institute Workshop on Microsatellite Instability for 
cancer detection and familial predisposition: development of international criteria 
for the determination of microsatellite instability in colorectal cancer. Cancer Res. 
58: 5248-5257. 
Bolukbas, C., F.F. Bolukbas, A. Kocyigit, M. Aslan, S. Selek, M. Bitiren, and M. 
Ulukanligil. 2006. Relationship between levels of DNA damage in lymphocytes 
and histopathological severity of chronic hepatitis C and various clinical forms of 
hepatitis B. J Gastroenterol Hepatol. 21: 610-616. 
Branda, R.F., L.M. Sullivan, J.P. O'Neill, M.T. Falta, J.A. Nicklas, B. Hirsch, P.M. 
Vacek, and R.J. Albertini. 1993. Measurement of HPRT mutant frequencies in T-
lymphocytes from healthy human populations. Mutat Res. 285: 267-279. 
Brownstein, M.J., J.D. Carpten, and J.R. Smith. 1996. Modulation of non-templated 
nucleotide addition by Taq DNA polymerase: primer modifications that facilitate 
genotyping. Biotechniques. 20: 1004-1006, 1008-1010. 
Cadet, J., T. Douki, D. Gasparutto, and J.L. Ravanat. 2003. Oxidative damage to DNA: 
formation, measurement and biochemical features. Mutat Res. 531: 5-23. 
  235 
Calkins, B.M. 1989. A meta-analysis of the role of smoking in inflammatory bowel 
disease. Dig Dis Sci. 34: 1841-1854. 
Cariello, N.F., G.R. Douglas, N.J. Gorelick, D.W. Hart, J.D. Wilson, and T. Soussi. 1998. 
Databases and software for the analysis of mutations in the human p53 gene, 
human hprt gene and both the lacI and lacZ gene in transgenic rodents. Nucleic 
Acids Res. 26: 198-199. 
Casetta, I., G. Iuliano, and G. Filippini. 2007. Azathioprine for multiple sclerosis. 
Cochrane Database Syst Rev: CD003982. 
Chalmers, A.H. 1974. Studies on the mechanism of formation of 5-mercapto-1-methyl-4-
nitroimidazole, a metabolite of the immunosuppressive drug azathioprine. 
Biochem Pharmacol. 23: 1891-1901. 
Chams-Davatchi, C., N. Esmaili, M. Daneshpazhooh, M. Valikhani, K. Balighi, Z. 
Hallaji, M. Barzegari, M. Akhyani, S.Z. Ghodsi, H. Seirafi, M.J. Nazemi, H. 
Mortazavi, and M. Mirshams-Shahshahani. 2007. Randomized controlled open-
label trial of four treatment regimens for pemphigus vulgaris. J Am Acad 
Dermatol. 57: 622-628. 
Cho, JH.  2008.  The genetics and immunopathogenesis of inflammatory bowel disease.  
Nat Rev Immunol.  8: 458-66.  
Clark, J.M. 1988. Novel non-templated nucleotide addition reactions catalyzed by 
procaryotic and eucaryotic DNA polymerases. Nucleic Acids Res. 16: 9677-9686. 
Cole, J. and T.R. Skopek. 1994. International Commission for Protection Against 
Environmental Mutagens and Carcinogens. Working paper no. 3. Somatic mutant 
frequency, mutation rates and mutational spectra in the human population in vivo. 
Mutat Res. 304: 33-105. 
Contreras, G., E. Tozman, N. Nahar, and D. Metz. 2005. Maintenance therapies for 
proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous 
cyclophosphamide. Lupus. 14 Suppl 1: s33-38. 
Cooper, D.N. 2002. Human gene mutation in pathology and evolution. J Inherit Metab 
Dis. 25: 157-182. 
Cuffari, C., D.Y. Li, J. Mahoney, Y. Barnes, and T.M. Bayless. 2004. Peripheral blood 
mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased 
interferon-gamma production in patients with Crohn's disease on AZA therapy. 
Dig Dis Sci. 49: 133-137. 
Curry, J., L. Karnaoukhova, G.C. Guenette, and B.W. Glickman. 1999. Influence of sex, 
smoking and age on human hprt mutation frequencies and spectra. Genetics. 152: 
1065-1077. 
Curtis, R.E., C. Metayer, J.D. Rizzo, G. Socie, K.A. Sobocinski, M.E. Flowers, W.D. 
Travis, L.B. Travis, M.M. Horowitz, and H.J. Deeg. 2005. Impact of chronic 
GVHD therapy on the development of squamous-cell cancers after hematopoietic 
stem-cell transplantation: an international case-control study. Blood. 105: 3802-
3811. 
David K.M., J.A. Morris, B.J. Steffen, K.S. Chi-Burris, V.P. Gotz, R.D. Gordon.  2005. 
Mycophenolate mofetil vs. azathioprine is associated with decreased acute 
  236 
rejection, late acute rejection, and risk for cardiovascular death in renal transplant 
recipients with pre-transplant diabetes.  Clin Transplant. 19: 279-285. 
Dawisha, S.M., F. Gmelig-Meyling, and A.D. Steinberg. 1994. Assessment of clinical 
parameters associated with increased frequency of mutant T cells in patients with 
systemic lupus erythematosus. Arthritis Rheum. 37: 270-277. 
Deeg, H.J., G. Socie, G. Schoch, M. Henry-Amar, R.P. Witherspoon, A. Devergie, K.M. 
Sullivan, E. Gluckman, and R. Storb. 1996. Malignancies after marrow 
transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris 
analysis of results in 700 patients. Blood. 87: 386-392. 
DeMarini, D.M. 2004. Genotoxicity of tobacco smoke and tobacco smoke condensate: a 
review. Mutat Res. 567: 447-474. 
Dervieux, T., J.G. Blanco, E.Y. Krynetski, E.F. Vanin, M.F. Roussel, and M.V. Relling. 
2001. Differing contribution of thiopurine methyltransferase to mercaptopurine 
versus thioguanine effects in human leukemic cells. Cancer Res. 61: 5810-5816. 
Dervieux T, Hancock M, Evans W, Pui CH, Relling MV. 2002. Effect of methotrexate 
polyglutamates on thioguanine nucleotide concentrations during continuation 
therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia 16: 209-
12. 
Dubinsky, M. 2008. Special issues in pediatric inflammatory bowel disease. World J 
Gastroenterol. 14: 413-420. 
Elion, G.B. 1989. Nobel Lecture. The purine path to chemotherapy. Biosci Rep. 9: 509-
529. 
Elion, G.B. 1993. The George Hitchings and Gertrude Elion Lecture. The pharmacology 
of azathioprine. Ann N Y Acad Sci. 685: 400-407. 
Ellegren, H. 2004. Microsatellites: simple sequences with complex evolution. Nat Rev 
Genet. 5: 435-445. 
Elsea, S.H., N. Osheroff, and J.L. Nitiss. 1992. Cytotoxicity of quinolones toward 
eukaryotic cells. Identification of topoisomerase II as the primary cellular target 
for the quinolone CP-115,953 in yeast. J Biol Chem. 267: 13150-13153. 
Erb, N., D.O. Harms, and G. Janka-Schaub. 1998. Pharmacokinetics and metabolism of 
thiopurines in children with acute lymphoblastic leukemia receiving 6-
thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol. 42: 266-
272. 
Euvrard, S., J. Kanitakis, and A. Claudy. 2003. Skin cancers after organ transplantation. 
N Engl J Med. 348: 1681-1691. 
Falta, M.T., M.A. Atkinson, M. Allegretta, P.M. Vacek, and R.J. Albertini. 2000. 
Azathioprine associated T-cell mutations in insulin-dependent diabetes mellitus. 
Scand J Immunol. 51: 626-633. 
Falta, M.T., G.K. Magin, M. Allegretta, L. Steinman, M.A. Atkinson, S.W. Brostoff, and 
R.J. Albertini. 1999. Selection of hprt mutant T cells as surrogates for dividing 
cells reveals a restricted T cell receptor BV repertoire in insulin-dependent 
diabetes mellitus. Clin Immunol. 90: 340-351. 
Feig DI, Loeb LA. 1994. Oxygen radical induced mutagenesis is DNA polymerase 
  237 
specific. J Mol Biol. 235: 33-41. 
Finette, B.A., A.C. Homans, and R.J. Albertini. 2000. Emergence of genetic instability in 
children treated for leukemia. Science. 288: 514-517. 
Finette, B.A., A.C. Homans, J. Rivers, T. Messier, and R.J. Albertini. 2001. 
Accumulation of somatic mutations in proliferating T cell clones from children 
treated for leukemia. Leukemia. 15: 1898-1905. 
Finette, B.A., H. Kendall, and P.M. Vacek. 2002. Mutational spectral analysis at the 
HPRT locus in healthy children. Mutat Res. 505: 27-41. 
Finette, B.A., T. Poseno, and R.J. Albertini. 1996. V(D)J recombinase-mediated HPRT 
mutations in peripheral blood lymphocytes of normal children. Cancer Res. 56: 
1405-1412. 
Finette, B.A., T. Poseno, P.M. Vacek, and R.J. Albertini. 1997. The effects of maternal 
cigarette smoke exposure on somatic mutant frequencies at the hprt locus in 
healthy newborns. Mutat Res. 377: 115-123. 
Finette, B.A., L.M. Sullivan, J.P. O'Neill, J.A. Nicklas, P.M. Vacek, and R.J. Albertini. 
1994. Determination of hprt mutant frequencies in T-lymphocytes from a healthy 
pediatric population: statistical comparison between newborn, children and adult 
mutant frequencies, cloning efficiency and age. Mutat Res. 308: 223-231. 
Fink, D., S. Nebel, P.S. Norris, S. Aebi, H.K. Kim, M. Haas, and S.B. Howell. 1998. The 
effect of different chemotherapeutic agents on the enrichment of DNA mismatch 
repair-deficient tumour cells. Br J Cancer. 77: 703-708. 
Fink, D., H. Zheng, S. Nebel, P.S. Norris, S. Aebi, T.P. Lin, A. Nehme, R.D. Christen, 
M. Haas, C.L. MacLeod, and S.B. Howell. 1997. In vitro and in vivo resistance to 
cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 57: 1841-1845. 
Frohberg, H. and M.S. Schencking. 1975. In vivo cytogenetic investigations in bone 
marrow cells of rats, Chinese hamsters and mice treated with 6-mercaptopurine. 
Arch Toxicol. 33: 209-224. 
Fulop, Z., B. Csernus, B. Timar, A. Szepesi, and A. Matolcsy. 2003. Microsatellite 
instability and hMLH1 promoter hypermethylation in Richter's transformation of 
chronic lymphocytic leukemia. Leukemia. 17: 411-415. 
Gafanovich, A., N. Ramu, S. Krichevsky, J. Pe'er, G. Amir, and D. Ben-Yehuda. 1999. 
Microsatellite instability and p53 mutations in pediatric secondary malignant 
neoplasms. Cancer. 85: 504-510. 
Garcia, R.F., C.E. Garcia, and P. McMaster. 2000. Chronic rejection of the liver: the role 
of immunosuppression. BioDrugs. 14: 283-297. 
Gartenhaus, R.B. 1997. Microsatellite instability in hematologic malignancies. Leuk 
Lymphoma. 25: 455-461. 
Ghosh, S., Z.E. Karanjawala, E.R. Hauser, D. Ally, J.I. Knapp, J.B. Rayman, A. Musick, 
J. Tannenbaum, C. Te, S. Shapiro, W. Eldridge, T. Musick, C. Martin, J.R. Smith, 
J.D. Carpten, M.J. Brownstein, J.I. Powell, R. Whiten, P. Chines, S.J. Nylund, 
V.L. Magnuson, M. Boehnke, and F.S. Collins. 1997. Methods for precise sizing, 
automated binning of alleles, and reduction of error rates in large-scale 
  238 
genotyping using fluorescently labeled dinucleotide markers. FUSION (Finland-
U.S. Investigation of NIDDM Genetics) Study Group. Genome Res. 7: 165-178. 
Gibbs, R.A., P.N. Nguyen, A. Edwards, A.B. Civitello, and C.T. Caskey. 1990. Multiplex 
DNA deletion detection and exon sequencing of the hypoxanthine 
phosphoribosyltransferase gene in Lesch-Nyhan families. Genomics. 7: 235-244. 
Glaab, W.E., K.L. Kort, and T.R. Skopek. 2000. Specificity of mutations induced by the 
food-associated heterocyclic amine 2-amino-1-methyl-6-phenylimidazo-[4,5-b]-
pyridine in colon cancer cell lines defective in mismatch repair. Cancer Res. 60: 
4921-4925. 
Glaab, W.E., J.I. Risinger, A. Umar, J.C. Barrett, T.A. Kunkel, and K.R. Tindall. 1998. 
Resistance to 6-thioguanine in mismatch repair-deficient human cancer cell lines 
correlates with an increase in induced mutations at the HPRT locus. 
Carcinogenesis. 19: 1931-1937. 
Goldblatt, F. and D.A. Isenberg. 2005. New therapies for systemic lupus erythematosus. 
Clin Exp Immunol. 140: 205-212. 
Goldrath, A.W. and M.J. Bevan. 1999. Selecting and maintaining a diverse T-cell 
repertoire.  Nature. 402: 255-262. 
Gorla, N., H. Garcia Ovando, and I. Larripa. 1999. Chromosomal aberrations in human 
lymphocytes exposed in vitro to enrofloxacin and ciprofloxacin. Toxicol Lett. 104: 
43-48. 
Greenman, C., P. Stephens, R. Smith, G.L. Dalgliesh, C. Hunter, G. Bignell, H. Davies, J. 
Teague, A. Butler, C. Stevens, S. Edkins, S. O'Meara, I. Vastrik, E.E. Schmidt, T. 
Avis, S. Barthorpe, G. Bhamra, G. Buck, B. Choudhury, J. Clements, J. Cole, E. 
Dicks, S. Forbes, K. Gray, K. Halliday, R. Harrison, K. Hills, J. Hinton, A. 
Jenkinson, D. Jones, A. Menzies, T. Mironenko, J. Perry, K. Raine, D. 
Richardson, R. Shepherd, A. Small, C. Tofts, J. Varian, T. Webb, S. West, S. 
Widaa, A. Yates, D.P. Cahill, D.N. Louis, P. Goldstraw, A.G. Nicholson, F. 
Brasseur, L. Looijenga, B.L. Weber, Y.E. Chiew, A. DeFazio, M.F. Greaves, 
A.R. Green, P. Campbell, E. Birney, D.F. Easton, G. Chenevix-Trench, M.H. Tan, 
S.K. Khoo, B.T. Teh, S.T. Yuen, S.Y. Leung, R. Wooster, P.A. Futreal, and M.R. 
Stratton. 2007. Patterns of somatic mutation in human cancer genomes. Nature. 
446: 153-158. 
Grisham, M.B., D. Jourd'heuil, and D.A. Wink. 2000. Review article: chronic 
inflammation and reactive oxygen and nitrogen metabolism--implications in DNA 
damage and mutagenesis. Aliment Pharmacol Ther. 14 Suppl 1: 3-9. 
Grossman, A.B., A.J. Noble, P. Mamula, and R.N. Baldassano. 2008. Increased dosing 
requirements for 6-mercaptopurine and azathioprine in inflammatory bowel 
disease patients six years and younger. Inflamm Bowel Dis. 14:750-5. 
Hackman, P., S.M. Hou, F. Nyberg, G. Pershagen, and B. Lambert. 2000. Mutational 
spectra at the hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus in 
T-lymphocytes of nonsmoking and smoking lung cancer patients. Mutat Res. 468: 
45-61. 
  239 
Hakoda, M., Y. Hirai, M. Akiyama, H. Yamanaka, C. Terai, N. Kamatani, and S. 
Kashiwazaki. 1995. Selection against blood cells deficient in hypoxanthine 
phosphoribosyltransferase (HPRT) in Lesch-Nyhan heterozygotes occurs at the 
level of multipotent stem cells. Hum Genet. 96: 674-680. 
Hardman, J., L. Limbird, and A. Gilman. 2001. Goodman & Gilman's The 
Pharmacological Basis of Therapeutics. 10: 1048-1050. 
Harms, D.O., U. Gobel, H.J. Spaar, U.B. Graubner, N. Jorch, P. Gutjahr, and G.E. Janka-
Schaub. 2003. Thioguanine offers no advantage over mercaptopurine in 
maintenance treatment of childhood ALL: results of the randomized trial 
COALL-92. Blood. 102: 2736-2740. 
Hartley-Asp, B. 1979. Metronidazole exhibits no cytogenetic effect in the micronucleus 
test in mice or on human lymphocytes in vitro. Mutat Res. 67: 193-196. 
Hattori Y, Nishigori C, Tanaka T, Uchida K, Nikaido O, Osawa T, Hiai H, Imamura S, 
Toyokuni S. 1996. 8-hydroxy-2'-deoxyguanosine is increased in epidermal cells 
of hairless mice after chronic ultraviolet B exposure. J Invest Dermatol. 107: 733-
7. 
Henderson, J.F. and K.Y. Khoo. 1965. On the Mechanism of Feedback Inhibition of 
Purine Biosynthesis De Novo in Ehrlich Ascites Tumor Cells in Vitro. J Biol 
Chem. 240: 3104-3109. 
Herbold, B.A., S.Y. Brendler-Schwaab, and H.J. Ahr. 2001. Ciprofloxacin: in vivo 
genotoxicity studies. Mutat Res. 498: 193-205. 
Hill, D.L. and L.L. Bennett, Jr. 1969. Purification and properties of 5-phosphoribosyl 
pyrophosphate amidotransferase from adenocarcinoma 755 cells. Biochemistry. 8: 
122-130. 
Holden, H.E., V.A. Ray, M.G. Wahrenburg, and J.D. Zelenski. 1973. Mutagenicity 
studies with 6-mercaptopurine. I. Cytogenetic activity in vivo. Mutat Res. 20: 
257-263. 
Holme, S.A., J.A. Duley, J. Sanderson, P.A. Routledge, and A.V. Anstey. 2002. 
Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in 
the UK. Qjm. 95: 439-444. 
Hu, G. 1993. DNA polymerase-catalyzed addition of nontemplated extra nucleotides to 
the 3' end of a DNA fragment. DNA Cell Biol. 12: 763-770. 
Hugot, J.P., P. Laurent-Puig, C. Gower-Rousseau, J.M. Olson, J.C. Lee, L. Beaugerie, I. 
Naom, J.L. Dupas, A. Van Gossum, M. Orholm, C. Bonaiti-Pellie, J. 
Weissenbach, C.G. Mathew, J.E. Lennard-Jones, A. Cortot, J.F. Colombel, and G. 
Thomas. 1996. Mapping of a susceptibility locus for Crohn's disease on 
chromosome 16. Nature. 379: 821-823. 
Hussain, S.P., P. Amstad, K. Raja, S. Ambs, M. Nagashima, W.P. Bennett, P.G. Shields, 
A.J. Ham, J.A. Swenberg, A.J. Marrogi, and C.C. Harris. 2000. Increased p53 
mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone 
chronic inflammatory disease. Cancer Res. 60: 3333-3337. 
  240 
(IARC) IAfRoC ed. (1981) Azathioprine. IARC Monographs on the evaluation of 
carcinogenic risk of chemicals to humans, some antineoplastic and 
immunosuppressive agents (IARC, Lyon). 
(IARC) IAfRoC ed. (1987) Azathioprine (Group1).IARC Monographs on the evaluation 
of the carcinogenic risk of chemicals to humans (IARC, Lyon). 
Ikbal, B., H. Dogan, H. Odabas, and I. Pirim. 2004. Genotoxic Evaluation of the 
Antibacterial Drug, Ciprofloxacin, in Cultured Lymphocytes of Patients with 
Urinary Tract Infection. Turk J Med Sci. 34: 309-313. 
Ionov, Y., M.A. Peinado, S. Malkhosyan, D. Shibata, and M. Perucho. 1993. Ubiquitous 
somatic mutations in simple repeated sequences reveal a new mechanism for 
colonic carcinogenesis. Nature. 363: 558-561. 
Ishibashi, H., A. Komori, S. Shimoda, and M.E. Gershwin. 2007. Guidelines for therapy 
of autoimmune liver disease. Semin Liver Dis. 27: 214-226. 
Itzkowitz, S.H. and X. Yio. 2004. Inflammation and cancer IV. Colorectal cancer in 
inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest 
Liver Physiol. 287: G7-17. 
Janeway, C.A., P. Travers, M. Walport, and M. Schlomchik. 2001. Immunobiology, The 
Immune System In Health and Disease. 5: 397, 416-417, 664. 
Jorga, A. and A. Johnston. 2005. Novel therapies in transplantation. Expert Opin Investig 
Drugs. 14: 295-304. 
Kandiel, A., A.G. Fraser, B.I. Korelitz, C. Brensinger, and J.D. Lewis. 2005. Increased 
risk of lymphoma among inflammatory bowel disease patients treated with 
azathioprine and 6-mercaptopurine. Gut. 54: 1121-1125. 
Kappelman, M.D., S.L. Rifas-Shiman, K. Kleinman, D. Ollendorf, A. Bousvaros, R.J. 
Grand, and J.A. Finkelstein. 2007. The prevalence and geographic distribution of 
Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol 
Hepatol. 5: 1424-1429. 
Karran, P. 2006. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br 
Med Bull. 79-80: 153-170. 
Kasiske, B.L., J.J. Snyder, D.T. Gilbertson, and C. Wang. 2004. Cancer after kidney 
transplantation in the United States. Am J Transplant. 4: 905-913. 
Kendall, H.E., P.M. Vacek, J.L. Rivers, S.C. Rice, T.L. Messier, and B.A. Finette. 2006. 
Analysis of genetic alterations and clonal proliferation in children treated for 
acute lymphocytic leukemia. Cancer Res. 66: 8455-8461. 
Kinlen, L.J. 1985. Incidence of cancer in rheumatoid arthritis and other disorders after 
immunosuppressive treatment. Am J Med. 78: 44-49. 
Kinlen, L.J. 1992. Malignancy in autoimmune diseases. J Autoimmun. 5 Suppl A: 363-
371. 
Koi, M., A. Umar, D.P. Chauhan, S.P. Cherian, J.M. Carethers, T.A. Kunkel, and C.R. 
Boland. 1994. Human chromosome 3 corrects mismatch repair deficiency and 
microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine 
tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 
54: 4308-4312. 
  241 
Kozuch, P.L. and S.B. Hanauer. 2008. Treatment of inflammatory bowel disease: A 
review of medical therapy. World J Gastroenterol. 14: 354-377. 
Krynetskaia, N.F., T.L. Brenner, E.Y. Krynetski, W. Du, J.C. Panetta, P. Ching-Hon, and 
W.E. Evans. 2003. Msh2 deficiency attenuates but does not abolish thiopurine 
hematopoietic toxicity in msh2-/- mice. Mol Pharmacol. 64: 456-465. 
Krynetskaia, N.F., X. Cai, J.L. Nitiss, E.Y. Krynetski, and M.V. Relling. 2000. 
Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. 
Faseb J. 14: 2339-2344. 
Krynetski, E.Y., N.F. Krynetskaia, Y. Yanishevski, and W.E. Evans. 1995. Methylation 
of mercaptopurine, thioguanine, and their nucleotide metabolites by 
heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol. 
47: 1141-1147. 
Lengauer, C., K.W. Kinzler, and B. Vogelstein. 1998. Genetic instabilities in human 
cancers. Nature. 396: 643-649. 
Lennard, L., J.S. Lilleyman, J. Van Loon, and R.M. Weinshilboum. 1990. Genetic 
variation in response to 6-mercaptopurine for childhood acute lymphoblastic 
leukaemia. Lancet. 336: 225-229. 
Lennard L, Lilleyman JS. 1989. Variable mercaptopurine metabolism and treatment 
outcome in childhood lymphoblastic leukemia. J Clin Oncol. 7:1816-23.  
Lennard L, Lilleyman JS. 1990. Variable mercaptopurine metabolism and treatment 
outcome in childhood lymphoblastic leukemia. J Clin Oncol. 8:567. 
Lepage, G.A. 1960. Incorporation of 6-thioguanine into nucleic acids. Cancer Res. 20: 
403-408. 
LePage, G.A. and J.P. Whitecar, Jr. 1971. Pharmacology of 6-thioguanine in man. 
Cancer Res. 31: 1627-1631. 
Li, G.M. 2003. DNA mismatch repair and cancer. Front Biosci. 8: d997-1017. 
Linder, N., J. Rapola, and K.O. Raivio. 1999. Cellular expression of xanthine 
oxidoreductase protein in normal human tissues. Lab Invest. 79: 967-974. 
Ling, Y.H., J.Y. Chan, K.L. Beattie, and J.A. Nelson. 1992. Consequences of 6-
thioguanine incorporation into DNA on polymerase, ligase, and endonuclease 
reactions. Mol Pharmacol. 42: 802-807. 
Lucci-Cordisco, E., I. Zito, F. Gensini, and M. Genuardi. 2003. Hereditary nonpolyposis 
colorectal cancer and related conditions. Am J Med Genet A. 122: 325-334. 
Macdonald, T.T. and G. Monteleone. 2005. Immunity, inflammation, and allergy in the 
gut. Science. 307: 1920-1925. 
Mark, S.C., L.E. Sandercock, H.A. Luchman, A. Baross, W. Edelmann, and F.R. Jirik. 
2002. Elevated mutant frequencies and predominance of G:C to A:T transition 
mutations in Msh6(-/-) small intestinal epithelium. Oncogene. 21: 7126-7130. 
Markowitz, S. 2000. DNA repair defects inactivate tumor suppressor genes and induce 
hereditary and sporadic colon cancers. J Clin Oncol. 18: 75S-80S. 
Matheson, E.C. and A.G. Hall. 2003. Assessment of mismatch repair function in 
leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia. 
Carcinogenesis. 24: 31-38. 
  242 
Maybaum, J. and H.G. Mandel. 1983. Unilateral chromatid damage: a new basis for 6-
thioguanine cytotoxicity. Cancer Res. 43: 3852-3856. 
McGinniss, M.J., M.T. Falta, L.M. Sullivan, and R.J. Albertini. 1990. In vivo hprt mutant 
frequencies in T-cells of normal human newborns. Mutat Res. 240: 117-126. 
Mitelman, F., B. Strombeck, and B. Ursing. 1980. No cytogenic effect of metronidazole. 
Lancet. 1: 1249-1250. 
Montaner, B., P. O'Donovan, O. Reelfs, C.M. Perrett, X. Zhang, Y.Z. Xu, X. Ren, P. 
Macpherson, D. Frith, and P. Karran. 2007. Reactive oxygen-mediated damage to 
a human DNA replication and repair protein. EMBO Rep. 8: 1074-1079. 
Montano Loza, A.J. and A.J. Czaja. 2007. Current therapy for autoimmune hepatitis. Nat 
Clin Pract Gastroenterol Hepatol. 4: 202-214. 
Moriwaki, Y., T. Yamamoto, M. Suda, Y. Nasako, S. Takahashi, O.E. Agbedana, T. 
Hada, and K. Higashino. 1993. Purification and immunohistochemical tissue 
localization of human xanthine oxidase. Biochim Biophys Acta. 1164: 327-330. 
Murray, J.E., J.P. Merrill, J.H. Harrison, R.E. Wilson, and G.J. Dammin. 1963. Prolonged 
survival of human-kidney homografts by immunosuppressive drug therapy. N 
Engl J Med. 268: 1315-1323. 
Nelson, J.A., J.W. Carpenter, L.M. Rose, and D.J. Adamson. 1975. Mechanisms of action 
of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res. 35: 2872-
2878. 
Noori, P., S. Hou, I.M. Jones, C.B. Thomas, and B. Lambert. 2005. A comparison of 
somatic mutational spectra in healthy study populations from Russia, Sweden and 
USA. Carcinogenesis. 26: 1138-1151. 
O'Donovan, P., C.M. Perrett, X. Zhang, B. Montaner, Y.Z. Xu, C.A. Harwood, J.M. 
McGregor, S.L. Walker, F. Hanaoka, and P. Karran. 2005. Azathioprine and UVA 
light generate mutagenic oxidative DNA damage. Science. 309: 1871-1874. 
Offman, J., G. Opelz, B. Doehler, D. Cummins, O. Halil, N.R. Banner, M.M. Burke, D. 
Sullivan, P. Macpherson, and P. Karran. 2004. Defective DNA mismatch repair in 
acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. 
Blood. 104: 822-828. 
Ohyashiki, J.H., K. Ohyashiki, S. Aizawa, K. Kawakubo, T. Shimamoto, H. Iwama, S. 
Hayashi, and K. Toyama. 1996. Replication errors in hematological neoplasias: 
genomic instability in progression of disease is different among different types of 
leukemia. Clin Cancer Res. 2: 1583-1589. 
Olipitz, W., G. Hopfinger, R.C. Aguiar, E. Gunsilius, M. Girschikofsky, C. Bodner, K. 
Hiden, W. Linkesch, G. Hoefler, and H. Sill. 2002. Defective DNA-mismatch 
repair: a potential mediator of leukemogenic susceptibility in therapy-related 
myelodysplasia and leukemia. Genes Chromosomes Cancer. 34: 243-248. 
O'Neill, J.P., M.J. McGinniss, J.K. Berman, L.M. Sullivan, J.A. Nicklas, and R.J. 
Albertini. 1987. Refinement of a T-lymphocyte cloning assay to quantify the in 
vivo thioguanine-resistant mutant frequency in humans. Mutagenesis. 2: 87-94. 
O'Neill, J.P., J.A. Nicklas, T.C. Hunter, O.B. Batson, M. Allegretta, M.T. Falta, R.F. 
Branda, and R.J. Albertini. 1994. The effect of T-lymphocyte 'clonality' on the 
  243 
calculated hprt mutation frequency occurring in vivo in humans. Mutat Res. 313: 
215-225. 
O'Neill, J.P., L.M. Sullivan, and R.J. Albertini. 1990. In vitro induction, expression and 
selection of thioguanine-resistant mutants with human T-lymphocytes. Mutat Res. 
240: 135-142. 
O'Neill, J.P., B.A. Finette.  1998. Transition mutations at CpG dinucleotides are the most 
frequent in vivo spontaneous single-base substitution mutation in the human 
HPRT gene. Environmental and Molecular Mutagenesis. 32: 188-191. 
Opelz, G. and R. Henderson. 1993. Incidence of non-Hodgkin lymphoma in kidney and 
heart transplant recipients. Lancet. 342: 1514-1516. 
Palace, J., J. Newsom-Davis, and B. Lecky. 1998. A randomized double-blind trial of 
prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis 
Study Group. Neurology. 50: 1778-1783. 
Peltomaki, P. 2003. Role of DNA mismatch repair defects in the pathogenesis of human 
cancer. J Clin Oncol. 21: 1174-1179. 
Penn, I. 1988. Tumors of the immunocompromised patient. Annu Rev Med. 39: 63-73. 
Penn, I. 1998. De novo malignances in pediatric organ transplant recipients. Pediatr 
Transplant. 2: 56-63. 
Penn, I. 1998. Primary malignancies of the hepato-biliary-pancreatic system in organ 
allograft recipients. J Hepatobiliary Pancreat Surg. 5: 157-164. 
Petit, E., S. Langouet, H. Akhdar, C. Nicolas-Nicolaz, A. Guillouzo, and F. Morel. 2008. 
Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on 
human hepatocytes. Toxicol In Vitro. 22: 632-642. 
Pinczowski, D., A. Ekbom, J. Baron, J. Yuen, and H.O. Adami. 1994. Risk factors for 
colorectal cancer in patients with ulcerative colitis: a case-control study. 
Gastroenterology. 107: 117-120. 
Podlutsky, A., A.M. Osterholm, S.M. Hou, A. Hofmaier, and B. Lambert. 1998. 
Spectrum of point mutations in the coding region of the hypoxanthine-guanine 
phosphoribosyltransferase (hprt) gene in human T-lymphocytes in vivo. 
Carcinogenesis. 19: 557-566. 
Podolsky, D.K. 2002. Inflammatory bowel disease. N Engl J Med. 347: 417-429. 
Poppe, D., I. Tiede, G. Fritz, C. Becker, B. Bartsch, S. Wirtz, D. Strand, S. Tanaka, P.R. 
Galle, X.R. Bustelo, and M.F. Neurath. 2006. Azathioprine suppresses ezrin-
radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav 
guanosine exchange activity on Rac proteins. J Immunol. 176: 640-651. 
Rappaport, H.P. 1993. Replication of the base pair 6-thioguanine/5-methyl-2-pyrimidine 
with the large Klenow fragment of Escherichia coli DNA polymerase I. 
Biochemistry. 32: 3047-3057. 
Ratanatharathorn, V., L. Ayash, H.M. Lazarus, J. Fu, and J.P. Uberti. 2001. Chronic 
graft-versus-host disease: clinical manifestation and therapy. Bone Marrow 
Transplant. 28: 121-129. 
  244 
Reeve, V.E., G.E. Greenoak, C.H. Gallagher, P.J. Canfield, and F.J. Wilkinson. 1985. 
Effect of immunosuppressive agents and sunscreens on UV carcinogenesis in the 
hairless mouse. Aust J Exp Biol Med Sci. 63 ( Pt 6): 655-665. 
Relling, M.V., J.E. Rubnitz, G.K. Rivera, J.M. Boyett, M.L. Hancock, C.A. Felix, L.E. 
Kun, A.W. Walter, W.E. Evans, and C.H. Pui. 1999. High incidence of secondary 
brain tumours after radiotherapy and antimetabolites. Lancet. 354: 34-39. 
Relling, M.V., Y. Yanishevski, J. Nemec, W.E. Evans, J.M. Boyett, F.G. Behm, and C.H. 
Pui. 1998. Etoposide and antimetabolite pharmacology in patients who develop 
secondary acute myeloid leukemia. Leukemia. 12: 346-352. 
Rioux, J.D., M.S. Silverberg, M.J. Daly, A.H. Steinhart, R.S. McLeod, A.M. Griffiths, T. 
Green, T.S. Brettin, V. Stone, S.B. Bull, A. Bitton, C.N. Williams, G.R. 
Greenberg, Z. Cohen, E.S. Lander, T.J. Hudson, and K.A. Siminovitch. 2000. 
Genomewide search in Canadian families with inflammatory bowel disease 
reveals two novel susceptibility loci. Am J Hum Genet. 66: 1863-1870. 
Robinson, D.R., K. Goodall, R.J. Albertini, J.P. O'Neill, B. Finette, M. Sala-Trepat, E. 
Moustacchi, A.D. Tates, D.M. Beare, M.H. Green, and et al. 1994. An analysis of 
in vivo hprt mutant frequency in circulating T-lymphocytes in the normal human 
population: a comparison of four datasets. Mutat Res. 313: 227-247. 
Rosenkranz, H.S. and G. Klopman. 1991. A re-examination of the genotoxicity and 
carcinogenicity of azathioprine. Mutat Res. 251: 157-161; discussion 163-154. 
Rosh, J.R., T. Gross, P. Mamula, A. Griffiths, and J. Hyams. 2007. Hepatosplenic T-cell 
lymphoma in adolescents and young adults with Crohn's disease: a cautionary 
tale? Inflamm Bowel Dis. 13: 1024-1030. 
Rubben, A., W. Kempf, M.E. Kadin, D.R. Zimmermann, and G. Burg. 2004. 
Multilineage progression of genetically unstable tumor subclones in cutaneous T-
cell lymphoma. Exp Dermatol. 13: 472-483. 
Rutter, M., B. Saunders, K. Wilkinson, S. Rumbles, G. Schofield, M. Kamm, C. 
Williams, A. Price, I. Talbot, and A. Forbes. 2004. Severity of inflammation is a 
risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 126: 
451-459. 
Satsangi, J., M. Parkes, E. Louis, L. Hashimoto, N. Kato, K. Welsh, J.D. Terwilliger, 
G.M. Lathrop, J.I. Bell, and D.P. Jewell. 1996. Two stage genome-wide search in 
inflammatory bowel disease provides evidence for susceptibility loci on 
chromosomes 3, 7 and 12. Nat Genet. 14: 199-202. 
Schaeffeler, E., C. Fischer, D. Brockmeier, D. Wernet, K. Moerike, M. Eichelbaum, 
U.M. Zanger, and M. Schwab. 2004. Comprehensive analysis of thiopurine S-
methyltransferase phenotype-genotype correlation in a large population of 
German-Caucasians and identification of novel TPMT variants. 
Pharmacogenetics. 14: 407-417. 
Schwartz, R. and W. Dameshek. 1959. Drug-induced immunological tolerance. Nature. 
183: 1682-1683. 
Schwartz, R., J. Stack, and W. Dameshek. 1958. Effect of 6-mercaptopurine on antibody 
production. Proc Soc Exp Biol Med. 99: 164-167. 
  245 
Silman, A.J., J. Petrie, B. Hazleman, and S.J. Evans. 1988. Lymphoproliferative cancer 
and other malignancy in patients with rheumatoid arthritis treated with 
azathioprine: a 20 year follow up study. Ann Rheum Dis. 47: 988-992. 
Smela ME, Currier SS, Bailey EA, Essigmann JM. 2001. The chemistry and biology of 
aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis. 
22: 535-45. 
Smith, C.C., G.E. Archer, E.J. Forster, T.R. Lambert, R.W. Rees, and A.M. Lynch. 1999. 
Analysis of gene mutations and clastogenicity following short-term treatment 
with azathioprine in MutaMouse. Environ Mol Mutagen. 34: 131-139. 
Smith, J.R., J.D. Carpten, M.J. Brownstein, S. Ghosh, V.L. Magnuson, D.A. Gilbert, J.M. 
Trent, and F.S. Collins. 1995. Approach to genotyping errors caused by 
nontemplated nucleotide addition by Taq DNA polymerase. Genome Res. 5: 312-
317. 
Southern, E.M. 1979. Measurement of DNA length by gel electrophoresis. Anal Biochem. 
100: 319-323. 
Speck, W.T. and H.S. Rosenkranz. 1976. Mutagenicity of azathioprine. Cancer Res. 36: 
108-109. 
Stanulla, M., E. Schaeffeler, T. Flohr, G. Cario, A. Schrauder, M. Zimmermann, K. 
Welte, W.D. Ludwig, C.R. Bartram, U.M. Zanger, M. Eichelbaum, M. Schrappe, 
and M. Schwab. 2005. Thiopurine methyltransferase (TPMT) genotype and early 
treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. 
Jama. 293: 1485-1489. 
Stet, E.H., R.A. De Abreu, J.P. Bokkerink, T.M. Vogels-Mentink, L.H. Lambooy, F.J. 
Trijbels, and R.C. Trueworthy. 1993. Reversal of 6-mercaptopurine and 6-
methylmercaptopurine ribonucleoside cytotoxicity by amidoimidazole 
carboxamide ribonucleoside in Molt F4 human malignant T-lymphoblasts. 
Biochem Pharmacol. 46: 547-550. 
Stojic, L., R. Brun, and J. Jiricny. 2004. Mismatch repair and DNA damage signalling. 
DNA Repair (Amst). 3: 1091-1101. 
Stout, J.T. and C.T. Caskey. 1985. HPRT: gene structure, expression, and mutation. Annu 
Rev Genet. 19: 127-148. 
Strauss, G.H., and R.J. Albertini.  1977.  6-Thioguanine resistant lymphocytes in human 
blood, in: D. Scott, B.A. Bridges and F.H. Sobels (Eds.), Progress in Genetic 
Toxocology, Elsevier, Amsterdam, pp. 327-334. 
Strauss, G.H., and R.J. Albertini.  1979.  Enumeration of 6-thioguanine resistant 
peripheral blood lymphocytes in man as a potential test somatic cell mutations 
arising iv vivo.  Mutation Res 61: 353-379. 
Suraweera, N., A. Duval, M. Reperant, C. Vaury, D. Furlan, K. Leroy, R. Seruca, B. 
Iacopetta, and R. Hamelin. 2002. Evaluation of tumor microsatellite instability 
using five quasimonomorphic mononucleotide repeats and pentaplex PCR. 
Gastroenterology. 123: 1804-1811. 
  246 
Swann, P.F., T.R. Waters, D.C. Moulton, Y.Z. Xu, Q. Zheng, M. Edwards, and R. Mace. 
1996. Role of postreplicative DNA mismatch repair in the cytotoxic action of 
thioguanine. Science. 273: 1109-1111. 
Tage-Jensen, U., P. Schlichting, H.F. Thomsen, G. Hoybye, and A.C. Thomsen. 1987. 
Malignancies following long-term azathioprine treatment in chronic liver disease. 
A report from the Copenhagen Study Group for Liver Diseases. Liver. 7: 81-83. 
Takahama, Y.  2006. Journey through the thymus: stromal guides for T-cell development 
and selection. Nature Reviews Immunology. 6: 127-135. 
Teml, A., E. Schaeffeler, K.R. Herrlinger, U. Klotz, and M. Schwab. 2007. Thiopurine 
treatment in inflammatory bowel disease: clinical pharmacology and implication 
of pharmacogenetically guided dosing. Clin Pharmacokinet. 46: 187-208. 
Thibodeau, S.N., G. Bren, and D. Schaid. 1993. Microsatellite instability in cancer of the 
proximal colon. Science. 260: 816-819. 
Tidd, D.M. and A.R. Paterson. 1974. A biochemical mechanism for the delayed cytotoxic 
reaction of 6-mercaptopurine. Cancer Res. 34: 738-746. 
Tidd, D.M. and A.R. Paterson. 1974. Distinction between inhibition of purine nucleotide 
synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 34: 
733-737. 
Tiede, I., G. Fritz, S. Strand, D. Poppe, R. Dvorsky, D. Strand, H.A. Lehr, S. Wirtz, C. 
Becker, R. Atreya, J. Mudter, K. Hildner, B. Bartsch, M. Holtmann, R. Blumberg, 
H. Walczak, H. Iven, P.R. Galle, M.R. Ahmadian, and M.F. Neurath. 2003. 
CD28-dependent Rac1 activation is the molecular target of azathioprine in 
primary human CD4+ T lymphocytes. J Clin Invest. 111: 1133-1145. 
Ulrich, C.M., J. Bigler, and J.D. Potter. 2006. Non-steroidal anti-inflammatory drugs for 
cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 6: 
130-140. 
Umar, A., C.R. Boland, J.P. Terdiman, S. Syngal, A. de la Chapelle, J. Ruschoff, R. 
Fishel, N.M. Lindor, L.J. Burgart, R. Hamelin, S.R. Hamilton, R.A. Hiatt, J. Jass, 
A. Lindblom, H.T. Lynch, P. Peltomaki, S.D. Ramsey, M.A. Rodriguez-Bigas, 
H.F. Vasen, E.T. Hawk, J.C. Barrett, A.N. Freedman, and S. Srivastava. 2004. 
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer 
(Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 96: 261-268. 
Umar, A., M. Koi, J.I. Risinger, W.E. Glaab, K.R. Tindall, R.D. Kolodner, C.R. Boland, 
J.C. Barrett, and T.A. Kunkel. 1997. Correction of hypermutability, N-methyl-N'-
nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by 
introducing chromosome 2 into human tumor cells with mutations in MSH2 and 
MSH6. Cancer Res. 57: 3949-3955. 
Uribe-Luna, S., J.D. Quintana-Hau, R. Maldonado-Rodriguez, M. Espinosa-Lara, K.L. 
Beattie, D. Farquhar, and J.A. Nelson. 1997. Mutagenic consequences of the 
incorporation of 6-thioguanine into DNA. Biochem Pharmacol. 54: 419-424. 
Velayos, F.S., E.V. Loftus, Jr., T. Jess, W.S. Harmsen, J. Bida, A.R. Zinsmeister, W.J. 
Tremaine, and W.J. Sandborn. 2006. Predictive and protective factors associated 
  247 
with colorectal cancer in ulcerative colitis: A case-control study. 
Gastroenterology. 130: 1941-1949. 
Vernole, P., R. Pepponi, and S. D'Atri. 2003. Role of mismatch repair in the induction of 
chromosomal aberrations and sister chromatid exchanges in cells treated with 
different chemotherapeutic agents. Cancer Chemother Pharmacol. 52: 185-192. 
Voogd, C.E. 1981. On the mutagenicity of nitroimidazoles. Mutat Res. 86: 243-277. 
Voogd, C.E. 1989. Azathioprine, a genotoxic agent to be considered non-genotoxic in 
man. Mutat Res. 221: 133-152. 
Voogd, C.E., J.J. van der Stel, and J.J. Jacobs. 1979. The mutagenic action of 
nitroimidazoles. IV. A comparison of the mutagenic action of several 
nitroimidazoles and some imidazoles. Mutat Res. 66: 207-221. 
Vora, A., C.D. Mitchell, L. Lennard, T.O. Eden, S.E. Kinsey, J. Lilleyman, and S.M. 
Richards. 2006. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine 
in childhood lymphoblastic leukaemia: a randomised trial. Lancet. 368: 1339-
1348. 
Wada, C., S. Shionoya, Y. Fujino, H. Tokuhiro, T. Akahoshi, T. Uchida, and H. Ohtani. 
1994. Genomic instability of microsatellite repeats and its association with the 
evolution of chronic myelogenous leukemia. Blood. 83: 3449-3456. 
Warnick, C.T. and A.R. Paterson. 1973. Effect of methylthioinosine on nucleotide 
concentrations in L5178Y cells. Cancer Res. 33: 1711-1715. 
Warren, D.J., A. Andersen, and L. Slordal. 1995. Quantitation of 6-thioguanine residues 
in peripheral blood leukocyte DNA obtained from patients receiving 6-
mercaptopurine-based maintenance therapy. Cancer Res. 55: 1670-1674. 
Watts RW, Watts JE, Seegmiller JE. 1965. Xanthine oxidase activity in human tissues 
and its inhibition by allopurinol (4-hydroxypyrazolo[3,4-d] pyrimidine). J Lab 
Clin Med. 66: 688-97. 
Webber, S.A., K. McCurry, and A. Zeevi. 2006. Heart and lung transplantation in 
children. Lancet. 368: 53-69. 
Weinshilboum, R.M. and S.L. Sladek. 1980. Mercaptopurine pharmacogenetics: 
monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J 
Hum Genet. 32: 651-662. 
Wotring, L.L. and J.L. Roti Roti. 1980. Thioguanine-induced S and G2 blocks and their 
significance to the mechanism of cytotoxicity. Cancer Res. 40: 1458-1462. 
Xicola, R.M., X. Llor, E. Pons, A. Castells, C. Alenda, V. Pinol, M. Andreu, S. Castellvi-
Bel, A. Paya, R. Jover, X. Bessa, A. Giros, J.M. Duque, D. Nicolas-Perez, A.M. 
Garcia, J. Rigau, and M.A. Gassull. 2007. Performance of different microsatellite 
marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl 
Cancer Inst. 99: 244-252. 
Xie, J. and S.H. Itzkowitz. 2008. Cancer in inflammatory bowel disease. World J 
Gastroenterol. 14: 378-389. 
Yadollahi-Farsani M, Gooderham NJ, Davies DS, Boobis AR. 1996. Mutational spectra 
of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine(PhIP) at the Chinese hamsters hprt locus. Carcinogenesis. 17: 617-24. 
  248 
Yamane, K., K. Taylor, and T.J. Kinsella. 2004. Mismatch repair-mediated G2/M arrest 
by 6-thioguanine involves the ATR-Chk1 pathway. Biochem Biophys Res 
Commun. 318: 297-302. 
Yamaoka, T., M. Yano, M. Kondo, H. Sasaki, S. Hino, R. Katashima, M. Moritani, and 
M. Itakura. 2001. Feedback inhibition of amidophosphoribosyltransferase 
regulates the rate of cell growth via purine nucleotide, DNA, and protein 
syntheses. J Biol Chem. 276: 21285-21291. 
Yan, T., S.E. Berry, A.B. Desai, and T.J. Kinsella. 2003. DNA mismatch repair (MMR) 
mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal 
a G2-M arrest in MMR-proficient RKO cells. Clin Cancer Res 9: 2327-2334. 
Yang, L. and Z. Pei. 2006. Bacteria, inflammation, and colon cancer. World J 
Gastroenterol. 12: 6741-6746. 
Yoshioka, M., J.P. O'Neill, P.M. Vacek, and B.A. Finette. 2001. Gestational age and 
gender-specific in utero V(D)J recombinase-mediated deletions. Cancer Res. 61: 
3432-3438. 
Yuan B, Wang Y. 2008. Mutagenic and cytotoxic properties of 6-thioguanine, S6-
methylthioguanine and guanine-S6-sulfonic acid. J Biol Chem.  
 
 








Distribution of G:C to A:T Transitions of non-








  250 
 Mutations at the HPRT locus that have been recovered from the in vitro selection 
of mutant clones primarily reflect mutagenic events at nucleotide positions that have 
resulted in the inactivation of the HPRT enzyme (Duan et al. 2004).  Thus although there 
are 570 possible nucleotide positions within the 657 bp coding region of the HPRT gene 
in which a substitution event may result in a missence or nonsense mutation, nucleotide 
substitutions have not been observed at certain positions while mutations have been 
frequently observed at specific positions referred to as mutation hotspots (Duan et al. 
2004). 
 Previous studies suggest that G:C to A:T transitions in both non-thiopurine and 
thiopurine treated subjects are endpoints that likely reflect the cumulative events of 
misinsertion of thymine opposite incorporated guanine (G), 6-thioguanine (6-TG), 
methylated 6-thioguanine (6-MeTG), or 2-aminopurine-6-sulfonate, proofreading of 
mispairs, and DNA repair of lesions that are influenced by local DNA sequence context 
as well as the stability of mispairs.  Kinetic studies of the frequency of thymine 
misinsertion opposite guanine and 6-MeTG using several bacterial polymerases have 
similarly demonstrated higher efficiencies of misinsertion opposite 6-methylthioguanine 
(6-MeTG) compared to guanine (G) containing templates (Spratt and Levy 1997).  
Waters showed that postreplicative mismatch repair complex, hMutSα, involved in the 
recognition of G:T and 6-MeTG:T mismatches to initiate the repair process, 
indiscrimantly bind to G:T mismatches independent of the 5’ flanking nucleotide while 
differentially binding to 6-MeTG:T mismatches with respect to the 5’ flanking nucleotide 
(Waters and Swann 1997), indicating potentially more efficient repair of G:T mismatches 
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overall and the influence of DNA sequence context on the repair of 6-MeTG:T lesions. 
Bohon and Santos more recently demonstrated that templates containing G:T, 6-TG:T, 6-
TG:C, and G:C base pairs showed increasing thermodynamic stability, and that base pair 
stability or the lifetime of G:T mismatch was undetectable compared to 6-TG:T, 6-TG:C, 
and canonical G:C base pair with lifetime of 2ms, 7ms, and 125ms, respectively (Bohon 
and Santos 2005).  The frequent opening of G:T mismatches may allow more access to 
proteins, possibly promoting more efficient repair of mispairs.  Since 2-aminopurine-6-
sulfonate was recently identified, there are no studies available that have evaluated the 
kinetics of misinsertion, thermostability of mispair, and DNA repair of the oxidized base. 
 These studies indicate that most mutations induced by thiopurines likely result 
from the incorporation of 6-TG nucleotide opposite cytosine during the first round of 
replication, forming 6-TG:C base pairs that are more thermodynamically stable compared 
to the direct formation of 6-TG:T (Rappaport 1988; Rappaport 1993; Bohon and Santos 
2005).  Then methylation of 6-TG to form 6-MeTG results in equal or more efficient 
misinsertion of thymine opposite 6-MeTG compared to the insertion of cytosine during 
the second round of replication (Swann et al. 1996; Spratt and Levy 1997; Yuan and 
Wang 2008).   In addition to these events, differential sequence context-dependent 
mismatch repair complex, hMutSα, recognition of 6-MeTG:T compared to G:T mispairs 
may explain the higher proportion of G:C to A:T mutation endpoints observed in 
thiopurine treated subjects compared to non-thiopurine subjects that we have 
demonstrated in Chapter 2 (Figure 1).  Furthermore, these endpoint G:C to A:T mutations 
may distribute in a sequence-context dependent manner.  In this section, we examined the 
  252 
distribution of G:C to A:T mutations at non-CpG sites in both non-thiopurine and 
thiopurine treated subjects to evaluate the potential influence of DNA sequence context 
on the frequency of G:C to A:T mutations at specific nucleotide positions.  
 
RESULTS AND DISCUSSION 
 Distributions of G:C to A:T transitions at non-CpG sites within coding region and 
non-coding regions at exon-intron borders of the HPRT gene among non-thiopurine and 
thiopurine treated subjects were examined in Figures 2 (A and B), 3 (A and B),  4 (A and 
B),  and Tables 1 (A, B, and C).  In total there are 152 guanines and 102 cytosines within 
the coding region that can undergo G:C to A:T or C:G to T:A transitions in the sense or 
antisense strand of the HPRT gene, respectively.  Forty-six G:C to A:T or C:G to T:A 
transitions were identified in non-thiopurine subjects, comprising of unique mutations 
from each subject that distributed within both coding region and exon-intron borders at 
nucleotide positions that participate in splicing reactions of exon regions.  Thirty-two of 
these transitions were a result of mutation events at 21 positions within the coding region 
(Figures 2A, 3A, 4A), with 3 events occurring at positions 538 and 551 and 5 events at 
617 (Supplemental Tables 1A and 1B).  Mutations at these positions either have been 
observed at higher frequency in the spectra of healthy subjects and/or inherited germline-
mutations that result in Lesch Nyhan disease (Duan et al. 2004). The remaining 14 
transitions, distributed at exon-intron borders of the eight introns within the HPRT gene 
(Figures 2A, 3A, 4A).  In addition to showing a higher frequency at specific positions, 
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G:C to A:T mutations appear to distribute in a sequence-context dependent manner 
(Tables 1A and 1B) and at higher frequency in the sense (coding) strand (Table 1C).  
Both 5’ and 3’ flanking nucleotides affect the frequencies of G:C to A:T transitions, 
which differed with respect to variations of the 5’, 3’, or specific combinations of 5’ and 
3’ flanking nucleotides (Tables 1A and 1B).  When targeted guanine (G) is flanked on the 
3’ end by guanine (G), adenine (A), or thymine (T), the highest proportions of G:C to 
A:T transitions were observed in sequences flanked 5’ by thymine (TGG), guanine 
(GGA), or thymine (TGT), respectively, in which the underlined G is mutated 
(Supplemental Table 1).  When targeted guanine is flanked on the 5’ side by guanine, 
adenine, or thymine, the highest proportions of G:C to A:T transitions were observed in 
sequences flanked 3’ by adenine (GGA), guanine (AGG) and adenine (AGA), or guanine 
(TGG) and thymine (TGT), respectively.  The frequent events of G:C to A:T transitions 
at positions 538 and 551 occurred in sequence context TGG and at position 617 in 
sequence context TGT (Supplemental Table 1, Tables 1A and 1B in which events are 
included in proportions highlighted red).  In both of these sequence contexts the highest 
total proportions of G:C to A:T transitions were also observed.  
 Among thiopurine treated subjects, 53 of 80 G:C to A:T transitions distributed 
across 25 positions within the coding region and 27 across 13 positions within non-
coding regions at exon-intron borders. G:C to A:T transitions were observed at higher 
frequency, representing 5% or more, at different positions 3 (4 events), 197 (7 events), 
463 (4 events), 485 (4 events), 539 (6 events) (Supplemental Table 1) within the coding 
region compared to untreated subjects.  Similar to non-thiopurine subjects, G:C to A:T 
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mutations were observed at higher frequency in the sense compared to antisense strand 
(Table 1C) and at different frequencies with respect to variations of the 5’, 3’, or specific 
combinations of 5’ and 3’ flanking nucleotides (Tables 1A and 1B).  When targeted G is 
flanked 3’ by guanine, adenine, or thymine, the highest proportions of G:C to A:T 
transitions were observed when the 5’ end is flanked by adenine (AGG) and thymine 
(TGG), guanine (GGA), or guanine (GGT) and thymine (TGT), respectively.  When 
targeted G is flanked 5’ by guanine, adenine, or thymine, the highest proportions of G:C 
to A:T transitions were observed when the 3’ end is flanked by adenine (GGA) and 
thymine (GGT), guanine (AGG), or guanine (TGG) and thymine (TGT), respectively.  
Frequent observations of G:C to A:T transitions at positions 3, 197, 485, and 463 and 539 
occurred in the sequence contexts TGG, TGT, AGG and GGA, respectively, 
(Supplemental Table 1, Tables 1 A and B in which events are included in proportions 
highlighted red).  In these sequence contexts, the highest total proportions of G:C to A:T 
transitions were also observed.  
  In comparison, thiopurine treated (consisting of exposure-specific and 
background mutations) and untreated (consisting of background mutations) subjects 
exhibited similarities as well as differences in the distribution of G:C to A:T transitions. 
A predominance of G:C to A:T mutations in both groups occurred in the sense (coding) 
DNA strand, connoting more efficient repair of background and exposure-specific lesions 
in the transcribing antisense strand, which has previously been observed (Hussain and 
Harris 1998).  Thiopurine treated and untreated subjects also share a higher occurrence of 
G:C to A:T mutations within sequence contexts TGG, GGA, and TGT that have been 
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frequently observed in healthy subjects.  While mutation hotspots for G:C to A:T 
transitions were distinctly observed in thiopurine treated and untreated subjects, they 
overlap with mutation hotspots that have been observed in healthy subjects, which may 
reflect insufficient number of G:C to A:T mutations to span the coding region in both 
groups or actual differences in sequence-specific dependency on the distribution of G:C 
to A:T mutations between both groups.  At least two fold differences in the overall 
proportions of G:C to A:T transitions were also observed within sequence contexts AGG, 
TGA, and GGT between thiopurine treated and untreated subjects.  Differential 
recognition of 6-MeTG:T mispairs and indiscriminant recognition of G:T and 6-TG:T 
mismatches by the mismatch repair system with respect to different 5’ flanking 
nucleotides cannot account for the prevalence of all G:C to A:T mutations within specific 
sequence contexts (Waters et al 1997; Griffin et al. 1994). It is likely that the similarities 
and differences in distribution of G:C to A:T transitions reflect sequence context 
dependent efficiency of misinsertion, proofreading of mispairs, or preferential DNA 
repair of specific lesions since observed mutations are endpoints of these processes.  To 
further elucidate the steps or interactions of steps that resulted in these endpoints, 
systematic investigations of each step with respect to variations in both 5’ and 3’ flanking 
nucleotides would be required. Although studies of several bacterial DNA polymerases 
have consistently demonstrated more efficient misinsertion of thymidine nucleotides 
opposite of 6-MeTG compared to guanine within the same sequence context (Spratt and 
Levy 1997), previous studies with eukaryotic DNA polymerases suggest the influences of 
different types of polymerases along with sequence context specificity in the observed 
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frequency of misinsertion of specific nucleotides across DNA lesions (Feig and Loeb 
1994). Thus these investigations should to be conducted with different eukaryotic DNA 
polymerases and repair systems to closely reflect the in vivo events in humans. 
 We were unable to compare the proportions of G:C to A:T mutations within 
specific sequence contexts within each group, including variations of the 5’ flanking 
nucleotides when the 3’ flanking nucleotide is cytidine triphosphate, as well as between 
thiopurine treated and untreated groups in which there were fewer observations. 
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Figure 1.  Distribution of classes of mutations in normal, non-thiopurine, and 
thiopurine treated subjects. 
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Figure 2.  Distribution of G:C to A:T Transitions in non-Thiopurine and Thiopurine Treated Subjects. 
A 
B 
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Figure 3.  Separate Distributions of G:C to A:T Transitions of Non-Thiopurine Subjects. 
B 
A 
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Figure 4. Separate Distributions of G:C to A:T Transitions among Thiopurine Subjects. 
A 
B 
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Table 1. Distribution of G:C to A:T Transitions with Respect to Sequence Context of non-Thiopurine and Thiopurine 
Treated subjects. 
 
A.  Influence of 5’ Flanking Nucleotide. 
 
B.  Influence of 3’ Flanking Nucleotide.  
 
C.  Proportion of G:C to A:T Transitions in Coding vs. Non-Coding DNA Strand. 
Influence of 5' 
Flanking 
Nucleotide
GGG AGG TGG GGA AGA TGA GGC AGC TGC GGT AGT TGT Total
non-Thiopurine 3 4 9 8 4 4 1 2 0 2 2 10 46
% of Total G->A 6.5% 8.7% 19.6% 17.4% 8.7% 8.7% 2.2% 4.3% 0.0% 4.3% 4.3% 21.7%
Thiopurine 3 14 10 14 7 0 2 1 3 9 3 11 80




AGG (AGG) TGG (TGG) GGA (GGA) Total
non-Thiopurine 4 0 6 3 8 0 46
% of Total G->A 8.7% 0.0% 13.0% 6.5% 17.4% 0.0%
Thiopurine 11 3 8 2 10 4 80
% of Total G->A 13.8% 3.8% 10.0% 2.5% 12.5% 5.0%
Influence of 3' 
Flanking 
Nucleotide
GGG GGA GGC GGT AGG AGA AGC AGT TGG TGA TGC TGT Total
non-Thiopurine 3 8 1 2 4 4 2 2 9 4 0 10 46
% of Total G->A 6.5% 17.4% 2.2% 4.3% 8.7% 8.7% 4.3% 4.3% 19.6% 8.7% 0.0% 21.7%
Thiopurine 3 14 2 9 14 7 1 3 10 0 3 11 80
% of Total G->A 3.8% 17.5% 2.5% 11.3% 17.5% 8.8% 1.3% 3.8% 12.5% 0.0% 3.8% 13.8%
Subject ID Clone Mutation Base Position
UC-033 B2 M3 551C->T 551
UC-061 B1 M4 617G->A 617
UC-062 B1 M1 617G->A 617
UC-058 B1 M3 27+5G->A 27+5
UC-003 B1 M1 610-16G->A 610-16
UC-064 B1 M12 3G->A 3
UC-041 B1 M10 119G->A 119
UC-048 B1 M5 134G->A 134
UC-044 B1 M10 197G->A 197
UC-025 B1 M1 208G->A 208
UC-054 B1 M15 208G->A 208
UC-051 B1 M3 400G->A 400
UC-046 B1 M33 485G->A 485
UC-043 B1 M1 538G->A 538
UC-034 B1 M1 538G->A 538
UC-064 B1 M3 538G->A 538
UC-068 B1 M4 551C->T 551
UC-055 B1 M1 551C->T 551
UC-049 B1 M7 569G->A 569
UC-050 B1 M1 589G->A 589
UC-071 B1 M5 599G->A 599
UC-037 B1 M2 610C->T 610
UC-037 B1 M5 617G->A 617
UC-027 B1 M1 384+1G->A 384+1
UC-035 B1 M2 385-1G->A 385-1
UC-041 B1 M7 385-1G->A 385-1
UC-016 B1 M2 402+1G->A 402+1
UC-040 B1 M25 403-1G->A 403-1
UC-068 B1 M8 609+1G->A 609+1
UC-055 B1 M3, M7 609+1G->A 609+1
UC-028 B1 M3 609+5G->A 609+5
UC-026 B1 M6 610-1G->A 610-1
CD-020 B1 M1 385-1G->A 385-1
CD-024 B1 M3 385-1G->A 385-1
CD-024 B1 M2 425C->T 425
CD-052 B1 M4 544G->A 544
CD-033 B1 M5 3G->A 3
CD-039 B1 M2 139G->A 139
CD-031 B1 M9 197G->A 197
CD-048 B1 M2 209G->A 209
 CD-008 B1 M5 212G->A 212
CD-032 B1 M2 454C->T 454
CD-029 B1 M1 617G->A 617
CD-033 B1 M8 617G->A 617
CD-033 B1 M11 628G->A 628
CD-032 B1 M4 28-1G->A 28-1
CD-049 B1 M2 485+1G->A 485+1
Thiopurine Treated Subjects with Inflammatory Bowel Disease
Thiopurine Treated Children with Ulcerative Colitis
Supplemental Table 1a:  Summary of All G:C to A:T Transitions
non-Thiopurine Subjects with Inflammatory Bowel Disease
non-Thiopurine Children with Crohn's Disease
non-Thiopurine Adults with Crohn's Disease
non-Thiopurine Children with Ulcerative Colitis
non-Thiopurine Adults with Ulcerative Colitis
262
Subject ID Clone Mutation Base Position
UC-005 B1 M4, M34, M35 197G->A 197
UC-056 B2 M37 617G->A 617
UC-056 B2 M13 134+1G->A 134+1
UC-007 B1 M2 319-1G->A 319-1
UC-009 B1 M17, M18, M20, M26 384+1G->A 384+1
UC-005 B1 M11 384+1G->A 384+1
UC-042 B1 M8 118G->A 118
UC-001 B2 M16 197G->A 197
UC-036 B1 M12 202C->T 202
UC-006 B1 M26 209G->A 209
UC-036 B1 M1 400G->A 400
UC-006 B1 M18 485G->A 485
UC-042 B1 M7 551C->T 551
UC-066 B1 M43 599G->A 599
UC-006 B1 M20 27+1G->A 27+1
UC-066 B1 M73 28-1G->A 28-1
UC-036 B1 M2 135-1G->A 135-1
UC-066 B1 M39 384+1G->A 384+1
UC-066 B1 M47 610-16G->A 610-16
 CD-013 B1 M34 3G->A 3
CD-035 B1 M67 74C->T 74
CD-028 B1 M23 113C->T 113
 CD-014 B1 M11 113C->T 113
 CD-015 B1 M2 118G->A 118
CD-054 B1 M1 119G->A 119
CD-050 B1 M26 197G->A 197
CD-021 B1 M23 197G->A 197
CD-019 B1 M2 325C->T 325
CD-025 B1 M4 400G->A 400
CD-053 B1
M14, M33, M15, M34, M43, 
M52
419G->A 419
CD040 B1 M33 454C->T 454
CD040 B1 M22 463C->T 463
 CD-013 B1 M15, M18, M41, M44 485G->A 485
 CD-004 B2_2 M40 485G->A 485
 CD-018 B1 
M27, M31, M47, M54, M79, 
M90, M91, M97
539G->A 539
 CD-004 B2_2 M2, M9 539G->A 539
CD-054 B1 M12 539G->A 539
CD-028 B1 M16 539G->A 539
CD-025 B1 M6 539G->A 539
 CD-014 B1 M12 568G->A 568
CD-035 B1 M25 610C->T 610
CD-054 B1 M7 610C->T 610
CD-026 B1 M22 617G->A 617
 CD-007 B1 M2 617G->A 617
CD-035 B1 M14, m33 28-1G->A 28-1
CD-021 B1 M21 319-1G->A 319-1
 CD-014 B1 M20 384+1G->A 384+1
CD-050 B1 M35, M41, M70 385-1G->A 385-1
CD-015 B1 M14 403-1G->A 403-1
CD-053 B1 M9, M42, M56 609+5G->A 609+5
 CD-014 B1 M5 609+5G->A 609+5
CD-028 B1 M33 610-1G->A 610-1
 CD-005 B1 M5 3G->A 3
CD-036 B1 M1 3G->A 3
 Thiopurine Treated Adults with Crohn's Disease 
Thiopurine Treated Adults with Ulcerative Colitis
Thiopurine Treated Children with Crohn's Disease
263
Subject ID Clone Mutation Base Position
CD-038 B1 M18, M45, M58 3G->A 3
CD-036 B1 M3 27G->A 27
CD-038 B1 M16 47G->A 47
CD-003 B1_2 M52 197G->A 197
CD-046 B1 M2 197G->A 197
 CD-010 B1_2 M16, M28, M34 197G->A 197
CD-038 B1 M5 208G->A 208
CD-051 B1 M1, M3, M5, M6, M8, M25 419G->A 419
CD-037 B1 M4 463C->T 463
CD-003 B1_2 M36 463C->T 463
CD043 B1 M24 463C->T 463
CD-023 B1 M3 485G->A 485
CD-034 B1 M16, M21 539G->A 539
CD-038 B1 M36 568G->A 568
CD-034 B1 M25 569G->A 569
CD-036 B1 M2 600G->A 600
CD-046 B1 M7 617G->A 617
CD-046 B1 M1 27+1G->A 27+1
CD-037 B1 M19 28-1G->A 28-1
CD043 B1 M6 134+1G->A 134+1
CD-003 B1_2 M22 319-1G->A 319-1
 CD-003 B1_2 M83 403-1G->A 403-1
 CD-043 B1 M15 403-1G->A 403-1
 CD-010 B1_2 M56 486-1G->A 486-1
CD-003 B1_2 M60 532+1G->A 532+1
 CD-012 B1 M1 609+5G->A 609+5
CD-034 B1 M18 610-1G->A 610-1
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UC-033 B2 551C->T 551 1 CCA->CTA TCCAG->TCTAG
UC-061 B1, UC-062 B1 617G->A 617 2 TGT->TAT TTGTG->TTATG
UC-058 B1 27+5G->A 27+5 1 agc->aac gagca->gaaca
UC-003 B1 610-16G->A 610-16 1 tgg->tag ctgga->ctaga
Total 5
UC-064 B1 3G->A 3 1 ATG->ATA ATGGC->ATAGC
UC-041 B1 119G->A 119 1 GGA->GAA TGGAC->TGAAC
UC-048 B1 134G->A 134 1 AGg->AAg CAGgt->CAAgt
UC-044 B1 197G->A 197 1 TGT->TAT CTGTG->CTATG
UC-025 B1, UC-054 B1 208G->A 208 2 GGG->AGG AGGGG->AGAGG
UC-051 B1 400G->A 400 1 GAA->AAA TGGAA->TGAAA
UC-046 B1 485G->A 485 1 AGg->AAg AAGgt->AAAgt
UC-043 B1, UC-034 B1, UC-064 
B1
538G->A 538 3 GGA->AGA TTGGA->TTAGA
UC-068 B1, UC-055 B1 551C->T 551 2 CCA->CTA TCCAG->TCTAG
UC-049 B1 569G->A 569 1 GGA->GAA AGGAT->AGAAT
UC-050 B1 589G->A 589 1 GAA->AAA ATGAA->ATAAA
UC-071 B1 599G->A 599 1 AGG->AAG CAGGG->CAAGG
UC-037 B1 610C->T 610 1 CAT->TAT agCAT->agTAT
UC-037 B1 617G->A 617 1 TGT->TAT TTGTG->TTATG
UC-027 B1 384+1G->A 384+1 1 Ggt->Gat AGgta->AGata
UC-035 B1, UC-041 B1 385-1G->A 385-1 1 agA->aaA tagAA->taaAA
UC-016 B1 402+1G->A 402+1 1 Agt->Aat AAgta->AAata
UC-040 B1 403-1G->A 403-1 1 agG->aaG aagGA->aaaGA
UC-068 B1, UC-055 B1 609+1G->A 609+1 2 Tgt->Tat ATgta->ATata
Supplemental Table 1b: Summary of G:C to A:T Transitions with Respect to Sequence Context
non-Thiopurine Subjects with Inflammatory Bowel Disease
non-Thiopurine Children with Ulcerative Colitis
non-Thiopurine Adults with Ulcerative Colitis
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UC-028 B1 609+5G->A 609+5 1 agt->aat aagta->aaata
UC-026 B1 610-1G->A 610-1 1 agC->aaC tagCA->taaCA
Total 26
CD-020 B1, CD-024 B1 385-1G->A 385-1 2 agA->aaA tagAA->taaAA
CD-024 B1 425C->T 425 1 ACA->ATA AACAA->AATAA
CD-052 B1 544G->A 544 1 GAA->AAA TTGAA->TTAAA
Total 4
CD-033 B1 3G->A 3 1 ATG->ATA ATGGC->ATAGC
CD-039 B1 139G->A 139 1 GAA->AAA CTGAA->CTAAA
CD-031 B1 197G->A 197 1 TGT->TAT CTGTG->CTATG
CD-048 B1 209G->A 209 1 GGG->GAG GGGGG->GGAGG
 CD-008 B1 212G->A 212 1 GGC->GAC GGGCT->GGACT
CD-032 B1 454C->T 454 1 CAG->TAG GGCAG->GGTAG
CD-029 B1, CD-033 B1 617G->A 617 2 TGT->TAT TTGTG->TTATG
CD-033 B1 628G->A 628 1 GAA->AAA GTGAA->GTAAA
CD-032 B1 28-1G->A 28-1 1 agA->aaA cagAT->caaAT
CD-049 B1 485+1G->A 485+1 1 Ggt->Gat AGgta->AGata
Total 11
UC-005 B1 197G->A 197 1 TGT->TAT CTGTG->CTATG
UC-056 B2 617G->A 617 1 TGT->TAT TTGTG->TTATG
UC-056 B2 134+1G->A 134+1 1 Ggt->Gat AGgta->AGata
UC-007 B1 319-1G->A 319-1 1 agA->aaA tagAA->taaAA
UC-009 B1, UC-005 B1 384+1G->A 384+1 2 Ggt->Gat AGgta->AGata
Total 6
non-Thiopurine Children with Crohn's Disease
non-Thiopurine Adults with Crohn's Disease
Thiopurine Treated Subjects with Inflammatory Bowel Disease
Thiopurine Treated Children with Ulcerative Colitis
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UC-042 B1 118G->A 118 1 GGA->AGA ATGGA->ATAGA
UC-001 B2 197G->A 197 1 TGT->TAT CTGTG->CTATG
UC-036 B1 202C->T 202 1 CTC->TTC TGCTC->TGTTC
UC-006 B1 209G->A 209 1 GGG->GAG GGGGG->GGAGG
UC-036 B1 400G->A 400 1 GAA->AAA TGGAA->TGAAA
UC-006 B1 485G->A 485 1 AGC->AAC AAGgt->AAAgt
UC-042 B1 551C->T 551 1 CCA->CTA TCCAG->TCTAG
UC-066 B1 599G->A 599 1 AGG->AAG CAGGG->CAAGG
UC-006 B1 27+1G->A 27+1 1 Ggt->Gat TGgtg->TGatg
UC-066 B1 28-1G->A 28-1 1 agA->aaA cagAT->caaAT
UC-036 B1 135-1G->A 135-1 1 agG->aaG tagGA->taaGA
UC-066 B1 384+1G->A 384+1 1 Ggt->Gat AGgta->AGata
UC-066 B1 610-16G->A 610-16 1 tgg->tag ctgga->ctaga
Total 13
 CD-013 B1 3G->A 3 1 ATG->ATA ATGGC->ATAGC
CD-035 B1 74C->T 74 1 CCT->CTT ACCTA->ACTTA
CD-028 B1, CD-014 B1 113C->T 113 2 CCT->CTT TCCTC->TCTTC
 CD-015 B1 118G->A 118 1 GGA->AGA ATGGA->ATAGA
CD-054 B1 119G->A 119 1 GGA->GAA TGGAC->TGAAC
CD-050 B1, CD-021 B1 197G->A 197 2 TGT->TAT CTGTG->CTATG
CD-019 B1 325C->T 325 1 CAG->TAG ACCAG->ACTAG
CD-025 B1 400G->A 400 1 GAA->AAA TGGAA->TGAAA
CD-053 B1 419G->A 419 1 GGC->GAC TGGCA->TGACA
CD040 B1 454C->T 454 1 CAG->TAG GGCAG->GGTAG
CD040 B1 463C->T 463 1 CCA->TCA ATCCA->ATTCA
 CD-013 B1, CD-004 B2_2 485G->A 485 2 AGC->AAC AAGgt->AAAgt
 Thiopurine Treated Adults with Ulcerative Colitis 
 Thiopurine Treated Children with Crohn's Disease 
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 CD-018 B1, CD-004 B2_2, CD-
054 B1, CD-028 B1, CD-025 B1 
539G->A 539 5 GGA->GAA TGGAT->TGAAT
 CD-014 B1 568G->A 568 1 GGA->AGA TAGGA->TAAGA
CD-035 B1, CD-054 B1 610C->T 610 2 CAT->TAT agCAT->agTAT
CD-026 B1, CD-007 B1 617G->A 617 1 TGT->TAT TTGTG->TTATG
CD-035 B1 28-1G->A 28-1 1 agA->aaA cagAT->caaAT
CD-021 B1 319-1G->A 319-1 1 agA->aaA tagAA->taaAA
 CD-014 B1 384+1G->A 384+1 1 Ggt->Gat AGgta->Agata
CD-050 B1 385-1G->A 385-1 1 agA->aaA tagAA->taaAA
CD-015 B1 403-1G->A 403-1 1 agG->aaG aagGA->aaaGA
CD-053 B1, CD-014 B1 609+5G->A 609+5 2 agt->aat aagta->aaata
CD-028 B1 610-1G->A 610-1 1 agC->gaC tagCA->tgaCA
Total 32
 CD-005 B1, CD-036 B1, CD-038 
B1 
3G->A 3 3 ATG->ATA ATGGC->ATAGC
CD-036 B1 27G->A 27 1 GTG->GTA GTGgt->GTAgt
CD-038 B1 47G->A 47 1 GGT->GAT AGGTT->AGATT
CD-003 B1_2, CD-046 B1, CD-010 
B1_2
197G->A 197 3 TGT->TAT CTGTG->CTATG
CD-038 B1 208G->A 208 1 GGG->AGG AGGGG->AGAGG
CD-051 B1 419G->A 419 1 GGC->GAC TGGCA->TGACA
CD-037 B1, CD-003 B1_2, CD043 
B1
463C->T 463 3 CCA->TCA ATCCA->ATTCA
CD-023 B1 485G->A 485 1 AGC->AAC AAGgt->AAAgt
CD-034 B1 539G->A 539 1 GGA->GAA TGGAT->TGAAT
CD-038 B1 568G->A 568 1 GGA->AGA TAGGA->TAAGA
CD-034 B1 569G->A 569 1 GGA->GAA AGGAT->AGAAT
CD-036 B1 600G->A 600 1 AGG->AGA AGGGA->AGAGA
 Thiopurine Treated Adults with Crohn's Disease  
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CD-046 B1 617G->A 617 1 TGT->TAT TTGTG->TTATG
CD-046 B1 27+1G->A 27+1 1 Ggt->Gat TGgtg->TGatg
CD-037 B1 28-1G->A 28-1 1 agA->aaA cagAT->caaAT
CD043 B1 134+1G->A 134+1 1 Ggt->Gat AGgta->AGata
CD-003 B1_2 319-1G->A 319-1 1 agA->aaA tagAA->taaAA
 CD-003 B1_2, CD043 B1 403-1G->A 403-1 2 agG->aaG aagGA->aaaGA
 CD-010 B1_2 486-1G->A 486-1 1 agC->aaC cagCT->caaCT
CD-003 B1_2 532+1G->A 532+1 1 Tgt->Tat CTgta->CTata
 CD-012 B1 609+5G->A 609+5 1 agt->aat aagta->aaata
CD-034 B1 610-1G->A 610-1 1 agC->aaC tagCA->taaCA
Total 29
269
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Introduction 
 In Chapter 2 we have demonstrated a dose-dependent accumulation of G:C to A:T 
transitions and an increase in the prevalence of clonal proliferation in association with 
thiopurine therapy among subjects treated for inflammatory bowel disease.  The 
significance of these mutagenic events on different cell lineages, dividing tissues, and 
disease participating immune cells may be further assessed from the patterns of clonal 
expansion.  HPRT mutations and/or unique T-cell receptors have been used as in vivo 
markers for tracing the occurrence of mutagenic events in different cell lineages (Hakoda 
et al. 1989),  identifying disease-participating T-cells in autoimmune disease multiple 
sclerosis (Allegretta et al. 1990), and assessing possible mechanisms of T-cell 
reconstitution (Williams et al. 2007).  These studies and others have led to the 
interpretations of the possible relationships between mutants in clonal expansions and the 
temporal approximation of mutagenic events (Figure 1), using the patterns of 
characterized HPRT mutations and TCRβ CDR3 regions in relation to T-cell 
development, which has been described in detail in Chapter 1 (Falta et al. 1999; Finette et 
al. 2000; Finette et al. 2001; O'Neill et al. 1994; Kendall et al. 2006).   
 Briefly, two or more mutants harboring the same HPRT mutation and TCRβ 
CDR3 region are considered to have arisen from a common thymocyte (thymocyte-
TCRβ) or post-thymic mature T-cell that has acquired the specific HPRT mutation 
following β chain gene rearrangement, which we refer to as a “post-β rearrangement 
intra-/post-thymic clonal proliferation”.  Mutants that share the same CDR3 region, but 
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have distinct HPRT mutations are hypothesized to have arisen from a thymocyte-TCRβ 
or post-thymic mature T-cell that have acquired independent mutations following β chain 
gene rearrangement through either extensive proliferation or proliferation of an ancestral 
clone with genetic instability.  This clonal expansion is referred to as “hyper-mutable 
post-β rearrangement intra-/post-thymic clonal proliferation”.  HPRT mutants that share 
identical mutation but harbor different T cell receptors are referred to as a “pre-β 
rearrangement pre-/intra-thymic clonal proliferation”, in which the specific HPRT 
mutation was acquired in an early precursor or committed progenitor prior to β chain 
gene rearrangement.   
 
RESULTS 
Patterns of Clonal Expansion 
 Our analysis of 621 HPRT mutations and 611 T cell receptor β (TCRβ) CDR3 
gene regions from 114 children and adults with two or more mutants showed distinct 
patterns of clonal proliferation exhibited by treated and untreated subjects.  Table 1 
provides a summary of subjects grouped by disease and status of treatment and the 
observed patterns and number of clonal expansions.  A detailed compilation of each 
subject’s profile, treatment status, total extent or ratio of clonality, and the types, 
numbers, and sizes of clonal expansions is provided in Table 2.  As previously discussed, 
untreated children did not display detectable clonal proliferation.  Untreated adult 
subjects with two or more mutants displayed primarily post-β rearrangement intra-/post-
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thymic clonal proliferations, with 7 expansions from 5 of 29 adults with ulcerative colitis 
and 2 expansions from 2 of 12 adults with Crohn’s disease.  Most expansions in these 
patients consisted of 2 of 3 to 6 total mutants analyzed, but two larger expansions 
consisted of 5 and 15 of 11 and 25 total mutants analyzed, respectively (Table 2).  In 
contrast to untreated subjects, treated children and adults displayed more diverse patterns 
of clonal proliferation.  Four of 5 children treated for ulcerative colitis showed 2 pre-β 
rearrangement pre-/intra-thymic and 6 post-β rearrangement intra-/post-thymic 
proliferations, while 12 of 17 children treated for Crohn’s disease displayed 4 pre-β 
rearrangement pre-/intra-thymic, 25 post-β rearrangement intra-/post-thymic, and 5 
“hyper-mutable” post-β rearrangement intra-/post-thymic clonal proliferations.  These 
expansions primarily involved 2 mutants, but larger expansions included up to 17 of 35 
total mutants analyzed in a pre-β rearrangement pre-/intra-thymic clonal proliferation and 
36 of 45 mutants analyzed in one post-β rearrangement intra-/post-thymic expansion 
(Table 2).  Seven of 12 adults treated for ulcerative colitis displayed 2 pre-β 
rearrangement pre-/intra-thymic and 12 post-β rearrangement intra-/post-thymic patterns 
of clonal proliferation while 10 of 15 adults treated for Crohn’s disease showed 4 pre-β 
rearrangement pre-/intra-thymic, 21 post-β rearrangement intra-/post-thymic, and 1 
“hyper-mutable” post-β rearrangement intra-/post-thymic clonal proliferations.  
Similarly, most expansions involved 2 mutants, but included as high as 22 of 43 mutants 
analyzed in a pre-β rearrangement pre-/intra-thymic expansion (Table 2).  Both treated 
children and adults showed similar percents of pre-β rearrangement pre-/intra-thymic 
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(14.3% vs. 15.0%) and post-β rearrangement intra-/post-thymic expansions (73.8% vs. 
82.5%), but differ in the “hyper-mutable” post-β rearrangement intra-/post-thymic pattern 
of clonal proliferation, with children displaying 11.9% and adults 2.5% of this type of 
clonal expansion (Table 1).  There did not appear to be significant differences in the 
patterns of clonal proliferation between ulcerative colitis and Crohn’s disease. 
Occurrence of G:C->A:T Transitions 
 From the patterns of clonal proliferation, we have traced the occurrence of G:C to 
A:T transitions in predicted cell lineages.  Table 3 provides a summary of subjects 
grouped by disease and treatment status, types of clonal expansion with predicted cell 
lineage, and the occurrence of G:C to A:T transitions.  A detailed compilation of each 
subject, the sizes and types of clonal expansion, and characterized HPRT mutations and 
TCRβ CDR3 regions is provided in Table 4.  Among untreated adults, one occurrence of 
G:C to A:T transitions was observed in 9 post-β rearrangement intra-/post-thymic 
proliferations, indicating that the mutagenic event originated in a thymocyte-TCRβ or 
mature T-cell.  On the other hand, treated children showed G:C to A:T transitions 
originating in an early precursor or committed progenitor in 3 of 6 pre-β rearrangement 
pre-/intra-thymic expansions (50.0%), in a thymocyte-TCRβ or mature T-cell in 13 of 31 
post-β rearrangement intra-/post-thymic clonal proliferations (41.9%), and in either a 
hyperproliferative or genetically unstable thymocyte-TCRβ or mature T-cell in 4 of 5 
hyper-mutable post-β rearrangement intra-/post-thymic proliferations (80.0%).  Treated 
adults also showed the occurrence of G:C to A:T transitions in an early precursor or 
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committed progenitor in 3 of 6 pre-β rearrangement pre-/intra-thymic expansions 
(50.0%) and in a thymocyte-TCRβ or mature T-cell in 8 of 33 post-β rearrangement 
intra-/post-thymic proliferations (24.2%).  Among all patterns of clonal proliferation, G:C 
to A:T transitions were observed at highest frequency in the hyper-mutable post-β 
rearrangement intra-/post-thymic proliferations, which occurred predominantly in 
children.  One of involved mutants in all 5 expansions of this pattern in children was also 
associated with other post-β rearrangement intra-/post-thymic proliferations (Tables 2 
and 4).  In pediatric subject CD014B1, 2 of 3 mutants involved in the hyper-mutable 
post-β rearrangement intra-/post-thymic proliferation acquired two independent G:C to 
A:T transitions.  
 
DISCUSSION 
 In vivo clonal expansions have been observed in healthy adults, subjects with 
autoimmune diseases who were treated with azathioprine, and cancer patients following 
cytotoxic therapy (O'Neill et al. 1994; Falta et al. 1999; Finette et al. 2000; Finette et al. 
2001; Kendall et al. 2006).   Early studies of healthy adults and patients with autoimmune 
diseases primarily described post-β rearrangement intra-/post-thymic clonal expansions 
from the identification of identical TCR patterns among T-cell clones, and attributed 
these occurrences to normal basal proliferation or immunological response, or when in 
association with an autoimmune disease, as the expansion of disease-participating T-cells 
(Falta et al. 1999; O'Neill et al. 1994).  T-cells reactive to myelin basic protein, an 
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antigen that elicits the autoimmune process in multiple sclerosis, have been identified by 
HPRT mutant selection using the T-cell cloning assay (Allegretta et al. 1990).  Following 
these studies, using both HPRT mutations and TCRβ CDR3 regions, analyses of children 
who received cytotoxic therapy for leukemia defined more diverse patterns of pre-β 
rearrangement pre-/intra-thymic, post-β rearrangement inra-/post-thymic, and hyper-
mutable post-β rearrangement inra-/post-thymic clonal proliferations (Finette et al. 2001).   
 In our comparisons using both HPRT mutations and TCRβ CDR3 regions from 
mutant isolates from children and adults with inflammatory bowel disease who received 
and did not receive thiopurine therapy, we likely observed clonal proliferations from 
basal proliferation, the underlying autoimmune disease in untreated and treated subjects, 
and T-cell reconstitution in response to cytotoxic therapy in treated subjects.  Since the 
number of mutants available from each subject limits the sensitivity of our analysis, we 
did not observe clonal proliferation in untreated children from whom we isolated 2 to 5 
mutants (Table 2).  With these numbers we are able to detect expansions that involve at 
least 40% of mutants in a majority of untreated children with IBD, suggesting that these 
children exhibited expansions involving fewer mutants.  We did observe proliferation 
events in untreated adult subjects who showed only post-β rearrangement intra-/post-
thymic expansions of clones with identical HPRT mutations and TCRs, which have been 
observed in healthy subjects and those with autoimmune diseases using TCR analysis 
(Falta et al. 1999; O'Neill et al. 1994).  In addition to post-β rearrangement intra-/post-
thymic proliferations, children and adults who received cytotoxic thiopurine treatment 
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exhibited pre-β rearrangement pre-/intra-thymic and hyper-mutable post-β rearrangement 
intra-/post-thymic patterns.  The prevalence of pre-β rearrangement pre-/intra-thymic 
proliferations, observed from the representation of the same HPRT mutation that occurred 
prior to β chain gene rearrangement in different mature T-cells with unique T-cell 
receptors, suggest normal thymopoiesis or reconstitution by thymopoiesis in response to 
cytotoxic therapy rather than peripheral basal, antigen-driven, and homeostatic 
proliferations observed in post-β rearrangement post-thymic expansion consisting of T-
cells with identical T-cell receptors.  In addition, for a mutation event, which originated 
in an early precursor or committed progenitor, to be observed in multiple peripheral 
mature T-cells that have undergone both positive and negative selection during T-cell 
development, extensive proliferation must have occurred possibly resulting in the 
mutation or following the acquisition of the mutation.  The hyper-mutable post-β 
rearrangement intra-/post-thymic proliferations, characterized by the expansion of an 
ancestral clone to give rise to progenies that harbor several different HPRT mutations, 
were observed at higher frequency among treated children compared to adults. This 
pattern of clonal proliferation was also observed in children with leukemia following 
cytotoxic therapy (Finette et al. 2000).  Based on the background mutation rate at the 
HPRT locus of approximately 5x10-6 per cell generation, it is unclear whether T-cells 
within these proliferations have been stimulated to divide extensively to acquire the 
observed HPRT mutations in children or that the ancestral clones, which gave rise to 
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progenies within these subpopulations, harbor genetic instability that allow for better 
survival in the presence of cytotoxic therapy. 
 We have demonstrated a dose-dependent increase in the occurrence of G:C to A:T 
transitions associated with thiopurine treatment in spectra comparisons of representative 
unique mutation events that have been corrected for the effect of mutant expansions.  
From the patterns of clonal proliferation, we observed these mutagenic events affecting 
early precursors or committed progenitors and thymocytes-TCRβ or mature T-cells 
involved in pre-β chain rearrangement pre-/intra-thymic and post-β chain rearrangement 
intra-/post-thymic clonal proliferations, respectively, in treated subjects.  G:C to A:T 
transitions unrelated to thiopurine mutagenicity may have accounted for some of the 
observed events, however, the higher frequency of their occurrence among mutant 
expansions in treated compared to untreated subjects suggest additional mutation events 
associated with thiopurine treatment.  These results indicate that tissues with a high 
proliferative rate in vivo are most susceptible to the mutagenicity of thiopurines, 
including proliferating cells within the bone marrow, previously demonstrated to 
incorporate higher levels of 6-thioguanine nucleotides (Lepage 1960; LePage and 
Whitecar 1971), disease-participating immune cells, and tissues undergoing repeated 
cycles of regeneration from chronic damage in inflammatory bowel disease or chronic 
graft versus host disease.  Both lymphocytes and skin epithelia of thiopurine treated 
subjects have also been shown to incorporate 6-thioguanine nucleotides (Cuffari et al. 
2004; O'Donovan et al. 2005).  Consistent with these observations, increased cancer risks 
of leukemia (Offman et al. 2004), lymphoma (Asten et al. 1999; Kandiel et al. 2005; 
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Penn 1988; Silman et al. 1988), and squamous cell carcinoma at sites affected by chronic 
graft versus host disease (Curtis et al. 2005) have been observed among thiopurine treated 
subjects. 
 Although we did not observe significant differences in the effects of thiopurine 
treatment between children and adults by Mf and mutation spectra comparisons in this 
cross-sectional study, the predominance of the unique “hyper-mutable” pattern of clonal 
proliferation showing the highest frequency of G:C to A:T mutations in children suggests 
that we may be capturing a subpopulation of T-cells with increased susceptibility to the 
mutagenicity of thiopurines which perhaps have a higher propensity to progress to 
lymphoma that predominates in transplant children (Penn 1998).   
  
Methods  
 Using both HPRT mutations and TCRβ CDR3 regions, relationships between 
mutants were interpreted as depicted in Figure 1 and recorded in Tables 2 and 4.  Several 
assumptions were made in this analysis when either HPRT mutation or TCRβ CDR3 
region was not available for a particular mutant within an expansion.  In a situation when 
a particular mutant is missing either an HPRT or TCR sequence, but is likely to belong to 
a larger group of mutants by harboring either an identical characterized TCR pattern or 
HPRT mutation, we assumed that the particular mutant belongs to the same pattern of 
clonal proliferation as the larger group of mutants.  We have color coded the 
interpretations in Table 4 to indicate the relationships that were certain from the 
availability of both HPRT mutations and TCRβ CDR3 regions by a black “x”, and in 
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relationships where assumptions had to be made by the color that highlighted either 
available TCR or HPRT sequence.   
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Figure 1.  Patterns of in vivo Clonal Expansion Derived from HPRT and TCRβ  CDR3 Regions from Mutant Isolates. 
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Children UC 7 0
CD 3 0
Total 10 0 0 0 0 0 0 0 0
Adults UC 29 5 7 100.0% 7
CD 12 2 2 100.0% 2
Total 41 7 0 0 9 100.0% 0 0 9
Children UC 5 4 2 25.0% 6 75.0% 0.0% 8
CD 17 12 4 11.8% 25 73.5% 5 14.7% 34
Total 22 16 6 14.3% 31 73.8% 5 11.9% 42
Adults UC 12 7 2 14.3% 12 85.7% 0.0% 14
CD 15 10 4 15.4% 21 80.8% 1 3.8% 26
Total 27 17 6 15.0% 33 82.5% 1 2.5% 40
Thiopurine Treated Subjects with Inflammatory Bowel Disease
Subjects
Patterns of Clonal Expansions in Subjects with Inflammatory Bowel Disease







Patterns of Clonal Expansions
Untreated Subjects with Inflammatory Bowel Disease
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in 1 or more 
clones
UC-062 B1 F 10.3 0.0 0.0 2.7 0.00 3
UC-030 B1 M 12.8 0.0 0.0 9.2 1
UC-003 B1 F 13.8 0.0 0.0 12.1 1
UC-058 B1 F 13.8 0.0 0.0 1.9 0.00 2
UC-059 B1 M 14.1 0.0 0.0 13.6 0.00 5
UC-024 B1 M 14.4 0.0 0.0 3.7 0.00 4
UC-057 B1 M 14.5 0.0 0.0 7.8 0.00 2
UC-033 B2 M 16.2 0.0 0.0 4.9 0.00 5
UC-061 B1 M 17.5 0.0 0.0 4.9 0.00 5
Average 14.2 0.0 0.0 6.7 0.00 3
Total 28 0 0 0 0
UC-071 B1 F 19.0 0.0 0.0 4.4 0.00 5
UC-043 B1 F 20.2 0.0 0.0 1.0 0.00 2
UC-008 B1 M 21.4 0.0 0.0 215.0 1
UC-050 B1 F 21.8 0.0 0.0 19.2 0.00 3
UC-037 B1 F 23.8 0.0 0.0 13.0 0.00 10
UC-038 B1 F 24.3 0.0 0.0 0.6 0.00 2
UC-068 B1 F 24.8 0.0 0.0 5.5 0.00 5
UC-011 B1 M 26.2 0.0 0.0 12.4 0.33 6 1 2 2
UC-021 B1 M 26.4 0.0 0.0 21.9 0.00 8
UC069 B1 F 27.5 0.0 0.0 6.0 0.00 5
UC-034 B1 M 28.7 0.0 0.0 2.1 1
UC-051 B1 F 30.4 0.0 0.0 25.1 0.67 3 1 2 2
UC-045 B1 F 30.5 0.0 0.0 3.7 0.00 4
UC-012 B1 M 32.6 0.0 0.0 13.4 0.33 6 1 2 2
UC-025 B1 F 33.3 0.0 0.0 7.2 0.00 6
UC-064 B1 F 34.9 0.0 0.0 16.9 0.00 5
UC-016 B1 F 38.5 0.0 0.0 30.6 1
UC-049 B1 M 39.6 0.0 0.0 6.3 0.00 5
UC-044 B1 F 41.9 0.0 0.0 7.7 0.00 7
UC-054 B1 M 42.6 0.0 0.0 7.4 0.00 10
UC-039 B1 M 45.9 0.0 0.0 11.3 0.00 7
UC-048 B1 F 46.1 0.0 0.0 8.9 0.00 5
UC-046 B1 M 46.4 0.0 0.0 13.0 0.68 25 2 2, 15 17
UC-015 B1 F 47.4 0.0 0.0 49.7 1
UC-035 B1 F 49.6 0.0 0.0 102.4 0.00 2
UC-040 B1 M 51.0 0.0 0.0 14.5 0.00 7
UC-041 B1 F 51.6 0.0 0.0 9.1 0.00 6
UC-028 B1 M 52.8 0.0 0.0 53.4 0.00 8
UC-055 B1 F 53.5 0.0 0.0 8.0 0.64 11 2 2, 5 7
UC-026 B1 F 54.5 0.0 0.0 68.5 0.00 6
Untreated Adults with Ulcerative Colitis (N=35)
Untreated Children with Ulcerative Colitis (N=9)
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UC-022 B1 F 58.6 0.0 0.0 28.8 0.00 3
UC-023 B1 M 63.1 0.0 0.0 7.4 0.00 2
UC-027 B1 M 70.4 0.0 0.0 10.0 1
UC-020 B1 M 70.5 0.0 0.0 13.2 1
UC-019 B1 F 76.4 0.0 0.0 17.0 0.00 2
Average 40.7 0.0 0.0 23.8 0.09 5
Total 182 0 7 0 30
CD-020 B1 F 14.0 0.0 0.0 3.5 0.00 3
CD-052 B1 M 16.0 0.0 0.0 4.9 0.00 5
CD-024 B1 M 16.5 0.0 0.0 5.1 0.00 5
Average 15.5 0.0 0.0 4.5 0.00 4
Total 0 0 0 0
CD042 B1 M 26.5 0.0 0.0 17.8 0.50 4 1 2 2
CD-029 B1 F 27.5 0.0 0.0 8.2 0.00 3
CD-008 B1 M 28.4 0.0 0.0 8.0 0.00 6
CD-044 B1 F 35.6 0.0 0.0 7.6 0.00 3
CD-030 B1 F 40.8 0.0 0.0 28.0 0.40 5 1 2 2
CD-033 B1 F 44.2 0.0 0.0 11.6 0.00 5
CD-049 B1 F 45.3 0.0 0.0 25.8 0.00 4
CD-039 B1 M 47.3 0.0 0.0 8.0 0.00 5
CD-048 B1 M 47.5 0.0 0.0 4.8 0.00 2
CD-045 B1 F 50.3 0.0 0.0 9.5 0.00 5
CD-032 B1 F 52.7 0.0 0.0 11.9 0.00 4
CD-011 B1 F 55.7 0.0 0.0 6.5 1
CD-031 B1 F 55.8 0.0 0.0 16.0 0.00 5
Average 42.9 0.0 0.0 12.6 0.08 4
Total 52 0 2 0 4
UC-014 B1 M 6.4 0.6 19.2 2.1 1
UC-060 B1 F 13.0 2.8 327.1 5.7 1
UC-007 B1 M 14.5 1.6 317.6 53.1 0.46 13 2 2, 4 6
UC-004 B1 M 15.0 0.6 110.9 93.3 0.00 2
UC-009 B1 F 18.0 5.2 745.8 33612.9 0.80 5 1 4 4
UC-056 B2 M 18.7 2.8 728.5 4584.2 0.50 14 2 2, 3 1 2 7
UC-005 B1 F 18.8 7.8 957.8 6031.5 0.33 18 2 2, 4 6
Average 14.9 3.1 458.1 6340.4 0.42 8
Total 54 2 6 0 23
UC-002 B1 M 19.6 1.0 252.5 41.1 0.28 18 2 2, 3 5
UC-042 B1 F 20.0 0.0 11.8 4.2 0.00 7
UC-001 B2 F 20.0 6.2 1322.9 74776.5 0.30 10 1 3 3
Treated Adults with Ulcerative Colitis (N=13)
Subjects with Inflammatory Bowel Disease, Treated with Purine Analogs
Treated Children with Ulcerative Colitis (N=7)
Untreated Adults with Crohn's Disease (N=13)
Untreated Children with Crohn's Disease (N=3)
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UC-006 B1 M 21.7 3.7 703.6 1505.9 0.52 21 1 2 4 2, 2, 2, 3 11
UC-065 B1 M 22.6 0.1 23.8 4.7 1
UC-070 B1 F 23.0 0.6 41.8 2.2 0.00 2
UC-018 B1 M 28.0 1.4 210.1 4.4 0.00 4
UC-066 B1 M 30.0 2.5 737.6 2000.8 0.00 10
UC-029 B1 F 33.6 0.1 10.1 7.4 0.00 2
UC-036 B1 M 39.7 10.5 2378.8 2826.0 0.18 22 1 2 1 2 4
UC-067 B1 M 43.9 0.3 44.0 15.0 0.88 8 2 2, 5 7
UC-031 B1 F 47.3 0.8 105.0 8.0 0.33 6 1 2 2
UC-047 B1 M 49.8 0.9 133.8 10.0 0.20 10 1 2 2
Average 30.7 2.2 459.7 6246.6 0.22 9
Total 121 2 12 0 34
CD-013 B1 M 7.8 1.4 142.8 17.8 0.66 35 1 (11), (6) 3 2, (2), (4) 23
CD-050 B1 F 9.5 2.8 184.7 1166.2 0.60 10 1 2 1 (3) 1 (2) 6
CD-001 B2 M 10.2 1.1 196.8 33.0 0.67 9 2 2, 4 6
CD-027 B1 M 11.7 4.3 546.7 15.7 0.40 10 2 2, 2 4
CD-035 B1 M 13.4 2.2 290.2 58.8 0.40 10 2 2, 2 4
CD-018 B1 F 13.6 1.1 90.3 74.4 0.91 45 1 (4) 1 (36) 1 (3) 41
CD-021 B1 M 13.6 2.7 267.8 161.0 0.24 17 1 4 4
CD-015 B1 F 14.3 4.2 805.9 405.8 0.77 31 1 2 4 2, 2, 7, 11 24
CD-004 B2_2 F 15.1 3.0 391.1 1167.1 1.00 10 3 2, 2, (5) 1 (2) 10
CD-016 B1 F 15.3 0.1 3.8 7.0 1
CD-054 B1 F 16.6 0.2 15.5 15.2 0.30 10 1 3 3
CD-026 B1 F 17.0 0.6 100.0 5.9 0.00 10
CD-028 B1 F 17.2 4.5 319.6 1761.7 0.00 6
CD-019 B1 F 17.4 0.6 70.0 8.2 0.00 3
CD-053 B1 F 17.8 0.7 90.9 247.9 0.90 10 2 3, (5) 1 (2) 9
CD-025 B1 M 18.0 0.0 35.3 8.1 0.00 5
CD-007 B1 F 18.6 1.1 135.3 4.3 1
CD040 B1 F 18.8 0.6 71.3 9.6 0.00 10
CD-014 B1 M 18.8 9.3 1265.7 1828.4 0.54 24 3 2, 3, (5) 1 (3) 13
Average 15.0 2.1 264.4 368.2 0.43 14
Total 257 4 25 5 147
CD-009 B1 F 19.2 5.4 880.0 26646.8 0.91 43 1 (22) 3 (2), (3), (14) 39
CD-051 B1 M 19.8 0.1 8.2 19.8 0.71 7 1 5 5
CD-037 B1 F 21.0 1.0 185.1 349.8 0.30 10 1 3 3
CD-023 B1 F 21.9 9.6 839.4 157177.2 0.38 8 1 3 3
CD-005 B1 M 24.4 0.3 45.4 4.7 0.00 4
CD-003 B1_2 F 26.2 2.0 330.7 1459.0 0.52 42 3 2, (2), 3 5 2, 2, (3), 4, 5 22
CD-036 B1 F 27.6 0.0 5.3 1.6 0.00 3
CD-046 B1 M 28.7 0.6 86.2 20.1 0.00 6
CD-006 B1 F 31.1 3.7 813.8 2293.3 0.32 28 4 2, 2, 2, 3 9
 Treated Adults with Crohn's Disease (N=15) 
Treated Children with Crohn's Disease (N=19)
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CD041 B1 M 33.7 1.2 208.3 14.9 0.00 4
CD-010 B1_2 F 39.7 4.0 686.2 7311.3 0.50 14 3 2, 2, 3 7
CD-012 B1 M 47.3 0.6 183.8 8.5 0.00 3
CD043 B1 F 48.2 1.3 153.3 23.9 0.40 5 1 2 2
CD-034 B1 F 55.6 9.1 1250.0 62163.2 0.20 10 1 2 2
CD-038 B1 M 58.6 2.7 480.0 979.8 0.70 10 2 3, 4 7
Average 33.5 2.8 410.4 17231.6 0.33 13
Total 197 4 21 1 99
Mutants in (  ) are in involved in another clonal expansion
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% of Total Total Clonal 
Expansion 
with G->A







Adults UC 7 7 1 14.3%
CD 2 2 0.0%
Total 9 9 1 11.1%
Children UC 8 2 1 50.0% 6 4 66.7%
CD 34 4 2 50.0% 25 9 36.0% 5 4 80.0%
Total 42 6 3 50.0% 31 13 41.9% 5 4 80.0%
Adults UC 14 2 1 50.0% 12 0.0%
CD 26 4 2 50.0% 21 8 38.1% 1 0.0%
Total 40 6 3 50.0% 33 8 24.2% 1 0.0%
Treated
Untreated
Pre-/Intra-thymic, Prior to !-Chain 
Rearrangement
Intra-/Post-thymic, Post !-Chain 
Rearrangement
Early Precursor or Committed T-cell 
Progenitor
Thymocyte-TCR! or Mature T-cellPredicted Cell Lineage
Patterns of Clonal Expansion




Thymocyte-TCR! or Mature T-cell
Subject ID Number of 
Clones












UC-011 B1 2 233T->A GEPAR x
UC-051 B1 2 222C->A TLLAGGG x
UC-012 B1 2 48_49delTTinsC x
UC-046 B1 7 539G->T SQQG x
UC-046 B1 7 SQQG x
UC-046 B1 1 539G->T x
UC-046 B1 1 610-1G->C VASGGL x
UC-046 B1 1 VASGGL, PLRD x
UC-055 B1 2 202C->G AKPTGTG x
UC-055 B1 2 609+1G->A PGGEP x
UC-055 B1 3 PGGEP x
CD042 B1 1 143G->A STKW x
1 143G->A x
CD-030 B1 2 51_52insGTAT QGG x
UC-007 B1 1 28-13_50del36 PPVTGR x
1 28-13_50del36 x
2 319-1G->A EMFSGT x
1 319-1G->A x
1 EMFSGT x
UC-009 B1 4 384+1G->A x
UC-056 B2 2 507delA STOP x
1 578T->G GSF x
1 578T->G PGQT x
1 578T->G TLTGPFW x
1 617G->A GRPLA x
1 617G->A RYPDRP x
UC-005 B1 1 197G->A GQEG x
Patterns of Clonal Expansion in Children and Adults with Inflammatory Bowel Diseasea
Treated Children with Ulcerative Colitis
Subjects with Inflammatory Bowel Disease, Not Treated with Purine Analogs
Untreated Adults with Ulcerative Colitis
Untreated Adults with Crohn's Disease
Subjects with Inflammatory Bowel Disease, Treated with Purine Analogs
289
Subject ID Number of 
Clones
















UC-002 B1 2 Deletion of Exons 7, 8 SPLDREE x
1 Deletion of Exons 7, 8 x
2 EETGLG x
UC-001 B2 3 LGG x
UC-006 B1 1 143G->A SPGQGA x
1 SPGQGA x
1 209G->A AQAPDRGK x
1 209G->A DYPGM x
1 28-1G->C FGQGA x
1 28-1G->C x
1 28-58_49del80 PRGLGG x
1 28-58_49del80 x
3 EVAGTST x
UC-036 B1 1 151C->T SLRDGN x
1 151C->T x
1 152G->C LLYRGLDPPN x
1 152G->C MRGY x
UC-067 B1 5 571_574dupTATG RETGD x
1 610-1G->T KGEK x
1 610-1G->T STOP x
UC-031 B1 1 3G->C SYGQGAR x
1 SYGQGAR x
UC-047 B1 1 468delG GPAQPS x
1 GPAQPS x
 CD-013 B1 3 485G->A GRGRGA x x
1 GRGRGA x
1 485G->A NRGEG x x
1 NRGEG x
1 485G->A RGGVSS x
Treated Adults with Ulcerative Colitis
Treated Children with Crohn's Disease
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1 485G->A SKWEPIL x
1 485G->A TADTTV x







3 385-1G->A DGAGGY x x
1 229G->T PATGG x
1 229G->T RRLGSEGQG x
CD-001 B2 2 134+1G->C TGER x
1 134+9delG SPLIG x
3 SPLIG x
CD-027 B1 2 151C->T x
2 37_49del13 GFTGS x
CD-035 B1 1 151C->T RVGSHLRRP x
1 151C->T x
2 28-1G->A x
 CD-018 B1 1




1 539G->A RTGAP x x
1 539G->A PTSGLR x
1 539G->A RDRGS x
33 539G->A DVGLAGGQRG x x
1 DVGLAGGQRG x
2 539G->A x
CD-021 B1 1 38_59delinsT ESQGRV x
3 38_59delinsT x
 CD-015 B1 2 118G->A RPYDLGTGVA x
4 RPYDLGTGVA x
1 118G->A x
2 151C->T VDMGLV x
8 VDMGLV x
1 151C->T x
1 568G->T LGAM x
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1 568G->T RGTGGL x
1 403-1G->A PSKGPTG x
1 PSKGPTG x
2 NGRGPQ x
 CD-004 B2_2 1 485G->A FPRGDM x
1 28-1_53del27 FPRGDM x x
4 28-1_53del27 x
2 319-2A->G ISLG x
1 539G->A VATG x
1 539G->A x
CD-054 B1 3 532+3A->C PRTSKA x
CD-053 B1 1 35_52del18 QGGSL x
5 419G->A QGGSL x x
1 609+5G->A PLAGGSG x
2 609+5G->A x
 CD-014 B1 3 113C->T CSTTLGQG x
1 134+1G->A (mixed) VGGSK x
1 609+5G->A VGGSK, QEG x
1 Deletion of Exons 4-9 VGGSK x
5 VGGSK x
1 542T->G IEVGGRAWG x
1 542T->G x
 CD-009 B1 614T->A ALAS x
3 614T->A ASGTP x x
2 614T->A TRLS x x
1 614T->A DHDRGA x
1 614T->A DPGTGGPY x
1 614T->A GAGRLF x
1 614T->A GQGG, GTGTR x
1 614T->A ILGGN x
1 614T->A LELAD x
1 614T->A LGQGAR x
1 614T->A LVQPGRTG x
1 614T->A NMYN x
1 614T->A nonfunctional x
 Treated Adults with Crohn's Disease 
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1 614T->A PVRGPSG x
1 614T->A RAGQSAT x
1 614T->A RPGLAGGW x
1 614T->A RRSGT x
1 614T->A RRTL x
1 614T->A SLGL x
1 614T->A SLIG x
1 614T->A VALGE x
1 614T->A YWGR x
14 614T->A x
CD-051 B1 5 419G->A RSNT x
CD-037 B1 3 152G->C GVGL x
CD-023 B1 1 385-2A->G SGSYG x
1 Presumed deletion of Exon 6 SGSYG x
1 SGSYG x
CD-003 B1_2 1 113C->T MDLVS x
3 MDLVS x
1 151C->T TSEREVGNQP x
4 151C->T x
1 197G->A LGQK x
1 197G->A QWDRG x
1 197G->A x
1 463C->T AGGRG x
1 463C->T NSG x
1 533-3T->G YSTR x
1 YSTR x
1 541T->C NRRTGLI x x
2 NRRTGLI x
1 541T->C VGGRDP, DRPS x
2 WELAGGPG x




1 533-2A->G SEPGY x
1 SEPGY x
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 CD-010 B1_2 2 151C->T x
3 197G->A LIGQGS x
2 319-4_319-14del11 x
CD043 B1 2 403-1G->A TATG x
CD-034 B1 2 539G->A ATS x
CD-038 B1 3 3G->A HYLVGSGTLP x
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Introduction 
We have previously discussed the implicated role of the mismatch repair system 
in signaling “DNA damage” or 6-MeTG:T mispairs to result in the cytotoxic effects of 
thiopurines.  Of concern is that chronic drug treatment may enrich for cells with 
mismatch repair deficiency, which are drug resistant and genetically unstable with 
potential to develop into tumors.  Increased resistance to thiopurines has been observed in 
association with mismatch repair deficiency (Aebi et al. 1997; Krynetskaia et al. 2003), 
and the enrichment for mismatch repair deficient cells with chronic thiopurine treatment 
has been demonstrated in vitro (Offman et al. 2004).  Offman and colleagues also 
demonstrated an azathioprine dose-dependent increased risk of acute myelogenous 
leukemia (AML) among treated transplant recipients, from whom they observed a high 
frequency of microsatellite instability in collected AML samples. 
To investigate whether drug selection for mismatch repair deficient mutants 
occurs in IBD subjects treated with thiopurines, several approaches have been taken 
based on the scientific assumptions that specific sequences of events have occurred. 
Scenario 1) We hypothesized that the observed elevation in frequency of somatic 
mutations among thiopurine treated IBD subjects reflects the selection of a subpopulation 
of T-cell clones with mismatch repair deficiency that have a high mutation rate, resulting 
in the acquisition of HPRT mutations.   In this scenario, HPRT mutants are screened for 
mismatch repair deficiency by analysis of microsatellite instability indicative of the 
functional deficiency of mismatch repair.  Mutants showing microsatellite instability will 
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be further characterized for alterations in protein expression of mismatch repair 
components. 
Scenario 2) We hypothesized that chronic thiopurine treatment selects for mismatch 
repair deficient mutants among the subpopulation of dividing T-cells.  Since thiopurines 
are prodrugs that require activation by the HPRT enzyme prior to exerting their cytotoxic 
effects, selection for mismatch repair deficiency would initially require that cells retain a 
functionally intact HPRT enzyme.  Also, since the signaling events involving the 
mismatch repair system occur following 6-thioguanine nucleotides incorporation into 
DNA, the proliferating subpopulation would be most susceptible to the selective pressure 
of drug treatment. To increase our sensitivity for measuring these events, we would 
initially enrich for and analyze the frequency of microsatellite instability in the 
subpopulation of CD45RO T-cells, comprising memory and effector T-cells generated 
from T-cell activation (Janeway et al. 2001). This cell population may be dividing as a 
result of the underlying inflammatory bowel disease and/or from repopulation in response 
to the cytotoxicity of thiopurine intervention. This subpopulation has a higher probability 
of accumulating replication errors, from previous or recent cell division, that have not 
been repaired in cells with mismatch repair deficiency. Furthermore, the activated 
lymphocyte subpopulation is more likely to harbor precursors of lymphomas that develop 
in patients receiving thiopurine treatment (Kandiel et al. 2005; Kinlen 1985). In this 
scenario, we would evaluate cells that may or may not harbor HPRT mutations for the 
enrichment of mismatch repair deficient mutants. 
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To complement these investigations, the background frequency of microsatellite 
instability in HPRT mutant and CD45RO T-cell clones from HNPCC patients, who have 
inherited germline mutations in genes encoding for mismatch repair components, will 
also be determined.  These subjects are different from the IBD group in that they are 
heterozygous for specific component gene of the mismatch repair system but do not have 
an underlying autoimmune disease and are also not treated with thiopurines.  However, 
their background frequency would provide information for future therapeutic 
intervention. 
In both scenarios 1 and 2, we will examine the frequency of microsatellite 
instability in relation to parameters that are hypothesized to influence and reflect in vivo 
drug selection, including the effects of age and duration of treatment or total dose as well 
as whether specific HPRT mutant expansions consist of cells that are genomically 
unstable.  Coolbaugh-Murphy and colleagues demonstrated an age-dependent increase in 
the frequency of microsatellite instability in mononuclear cells of healthy subjects 
(Coolbaugh-Murphy et al. 2005), suggesting that older individuals may harbor more cells 
with MMR deficiency as a result of inactivating mutations or methylation of mismatch 
repair component genes that have accumulated with time.  This is consistent with the 
higher frequency of microsatellite instability observed in acute myelogenous leukemia 
and lymphoma that develop among the elderly (Scarisbrick et al. 2003; Starostik et al. 
2000; Zhu et al. 1999).  Duration and total dose of treatment would also highly influence 
the enrichment of genetically unstable cells, as several in vitro studies have demonstrated 
the selection for mismatch repair deficient mutants following chronic treatment from low 
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to high drug doses (Aquilina et al.  1990).  Lastly, among treated subjects, we observed a 
unique “hyper-mutable” pattern of clonal expansion, in which mutant T-cells arising from 
a common ancestral T-cell clone expressing identical TCRβ  CDR3 region have diverged 
to acquire several independent HPRT mutations.  It is unclear whether the acquisition of 
these mutations is a result of extensive proliferation and/or a manifestation of genetic 
instability.   
 
RESULTS AND DISCUSSION 
 A preliminary analysis of the frequency of microsatellite instability in HPRT 
mutant T-cell clones from treated IBD subjects was performed to assess whether chronic 
thiopurine treatment resulted in the selection of mismatch repair deficient mutants, which 
then acquire HPRT mutations (scenario 1).  Thirteen treated subjects were selected based 
on their age, total dose and duration of treatment, and mutant frequency, which range 
from 7.8 to 39.7 years of age, 0 – 1266 mmoles of thiopurines, 0 - 9.3 years of treatment, 
and 4.7 to 33, 613x10-6 in mutant frequency values, to examine the possible effects of 
these variables on the frequency of microsatellite instability.  Tables 1a and 1b provide 
the summaries for each subject profile and the number of mutant HPRT T-cell clones that 
have been analyzed, using Group I and II microsatellite markers, consisting of an analysis 
of 22 microsatellite loci in each cell.  A total of 248 clones was analyzed from 13 subjects 
with Group I markers and 156 clones from 10 subjects with Group II markers, ranging 
from 3 to 43 T-cell clones from each subject.  Reference values for the frequency of 
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microsatellite instability of HPRT mutant T-cell clones from healthy subjects and tumor 
samples from subjects with HNPCC are provided in Tables 1c and 1d.  Hackman and 
colleagues observed microsatellite instability in 1.7% of HPRT T-cell clones at a 
frequency of 0.29% mutation per allele, in an analysis of 178 clones from 28 subjects 
(Hackman et al. 1995).  Tumor samples from HNPCC patients display a frequency of 28-
65% and 17.6% mutation per allele in colon and endometrial cancers, respectively 
(Aaltonen et al. 1993; Burks et al. 1994).  Our initial analysis of 248 T-cell clones from 
13 subjects did not reveal microsatellite instability at any of the loci.  These results may 
suggest that chronic thiopurine treatment does not sufficiently enrich for HPRT mutant 
clones that also harbor mismatch repair deficiency perhaps because the sequential events 
of loss of mismatch repair function followed by the acquisition of an HPRT mutation are 
relatively rare compared to directly acquiring an HPRT mutation.  On the other hand, we 
may not have evaluated enough subjects and thus sampled the genetic diversity to capture 
these events. 
 Mutant HPRT T-cell clones have been isolated for microsatellite analysis and 
correlation with measured mutant frequencies for several HNPCC subjects.  Table 2 
shows HPRT mutant frequency values for 4 HNPCC subjects along with identified 
germline mutations of affected mismatch repair component gene and the types of cancers 
that have developed in these patients.  Among four subjects, two showed significantly 
elevated mutant frequency of 45.1 and 48.9 per million compared to average healthy 
adult values of 9 and 14.5 per million at 34 and 52 years of age, respectively.  At this 
time it is unclear whether the elevated frequencies in these individuals represent clonal 
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expansions, haploinsufficiency following specific mutations in MSH2 component gene, 
or loss of heterozygosity of the remaining wildtype allele in a subset of clones.  Marra 
and colleagues demonstrated that human lymphoblastoid cell lines, heterozygous for 
MSH2 by different inactivating mutations, may have higher resistance to the methylating 
agent temozolomide when compared to cells heterozygous for MLH1, which display drug 
sensitivity similar to wildtype cells (Marra et al. 2001).  They correlated this difference to 
lower steady state protein levels associated with heterozygosity for MSH2 compared to 
MLH1.  Although repair capacities in these cells were compromised to a lesser extent, 
cells heterozygous for MSH2 displayed lower capacities than wildtype cells and cells 
heterozygous for MLH1.  These observations by Marra and colleagues suggest possible 
phenotypic heterogeneity among carrier states, which may be what we are observing.  At 
this time it is difficult to draw conclusions from the observations of a small number of 
samples.  The analysis of additional patient samples and correlative MSI data will 
provide more information. 
We have also proceeded with the evaluation of microsatellite instability in the 
CD45RO T-cell subpopulation among select IBD and HNPCC subjects, which have been 
enriched for by flow sorting with anti CD2 and anti CD45RO antibody labeled T-cells.  
Our initial sorting of mononuclear cells from six subjects showed that CD45RO T cells 
represent about 20 to 25% of the total T-cell population.  By this approach, we have 
enriched for and increased our detection sensitivity by four fold of the subpopulation of 
cells that are likely to have undergone cell division. 
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Materials and Methods 
High-throughput Microsatellite Analysis – details of sample preparation, PCR conditions, 
and automated data processing have been optimized and discussed in Chapter 3. 
Determination of HPRT mutant frequency was performed by using the T-cell cloning 
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Table 1a.  Frequency of Microsatellite Instability of HPRT Mutant Clones in IBD Subjects with Group I 
Markers.   
248 HPRT mutant T-cell clones from 13 subjects analyzed for microsatellite instability using 6 Group I microsatellite 
markers.  Data are sorted by the theoretical total dose to which subjects were exposed. 
 






) # of Clones # of Clones (+) 
MSI
1 CD008B1 M 28.4 0.0 0.0 8.0 7 0
2 CD005B1 M 24.4 45.4 0.3 4.7 5 0
3 CD013B1 M 7.8 142.8 1.5 17.8 23 0
4 UC002B1 M 19.6 252.5 1.0 41.1 10 0
5 CD003B1_2 F 26.2 330.7 2.0 1459.0 38 0
6 CD010B1_2 F 39.7 686.2 4.0 7311.3 13 0
7 UC006B1 M 21.7 703.6 3.7 1505.9 3 0
8 UC009B1 F 18.0 745.8 5.2 33612.9 3 0
9 CD015B1 F 14.3 805.9 4.2 405.8 43 0
10 CD006B1 F 31.1 813.8 3.7 2293.3 42 0
11 CD009B1 F 19.2 880.0 5.4 26646.8 31 0
12 UC005B1 F 18.8 957.8 7.8 6031.5 6 0
13 CD014B1 M 18.8 1265.7 9.3 1828.4 24 0
Total 13 248 0
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Table 1b.  Frequency of Microsatellite Instability of HPRT Mutant Clones in IBD Subjects with Group II 
Markers.   
156 HPRT mutant T-cell clones from 10 subjects used to analyze with Group I markers were also analyzed for 
microsatellite instability using 5 Group II microsatellite markers.  Data are sorted by the theoretical total dose to which 
subjects were exposed.   
 






) # of Clones # of Clones (+) 
MSI
1 CD013B1 M 7.8 142.8 1.5 17.8 3 0
2 UC002B1 M 19.6 252.5 1.0 41.1 5 0
3 CD003B1_2 F 26.2 330.7 2.0 1459 32 0
4 CD010B1_2 F 39.7 686.2 4.0 7311.3 8 0
5 UC006B1 M 21.7 703.6 3.7 1505.9 3 0
6 UC009B1 F 18.0 745.8 5.2 33612.9 3 0
7 CD015B1 F 14.3 805.9 4.2 405.8 33 0
8 CD006B1 F 31.1 813.8 3.7 2293.3 41 0
9 CD009B1 F 19.2 880 5.4 26646.8 25 0
10 UC005B1 F 18.8 957.8 7.8 6031.5 3 0
Total 10 156 0
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Table 1c.  Frequency of Microsatellite Instability of HPRT Mutant Clones in Healthy Subjects.  178 HPRT 
mutant T-cell clones analyzed at 1028 loci for microsatellite instability. 
 
Reference # of Subjects # of Clones # of Clones (+) 
MSI
% Clones (+) 
MSI
# of Alleles 
Analyzed 
# of Alleles  
(+) MSI
% of Alleles  
(+) MSI
Hackman et al., 1995. 28 178 3 1.7% 1028 3 0.29%  
 
Table 1d.  Frequency of Microsatellite Instability in Tumor Samples from HNPCC Subjects. 
Reference Type of Tumor
Aaltonen et al., 1993. HNPCC Colon Cancer
Burks et al., 1994 HNPCC Endometrial Cancer
% of Alleles  (+) MSI
28-65%
17.6%  
Table 2.  HNPCC Subjects: Germline Mutation of MMR Component Gene and Mutant Frequency Values. 
Subject ID Gender Age Germline Mutation Age at Diagnosis and Cancers Mf (10-6) Mean Mf 
(10-6) 
HN-001 F 38.3 MSH2, intron 5, IVS5+3 A-
>T 
32 yrs., Polyp, Adenoma, Right Colon; 35 yrs., Melanoma of Skin of 
Lower Right; 36 yrs., Polyp, Adenoma, Rectum and Transverse Colon 
19.5, 30.8 25.2 
HN-002 M 35.8 MSH2, codon 406 Arg->stop 
(CGA->TGA), 1216C->T 
48 yrs., Polyp, Adenonoma, NOS, Sigmoid Colon; 63 yrs., 
Adenocarcinoma, NOS, Sigmoid Colon; 64 yrs., Actinic Keratosis, Skin 
45.1  
HN-003 M 35.3 MSH2, codon 636 Ala->Pro, 
1906G->C 
35 yrs., Adenocarcinoma, Transverse Colon 48.9  
HN-005 F 48.0 MSH2, codon 824 Gln->stop 37 yrs., Mucinous Adenocarcinoma, Hepatic Flexure of Colon; 41 yrs., 
Adenocarcinoma, Uterine 
7.5  










   9.0 + 7.4 
14.5+11.2 
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INCREASING THROUGHPUT OF GENOTYPING 
BY EXOSAP TREATMENT OF MULTIPLEX PCR 
REACTIONS TO ALLOW FOR THE 
SIMULTANEOUS SEQUENCING OF MULTIPLE 
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Mutation or nucleotide sequence analysis is typically performed by PCR 
amplification of gene regions of interest, DNA product separation with gel 
electrophoresis and purification by binding to silica or ion-exchange resins, extraction 
with phenol chloroform, or electrocution, and then followed by DNA sequencing of 
individual purified products.  These steps can be time-consuming and labor-intensive 
when there are numerous samples to process. 
The throughput of genotyping can be increased by combining amplifications of 
gene regions into multiplex PCR reactions followed by exonuclease I and shrimp alkaline 
phosphatase (EXOSAP) treatment of reactions to digest remaining primers and dNTPs 
that may compete with substrates in sequencing reactions, a previously described 
methodology used in the purification of single amplified PCR products for DNA 
sequencing (Werle et al. 1994).  Here, we demonstrate that EXOSAP treatment of 
multiplex PCR reactions additionally allows for the direct and simultaneous sequencing 
of all amplified products from the original PCR reaction (depicted in Figure 1), 
increasing throughput and minimizing reagent costs and handling as well as sample mix-
ups.  Optimized EXOSAP treatment conditions are provided in the materials and methods 
section.  The prerequisites for optimal sequencing performance include good yield of 
PCR amplified products; however, lower yield reactions may be tolerated with the use of 
specific internal primers in sequencing reactions to minimize cross priming of non-
specific products.  We have tested several conditions to demonstrate the possible 
simultaneous sequencing of up to eight gene regions of the HPRT gene that have been 
amplified in multiplex PCR reactions.  Figure 2 shows the quality of DNA sequences that 
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can be obtained for gene regions A, B, C, and D that have been amplified in a single 
muliplex PCR reaction (indicated by the arrow in gel analysis), undergone EXOSAP 
treatment, and then simultaneously sequenced from the products of this reaction with 
optimized primers.  
To further increase throughput, the entire process of multiplex PCR 
amplifications of gene regions and EXOSAP treatment can be adapted to a 96 or 384-
well plate format for routine mutation or single nucleotide polymorphism (SNP) analyses. 
 
Materials and Methods 
Multiplex PCR amplifications of HPRT gene regions were performed using PCR 
conditions that were optimized by Gibbs and colleagues (Gibbs et al. 1990).   
Reagents and Conditions for EXOSAP Treatment: 
Shrimp alkaline phosphatase (SAP) stock: 1 unit/µL USB  
Exonuclease I (EXO) stock: 10 units/µL USB 
Buffer for diluting Exonuclease I (Buffer): 20mM Tris pH 7.5, 0.5mM EDTA, 5mM Beta 
Mercaptoethanol, 50% glycerol. 
 
EXOSAP final reagent [.5 unit/µL SAP, 1.5 units/µL EXO + 7mM Tris pH7.5] - 5 parts 
SAP + 1.5 parts EXO + 3.5 parts Buffer.  
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Sample Treatment: 2 parts sample + 1 part EXOSAP; Incubate 30-45 minutes at 37°C 
(treat for 45 minutes if PCR yield is not high and if used higher concentrations of 
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 Figure 1.  Increasing Throughput of Genotyping by Multiplex PCR and EXOSAP Treatment. 
Sequencing of PCR products 
using internal primer specific 
to amplified gene regions 
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Figure 2.  Sequences of Multiplex PCR Products Following EXOSAP Treatment. 
 
 
 Gene Regions: 
            A 
           B 
          C 






  316 
REFERENCES 
Gibbs, R.A., P.N. Nguyen, A. Edwards, A.B. Civitello, and C.T. Caskey. 1990. Multiplex 
DNA deletion detection and exon sequencing of the hypoxanthine 
phosphoribosyltransferase gene in Lesch-Nyhan families. Genomics 7: 235-244. 
 
Werle E, Schneider C, Renner M, Völker M, Fiehn W. 1994. Convenient single-step, one 
tube purification of PCR products for direct sequencing. Nucleic Acids Res. 22: 
4354-5. 
